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ABSTRACT 
Atherosclerosis is a chronic inflammatory disorder characterised by lipid 
accumulation in the arterial wall. Nutraceuticals represent promising alternatives to 
pharmaceuticals in the prevention and management of this disease. Previous work 
has shown an omega-6 fatty acid, dihomo-gamma-linolenic acid (DGLA) to inhibit 
atherosclerosis in a mouse model of the disease. Understanding the molecular 
mechanism underlying the action of DGLA in atherosclerosis is crucial to evaluating 
the role of this PUFA as a new agent in the prevention/treatment of the disease. 
In vitro analysis utilised macrophage cell lines THP-1 and RAW264.7 together with 
primary cultures of human monocyte-derived macrophages to study the effects of 
DGLA on aspects of macrophage foam cell formation, an early event in 
atherosclerosis. Data presented in the thesis showed that DGLA had an effect on a 
number of key events that contribute to foam cell formation in macrophages; reducing 
monocyte migration, pro-inflammatory cytokine induced gene expression, modified 
LDL uptake, scavenger receptor expression, macropinocytosis and cholesteryl ester 
accumulation and stimulating cholesterol efflux.  
Uptake of DGLA into lipid fractions was studied in vitro and in vivo using thin layer 
chromatography and gas chromatography. DGLA was significantly incorporated in a 
dose-dependent manner into lipid fractions of THP-1 macrophages in vitro. In vivo, 
mice fed a 4.4% DGLA containing diet assimilated the PUFA into serum, liver, kidney 
and adipose tissue lipid fractions.  
Finally, the metabolism of DGLA was investigated in vitro. DGLA supplementation 
stimulated the production of PGE1 and 15-HETrE in macrophages. PGE1 inhibited 
monocyte migration and IFN-γ induced expression of monocyte chemotactic protein 
1 (MCP-1). RNA interference assays showed a key role for COX enzymes in the IFN-
γ-mediated induction of MCP-1 expression.  
Findings in the thesis demonstrate key mechanisms underlying the anti-atherogenic 
role of DGLA and highlight its potential as a therapeutic/preventative agent in this 
disease.   
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CHAPTER 1 
INTRODUCTION  
1.1 Cardiovascular disease and atherosclerosis 
Cardiovascular disease (CVD) causes more deaths annually than any other disease 
in Western society. It has been estimated that 17.5 million people died from CVD in 
2012 representing 31% of world deaths, with this figure set to rise to 23.3 million by 
2030 (Buckley and Ramji 2015). In addition to the predicted increase in mortality 
rates, an increase in incidence of CVD adds to the already considerable burden on 
costs to public healthcare systems (Oldridge 2008; Buckley and Ramji 2015). In 2009, 
CVD cost the UK economy £19 billion (British Heart Foundation, 2016). Given the 
predicted increase in mortality rates and the subsequent burden on healthcare 
systems, research into understanding the underlying causes of CVD and identifying 
novel targets and therapies is crucial. 
The primary cause of CVD is atherosclerosis, a chronic inflammatory disorder of the 
vasculature (Michael et al. 2012). Atherosclerosis is a progressive disease initiated 
by the accumulation of lipids in medium and large arteries, a precursor event 
providing the basis to the formation of advanced plaques (Lusis 2012). Over a number 
of years plaques can become increasingly large and complex eventually leading to 
their rupture. Plaque rupture releases large amounts of necrotic debris into the 
circulation increasing the risk of blood clots which in some circumstances can result 
in myocardial infarction and/or stroke (Lusis 2000).  
1.1.1 Mouse models 
Development of mouse models of atherosclerosis has been a critical advancement in 
understanding the factors affecting the disease and identifying new therapeutic 
targets. Apolipoprotein E deficient mice (ApoE-/-) are commonly used as a model 
system due to their ability to form spontaneous atherosclerotic lesions on standard 
chow diet (Meir and Leitersdorf 2004). ApoE is a glycoprotein synthesised mainly in 
the liver and is a component of lipoproteins (except low density lipoprotein (LDL)). 
The protein functions as a ligand for receptors which aid in the clearance of 
chylomicrons and very low density lipoproteins (VLDL) (Meir and Leitersdorf 2004). 
ApoE is also synthesised in monocytes and macrophages in the vessel wall and has 
a local effect on cholesterol homeostasis (Curtiss 2000; Greenow et al. 2005). ApoE 
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deficient mice fed a normal chow diet display five times higher plasma cholesterol 
levels, a reduced concentration and particle size of high density lipoprotein (HDL) and 
an increase in triacylglycerol (TAG), in comparison to wild type (WT) controls (Zhang 
et al. 1992). Fatty streaks and foam cell deposition in arteries are visible after three 
months and advanced lesions after eight months (Zhang et al. 1992). When fed a 
high fat diet, plasma cholesterol levels are a dramatic fourteen times higher in ApoE-
/- mice in comparison to WT mice (Plump et al. 1992). Atherosclerotic lesions are 
typically visible within just 10 weeks in the aorta and coronary and pulmonary arteries 
(Plump et al. 1992). A second commonly used mouse model is the LDL receptor 
knockout (LDLr-/-) mouse. LDLr deficiency is the cause of familial 
hypercholesterolemia in humans (Zadelaar et al. 2007). The LDLr-/- mice display a 
moderate increase in plasma cholesterol levels, with cholesterol mainly contained 
within LDL, on normal chow diet (Ishibashi et al. 1993; Zadelaar et al. 2007). High fat 
diet induces a 6-fold increase in plasma cholesterol levels, an increase in VLDL and 
LDL levels and a decrease in HDL (Ishibashi et al. 1994). In addition, after 7 months 
on a high fat diet, LDLr-/- mice develop atherosclerotic lesions in the aorta with the 
aortic valve wall thickened by a mass of cholesterol-loaded macrophages (Ishibashi 
et al. 1994).  
There are many advantages and disadvantages associated with both models of 
atherosclerosis. The plaque morphology in ApoE-/- and LDLr-/- mice are comparable 
and resemble those in the human counterparts (Zadelaar et al. 2007) so represent 
good models for the study of this disease. However, there are of course a number of 
species differences between mouse and humans which may impact on the reliability 
of these models. The levels of HDL and LDL differ significantly between the species. 
Mice have high concentrations of HDL and low levels of LDL whereas humans display 
the opposite (Zhang et al. 1992). Mice also lack the cholesterol ester transfer protein 
which transfers cholesteryl esters from HDL to VLDL and LDL (Zhang et al. 1992). 
This being said, ApoE-/- mice have remarkably similar phenotypes to that of human 
ApoE deficiency (Zhang et al. 1992) and plasma lipoprotein profile of LDLr-/- 
resembles that of humans with cholesterol mainly contained in LDL fraction (Zadelaar 
et al. 2007). Deficiency of ApoE also has an effect on other processes. ApoE can be 
synthesised locally by macrophages where it can play a role in inflammation, 
monocytosis, reverse cholesterol transport and oxidation of LDL (Curtiss 2000; 
Ruston and Drevon 2001; Baitsch et al. 2008; Murphy et al. 2011; Westerterp et al. 
2013). With these processes disrupted in ApoE-/- mouse models, limitations lie in 
studying pathways associated with these processes. Despite the drawbacks of these 
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mouse models, they have been widely used in the study of atherosclerosis and have 
benefited the field immeasurably.   
1.1.2 Risk factors 
Atherosclerosis is a complex disease with a number of risk factors both at a genetic 
and environmental level. Elevated blood pressure, history of family obesity and 
diabetes together with gender are examples of genetic factors linked to 
atherosclerosis (Lusis 2000). Environmental factors include high fat diet, smoking and 
low exercise levels (Lusis 2000). Table 1.1 details some of the risk factors in more 
detail. Given the importance of lipids and inflammation in atherosclerosis, these 
factors will be discussed further in more detail.  
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Table 1.1 – Details of genetic and environmental risk factors and their 
association with atherosclerosis 
Risk Factor Role in disease   
Genetic  
Mutations Familial hypercholesterolemia – mutation in the LDLr gene that 
increases levels of LDL (Lusis et al. 2004). Mutation in the ApoA1 
gene results in reduced levels of HDL (Lusis et al. 2004) 
Age Increased vascular stiffness, hypertension, pro-inflammatory 
signalling and cellular senescence linked to increase in 
atherosclerosis (Wang and Bennett 2012) 
Inflammation Elevated levels of C reactive protein (CRP) linked to an increase in 
CVD (Lusis 2000) 
Disease Obesity and type 1 diabetes increase risk of CVD (Lusis 2000) 
Gender Men under 60 are twice as likely to develop atherosclerosis than 
women (Lusis 2000) 
Environmental   
Smoking Increase inflammation, thrombosis and oxidative stress (Ambrose 
and Barua 2004) 
High 
cholesterol  
Elevated levels of LDL causes endothelial activation and initiation 
of foam cell formation (Lusis 2000) 
Exercise Lack of exercise has significant association with development of 
CVD. Increased exercise has an athero-protective role (Okabe et 
al. 2006) 
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1.2 Lipids in atherosclerosis 
Atherosclerosis is the result of dysfunctional lipid metabolism and is characterised by 
the accumulation of lipid-rich plaques in the walls of medium and large arteries (Lusis 
et al. 2004). The importance of lipids in atherosclerosis can be gauged by the 
reduction in CVD mortality that has been achieved with statins, which inhibit the 
biosynthesis of cholesterol. Currently, statins are the most successful therapy used 
in combatting atherosclerosis and other CVD’s. Statins work by inhibiting  3-
hydroxymethylglutaryl CoA reductase (HMG-CoAR), a key enzyme in the de novo 
synthesis of cholesterol, thereby decreasing the levels of cholesterol and LDL in 
circulation (Michael et al. 2012). It has also been observed that statins act to increase 
levels of HDL in circulation, regulate the expression of macrophage scavenger 
receptors and reduce levels of both oxidative stress and oxidised LDL (oxLDL) (Jain 
and Ridker 2005). Given the key role of lipids in the disease, it is important to 
understand their function in the body during physiological and pathophysiological 
conditions.  
1.2.1 Fatty acids 
Fatty acids are produced during the metabolism of dietary lipids or by de novo 
synthesis. They are composed of a polar carboxyl head group attached to a long 
hydrophobic hydrocarbon chain. Hydrocarbon chains can be saturated or 
unsaturated. Saturated hydrocarbon chains are straight with, usually, an even 
number of carbons (between 12 and 22) (Ruston and Drevon 2001). Fatty acids are 
named after the length of the hydrocarbon chain. The carbon atoms are either 
numbered from the carboxyl terminal, using the delta numbering system, or from the 
methyl end using the omega system (Pelley 2011). A list of the most common fatty 
acids is shown in Table 1.2.  
Unsaturated hydrocarbon chains can contain one or more double bond. Their 
systematic names are followed by the ‘enoic’ suffix and the position of the double 
bond (numbered from the methyl end) (Vasudevan 2013). Shorthand notations are 
also used with the number of carbons followed by the number of double bonds and 
the position of those double bonds from the methyl end. For example, unsaturated 
fatty acids with a double bond between the 3rd and 4th carbons from the methyl end 
are named omega-3 (or n-3) fatty acids.  The omega-3 fatty acid EPA has the 
shorthand 20:5n3 and the chemical name cis-5, 8, 11, 14, 17-eicosapentaenoic acid. 
EPA has 20 carbons and 5 double bonds at positions 5, 8, 11, 14 and 17 (using the 
delta system), with the position of the first double bond at carbon 3 (using the omega 
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system). The presence of a double bond ‘kinks’ the chain and restricts mobility 
(Ruston and Drevon 2001).  
Unsaturated fatty acids named monounsaturated fatty acids (MUFA) contain one 
double bond which can be in the cis or trans orientation. The most common MUFAs 
have a double bond in the cis orientation and a chain length between 16 to 22 (Ruston 
and Drevon 2001). Trans MUFA can be produced in industrial processing of 
unsaturated oils. Cis MUFA are less thermo stable and have a lower melting point 
than trans MUFA (Ruston and Drevon 2001).  
Polyunsaturated fatty acids (PUFA) contain one or more double bonds. They are 
synthesised in plants and phytoplankton and some are essential to higher organisms 
such as mammals and therefore must be obtained in the diet (Ruston and Drevon 
2001). For example, omega-3 and omega-6 PUFAs are not synthesised in the human 
body but are essential nutrients. Once obtained from the diet, PUFA can be 
metabolised by the addition of carbon and the removal of hydrogen (desaturation) 
(Ruston and Drevon 2001) by enzymes to produce a number of different products. 
Enzymes synthesised in the human body can only add new double bonds within 10 
carbons from the carboxylic end of fatty acid chains, therefore cannot enzymatically 
create the double bond at the omega-3 and -6 positions (Neitzel 2010).  
Fatty acids can be incorporated into various lipid structures that are used to make up 
cellular membranes and provide energy storage. In addition, fatty acids are important 
signalling molecules. Fatty acid signalling will be discussed in detail in Section 1.4.2.  
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Table 1.2 – Common naturally occurring fatty acids 
Chemical name Shorthand Common name Abbreviation 
Tetradecanoic 14:0 Myristic acid - 
Hexadecanoic 16:0 Palmitic acid - 
Cis-9-hexadecenoic  16:1n7 Palmitoleic acid - 
Cis-7-hexadecenoic 16:1n9 - - 
Octadecanoic  18:0 Stearic acid - 
Cis-11-octadecenoic 18:1n7 Cis-Vaccenic acid - 
Cis-9-octadecenoic 18:1n9 Oleic acid - 
Cis-9,12-octadecadienoic 18:2n6 Linoleic acid LA 
Cis-9,12,15-octadecatrienoic 18:3n3 α-Linolenic acid ALA 
Cis-6,9,12-octadecatrienoic 18:3n6 γ-Linolenic acid GLA 
Cis-8,11,14-eicosatrienoic 20:3n6 Dihomo-γ-linolenic 
acid 
DGLA 
Cis-5,8,11,14-eicosatetraenoic 20:4n6 Arachidonic acid AA/ARA 
Cis-5,8,11,14,17-
eicosapentaenoic 
20:5n3 Eicosapentaenoic 
acid 
EPA 
Cis-7,10,13,16,19-
docosapentaenoic 
22:5n3 Docosapentaenoic 
acid 
DPA 
Cis-4,7,10,13,16,19-
docosahexaenoic 
22:6n3 Docosahexaenoic 
acid 
DHA 
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1.2.1.1 Membrane lipids; Glycerophospholipids 
The glycerophospholipids are composed of fatty acids esterified to a glycerol 
backbone at the sn-1 and sn-2 position with a  phosphate and additional group at the 
3-position (Brown and Marnett 2011) (Figure 1.1). Glycerophospholipids, or 
phospholipids, are the main components of eukaryotic membranes along with various 
other protein and carbohydrate molecules. Different head groups allow for numerous 
phospholipids; phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
Phosphatidylserine (PS) and phosphatidylinositol (PI) being the most common in 
eukaryotic membranes.  Cleavage from phospholipids allow fatty acids and their 
metabolites to act as lipid messengers in signal transduction pathways (van Meer et 
al. 2008).  
 
 
 
 
 
 
 
Figure 1.1 - Basic structure of a glycerophospholipid.  
Numerous combinations of fatty acid groups attached to a glycerol backbone allow for a wide 
range of lipid diversity. Amino alcohol group can include choline, ethanolamine or serine, 
which form PC, PE and PS respectively.  
 
1.2.1.2 Lipid storage; triacylglycerol (TAG)  
Due to their reduced state, fatty acids can be used for energy storage. The primary 
lipid structure used for energy storage is triacylglycerol in lipid droplets (van Meer et 
al. 2008). This structure is composed of three fatty acids bound to a glycerol backbone 
(Figure 1.2). These structures are useful energy stores due to the supply of carbon in 
fully reduced form which will yield maximum energy when undergoing oxidation.  
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Figure 1.2 – Basic diagram of TAG 
Fatty acids provide a source of carbon in reduced form available for oxidation. 
 
1.2.1.3 Cholesterol 
Cholesterol is a sterol with important roles in membrane fluidity and lipid raft assembly 
and function (McLaren et al. 2011a). See Figure 1.3 for structure. High concentration 
of cholesterol in the body is a major risk factor in atherosclerosis. Cholesterol can be 
obtained from dietary lipids or synthesised in the liver (McLaren et al. 2011a). 
Cholesterol is synthesised from acetate in series of enzymatic reactions. An important 
regulatory step in synthesis is the enzyme HMG-CoAR which generates mevalonate 
(Ikonen 2006). 
 
 
 
 
 
 
 
Figure 1.3 – Structure of cholesterol 
Cholesterol is composed of a fused tetracyclic ring. It is an important component of cell 
membranes (especially plasma membranes) and lipid rafts. 
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1.2.2 Lipid metabolism and transport  
Lipid transport around the body is a complex process with numerous enzymes and 
lipoproteins playing a role. It is important to understand the process in order to target 
potential imbalances that may contribute to atherosclerosis. Cholesterol metabolism 
and transport around the body, as well as fatty acids and TAG, play a key role in the 
pathology of atherosclerosis.   
1.2.2.1 Role of lipoproteins 
Lipids are transported through the circulation with the aid of proteins. These 
complexes are termed lipoproteins (Lusis et al. 2004). Lipoproteins are composed of 
a monolayer of hydrophilic lipids (i.e. phospholipids and free cholesterol) surrounding 
a core of hydrophobic lipids (triacylglycerols and cholesteryl esters) (Figure 1.4).  
They also contain apolipoprotein molecules which function in the packaging and 
secretion of lipids from cells, as well as ligands for cellular receptors (Lusis et al. 
2004). Types of lipoproteins include chylomicrons, VLDL, intermediate density 
lipoprotein (IDL), LDL and HDL. The type of lipoprotein a lipid is packaged into is 
dependent on the source of the lipid.  For example, chylomicrons are primarily used 
in the transport of dietary TAG from the intestine for use in peripheral tissues (Ikonen 
2006; Buckley and Ramji 2015). On the other hand, cholesterol synthesised in the 
liver is packaged into VLDL. IDL and LDL are formed from VLDL in a series of 
reactions catalysed by lipoprotein lipase (LPL) and hepatic lipase (HL) that hydrolyse 
the TAG component (McLaren et al. 2011a). LDL functions to carry cholesterol to 
peripheral tissues where it can be used in membranes or for the synthesis of steroid 
hormones. Finally, HDL acts as a carrier to return any excess cholesterol back to the 
liver for catabolism and excretion (van der Velde 2010). Levels of circulating 
lipoproteins have been linked to atherosclerosis. Increased levels of LDL in the blood 
and lower circulating HDL have both been linked to an increased risk of 
atherosclerosis (McLaren et al. 2011a).   
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Figure 1.4 – Structure of lipoprotein particles 
Phospholipid monolayer encases a core of TAG and cholesteryl ester. Apoliproteins differ 
depending on the lipoprotein. They influence structural and functional properties of the 
particle. Taken from (Wasan et al. 2008). 
 
The process of cholesterol transport is summarised in Figure 1.5. Cholesterol,  TAG 
and fatty acids from dietary origin are absorbed through the intestine (Lusis et al. 
2004). Dietary TAG are hydrolysed into fatty acids and monoglycerides and together 
with bile acids, form micelles in the intestinal lumen (Ikonen 2006; Georgiadi and 
Kersten 2012). Fatty acids are then re-esterified to TAG and along with cholesterol, 
are packaged into chylomicrons containing Apo-B, -A, -C and -E (McLaren et al. 
2011a). Chylomicrons are subject to lipolysis by LPL, located on the capillary 
endothelium (Georgiadi and Kersten 2012), releasing free non esterified fatty acids 
and 2-monoacyl glycerol for uptake by various tissue types. The majority of fatty acids 
taken up by tissues are TAG-derived fatty acids or free fatty acids (Georgiadi and 
Kersten 2012).  
Circulating adipose-derived free fatty acids and remnant chylomicron particles are 
taken up largely by the liver. Newly synthesised TAG and cholesterol in the liver are 
packaged into VLDL containing ApoB100. VLDL gains Apo-A, -C and -E from 
circulating HDL. The TAGs in VLDL undergo lipolysis in circulation by LPL and HL to 
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form IDL followed by LDL (Buckley and Ramji 2015). LDL, an apolipoprotein B (ApoB) 
containing  lipoprotein, is the primary cholesterol carrier in the blood (Lusis et al. 
2004). The ApoB constituent of LDL allows recognition of the lipoprotein particle by 
the LDLr expressed on the cell surface and subsequent receptor-mediated 
endocytosis. LDL is internalised into lysosomes where cholesteryl ester and TAG are 
hydrolysed (Buckley and Ramji 2015). The expression of LDLr is under negative 
feedback inhibition in order to control the amount of LDL, and therefore cholesterol 
and TAG, uptake by cells (Ghosh et al. 2010). Elevated levels of circulating LDL 
increase the risk of accumulation of the lipid-rich particles in the artery walls, a key 
mechanism in atherosclerosis.  
Cholesteryl esters released from LDL are hydrolysed by lysosomal acid lipase to free 
cholesterol. When in excess, free cholesterol can be re-esterified by the enzyme 
acetyl-coenzyme A acetyltransferase (ACAT). Cholesteryl esters reduce the solubility 
of the molecule and promote storage into lipid droplets located in the cytoplasm 
(Buckley and Ramji 2015). The process depends on the availability of fatty acids and 
cholesteryl ester hydrolysis, which are dependent on the enzymes carnitine 
palmitoyltransferase-1 (CPT-1) and neutral cholesterol ester hydrolase (nCEH) 
respectively. In addition to this, storage of excess TAG and cholesterol into lipid 
droplets is promoted by the activity of adipocyte differentiation-regulated protein 
(ADRP), which induces their synthesis and prevents removal from the cell (McLaren 
et al. 2011a). An accumulation of cholesteryl esters and TAG play an important role 
in atherosclerosis. Under normal circumstances however, excess cholesterol is 
efficiently dealt with by cellular homeostatic mechanisms.  
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Figure 1.5 – Overview of cholesterol transport  
Lipids obtained from the diet are packaged into chylomicrons and after lipolysis by LPL, are 
taken up by peripheral tissues. Remnant dietary lipids and chylomicrons are transported to 
the liver for catabolism or repackaging (1). Along with lipids synthesised in the liver, these are 
packaged into VLDL (2) containing ApoB and ApoE (E3). VLDL is hydrolysed to IDL and then 
LDL by the action of lipases. ApoB allows for binding of LDL particles to LDLr, internalisation 
and subsequent degradation in the lysosome (Lusis et al. 2004). Scavenger receptors such 
as scavenger receptor A (SRA) and cluster differentiation 36 (CD36) present on macrophages 
bind and internalise modified forms of LDL in an unregulated manner (3). Lysosomal acid 
lipase hydrolyses the cholesteryl esters packaged in LDL to free cholesterol (4). Free 
cholesterol has two fates; transport out of cell or storage in lipid droplets. Free cholesterol can 
be removed from the cell by reverse cholesterol transport (RCT) using ATP binding cassette 
(ABC) transporters such as ABCA-1 and scavenger receptor B1 (SR-B1) (van der Velde 2010) 
(5). Free cholesterol is packaged into HDL with its ApoA component, and delivered to the liver 
(6). Alternatively, free cholesterol is re-esterified by ACAT-1 in the endoplasmic reticulum. This 
re-esterified cholesterol can by hydrolysed to free cholesterol by nCEH and removed by RCT 
or stored as lipid droplets in the cytoplasm (Ikonen 2006) (7). The latter is regulated by ADRP.  
The availability of fatty acids for cholesterol ester accumulation is under the control of CPT-1. 
Niemann-Pick type C (NPC) proteins, NPC-1 and NPC-2 act to regulate cholesterol trafficking 
around the cell (Buckley and Ramji 2015). Taken from Buckley and Ramji, 2015. 
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1.2.2.3 Reverse cholesterol transport (RCT) 
Excess cholesterol within cells is toxic and can be removed from the periphery to the 
liver and intestine for catabolism and excretion (van der Velde 2010). The primary 
pathway by which this is achieved is RCT. Free cholesterol can be removed from 
cells using a number of transporter proteins. These include the ABC transporter 
proteins; ABCA1 and ABCG1 (Chinetti-Gbaguidi and Staels 2009; Buckley and Ramji 
2015). Scavenger receptor SR-B1 can also act to promote cholesterol efflux. This 
receptor has a dual role, however, as it also acts to bind and internalise modified LDL 
and, therefore, its role in atherosclerosis is controversial (McLaren et al. 2011a). 
Cholesterol is captured by HDL particles where it is esterified (McLaren et al. 2011a). 
HDL complexes are formed in the circulation from remnants of chylomicron and 
VLDL, ApoA1 and precursor molecules (secreted by the liver and intestine) (Lusis et 
al. 2004).  Lecithin cholesterol acyl transferase (LCAT) is present on the surface of 
HDL and has the ability to catalyse the formation of cholesteryl esters by transferring 
fatty acids from phospholipids to free cholesterol (van der Velde 2010). This converts 
nascent HDL particles to smaller HDL3 particles. The mature HDL3 can deliver its 
contents directly to the liver or transfer its cholesteryl ester to ApoB-containing 
lipoproteins (Ng 2006). HDL3 particles remove some of its cholesteryl ester to LDL or 
VLDL, in exchange for TAG catalysed by the enzyme cholesteryl ester transfer protein 
(CETP), and are taken up by the liver by the LDLr receptor (Ng 2006). The remaining 
HDL particle, following acquisition of TAG and additional apoliprotein molecules, 
forms an even smaller HDL2 particle which are delivered to the liver (McLaren et al. 
2011a). Once at the liver, hepatocytes can take up HDL cholesteryl ester in a number 
of ways; uptake of whole HDL2 particles, selective uptake of cholesteryl esters by SR-
B1 or finally transfer of cholesteryl ester to LDL for uptake by LDLr. Cholesteryl ester 
can be hydrolysed and removed from the body as bile acids and neutral steroids in 
bile (McLaren et al. 2011a). 
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1.3 Inflammation in atherosclerosis 
The link between atherosclerosis and lipids has been regarded as the major 
underlying cause of the disease for many years due to the key association with 
cholesterol. This concept has now been extended to consider atherosclerosis as an 
inflammatory disease involving the immune system with inflammation initiated by 
dysfunctional lipid homeostasis (Libby 2012). 
As discussed previously in Section 1.2 statins are currently widely used in the 
treatment of atherosclerosis due to their lipid-lowering effects. In addition to this, it 
has been suggested that they may also have anti-inflammatory actions unrelated to 
their primary use.  In a study of high-risk patients with hyperlipidaemia, treatment with 
atorvastatin reduced the expression of a key inflammatory marker of atherosclerosis, 
CRP. This decrease in CRP was unrelated to the expected decrease in total 
cholesterol and LDL levels (Gomez-Gerique et al. 2002). Another study performed in 
ApoE-/-/LDLr-/- mice indicated that alongside the reduction in plasma LDL, treatment 
with atorvastatin also decreased the expression of MCP-1, intercellular adhesion 
molecule 1 (ICAM-1) and vascular cellular adhesion molecule 1 (VCAM-1) (Nachtigal 
et al. 2008). It therefore seems that statins have an unexpected dual role in the 
treatment of atherosclerosis targeting both inflammation and cholesterol levels. 
Despite the beneficial role of statins, there are various limitations associated with 
them. The maximum reduction in mortality from CVD that can be attributed to 
treatment with statins is 30%, with some individuals unresponsive to treatment and 
failing to attain target LDL levels even with the maximal dose (Mishra and Routray 
2003). In addition to this, side effects of statins can include liver toxicity and muscle 
pain (Mishra and Routray 2003). Given the drawbacks of statins and the ever 
increasing risk of CVD and atherosclerosis, it is crucial that new therapeutic targets 
are developed. The association between inflammatory mechanisms and 
atherosclerosis suggests that the use of anti-inflammatory agents would aid in the 
prevention and the treatment of the disease (Paoletti et al. 2004).  
Acute inflammation is a normal response mechanism in the body to provide protection 
against invading pathogens. Activation of an immune response involves numerous 
cell types and regulation of many signalling pathways (Calder 2012). Normally, the 
process is regulated by negative feedback mechanisms to ensure no excess damage 
occurs. However loss of regulatory processes results in chronic inflammation (Calder 
2002), a feature important in the pathology of atherosclerosis. In vivo microscopic 
studies of atherosclerotic mice indicate the adhesion and transmigration of immune 
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cells across the endothelial surface of arteries (Eriksson et al. 2001), a key 
inflammatory  process in the initiation stage of atherosclerosis.  Under the control of 
cytokines and chemokines, continued recruitment of immune cells and development 
of lipid-rich foam cells contributes to a growing necrotic core. As atherosclerosis 
progresses and plaques develop, inflammatory mediators can act to weaken the 
fibrous cap that encapsulates the atherosclerotic plaque, possibly leading to plaque 
rupture and thrombosis (Paoletti et al. 2004). Inflammation is therefore important at 
all stages of atherosclerosis.  Many cell types play a role in the initial inflammatory 
response in atherosclerosis as well as contributing to plaque formation. These include 
monocytes, endothelial cells, lymphocytes, dendritic cells and smooth muscle cells 
(Moore et al. 2013).  Substantial research has focused on macrophages due to their 
role in ‘foam cell’ formation, the central inflammatory process leading to formation of 
fatty streak in arteries, the foundation of advanced plaques (Moore et al. 2013). The 
association between inflammatory mechanisms and atherosclerosis suggests the 
promising potential of anti-inflammatory drugs to aid in the prevention and treatment 
of the disease (Paoletti et al. 2004).   
1.3.1 Macrophage foam cell formation  
1.3.1.1 Initiation/endothelial cell activation 
The primary event leading to the initiation of an immune response in atherosclerosis 
pathology is the accumulation and retention of ApoB containing lipoproteins, for 
example LDL, in the sub endothelial matrix in the intima of arteries (McLaren et al. 
2011a; Lusis 2012). The endothelium lining the walls of arteries functions as a 
selective barrier between blood and tissues and can generate signalling molecules 
that act to regulate thrombosis, inflammation, vascular tone and remodelling (Lusis 
2000).  LDL passively diffuses through endothelial cell junctions particularly in areas 
of arterial curvature where blood flow is disturbed and endothelial cells have irregular 
polygonal shapes (Lusis 2000). Retention of LDL in the arterial wall is maintained 
through an interaction between the ApoB constituent of lipoproteins and matrix 
proteoglycans (Lusis et al. 2004) (Figure 1.6).  
Once retained in the arterial matrix, LDL is susceptible to modification. Lipid 
peroxidation of LDL is one of the earliest events in atherosclerosis (Matsuura et al. 
2008). As discussed in Section 1.2.2.1, LDL contains free cholesterol, cholesteryl 
esters, phospholipids and triacylglycerols which are vulnerable to oxidation (Tsimikas 
and Miller 2011). In addition to this, ApoB can also be oxidised at numerous exposed 
tyrosine and lysine amino acid residues (Tsimikas and Miller 2011). LDL oxidation 
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can occur through a number of different mechanisms including free radical oxidation 
and enzymatic oxidation by reactive oxygen species (ROS), nitric oxide (NO) and 
lipooxygenase (LOX) (Tsimikas and Miller 2011). Modified LDL can induce an 
immune response due the peroxidation of lipids creating reactive oxidation species. 
This promotes endothelial dysfunction, activation of endothelial cells and recruitment 
of monocytes (Matsuura et al. 2008; Wraith et al. 2013). In the initial stages of 
atherosclerosis, LDL oxidation is low and modifications to LDL are termed minimally 
modified LDL (mmLDL) (Berliner et al. 1990). As atherosclerosis advances, highly 
oxLDL is present in plaques (Berliner et al. 1990). In contrast to oxLDL, mmLDL are 
not recognised by scavenger receptors (Miller et al. 2003). However, current theory 
suggests mmLDL initiates an immune response (Moore and Freeman 2006).   
1.3.1.2 Monocyte recruitment  
Accumulation of modified LDL in the artery wall stimulates endothelial cells to initiate 
an immune response resulting in the release of pro-inflammatory signalling 
molecules, chemokines, cytokines and expression of adhesion proteins (Lusis 2000). 
Cytokines play an important role in atherosclerosis and will be discussed in more 
detailed in Section 1.4.1. Leukocytes, including neutrophils, T lymphocytes, B cells, 
mast cells, natural killer cells, dendritic cells and monocytes, are activated as part of 
the immune response and recruited to the site of activation (Galkina and Ley 2009). 
Each play an important role in inflammatory mechanisms underlying atherosclerosis 
and have both resolving and contributing effects (Galkina and Ley 2009). The role of 
monocyte-derived macrophages has been well characterised in atherosclerosis given 
their role in the formation of foam cells. Atherosclerotic plaques contain a mass core 
of macrophage foam cells and are the main constituent of the plaque (Aqel et al. 
1985; Gown et al. 1986; Yano et al. 2000).  
Monocytes are recruited to the activated endothelium down a chemoattractant 
gradient (Denholm and Lewis 1987), the process is summarised in Figure 1.6. 
Numerous chemotactic factors are released which act to attract monocytes to the site 
of activation. MCP-1 is key to monocyte recruitment and a marker of inflammation. 
Rolling and tethering of monocytes along the endothelium is achieved through the 
expression of selectins, a family of adhesion proteins (Bobryshev 2006). P-selectin 
and E selectin are expressed on the endothelium while L-selectin is found on the 
surface of monocytes, all recognising carbohydrate ligands (Bobryshev 2006). Firm 
adhesion is obtained through an interaction between integrins β1 and β2 expressed 
on monocytes and ICAM-1 and VCAM-1 expressed by endothelial cells (Bobryshev 
 
 
18 
 
2006). Monocytes can then transmigrate through the endothelial cell junctions and 
into the arterial matrix where they undergo differentiation into macrophages.  
 
 
 
 
 
 
 
Figure 1.6 - Overview of foam cell formation 
Retention of ApoE-containing lipoproteins, including LDL, in the arterial wall initiates an 
inflammatory response (Libby 2012) involving the release of numerous cytokines and 
chemokines by endothelial cells. As a result, monocytes are recruited to the arterial wall and 
transmigrate into the arterial intima where they are induced to differentiate into macrophages 
(Bobryshev 2006). Macrophages internalise large, unregulated amounts of modified LDL 
leading to an accumulation of cholesteryl esters as lipid droplets and thereby transforming 
them into ‘foam cells’ (Bobryshev 2006). Over time foam cells aggregate and contribute to a 
necrotic core (Lusis 2012). Apoptosis of foam cells, accumulation of extracellular lipids and 
cellular debris continue to build up in the necrotic core (Bobryshev 2006). Smooth muscle cells 
migrate from the media to the intima to form a fibrous cap overlaying the necrotic core and 
leads to the formation of an atherosclerotic plaque (Lusis 2012).  
 
1.3.1.3 Macrophage differentiation and heterogeneity 
Differentiation of monocytes into macrophages is largely regulated by the chemokine 
macrophage colony stimulating factor (M-CSF) (Bobryshev 2006), released by 
endothelial cells as part of the inflammatory response. Macrophages are 
heterogeneous in nature and have a wide variety of roles. Their phenotypes are 
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commonly classified into two broad subsets, classically activated M1 or alternatively 
activated M2 (Johnson and Newby 2009). Classification into these sub sets is often 
determined by analysis of complex gene and protein expression profiles (Moore and 
Tabas 2011). The M1 phenotype is in general associated with pro-inflammatory 
mechanisms, while M2 can play an anti-inflammatory role (Johnson and Newby 
2009). M1 macrophage polarisation is activated by pro-inflammatory stimuli, 
commonly interferon-γ (IFN-γ), lipopolysaccharide (LPS) and  tumour necrosis factor 
α (TNF-α) and results in expression of  interleukin-12 (IL-12), IL-1, IL-6 and inducible 
nitric oxide synthase (iNOS) (Martinez and Gordon 2014). They are key to innate 
immunity and act in killing of intracellular pathogens. M2 macrophages are classically 
activated by IL-4, IL-13 and produce the anti-inflammatory cytokine IL-10. They have 
a number of roles in allergic response, immunoregulation, matrix deposition and 
tissue remodelling (Martinez and Gordon 2014). The classification of macrophages 
into these two subsets is very general and it is likely that the groups can be further 
divided and additional phenotypes exist (Johnson and Newby 2009). Understanding 
the involvement of M1 and M2 macrophages in atherosclerosis is complex and not 
fully understood. Atherosclerotic lesions accumulate both subsets of macrophages 
(Stoger et al. 2012). M1 macrophages are dominant at rupture prone regions of 
plaque, while the vascular adventitia indicated macrophages comparable to a M2 
profile (Stoger et al. 2012). There was no difference between the groups at the fibrous 
cap and foam cell macrophages displayed an overlap of both M1 and M2 markers 
indicating that both subsets were present (Stoger et al. 2012). The heterogeneity of 
macrophages is complex and further evaluation is needed to determine the roles of 
M1 and M2 in disease.  
1.3.1.4 Macrophage foam cells  
Macrophages are bone marrow-derived phagocytes which act to scavenge foreign 
particles around the body. To do this macrophages express a number of pattern-
recognition receptors (PRRs) including scavenger receptors (SR) and toll-like 
receptors (TLR) to recognise and bind foreign particles (Libby 2012). Scavenger 
receptors are a family consisting of 8 structurally unrelated receptors which along with 
their role in immunity, possess the ability to bind modified LDL (Moore and Freeman 
2006). Uptake of LDL in most peripheral tissues is under the control of the LDLr. 
Feedback inhibition mechanisms prevents excessive uptake (Ghosh et al. 2010). 
Expression of scavenger receptors however is not under negative feedback control 
by cellular cholesterol content (Chinetti-Gbaguidi and Staels 2009) therefore these 
receptors can continually bind and internalise LDL. SRA and CD36 among others 
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have been directly linked to atherosclerosis (Moore and Freeman 2006; Kuchibhotla 
et al. 2008).  
Uptake of modified LDL however, is not completely a receptor-dependant process as 
lipid uptake by macrophages can occur in the absence of CD36 and SRA (Kruth et 
al. 2002; Moore et al. 2005). Macrophages can also uptake large unregulated 
amounts of modified LDL through a mechanism of macropinocytosis (Michael et al. 
2013). Macropinocytosis is a form of fluid phase endocytosis which allows for uptake 
of modified LDL and native LDL in large, unregulated amounts by formation of 
endocytic vesicles (Swanson and Watts 1995; Jones and Willingham 1999; Kruth et 
al. 2002). 
Once LDL has been taken up by macrophages, the lipoprotein is degraded and a 
mass of cholesteryl esters and TAG released (Ghosh et al. 2010). Normally, cells can 
remove any excess cholesterol to the liver to be degraded via reverse cholesterol 
transport mechanisms (discussed in detail in Section 1.2.2.3). The excessive uptake 
of cholesterol by macrophages causes an imbalance between influx and efflux of 
cholesterol, in favour of influx. This results in an accumulation of cholesteryl ester 
which is stored in lipid droplets in the cytoplasm (Ghosh et al. 2010). Lipid droplets 
under the microscope give macrophages a ‘foamy’ appearance leading to them being 
termed foam cells. 
1.3.2 Additional roles of macrophages 
In atherosclerosis, macrophages have a number of important roles. In addition to 
foam cell formation, macrophages present in atherosclerotic plaques can contribute 
further to the inflammatory response (McLaren et al. 2011a). Resident plaque 
macrophages produce chemokines and cytokines which act to recruit further 
monocytes and promote diapedesis into the lesion (Charo and Taubman 2004; 
Zernecke et al. 2008). For example, the chemokine MCP-1 is expressed from 
macrophages on stimulation with pro-inflammatory cytokines IFN-γ and TNF-α 
(Charo and Taubman 2004; Popa et al. 2007; McLaren and Ramji 2009). 
Macrophages can also express matrix metalloproteinases (MMPs) which act to 
breakdown structural components of the extracellular matrix (ECM) of a 
atherosclerotic plaque and increase the risk of rupture (Newby 2008). In addition, 
macrophages have been indicated to promote the migration of smooth muscle cells 
(SMCs) to growing lesions (Rudijanto 2007) and induce their apoptosis which once 
again increases the risk of plaque rupture (Boyle et al. 2001).  
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1.3.3 Smooth muscle migration and plaque progression 
Over time foam cells undergo apoptosis due to the lack of nutrients available for them 
to survive and toxicity by intracellular cholesterol (McLaren et al. 2011a) and release 
their lipid-rich mass into an increasingly large necrotic core (Lusis et al. 2004). As 
discussed above in Section 1.3.2, expression of various growth factors and cytokines 
from resident plaque macrophages promotes the activation of SMCs and their 
migration (Rudijanto 2007). SMCs themselves can also form foam cells through the 
uptake of modified forms of LDL by scavenger receptors expressed on their surface. 
Accumulation of foam cells in the arterial intima cause cells to aggregate forming ‘fatty 
streaks’ in the artery wall. Fatty streaks are not clinically significant but are the 
underlying foundations of advanced plaques (Lusis 2000). They are characterised by 
macrophage- and SMC-derived foam cells and other immune cells such as T cells 
(Buckley and Ramji 2015). 
The formation of an intermediate lesion is characterised by an increase in SMC 
migration and proliferation into the inflamed area. SMCs continue to migrate from the 
tunica media of the artery wall into the intima and proliferate forming a fibrous cap 
surrounding the growing plaque (Rudijanto 2007; McLaren et al. 2011a; Michael et 
al. 2012) Resident macrophages and SMCs can produce various proteins including 
collagen, elastin, glycoproteins and proteoglycans (Katsuda and Kaji 2003) to form 
the ECM of the plaque. Stable plaques are identified by the presence of a fibrous cap 
overlying the growing lesion, supported by an ECM (Buckley and Ramji 2015). 
1.3.4 Plaque rupture 
A key event in the formation of advanced atherosclerotic plaques is failure to resolve 
inflammation (Tabas 2010). This includes failure to supress infiltration of inflammatory 
cells, efferocytosis (clearance of apoptotic cells) and egress of inflammatory cells 
from the arterial wall (Tabas 2010). As atherosclerosis advances, foam cells continue 
to contribute to the lipid-rich necrotic core and plaques become increasingly complex 
with calcification and ulceration at the luminal surface (Lusis 2000). Large plaques 
can protrude into the arterial lumen reducing blood flow, moreover large plaques are 
increasingly unstable and are at risk of rupture (Lusis et al. 2004). Growth factors and 
cytokines expressed in the inflammatory response induces apoptosis of SMC (Boyle 
et al. 2001) causing thinning of the fibrous cap (McLaren et al. 2011a). ECM 
degrading enzymes, including MMPs, are released from apoptotic SMCs and resident 
macrophages which breakdown the ECM network of the plaque. Both these 
processes destabilise the plaque which often results in rupture and the release of the 
lipid-rich necrotic core into the circulation (Michael et al. 2012). Once released into 
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the circulation, the mass of lipid and dead cells is exposed to coagulating factors 
present in the blood resulting in thrombosis. This can cause restriction of blood and 
oxygen to vital organs and ultimately myocardial infarction and stroke (Michael et al. 
2012).  
1.4 Signalling in atherosclerosis 
In atherosclerosis, a number of changes in key signalling pathways occur, which 
results in altered gene expression and contributes to lesion formation. In response to 
extracellular stimuli (cytokines, chemokines, hormones and lipid mediators) utilising 
cellular receptors, signalling pathways can be up or down regulated. A number of key 
components in signalling pathways have been implicated in the pathology of 
atherosclerosis. Examples include; extracellular signal-regulated kinase (ERK), p38, 
c-Jun N terminal kinases (JNKs) (all form the mitogen-activated protein kinases 
(MAPKs) signalling cascade), nuclear factor кB (NF-кB) and phosphoinositide-3-
kinase (PI3K). The roles of these pathways in the disease are detailed in Table 1.3. 
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Table 1.3 – Pathways activated in atherosclerosis and their role in the disease 
Pathway Role in atherosclerosis 
ERK1/2 IFN-γ mediated uptake of modified LDL and expression of MCP-1 is 
attenuated by ERK1/2 inhibition in macrophages (Li et al. 2010). 
Immunofluorescence in rabbit atherosclerotic lesions revealed 
ERK1/2 localised to cap and base of plaques. Expression was 3 fold 
higher and activity 3-5 fold higher in comparison to normal vessel. 
LDL-induced SMC proliferation was abrogated when ERK was 
inhibited in vitro (Hu et al. 2000). Inhibition of ERK1/2 in macrophages 
significantly increased cholesterol efflux to ApoA1 and HDL via an 
increased expression of ABCA1 (Zhou et al. 2010). In ApoE-/- mice 
combined ERK1/2 inhibition and liver X receptor (LXR) activation 
reduced macrophage accumulation in the aorta and formation of foam 
cells and induced RCT thereby decreasing atherosclerotic lesions 
(Chen et al. 2015).  
p38 Patients with atherosclerosis receiving high doses of p38 inhibitor 
demonstrate reduced vascular inflammation in the most inflamed 
regions (Elkhawad et al. 2012). ApoE-/- mice receiving another p38 
inhibitor showed a significant reduction in progression of 
atherosclerosis (Seeger et al. 2010). In macrophages, p38 increased 
LDL uptake, cellular cholesterol levels and cholesteryl ester 
accumulation (Mei et al. 2012). Moreover in ApoE-/- mice with 
macrophage deficient p38-α, atherosclerotic plaques contained 
significantly less collagen and a thin fibrous plaque indicating a role 
for p38 in plaque stability. In addition p38 deficiency in macrophages 
increased endoplasmic reticulum-stress induced apoptosis (Seimon et 
al. 2009). 
JNK Inhibition of JNK in ApoE-/- mice showed a decrease in lesion formation 
at regions of low stress. In addition, JNK inhibition attenuated 
activation of NF-кB and VCAM-1 expression (Wang et al. 2011). 
Double ApoE-/- JNK2-/- knockout mice developed less atherosclerosis 
compared to ApoE-/- controls. This was not observed in ApoE-/- JNK1-
/- mice. JNK deficient macrophages decreased phosphorylation of 
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SRA which in turn reduced lipoprotein uptake and foam cell formation 
(Ricci et al. 2004). 
NF-кB Deficiency of NF-κB in endothelial cells in ApoE-/- mice resulted in 
strongly reduced atherosclerosis. NF-κB  deficient cells showed a 
reduction in adhesion molecule expression, macrophage recruitment 
and cytokine and chemokine expression (Gareus et al. 2008). 
However, a study in LDLr-/- mice has shown contrasting results. 
Inhibition of NF-κB activation in macrophages in these mice increased 
atherosclerosis. There was an increase in lesion necrosis along with 
cell number (Kanters et al. 2003).  
PI3K PI3K/ Akt pathway is activated by oxLDL and inflammatory 
chemokines in macrophages. This response is attenuated on deletion 
of the catalytic subunit of PI3K, p110γ (Chang et al. 2007). Activation 
of pathway induced atherosclerosis in ApoE-/- mice but this is 
significantly inhibited in ApoE-/- p110γ-/- mice (Chang et al. 2007). PI3K 
inhibitor attenuated the uptake of modified LDL and macropinocytosis 
in macrophages. Expression of scavenger receptors SRA and CD36 
was also attenuated (Michael et al. 2015). IFN-γ induced expression 
of chemokine MCP-1 is also inhibited by a PI3K inhibitor in 
macrophages (Harvey et al. 2007) indicating its role in foam cell 
formation. 
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1.4.1 Cytokines 
Cytokines is a general term used to describe a group of more than 50 secreted factors 
involved in cellular communication together with the immune and inflammatory 
responses. They are classified into groups as follows: interleukins, tumour necrosis 
factors, interferons, colony stimulating factors, transforming growth factors and 
chemokines (Tedgui and Mallat 2006). Cytokines can be broadly separated into two 
classes’ dependant on their actions in an immune response; pro- and anti-
inflammatory. For example, IL-4, IL-10, IL-33 and transforming growth factor (TGF) -
β promote anti-inflammatory conditions (Tedgui and Mallat 2006; Miller 2011) in 
contrast TNF-α, IL-1β, IL-12 and IFN-γ exert classically pro-inflammatory responses 
(Tedgui and Mallat 2006; McLaren and Ramji 2009). The role of cytokines in the 
inflammatory response in atherosclerosis is complex with involvement at all stages 
from initiation of immune response to plaque progression. Release of pro-
inflammatory cytokines during an inflammatory response has numerous roles in foam 
cell formation and other steps in atherosclerosis. Release of IL-1, IL-6, IL-10, IL-12 
and TNF-α activate circulating monocytes in the blood stream allowing them to adhere 
to the activated endothelium (Bobryshev 2006). During plaque formation, release of 
cytokines aids in the migration of smooth muscle cells to the arterial intima and 
formation of the extracellular matrix (Lusis 2000). Table 1.4 summarises the roles of 
a select number of cytokines in the pathology of atherosclerosis.   
Targeting signalling of pro-inflammatory cytokines in atherosclerosis, using inhibitors 
or gene targeting in vitro and in vivo, has been widely used to delineate their roles in 
the disease and identify potential therapeutic targets for atherosclerosis. Studies have 
proved controversial with contrasting results in some cases; however it is clear that 
reduced pro-inflammatory cytokine signalling has beneficial effects in the disease 
(Gupta et al. 1997; Whitman et al. 2002; Kirii et al. 2003; Chamberlain et al. 2009; 
Schuett et al. 2012). The signalling and roles of three pro-inflammatory cytokines will 
be discussed in more detailed: IFN-γ, IL-1β and TNF-α, as they are directly relevant 
to the studies carried out in this thesis.  
 
 
 
 
 
 
26 
 
Table 1.4 – Examples of cytokines expressed in an inflammatory response and 
their role in atherosclerosis 
Cytokine Role in atherosclerosis 
IL-1β Lack of IL-1β in ApoE-/- mice decreased atherosclerosis and reduced 
inflammatory markers MCP-1 and ICAM-1 (Kirii et al. 2003). Similar results 
were observed in ApoE-/- IL1 receptor knockout mice (Chamberlain et al. 2009) 
and mice targeted with an anti-IL-1β antibody (Bhaskar et al. 2011).  
IL-6 Injection into ApoE-/- mice increased levels of pro-inflammatory cytokines and 
lesion size (Huber et al. 1999). IL-6 inhibitor in LDLr-/- mice decreased 
atherosclerosis, along with a reduction in SMC infiltration, monocyte migration 
and endothelium activation (Schuett et al. 2012). However IL-6 deficiency in 
ApoE+/- heterozygous model augmented atherosclerosis, increasing pro-
inflammatory signalling and destabilising plaques (Madan et al. 2008). 
IL-10 Double knockout ApoE-/- IL-10-/- mice showed increased atherosclerotic lesion 
sizes together with pro-coagulant activity of the plaque indicating that the 
cytokine plays a role in stabilisation (Caligiuri et al. 2003). Treatment of LDLr-/- 
mice with IL-10 encoding virus delivery vector also resulted in decreased 
atherosclerotic lesions (Liu et al. 2006). IL-10 expressing macrophages 
inhibited atherosclerosis in LDLr-/- mice. A reduction in cholesteryl ester 
accumulation and an increase in cholesterol uptake and efflux was also 
observed (Han et al. 2010). 
IL-17 Atherosclerosis was reduced in LDLr-/- mice transplanted with IL-17r deficient 
bone marrow. There was a decrease in IL-6 production and an up regulation in 
IL-10 (van Es et al. 2009). A comparable effect was seen in ApoE-/- mice treated 
with an anti-IL-17A antibody. Atherosclerotic lesion size was reduced along 
with plaque vulnerability, cellular infiltration and cytokine and chemokine 
production (Erbel et al. 2009). However, loss of suppressor of cytokine 
signalling 3 (SOCS3) expression in T-cells increased IL-17 production and 
induced an anti-inflammatory macrophage phenotype and reduction in lesion 
development and vascular inflammation (Taleb et al. 2009).  
IL-33 Reduction in atherosclerosis in ApoE-/- mice injected with IL-33. Decreased 
levels of IFN-γ and induced oxLDL antibody (Miller 2011). In vitro, IL-33 
reduced foam cell formation. Modified LDL uptake was reduced and cholesterol 
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efflux increased (McLaren et al. 2010). ApoE-/- mice treated with soluble ST2, 
a decoy receptor which neutralises IL-33, showed a significant increase in 
lesion size (Miller et al. 2008). However ApoE-/- mice deficient in IL-33 had no 
major impact on development of atherosclerosis (Martin et al. 2015). 
IFN-α Treatment with IFN-α in LDLr-/- mice showed an increase in plasma cholesterol 
and TAG levels and an increase in atherosclerotic lesion size (Levy et al. 2003) 
. 
IFN-β Attenuated angiotensin II induced atherosclerosis in ApoE-/- mice (Zhang et al. 
2008). 
IFN-γ Deficiency in ApoE-/- mice attenuates atherosclerosis (Gupta et al. 1997). 
Decreases cholesterol efflux (Harvey and Ramji 2005) and cholesterol 
transport in macrophages thereby augmenting foam cell formation (Reiss et al. 
2004). Administration of IFN-γ in ApoE-/- deficient mice decreased serum 
cholesterol levels. However despite this, atherosclerotic lesions were 
significantly increased along with the number of T-cells (Whitman et al. 2000).  
TGF-β Inhibition of TGF-β signalling in ApoE-/- mice accelerates atherosclerosis, 
increasing inflammatory content and reducing stability of plaques (Mallat et al. 
2001). ApoE-/- mice with deficient signalling in T-cells showed an increase in the 
size of atherosclerotic lesions. In addition, there was an  increase in IFN-γ 
expression, T-cell and macrophage activation and vulnerability of the plaques 
(Robertson et al. 2003). ApoE-/- mice with TGF-β overexpression in 
macrophages developed significantly less lesions. There was a reduction in the 
number of macrophages together with an increase in SMCs and collagen 
content in plaques indicating a more stable plaque (Reifenberg et al. 2012). 
TNF-α In ApoE-/- TNF-α-/- mice, atherosclerosis was attenuated along with a decrease 
in the levels of pro-inflammatory cytokines, chemokines and adhesion 
molecules (Xiao et al. 2009). Another study using the same knockout model 
also observed a decrease in oxLDL uptake and SRA expression in 
macrophages (Ohta et al. 2005). 
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1.4.1.1 IFN-γ 
IFNs are classified into two groups depending on receptor specificity and sequence 
homology. Type I IFNs, which include IFN-α, -β and -ω subtypes, are structurally 
related and bind to a common receptor (Schroder et al. 2004). IFN-γ is the only type 
II IFN as it is structurally unrelated to type I IFNs and binds to a different receptor 
(Schroder et al. 2004). IFN-γ is produced by a number of immune cells such as T-
lymphocytes, B-lymphocytes, natural killer cells, dendritic cells and macrophages 
(McLaren and Ramji 2009).  
1.4.1.1.1 Signalling through JAK/STAT 
IFN-γ is classified as a pro-inflammatory cytokine and is involved at all stages of 
atherosclerosis (McLaren and Ramji 2009). Responses are driven by signalling 
through the Janus kinase (JAK)/ Signal transducer and activator of transcription 
(STAT) pathway. The JAK/STAT pathway is employed by over 50 cytokines and is 
one of the best understood mechanism by which signals are propagated (Schroder 
et al. 2004). An overview of this pathway is detailed in Figure 1.7.  
The IFN-γ receptor (IFN-γR) is made up of two subunits; IFN-γR1 and IFN-γR2. 
Ligand binding induces a conformational change in the intracellular domain of the 
receptor allowing for association with downstream signalling partners (Schroder et al. 
2004). IFN-γ binding to IFN-γR induces JAK2 autophosphorylation which can then 
transphosphorylate JAK1 (Schroder et al. 2004). Activated JAK1 phosphorylates the 
IFN-γ receptor at tyrosine residue 440 of the IFN-γR1 chain. This allows docking of 
the SH2 domain of STAT1 to the receptor tails and its phosphorylation at TYR701 by 
JAKs. Phosphorylation induces release of STAT1 from the receptor. STAT1 form 
homodimers which can be further phosphorylated at SER727 by additional kinases. 
Homodimers translocate into the nucleus where they bind to gamma activating 
sequences (GAS) in the regulatory regions of target genes and induce their 
transcription (Schroder et al. 2004; Platanias 2005; McLaren and Ramji 2009).  IFN-
γ is highly effective at low concentrations and can up or down regulate the expression 
of numerous genes very quickly (Kerr and Stark 1991). Many of the genes first 
induced by the cytokine are transcription factors. This includes interferon regulatory 
factors (IRFs). IRFs are a family of transcription factors of which some members 
participate in IFN-γ signalling; notably IRF-1, IRF-3 and IRF-9 (Schroder et al. 2004; 
Platanias 2005). IRFs can form complexes with STAT homodimers (for example 
STAT1:STAT2:IRF-9) which bind IFN-γ stimulated response elements (ISREs) and 
control the transcription of genes containing these sequences (Platanias 2005). 
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Figure 1.7 – IFN-γ signalling through the JAK/STAT pathway  
Diagram depicts an overview of IFN-γ signalling through the JAK/STAT pathway 1. IFN-γR is 
composed of two subunits:  R1 and R2. 2. Binding of IFN-γ causes dimerisation of subunits 
allowing phosphorylation of tyrosine kinases JAK1 and JAK2, which are attached to the IFN-
γR complex via their N-terminus. Activated JAK1/2 phosphorylate IFN-γR subunits at tyrosine 
residues, via their catalytic domain 3. Phosphorylated IFN-γR subunits bind STAT1 monomers 
from the cytoplasm via their SH2 domain and are phosphorylated at TYR701 4. Phosphorylated 
STAT1 monomers are released from the receptor 5. STAT1 monomers dimerise: 
STAT1:STAT1. 6. Phosphorylation of STAT1 dimers at position SER727 by PI3-K, p38 MAPK 
and ERK is required for maximal activity. 7. STAT1:STAT1 trans-locates into the nucleus 
where they can bind to GAS in the promoter regions of IFN-γ-inducible genes. Adapted from 
(McLaren and Ramji 2009). 
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1.4.1.1.2 Role of IFN-γ in atherosclerosis  
IFN-γ is involved in all aspects of atherosclerosis pathology. ApoE-/- IFN-γR-/- mice 
showed significant reduction in atherosclerotic lesion size together with reduced 
lesion lipid accumulation and lesion cellularity (Gupta et al. 1997). This suggests that 
IFN-γ promotes atherosclerosis and impacts on various aspects of the disease. IFN-
γ  can impact on levels of chemokines expressed in atherosclerosis as seen by the 
dramatic increase in MCP-1 expression on treatment with IFN-γ  in a human 
osteoblastic cell line (Valente et al. 1998). IFN-γ also induces the expression of 
adhesion molecules ICAM-1 and VCAM-1 (Li et al. 1993; Chung et al. 2002). Once 
monocytes have differentiated into macrophages, IFN-γ plays a role in the expression 
of scavenger receptors which bind modified forms of LDL. IFN-γ  up regulates the 
expression of scavenger receptor Chemokine (C-X-C motif) ligand 16/ Scavenger 
receptor for phosphatidylserine and oxidised lipoprotein (CXCL16/SR-PSOX) which 
mediate oxLDL uptake (Wuttge et al. 2004) thereby promoting foam cell formation. 
The cytokine also plays a role in cholesterol accumulation in macrophages. IFN-γ  
has been shown to decrease cholesterol efflux (Harvey and Ramji 2005) and impede 
reverse cholesterol transport in THP-1 macrophages (Reiss et al. 2004). As the 
disease progresses, IFN-γ continues to play a role. In the later stages of 
atherosclerosis, IFN-γ  can act to destabilise atherosclerotic plaques by inhibition of 
SMC proliferation and matrix synthesis, thereby affecting the fibrous cap, and up 
regulates the expression and activities of matrix metalloproteinases which break 
down the extracellular matrix of the plaque (Harvey and Ramji 2005). Both these roles 
act to destabilise the plaque increasing the risk of plaque rupture. 
There are, however, some conflicting anti-inflammatory roles for IFN-γ in 
atherosclerosis. Despite the increase in the CXCL16/SR-PSOX scavenger receptor 
expression, IFN-γ has been shown to inhibit the expression of two other important 
scavenger receptors SRA and CD36 (Nakagawa et al. 1998; Grewal et al. 2001). It 
has also been shown that IFN-γ  may act to inhibit pro-inflammatory LPL expression 
by macrophages and macrophage-mediated LDL oxidation (Harvey and Ramji 2005). 
Despite these controversial roles of IFN-γ, the balance between pro and anti-
atherosclerotic roles of IFN-γ favours the cytokine as pro-inflammatory which 
significantly increases atherosclerosis in vitro.  In addition, studies in vivo have 
demonstrated consistently a pro-atherosclerotic role for the cytokine (Table 1.4) 
(Harvey and Ramji 2005; McLaren and Ramji 2009).  
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1.4.1.2 IL-1β 
The IL-1 family consists of three members; IL-1α, IL-1β and IL-1 receptor antagonist 
(IL-1ra) (Fearon and Fearon 2008). IL-1 signalling is tightly controlled with binding of 
IL-1-α and -β to IL-1 type 1 receptor inducing downstream pro-inflammatory signalling 
events. On the other hand, the binding of IL-1  to IL-1 type II decoy receptor and IL-
1ra binding to type I receptor acts to inhibit signalling (Fearon and Fearon 2008).  IL-
1 is produced by a number of cells including endothelial cells, SMCs and 
macrophages. Increased levels of IL-1 stimulates release of cytokines and 
chemokines, increased expression of adhesion molecules, macrophage recruitment 
and SMC proliferation during atherosclerosis (Fearon and Fearon 2008). The role of 
IL-1β has been well characterised as an important pro-inflammatory factor in 
atherosclerosis and will be discussed in more detail.  
1.4.1.2.1 Activation of IL-1β 
IL-1β activation is under tight regulation. It is synthesised as an inactive precursor 
molecule (proIL-1β) which remains within the cell (Dinarello 1998). In order to elicit a 
response, proIL-1β must first be cleaved. Therefore two mechanisms are required for 
the maturation and release of active IL-1β; production of proIL-1β and activation of 
the cytokine through cleavage. Caspases are a family of cysteine proteases that 
cleave substrates at aspartate residues. They are involved in pro-inflammatory and 
pro-apoptotic pathways (Franchi et al. 2009). Caspases -1, -4 and -5 have been 
identified as pro-inflammatory in humans (Schroder and Tschopp 2010) and caspase 
1 plays a key role in the activation of IL-1β (Franchi et al. 2009). Caspase 1 cleaves 
proIL-1β at an aspartic residue located at position 116 to form the active cytokine 
which can be secreted by the cell (Dinarello 1998). Along with IL-1β activation, 
activation of caspase 1 is also tightly regulated. Caspase 1 must also undergo 
cleavage itself, which is achieved by multi-protein complexes called inflammasomes 
(Schroder and Tschopp 2010). 
Immune cells express PRRs on their surface to detect pathogen associated molecular 
patterns (PAMPs) and danger associated molecular patterns (DAMPs). These 
include nucleotide oligomerization domain (NOD) like receptors (NLRs) (Schroder 
and Tschopp 2010). The inflammasome is a large multi-protein complex which 
includes members of the NLR family along with adaptor protein apoptosis-associated 
speck-like protein containing CARD (ASC) (Franchi et al. 2009). A number of 
members of the NLR family have been implicated to play a role in the inflammasome 
including NLRP1 and NLRP3. The NLRP3 inflammasome has been well 
characterised. It can be activated by a number of extracellular stimuli including 
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PAMPs, extracellular glucose, amyloid β peptide, uric acid, cholesterol crystals and 
oxLDL (Rajamaki et al. 2010; Schroder and Tschopp 2010; Liu et al. 2014). There are 
a number of different theories surrounding the mechanism by which the NLRP3 
inflammasome is activated. These include direct activation by agonist, activation by 
lysosomal contents released on engulfment of agonist and, finally, activation by ROS 
produced by the agonist (Schroder and Tschopp 2010). Once activated, the NLRP3 
inflammasome assembles and recruits pro-caspase 1. Auto cleavage of pro-caspase 
1 forms the active protease. Caspase 1 can then cleave pro-IL-1 β to its active form.  
1.4.1.2.2 Role in atherosclerosis 
IL-1β is a well-established pro-inflammatory cytokine whose expression is up 
regulated in atherosclerosis. IL-1β expression was found to be increased in the vessel 
walls of atherosclerotic arteries and plaque macrophages (Galea et al. 1996). ApoE-
/- IL-1β-/- mice showed a 30% decrease in atherosclerotic lesions at the aortic sinus in 
comparison to controls. It was also observed that the mRNA levels of VCAM-1 and 
MCP-1 were significantly reduced in such lesions (Kirii et al. 2003). Similarly, 
administration of an anti-IL-1β antibody to ApoE-/- mice inhibited atherosclerotic lesion 
formation (Bhaskar et al. 2011). In addition, inhibition of IL-1β increased plasma HDL 
levels, decreased plaque lipid and macrophage content and reduced secretion of IL-
6, IL-8, MCP-1 and TNF-α (Bhaskar et al. 2011). Interestingly, the therapeutic 
potential of neutralising IL-1β antibodies are currently being evaluated in a multi-
centre phase III Canakinumab Anti-inflammatory Thrombosis Outcomes Study 
(CANTOS) (Ridker et al. 2011). 
1.4.1.3 TNF-α 
TNF-α is member of a growing family of cytokines (Popa et al. 2007). Initially 
discovered as a circulating factor, it has since been identified as a key component of 
the innate immune system and its expression is up-regulated in response to stress 
signals (Kleinbongard et al. 2010). It is a pro-inflammatory cytokine produced by a 
number of immune cells including macrophages, monocytes and T-cells (Popa et al. 
2007). TNF-α is first synthesised as a transmembrane protein and cleavage of the 
extracellular domain releases a soluble form of the cytokine. Both the transmembrane 
and soluble form of TNF-α are biologically active and can bind TNF-receptor (TNFR) 
I/II (Olmos and Llado 2014). Both the receptors belong to the TNF-receptor 
superfamily, which also includes FAS, CD40, CD27 and RANK (Idriss and Naismith 
2000). TNFR1 and TNFR2 elicit different responses and are structurally different. 
TNFR1 (55kDa) contains a death domain and is linked to cell death by apoptosis 
while TNFR2 (75kDa) lacks the death domain and plays a role in cell survival and 
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proliferation response. However, studies now report overlapping functions of the two 
receptors (Olmos and Llado 2014). Binding of TNF-α, as a trimer to its cognate 
receptors (Idriss and Naismith 2000), initiates a downstream cascade which results 
in the activation of a number of signalling pathways, including NF-κB, ERK, JNK, and 
p38 (Popa et al. 2007; Olmos and Llado 2014). Activation of these pathways has a 
number of pro and anti-inflammatory effects in atherosclerosis, the details of which 
can be found in Table 1.4.    
1.4.1.3.1 Role in atherosclerosis 
TNF–α is highly expressed by macrophages present in atherosclerotic plaques 
(Arbustini et al. 1991) and in one study it was detected in 88% of atherosclerotic 
plaques (Barath et al. 1990). Increased release of TNF-α in response to stress signals 
stimulates the expression of adhesion molecules on endothelial cells and promotes 
the recruitment and activation of immune cells (Popa et al. 2007). It is therefore an 
important factor in the initial stages of foam cell formation. In addition to this, TNF-α 
expression can increase apoptosis, thrombin formation and increase cholesterol 
uptake by macrophages (Kleinbongard et al. 2010). ApoE-/- TNF-α-/- mice show a 
decrease in lipid accumulation and fatty streaks in comparison to control mice, as well 
as a decrease in the expression of IL-1β, IFN-γ, ICAM-1, VCAM-1, MCP-1, GM-CSF 
along with activation of NF-κB (Xiao et al. 2009). Similarly, ApoE-/- TNF-α-/- mice show 
a reduction in the size of atherosclerotic plaques present in the aortic luminal surface 
and aortic sinus compared to ApoE-/- control mice (Ohta et al. 2005). A decrease in 
the expression of ICAM-1, VCAM-1 and MCP-1 was again observed, along with a 
decreased uptake of oxLDL and reduced expression of SRA in response to TNF-α 
deficiency (Ohta et al. 2005).  
1.4.2 Fatty acids as signalling molecules 
As well as energy storage and their importance in cellular membranes, lipids can also 
act as signalling molecules. Fatty acids are delivered to tissues as TAG-derived fatty 
acids or non-esterified fatty acids (NEFAs). They can be taken up by the cells using 
fatty acid transporters and bound to fatty acid binding proteins (Georgiadi and Kersten 
2012). From here they can be subject to a number of fates including oxidation for 
energy, esterification, incorporation into phospholipids of membranes or storage as 
lipid droplets. Most of the signalling actions of fatty acids are linked to their 
metabolites; however they themselves can directly activate signalling pathways 
Second messengers, such as diacylglycerols (DAG), are produced by enzyme-
catalysed hydrolysis of membrane phospholipids. The composition of fatty acids in 
DAG determines their effect on signalling (Calder 2012). Roles of fatty acids in 
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atherosclerosis are summarised in Table 1.5. Fatty acids cleaved from phospholipid 
membranes and NEFAs can directly, or indirectly through their metabolites, activate 
numerous signalling pathways by acting on receptors and transcription factors. These 
include peroxisome proliferator activated receptors (PPARs), TLRs, G protein-
coupled receptors (GPCRs) and transcription factor sterol regulatory element binding 
protein (SREBP) (Georgiadi and Kersten 2012).  
1.4.2.1 PPARs 
These are members of nuclear hormone receptor superfamily and three subtypes 
exist; α, δ and γ. PPARα and PPARδ are expressed in most tissues and cells. PPARγ 
expression however is more restricted to mainly adipocytes and macrophages. 
PPARs function by forming heterodimers with retinoid-x-receptors. The heterodimers 
bind DNA sequences named peroxisome proliferators response elements (PPREs) 
present in promoter sequences of target genes (Tyagi et al. 2011; Georgiadi and 
Kersten 2012). They act to regulate lipid metabolism, glucose homeostasis and 
inflammation and are activated by fatty acids and their derivatives (Duval et al. 2002). 
PPAR-α and -γ have been implicated to play a protective role in atherosclerosis and 
inflammation (Duval et al. 2002). Activation of PPARγ by oxidised linoleic acid has 
been found to inhibit the MCP-1 receptor C-C chemokine receptor 2 (CCR2) and 
block monocyte chemotaxis. (Han et al. 2000). PPARγ agonist prostaglandin J2 
(PGJ2), but not PPARα agonists EPA and DHA, inhibited the IFN-γ-mediated 
induction of pro inflammatory CXC chemokines. This included the IFN-inducible T-
cell α chemoattractant (I-TAC), IFN-inducible protein of 10kDa (IP-10) and monokine 
induced by IFN-γ (Mig) (Marx et al. 2000). The expression of MCP-1 was not affected 
in the study (Marx et al. 2000). PPARα agonists inhibited TNF-α-mediated expression 
of VCAM-1 by human endothelial cells that was not seen with the activation of PPARγ 
(Marx et al. 1999). Disruption of the PPARγ gene in mice reduced the expression of 
LPL, CD36, LXRα, ABCA1 and ApoE which, in turn, reduced cholesterol efflux to HDL 
from cholesterol loaded macrophages (Akiyama et al. 2002). LDLr-/- mice 
reconstituted with bone marrow from PPARα+/+ and PPARα-/- mice were fed a high fat 
diet. PPARα-/- LDLr-/-  mice developed significantly larger atherosclerotic lesions, 
increased oxLDL uptake and decreased cholesterol efflux  in comparison to controls 
(Babaev et al. 2007). PPARα+/+ LDLr-/- developed significantly smaller atherosclerotic 
lesions in comparison to PPARα-/-  LDLr-/- mice (Babaev et al. 2007). The role of 
PPARδ is controversial and needs more study. However activation of PPARδ with 
agonist promotes lipid accumulation in human macrophages, increases SRA and 
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CD36 expression and attenuates ApoE expression. This suggests a pro-atherogenic 
role for this receptor (Vosper et al. 2001). 
1.4.2.2 TLR4 
This is a type I transmembrane protein and belongs to the TLR family with at least 10 
members, each with different ligands (Li and Sun 2007). TLR4 was identified as the 
first human homologue that is activated by LPS and saturated fatty acids (SFA) 
(Suganami et al. 2007; Tsukumo et al. 2007) and, therefore, is a candidate receptor 
in fatty acid signalling.  TLR4 plays an important role in inflammation, immunity and 
insulin resistance (Tsukumo et al. 2007). The receptor is expressed by immune cells, 
neutrophils, macrophages, dendritic cells, B-cells and T-cells (Li and Sun 2007). 
Treatment of macrophages with SFA leads to an increase in pro-inflammatory 
cytokine expression (TNF-α and IL-1β). SFA also activates NF-κB targets in 
macrophages through activation of TLR4. Macrophages from TLR4-/- mice show an 
attenuation in TNF-α production (Suganami et al. 2007). In TLR4 deficient mice fed a 
high fat diet, monocyte infiltration and expression of MCP-1 was reduced in adipose 
tissue. This was accompanied by less NF-κB activation. However, there was no 
difference observed in TNF-α or IL-6 expression in comparison to WT mice (Davis et 
al. 2008). TLR4-/- mice were resistant to diet-induced obesity and showed improved 
insulin sensitivity. In addition, SFA-induced insulin resistance was inhibited in the 
muscle tissue of these mice (Tsukumo et al. 2007). LDLr-/- TLR4-/- mice showed 
improved plasma cholesterol and TAG levels but still developed obesity and glucose 
intolerance comparable to LDLr-/- mice. Despite this, the development of 
atherosclerosis in double knockout mice was significantly attenuated (Ding et al. 
2012). In addition, TLR4 expression and signalling in atherosclerosis is up-regulated 
by oxLDL and induces a pro-inflammatory response in endothelial cells and 
macrophages, SMC migration and secretion of proteolytic enzymes MMPs (Li and 
Sun 2007). However, an atheroprotective role for TLR4 was observed in response to 
infection (with common oral pathogen) in ApoE-/- TLR4-/- mice (Hayashi et al. 2012).  
1.4.2.3 GPCRs 
GPCRs are a large family of cell surface receptors that share common structural 
motifs and the ability to activate heterotrimeric G proteins (Oh et al. 2010). Ligand 
binding can stimulate a number of second messenger pathways; cyclic adenosine 
monophosphate (cAMP) production, opening of ion channels and activation of MAPK 
pathways. There are estimated to be over 850 human GPCRs, which differ in cell 
specificity and tissue expression (Talukdar et al. 2011). GPR-40, -41, -43, -84 and -
120 can be activated by NEFAs. Short chain fatty acids (4-8 carbons) activate GPR-
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41 and -43; medium chain fatty acids (10-14 carbons) activate GPR-84; and long 
chain fatty acids (16-18 carbons) activate GPR-40 and -120 (Oh et al. 2010). GPR-
120 is expressed in adipocytes and pro-inflammatory macrophages. Activation of this 
receptor induces numerous responses, commonly related to insulin sensing and 
inflammation. Studies have focused on omega-3 signalling through GPR-120 and the 
resulting anti-inflammatory effects. EPA and DHA can exert anti-inflammatory effects 
through GPR-120 in macrophages. DHA signalling through GPR-120 inhibited LPS 
induced phosphorylation of JNK and pro-inflammatory cytokine gene expression in 
macrophages. This was also observed in vivo (Oh et al. 2010). A high fat diet in GPR-
120 knockout mice and wild type mice resulted in induction of insulin resistance. 
However, supplementation with omega-3 fatty acids produced improved glucose 
tolerance in wild type mice only and not in GPR-120 deficient animals (Talukdar et al. 
2011). In another study, pre-treatment of neurone cells with DHA prevented a TNF-α 
induced inflammatory response (Wellhauser and Belsham 2014). This effect was 
independent of ERK and PI3K/Akt activation and abolished on reduction of 
endogenous GPR-120 levels (Wellhauser and Belsham 2014). This suggests omega-
3 fatty acids may exert anti-inflammatory effects through GPR-120 signalling.  
1.4.2.4 SREBPs 
SREBPs are a family of basic helix-loop-helix, leucine zipper transcription factors. 
They are synthesised in a membrane bound form on the endoplasmic reticulum 
complexed with SREBP cleavage activating protein (Karasawa et al. 2011). A 
reduction in cellular cholesterol levels induces SREBP cleavage activating protein to 
escort SREBP to the Golgi apparatus where it is cleaved by proteases. The cleaved 
transcription factor can next move into the nucleus and activate downstream 
pathways (Karasawa et al. 2011). Three isoforms exist; SREBP-1a, SREBP-1c and 
SREBP-2. The primary role of these factors involves transcriptional activation of 
genes involved in de novo lipogenesis and the uptake of cholesterol, fatty acids, TAG 
and phospholipids (Karasawa et al. 2011). LDLr-/- mice overexpressing hepatic 
SREBP-1c results in hypertriglyceridemia, an increase in VLDL levels and a decrease 
in HDL resulting in atherosclerosis (Karasawa et al. 2011). In contrast, deficiency of 
SREBP-1 attenuated atherosclerosis in these mice (Karasawa et al. 2011). PUFAs 
have been indicated to inhibit lipogenic gene expression by down regulating SREBPs. 
In one study PUFA increased the decay of SREBP-1a and SREBP-1c in rat 
hepatocytes. Treatment with AA and EPA decreased the half-life of total SREBP-1 
mRNA by 50% (Xu et al. 2001). In mice, supplementation with PUFAs decreased the 
cleaved form of mature SREBP-1 protein in the nucleus as well as enzymes involved 
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in lipid synthesis such as fatty acid synthase and acetyl-CoA carboxylase (Yahagi et 
al. 1999). Studies indicate that PUFA can attenuate lipid synthesis by regulating 
expression and post-transcriptional mRNA stability of SREBP and that this may be 
beneficial in the pathology of atherosclerosis.   
1.5.2.5 Role of fatty acids in atherosclerosis 
As discussed previously, fatty acids can be classified as saturated and unsaturated. 
PUFA hydrocarbon chains contain more than one double bond and are important 
signalling molecules. Table 1.5 summarises some of the roles fatty acids play in the 
pathology of atherosclerosis. Generally speaking, SFA are commonly referred to as 
‘bad fat’ as consumption has been linked to increased cholesterol levels and 
inflammatory processes, therefore increasing the risk of CVD (Xu et al. 2006). Diets 
rich in PUFA however, indicate a significant athero-protective role (Dyerberg 1989) 
and have been shown to modify inflammation (Suresh and Das 2003a, b; Wang et al. 
2012; Dawczynski et al. 2013). Two important classes of PUFA will be discussed in 
more detail; omega-3 and omega-6 fatty acids. 
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Table 1.5 – Fatty acids and their role in atherosclerosis 
Class Name Possible role in atherosclerosis 
SFA Myristic acid Increases plasma LDL cholesterol (Xu et al. 2006). 
 Decreases HDL to LDL ratios in humans (Zock et al. 1994).  
Correlates with an increase in large dense LDL particles (Deron et al. 1999). 
SFA Palmitic acid Raises cholesterol levels and increases uptake of oxLDL by macrophages via expression of LOX-1 receptor 
therefore promoting atherosclerosis (Xu et al. 2006; Ishiyama et al. 2010).  
Activates TLR2 to induce inflammasome activation and pro IL-1β cleavage (Snodgrass et al. 2013) 
 Decreases HDL to LDL ratios in humans (Zock et al. 1994).  
 Correlates with an increase in large dense LDL particles (Deron et al. 1999). 
SFA Stearic acid Lowers LDL  cholesterol  levels in vivo in comparison to trans-saturated fatty acids (Hunter et al. 2010).  
No significant association with lipoprotein concentrations (Deron et al. 1999). 
 
 
39 
 
MUFA Palmitoleic acid Increases insulin sensitivity and reduces pro-inflammatory gene expression in mice with type 2 diabetes 
(Yang et al. 2011).  
Association found between the content of palmitoleic acid in red blood cell membrane and CVD (Djousse 
et al. 2012). 
MUFA Oleic acid Hamsters supplemented with an oleic acid-rich oil showed decreased atherosclerosis and foam cell 
formation in comparison to a diet rich in LA (Nicolosi et al. 2002). 
In mouse model, oleic acid displayed anti-oxidant activity against LDL oxidation. Strongly inhibited oxLDL 
uptake by THP-1 macrophages (Cho et al. 2010).  
ApoE-/- deficient mice fed an oleic acid-rich diet resulted in an increase in FFA and enhanced 
atherosclerosis compared to normal chow diet (Ma et al. 2011).  
MUFA Vaccenic acid In red blood cells, fatty acid levels were inversely associated with CVD (Kris-Etherton and Nutrition 1999; 
Djousse et al. 2012). 
Anti-atherogenic effects in LDLr-/- mice (Bassett et al. 2010). 
n-6 PUFA Linoleic acid Precursors of DGLA and AA. Results in both pro- and anti-inflammatory actions as a result of metabolism 
to these two fatty acids (Wang et al. 2012). 
Diet rich in LA inversely related to risk of atherosclerosis (Djousse et al. 2003; Djousse et al. 2005) 
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LDLr-/- mice fed an omega-6 LA rich diet showed significantly lower atherosclerosis by a lowering of total 
cholesterol levels (Machado et al. 2013). 
n-6 PUFA GLA Inhibited atherosclerosis in LDLr-/- and ApoE-/- mice (Fan et al. 2001; Machado et al. 2013) 
Inhibited atherosclerosis induced in rats fed a high fat diet. Reduced total cholesterol levels, oxLDL, NO 
and LDL (Shi et al. 2008) 
Decreased IL-1β secretion from human monocytes (Furse et al. 2001). 
n-6 PUFA DGLA Inhibited atherosclerosis in ApoE-/- mice and reduced expression of inflammatory markers (Takai et al. 
2009). 
Attenuated TNF-α production from leukocytes (Dooper et al. 2003). 
n-6 PUFA AA High AA/EPA ratio linked to a risk of CVD (Ninomiya et al. 2013). 
Metabolites of AA (for example PGE2 and LBT4) have pro-inflammatory and pro-thrombotic actions (Levin 
et al. 2002; Gomolka et al. 2011; Wang et al. 2012). 
n-3 PUFA α-linolenic acid Diabetic ApoE-/- mice fed a diet supplemented with ALA showed a decrease in markers of oxidative stress, 
and this prevented increase of plasma cholesterol and atherosclerosis (Yi and Maeda 2006). 
Increased consumption linked to a reduction in CVD (Kris-Etherton et al. 2003; Harris et al. 2007). 
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n-3 PUFA EPA Significantly reduced in patients experiencing CVD events (Harris et al. 2007). 
Low EPA/AA ratio associated with risk of cardiovascular disease (Ninomiya et al. 2013). 
Dietary supplementation of EPA in ApoE-/- mice  regressed atherosclerotic plaques and decreased immune 
cell content (Nakajima et al. 2011). 
Inhibits modified LDL uptake and macropinocytosis in vitro (McLaren et al. 2011b). 
n-3 PUFA DPA Significantly reduced in patients experiencing CVD events (Harris et al. 2007). 
Reduced total plasma cholesterol and non-HDL associated cholesterol. Down-regulated expression of 
HMG-CoA reductase. Less tension and more relaxed aorta due to inhibition of Cyclooxygenase (COX)-2 
(Chen et al. 2012). 
n-3 PUFA DHA Increased consumption linked to a reduction in CVD (Kris-Etherton et al. 2003; Harris et al. 2007). 
Reduced total plasma cholesterol and non-HDL associated cholesterol. Down regulated HMG-CoA 
reductase. Less tension and more relaxed aorta due to inhibition of COX-2 (Chen et al. 2012). 
Inhibits oxLDL uptake and macropinocytosis in vitro (McLaren et al. 2011b). 
Inhibited TLR1 and TLR2 dimerisation and inflammasome-mediated secretion of IL-1β (Snodgrass et al. 
2013). 
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1.5.2.6 Omega-3 and 6 fatty acids 
Omega-3 and -6 fatty acids include the essential fatty acids (EFA) linoleic acid and α-
linolenic acid. EFA are important constituents of cell membranes and can therefore 
alter their behaviour and those of bound enzymes and receptors (Das 2007). 
Changes in the dietary intake of EFA can modulate the production of eicosanoids. 
Omega-3 and -6 PUFA are cleaved from cellular membranes via the action of 
phospholipase A2 (PLA2) in response to cellular signals. This release induces the 
production of eicosanoids through the LOX, COX and P-450 enzymatic pathways 
(McDaniel et al. 2011). Eicosanoids are a family of bioactive lipid mediators, 20 
carbons in length, with a wide variety of actions. The eicosanoid family includes 
prostaglandins (PG), leukotrienes (LT), thromboxanes (TX) and numerous hydroxy 
fatty acids (McDaniel et al. 2011). These mediators act quickly and locally and remain 
active for only a short period of time before they are degraded (Arita 2012). 
Eicosanoids elicit a number of actions which are both pro- and anti-inflammatory 
(Figure 1.8).  
Several studies have indicated that in CVD, essential fatty acid metabolism is 
abnormal such that plasma and tissue level of omega-3 and -6 fatty acids are low 
(Das 2007). Omega-3 PUFA are well documented to impart anti-inflammatory actions 
in CVD including atherosclerosis and in other chronic inflammatory diseases 
(Bannenberg and Serhan 2010). Numerous studies have detailed the beneficial 
actions of omega-3 PUFA, primarily EPA and DHA, in a wide variety of inflammatory 
diseases including heart disease (Dawczynski et al. 2013; Masson et al. 2013) and 
stroke (Larsson et al. 2012). EPA and DHA are abundant in fish oils (Arita 2012) and 
sold as dietary supplements worldwide. A study performed in the human macrophage 
cell line THP-1 showed an inhibition of acetylated LDL (acLDL) and oxLDL uptake on 
incubation with EPA and DHA (McLaren et al. 2011b). In addition, dietary 
supplementation of EPA containing fish oils prevented the development of 
atherosclerosis in mice (Takai et al. 2009). EPA and DHA therefore exhibit athero-
protective effects.  
A number of studies have focussed on the role of omega-6 fatty acids in CVD with 
controversial results. Many recommend reductions in omega-6 dietary intake 
(Hamazaki and Okuyama 2003; Simopoulos 2008; Harris et al. 2009) and 
consumption of a diet with a high omega-6/omega-3 ratio has been associated with 
an increased risk of CVD, inflammatory diseases and cancer (Dawczynski et al. 
2013).  AA is well documented to play a pro-inflammatory role in disease. Diets rich 
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in the EFA omega-6 fatty acid LA have been advised against with the understanding 
that an increase in LA will lead to an increase in its metabolite AA. Reducing LA intake 
would reduce AA accumulation and its pro-inflammatory potential (Harris et al. 2009). 
However intake of LA does not always manifest in the levels of AA due to the rate-
limiting steps in the omega-6 pathway. Studies have indicated that the extent of 
conversion of dietary LA to AA is 0.2% (Hussein et al. 2005).  
Despite this, a large number of studies have suggested that increasing the levels of 
omega-6 in the diet has no association or reduces the risk of CVD. The alpha-
tocopherol beta-carotene cancer prevention study (Pietinen et al. 1997) concluded 
that there was no association between the LA content of the diet and CVD. On the 
other hand, The Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study 
(Laaksonen et al. 2005) and the Western Electric Study (Shekelle et al. 1981) both 
reported inverse associations between dietary LA and CVD risk. In a meta-analysis 
of 25 case control studies, dietary content of LA was inversely related to CVD risk 
while AA was unrelated (Harris et al. 2007). Large intakes of LA have also been 
shown to have no link to the risk of acute myocardial infarction (Kark et al. 2003). It 
has therefore been suggested that decreasing the omega-6 fatty acid intake in the 
diet would more than likely increase the risk of CVD (Harris et al. 2009). Furthermore, 
dietary approaches with omega-6 fatty acids GLA and DGLA have indicated potent 
anti-inflammatory effects in inflammatory disease (Kawashima et al. 2008; Takai et 
al. 2009; Wang et al. 2012).   
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Figure 1.7 – Overview of omega-3 and -6 pathways 
Green boxes represent eicosanoids with anti-inflammatory roles; red boxes indicate pro-inflammatory roles. See table 1.2 for list of fatty acid abbreviations. 
COX – cyclooxygenase, LOX – lipooxygenase. HETE - hydroxyeicosatetraenoic acid, HETrE - hydroxyeicosatrienoic acid 
15-HETrE 
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1.5 DGLA  
1.5.1 Relation to disease 
Omega-6 PUFAs are commonly referred to as pro-inflammatory due to the actions of 
metabolites of AA. Controversially however, metabolic precursors of AA have been 
demonstrated to have key anti-inflammatory roles. Dietary supplementation with GLA 
has been implicated as beneficial in a number of inflammatory diseases. For example 
treatment with GLA significantly reduced the signs and symptoms in patients with 
rheumatoid arthritis (Zurier et al. 1996) and atopic eczema (Umeda-Sawada et al. 
2006). GLA also inhibited atherosclerosis and smooth muscle cell proliferation in 
ApoE-/- mice (Fan et al. 2001). In human monocytes, GLA inhibited the secretion of 
IL-1β in a dose dependant manner (Furse et al. 2001). GLA is elongated to DGLA 
which is incorporated into cellular membranes, cleaved or metabolised to produce 
anti-inflammatory mediators. Many studies use GLA to indirectly increase the fatty 
acid pool of DGLA. However this process does not allow for a sufficient increase of 
the fatty acid (Teraoka et al. 2009). DGLA is the bioactive form of GLA (Kapoor and 
Huang 2006) but, as there were previously no major source of DGLA available, direct 
supplementation with this fatty acid was not possible. Due to the development of new 
sources of DGLA, a small number of studies have investigated the anti-inflammatory 
roles of DGLA, some in relation to a number of diseases, including atherosclerosis.  
ApoE deficient mice fed a normal diet supplemented with DGLA showed a significant 
reduction in the development of atherosclerosis (Takai et al. 2009). In addition, DGLA 
supplementations attenuated expression of ICAM-1 and VCAM-1 markers of 
inflammation, along with a decrease in NADPH oxidase subunits p22phox and gp91phox 
indicating a potential increase in vascular relaxation (Takai et al. 2009). In human 
leukocytes it was observed that DGLA inhibited TNF-α production and specifically 
altered cytokine levels, changes that were not seen with GLA or EPA (Dooper et al. 
2003). Supplementation with DGLA oil in the diet of a mouse model of atopic 
dermatitis significantly reduced severity of skin scores as well as scratching behaviour 
(Kawashima et al. 2008). Mice that were orally administered with DGLA also showed 
significant reduction in inflammation of the ear following induction with inflammatory 
stimuli. DGLA inhibited swelling and cell infiltration after 7 days of treatment 
(Watanabe et al. 2014). 
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Studies have also indicated a role for DGLA in cancer. Free radicals produced as a 
result of oxygenation of DGLA, heptanoic acid (HTA) and 8 hydroxyoctanoic acid (8-
HOA), had an anti-proliferative effect on cancerous colon cells  (Xu et al. 2014b). The 
free radicals arrested the cell cycle in cancer cells and promoted apoptosis. In 
addition, in combination with the DGLA-derived free radicals, the efficiency and 
cytoxicity of the colon cancer drug 5-fluoruracil, was increased (Xu et al. 2014b). 
1.5.2 Synthesis and metabolism  
DGLA is a 20 carbon omega-6 PUFA metabolised from linoleic acid (Wang et al. 
2012). See Figure 1.8. Linoleic acid is an essential fatty acid required by humans at 
around 1-2% of total dietary energy to prevent deficiency (Wang et al. 2012). 
Synthesis of DGLA through the omega-6 pathways is detailed in Figure 1.8. The 
omega-6 pathway competes with the omega-3 pathway as they share a common set 
of desaturase enzymes (Calder 2012)  Briefly, linoleic acid is metabolised by Δ6 
desaturase to GLA. GLA is then elongated to DGLA which can be further metabolised 
by Δ5 desaturase to form AA.  
 
 
 
 
Figure 1.8 – Structure of DGLA 
Figure depicts the structure of DGLA. The PUFA contains 20 carbons and 3 double bonds, 
with the first double bond at carbon 6 (using the omega numbering system). 
 
The omega-6 pathway contains two desaturation steps, both of which are flux 
controlling enzyme steps (Kapoor and Huang 2006). Desaturation is a slow process; 
this means that conversion of LA to GLA is limited and can lead to deficiencies of 
GLA particularly in inflammatory conditions, which imposes further restrictions 
(Kapoor and Huang 2006). A reduced capacity of conversion of LA to GLA and DGLA 
has been linked to physiological and disease states such as aging, diabetes, atopic 
dermatitis, rheumatoid arthritis, cancer and CVD (Fan and Chapkin 1998; Kapoor and 
Huang 2006; Wang et al. 2012).The desaturation of DGLA to AA is also a slow 
process and only a small amount of DGLA is converted to AA (Fan and Chapkin 
HO 
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1998). This suggests that direct supplementation of DGLA would bypass the first 
desaturation step in the pathway, increasing availability of DGLA which can be 
incorporated into cell membranes and metabolised without a large increase in the 
accumulation of AA  (Fan and Chapkin 1998). This is observed in a study which 
investigated the supplementation of DGLA in rats. It was observed that on 
supplementation with DGLA there was an increase in DGLA concentrations in liver, 
serum and brain without accumulation of AA (Umeda-Sawada et al. 2006). This is an 
important feature of DGLA supplementation as this selectively increases the 
production of anti-inflammatory eicosanoids without an increase in pro-inflammatory 
eicosanoids from AA to counteract any actions. Both DGLA and AA are competing 
substrates for COX and LOX enzymes yielding a wide variety of eicosanoids. Specific 
metabolites of DGLA and AA are detailed in Figure 1.7. 
AA is cleaved from phospholipid membranes by PLA2 where it is immediately 
metabolised by COX or LOX pathways generating PGs and TXs, and LTs, LXs and 
hydroxy-eicosatetraenoic acids (HETEs) respectively (Arita 2012). Eicosanoids 
derived from AA are well documented to play a role in the initiation of inflammation 
and chronic inflammation. The 5-LOX metabolite LTB4 is a potent chemoattractant 
for leukocytes along with COX-2 metabolite PGE2 (Bannenberg and Serhan 2010). 
DGLA however, gives rise to two important metabolites with highly desirable actions; 
PGE1 and 15- hydroxy-eicosatrienoic acids (15-HETrE) (Horrobin 1991). PGE1 lowers 
blood pressure, inhibits platelet aggregation, promotes cholesterol efflux from cells 
and inhibits cholesterol biosynthesis, along with various other anti-inflammatory 
effects (Horrobin 1991). 15-HETrE also inhibits 5-LOX and 12-LOX which, in turn, 
inhibits the production of pro-inflammatory eicosanoids derived through the actions of 
these enzymes on AA (Horrobin 1991).  
1.5.3 Source of DGLA 
Principle sources of PUFA have previously relied on fish oils. Due to an increase in 
both fish consumption and marine pollution, fish stocks are ever decreasing 
(Watanabe et al. 2014). This highlights the need for alternative sources for PUFA 
production. New sources of DGLA have been obtained through manipulation of fatty 
acid pathways in yeast, fungi and algae.  
The yeast Saccharomyces cerevisiae has been genetically manipulated to produce 
DGLA. S.cerevisiae produces oleic acid as a result of its desaturase enzyme, Δ9 
desaturase. By genetically introducing Δ5 and Δ6 desaturase enzymes, this allowed 
the yeast to convert oleic acid to LA and then DGLA (Watanabe et al. 2014). 
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Mortierella alpina is arachidonic acid-producing fungus. A mutant strain was 
manipulated to be Δ5 desaturase-defective (1S-4). Under optimum conditions, 1S-4 
produced 43.9% of its fatty acids as DGLA (Kawashima et al. 2000). Alternatively, an 
algae has also been used as a source of DGLA and was the source employed for 
some studies in this thesis. A mutant of the phototrophic green microalgae 
Parietochloris incisa has recently been utilised in production of DGLA (Iskandarov et 
al. 2011). P. incisa produces large amounts of AA but chemical mutagenesis allowed 
for a nonsense mutation in the Δ5 desaturase gene (Iskandarov et al. 2011). This 
resulted in a significant increase in percentage of DGLA in total fatty acids (TFA). Wild 
type algae are comprised of approximately 1% DGLA and 58% AA (TFA) in 
comparison to mutant whereby percentage of AA was negligible and the proportion 
of DGLA increased to 32% (Iskandarov et al. 2011). DGLA can be isolated through 
lipid extraction, purified and subsequently used for experimentation.  
1.6 Aims of project 
Atherosclerosis is the primary cause of CVD, a disease responsible for more deaths 
annually than any other disease in Western society. The increasingly large burden on 
the health system to treat the disease is a major economic cost. Statins are commonly 
used in treatment of atherosclerosis but can only account for a 30% improvement in 
the disease, with some patients unresponsive to treatments (Mishra and Routray 
2003). With CVD events set to rise, new preventative and therapeutic options need 
to be made available. Atherosclerosis is a chronic inflammatory disorder 
characterised by lipid accumulation in vascular walls. Macrophages are key in the 
pathology of the disease given their important role in foam cell formation, an initial 
step in disease pathology. Targeting foam cell formation in macrophages is therefore 
a good candidate for therapeutic intervention. 
PUFA are important signalling molecules in disease. Signalling through a number of 
receptors and transcription factors, they play a role in immunity, inflammation and 
lipogenesis. Omega-3 and -6 fatty acids have been reported to have numerous anti-
inflammatory roles in diseases, including atherosclerosis. DGLA, an omega-6 fatty 
acid has been shown to have an anti-inflammatory and anti-atherosclerotic role in 
mouse models of the disease (Takai et al. 2009). However, the study had various 
limitations and failed to elucidate any underlying mechanisms. For example, the study 
provided no indications of the effects of DGLA on several key biological processes in 
atherosclerosis such as parameters related to foam cell formation. Further studies 
are therefore required on the molecular mechanisms underlying the anti-inflammatory 
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and anti-atherogenic actions of DGLA given its promise as a preventative/therapeutic 
agent. Genetic manipulation of green algae P. incisa, has allowed for a new source 
of DGLA to be made available (Iskandarov et al. 2011). Further studies could 
therefore be undertaken into understanding the molecular basis of the action of DGLA 
and evaluating the mutant algae as a viable and useful source.  
Given the promising initial studies using DGLA supplementation in reducing 
atherosclerosis, the aim of this study was to evaluate the underlying molecular 
mechanisms. The experimental aims of the project were designed to investigate if 
DGLA is a potentially new source of therapeutic value in the prevention of 
atherosclerosis. The project can be split into 3 main aims. 
 Evaluating the uptake and incorporation of pure DGLA into macrophage lipid 
classes in vitro together with its metabolism. In addition, investigate the role 
of DGLA supplementation on mouse plasma and tissue lipid fractions in vivo 
using DGLA from P. incisa algal powder  
 Using macrophages, determine the role of DGLA on aspects of foam cell 
formation, ROS production, monocytic migration, cytokine induced pro-
inflammatory gene expression, cytokine release, inflammasome activation, 
modified LDL uptake, cholesteryl ester accumulation and cholesterol efflux in 
vitro.  
 Delineate the molecular mechanism underlying the action of DGLA in foam 
cell formation and other key processes implicated in atherosclerosis together 
with the role of its metabolites in vitro.  
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Materials 
A list of the materials used throughout the project and their sources are listed in Table 
2.1.  
Table 2.1- Details of materials  
Supplier Area Material 
ABCAM UK ROS kit; Lactate dehydrogenase (LDH) kit 
ABD Serotech UK ABCG1 antibody (0650-1904) 
Amersham UK 14C-cholesterol 
Amresco USA Ribozol™ 
Biotrend Germany acLDL; Dil-oxidised LDL (oxLDL) 
Cayman Chemical USA PGE1; PGE1-d4; 15(S)-hydroxyeicosatrienoic 
acid (HETrE); 15(S)-hydroxyeicosatetraenoic 
acid (HETE)-d8 
Cell Signalling 
Technology 
USA Phospho-STAT1 TYR701 Rabbit mAB 
(#91675); Phospho-STAT1 SER727 Rabbit 
mAB (#91775) 
Greiner UK 6/12/24 well tissue culture plates; 10/25 ml 
stripettes; cell scrapers, 75/175 cm3 tissue 
culture flasks; 1 ml Cyro tubes 
LabTech UK Foetal calf serum, South America origin 
Lonza Switzerland RPMI media with stable glutamine 
NBS Biologicals UK RNA spin kit 
New England 
Biolabs 
UK Low molecular weight DNA ladder; Taq DNA 
polymerase 
Novus Biologicals USA ABCA1 antibody (NB400-105) 
NU-CHEK US GC standard (GLC-411); DGLA 
Nycomed 
Pharmaceuticals 
Switzerland Lymphoprep™ 
Perkin-Elmer USA Super polyethylene vials  (20 ml); OPTI-
FLUOR®; 14C-Acetate  
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Peprotech UK Human/mouse IFN-γ, IL-1β, IL-4, TNF-α, 
MCP-1 
Promega UK Deoxynucleotide (dNTPs); Molony murine 
leukemia virus (MMLV) reverse transcriptase; 
RNasin ribonuclease inhibitor; Random 
hexamer primers 
Qiagen UK COX-1 siRNA; COX-2 siRNA 
R&D systems USA IL-1β ELISA kit 
Roche Applied 
Scientific 
USA Lumi-film chemiluminescent detection film; 
PhophoSTOP phosphatase inhibitor; 
Protease inhibitor tablets 
Santa Cruz 
Biotechnologies 
USA Anti-rabbit secondary antibody IgG-AP; anti-
goat secondary antibody IgG-AP; COX-1 
antibody (Sc-1752); COX-2 antibody (Sc-
1745) STAT1 Rabbit mAb (Sc-592); β-actin 
(Sc-130656); SRA antibody (Sc-20660); 
CD36 antibody (Sc-9154); ABCG1 antibody 
(Sc-11150) 
Sigma-Aldrich UK Phorbol 12-myristate 13-acetate (PMA); 
Tween 20; SYBR® green; Dimethyl 
sulphoxide (DMSO); Accuspin tubes; RIPA 
buffer; phosphate buffer saline (PBS) tablets; 
tris-borate EDTA (TBE); DNA oligonucleotide 
primers; Acetic acid; Heptadecanoic acid 
(internal standard); Ammonium hydroxide; 
Boric acid; Ethanol; Chloroform; Diethyl ether; 
Isopropanol; Hexane; Methanol; Sulphuric 
acid, Formaldehyde 37% (v/v); RAW264.7 cell 
line; Copper II sulphate; THP-1 cell line; SYBR 
Green Taq readymix; Ponceau S; Tri sodium 
citrate, Sodium hydroxide; Sodium chloride; 
Potassium chloride;  Cholesterol; thin layer 
chromatography plates; Bovine serum 
albumin (BSA); ApoA1; Crystal violet; Lucifer 
yellow 
Source Bioscience UK Polyplus Interferin® transfection reagent  
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Star labs UK 96-well PCR plates; PCR plate covers; 0.5 ml 
Eppendorph tubes; 1.5 ml Eppendorph tubes; 
Latex diamond gloves; 15/50 ml Falcon tubes 
Thermo Fisher 
Scientific 
USA BCA protein assay kit; Magic marker XP 
western protein standard; NuPAGE® Novex 
Bis-Tris Gel 4-12% (w/v), 1.0mm (x10); 
NuPAGE® transfer buffer (20x); NuPAGE® 
MOPS SDS Running Buffer; NuPAGE® LDS 
sample buffer  (4x); Negative control siRNA; 
Agarose powder; penicillin/streptomycin 
(10,000U); Nuclease free water; GIBCO ® 
PBS; Gel sample buffer (GSB); I -Block; 
Potassium dihydrogen orthophosphate; 
Dipotassium phosphate; Potassium 
hydroxide; Hydrochloric acid 
VWR UK 8 µM cell inserts; 12 well compatible tissue 
culture plates for inserts 
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2.2 Methods 
2.2.1 Preparation of glassware and solutions 
Glassware and solutions were autoclaved (if necessary) for 20-30 minutes at 121˚C 
(975kPa). 
2.2.2 Cell lines 
2.2.2.1 THP-1 
THP-1 is an established cell line commonly utilised in the study of atherosclerosis due 
to its ability to accurately mimic the physiological and biochemical properties of native 
human monocyte-derived macrophages (Auwerx 1991; Qin 2012). Due to this, THP-
1 cells are an excellent model for studying the properties of macrophages such as 
gene/protein expression and various cell signalling mechanisms. THP-1 cells are 
non-adherent monocytes which require treatment with Phorbol 12-myristate 13-
acetate (PMA) to allow differentiation into macrophages.  
2.2.2.2 RAW264.7 
RAW264.7 cell line is a mouse macrophage cell line also utilised in in vitro studies of 
the molecular basis of atherosclerosis. The cell line was initially derived from a 
BALB/14 mouse and can be transfected with high efficiency with exogenous nucleic 
acids (Hartley et al. 2008).  RAW264.7 macrophages are adherent to tissue culture 
flasks and therefore do not require differentiation with phorbol esters.  
2.2.3 Maintenance of cell lines 
THP-1 and RAW264.7 cells were grown and maintained in RPMI-1640 containing 
stable glutamine. Media was supplemented with 10 % (v/v) heat-inactivated foetal calf 
serum (HI-FCS) (56ºC for 30 minutes) along with penicillin (100 U/ml) and 
streptomycin (100 µg/ml) (pen/strep). Cells were grown at 37˚C in a humidified 
incubator containing 5% (v/v) CO2.  
2.2.3.1 Sub culturing of cells 
2.2.3.1.1 THP-1 
THP-1 cells were cultured in 75cm3 tissue culture flasks and used in experiments 
when they reached approximately 60% confluence (6 x 105 cells/ml). Cell suspension 
was transferred into a polypropylene tube (Falcon tube) and subjected to 
centrifugation at 110 x g for 5 minutes at room temperature. After removing the media, 
the pellet was resuspended in a small volume of fresh media containing 10% (v/v) HI-
FCS and pen/strep. Cells were split at a ratio of approximately 1:30 to allow growth 
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of up to 60% confluence in 7 days. For experimental use, cells between passage 1 
and 10 were used.  
2.2.3.1.2 RAW264.7 
RAW264.7 cells were cultured in tissue culture dishes and used for experiments when 
they reached about 80% confluence. Adherent RAW264.7 cells were dislodged from 
the dish surface via scrapping. The cell suspension was transferred into a Falcon tube 
and subjected to centrifugation at 110 x g for 5 minutes at room temperature. After 
suspending the pellet in fresh medium containing 10% (v/v) HI-FCS and pen/strep, 
RAW264.7 cells were split at a ratio of 1:15 to allow cells to reach requisite confluence 
in approximately 3 days.  
2.2.3.2 Freezing down cell lines 
The cells were centrifuged at 110 x g for 5 minutes at room temperature and 
resuspended in HI-FCS with 10% (v/v) DMSO. Cells (density approximately 5 x 106) 
were then transferred into 1ml cryo tubes and placed in a Nalgene™Cryo 1oC freezing 
container overnight at -80oC. Cell stocks were transferred to liquid nitrogen for long-
term storage. Only cells of passage 3 or less were frozen for stock.  
2.2.3.3 Growing up frozen cell lines 
Cell stocks from liquid nitrogen were defrosted in a 37˚C water bath. Cells were then 
transferred into 10 ml of HI-FCS and centrifuged at 110 x g for 5 minutes at room 
temperature. Cell pellet was resuspended in pre-warmed RPMI-1640 with stable 
glutamine media containing 10% (v/v) HI-FCS and 10% Pen/strep and transferred 
into a culture flask or dishes as detailed above.  
2.2.3 Counting cells 
A haemocytometer was used to count cells. After centrifugation as above, the cell 
pellet was resuspended in a small volume of media containing 10% (v/v) HI-FCS and 
pen/strep. The haemocytometer was covered with a glass cover slip and 10 µl of the 
cell suspension applied. An average of the number of cells contained within the four 
outer grids of the haemocytometer was taken. Number of cells/ml was calculated by 
multiplying the average number of cells by 104.  
2.2.4 Treatment of the cells 
2.2.4.1 THP-1 
For RNA extraction, 5 x 105 cells were split into a 12-well plate containing 1ml of 
complete RPMI media, containing 10% HI-FCS and pen/strep, per well. To allow 
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differentiation of THP-1 monocytes into adherent macrophages, the medium was 
supplemented with 0.16 µM PMA. Cells were left to differentiate for 24 hours at 37ºC 
in a humidified 5% CO2 (v/v) incubator. The media was then removed and the cells 
were washed in PBS followed by addition of 1 ml of fresh RPMI media with 10% (v/v) 
HI-FCS and pen/strep. THP-1 macrophages were next pre-treated with DGLA or 
DMSO vehicle for 24 hours followed by cytokine or vehicle (water) (concentration 
used dependent on the cytokine). RNA was then extracted as described in Section 
2.2.7.2.  For protein analysis by western blotting, 1 x 106 cells were seeded in 6 well 
plates with 2 ml RPMI media containing 10% (v/v) HI-FCS and pen/strep whereas 4 
x 106 cells were seeded in 6 well plates with 3 ml RPMI media containing 10% (v/v) 
HI-FCS and pen/strep for lipid analysis. The conditions for differentiation and 
treatment with the various agents were exactly as detailed above.  
2.2.4.2 RAW264.7 
For RNA extraction, 2 x 105 cells were split into a 12-well plate containing 2 ml of 
complete RPMI media containing 10% (v/v) HI-FCS and pen/strep. Cells were 
allowed to grow for 24 hours at 37ºC in a humidified 5% (v/v) CO2 incubator. The cell 
media was removed and the cells were washed in PBS and incubated with 2ml of 
fresh RPMI media with 10% (v/v) HI-FCS and pen/strep. Cells were pre-treated with 
DGLA or vehicle for 24 hours before cytokine stimulation (incubation with cytokine 
dependant on individual experiment).  
2.2.5 Primary human monocyte-derived macrophages (HMDM) 
Human blood buffy coats were obtained from the National Blood Service Wales. 
White blood cells were isolated using LymphoprepTM. Briefly for 25 ml of blood and 
15 ml of LymphoprepTM at room temperature was placed in 50 ml AccuspinTM tubes 
and subjected to centrifugation for 1 minute at 1000 x g to place the LymphoprepTM in 
the bottom chamber. Then, 25 ml of blood was added to the top chamber and 
centrifuged at 800 x g for 10 minutes at room temperature, without brake. The 
mononuclear layer was collected and transferred into a Falcon tube. An equal amount 
of ice-cold PBS 0.4% (w/v) tri-sodium citrate was added and centrifuged at 1000 x g 
for 5 minutes at room temperature. To lyse red blood cells, the cell pellet was 
resuspended in 10 ml of 0.2% (v/v) saline for 30 seconds on ice immediately followed 
by the addition of 10 ml of 1.6% (v/w) saline. This mixture was immediately 
centrifuged at 1000 x g for 5 minutes at room temperature. The pellet was then 
resuspended in ice-cold PBS-0.4% (v/w) tri sodium citrate and centrifuged at 800 x g 
for 5 minutes at room temperature. This step was repeated 6-10 times to ensure 
removal of platelets. The cell pellet was then resuspended in RPMI-1640 media 
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containing 10% (v/v) HI-FCS and pen/strep and seeded into 12 well plates. Each well 
was made up to 2 ml with complete RPMI containing 10% (v/v) HI-FCS and pen/strep 
media. Cells were left to differentiate for 10 days before use. Cells were washed three 
times in RMPI-1640 containing 10% (v/v) HI-FCS and pen/strep to remove any 
unattached cells/debris before subsequent experiments were carried out.  
2.2.6 Cellular assays 
2.2.6.1 Crystal violet 
THP-1 monocytes were differentiated as previously described (Section 2.2.4.1) and 
seeded in 96 well plates at a density of 140,000 cells in complete RPMI media 
containing 10% (v/v) HI-FCS and pen/strep. After incubation as required for the 
experimental conditions, the cells were washed with PBS and 250 µl of crystal violet 
solution (0.2% (w/v) in 10% ethanol) was added per well. The cells were washed three 
times in PBS followed by the addition of 250 µl of solubilisation buffer (0.1M NaH2PO4 
in 50% (w/v) ethanol). The plate was left for 5 minutes on a rocking platform at room 
temperature before determining absorbance on a Bio-Rad micro plate reader at 590 
nm. Crystal violet binds to DNA of adherent cells, those that have died or detached 
from the well remain in suspension and will be washed away. The results were 
expressed as percentage cell death in comparison to the control conditions.  
2.2.6.2 Lactate dehydrogenase (LDH) assay 
LDH is a cellular cytosolic enzyme. Damage to the plasma membrane of a cell 
releases LDH into the culture media which can then be directly measured using the 
LDH assay kit by utilising an enzymatic reaction. Extracellular LDH catalyses a 
reaction that reduces NAD+ to NADH. Diaphorase utilises NADH to reduce 
tetrazolium salt (INT) to a red product that can be measured at 490 nm. The 
concentration of cellular LDH levels is directly proportional to the amount of red 
product formed. THP-1 macrophages were cultured and subjected to the 
experimental conditions (Section 2.2.4.1). Cell lysis buffer was added to ‘positive 
control’ cells to achieve 100% cellular lysis and left to incubate at 37ºC for 45 minutes. 
A negative control was also included containing media alone for a background 
reading. For other samples, 50 µl of supernatant was transferred into a separate well 
of a 96 well plate and mixed with an equal volume of LDH assay buffer (supplied with 
the kit), left for a further 30 minutes at 37ºC and absorbance read immediately at 490 
nm on a Dynex Technology MRX Model 680 Microplate reader from BioRad. Negative 
control values were subtracted from readings and expressed as fold-change in 
comparison to the control.  
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2.2.6.3 ROS production 
Measurement of ROS production was performed as per manufacturer instructions 
(AbCAM). The kit utilises fluorogenic dye dichlorofluorescin diacetate (DCFDA) to 
measure ROS activity within the cell.  Briefly, monocytes or macrophages were 
incubated with 35 μM DCFDA which diffuses into cells and is deacetylated by cellular 
esterases to a non-fluorescent compound, later oxidised by ROS to a fluorescent 
compound 2’,7, dichlorofluorescein (DCF). A positive control supplied by the kit, tert-
butyl hydrogen peroxide (TBHP), was used to induce ROS production by monocytes 
and macrophages. Monocytes and macrophages were co- or pre-incubated with 50 
μM DGLA followed by incubation with 100 μM TBHP for 3 hours. DCF was measured 
by fluorescence spectroscopy with excitation and emission spectra of 495 nm and 
529 nm respectively. 
2.2.7 RNA/DNA techniques 
2.2.7.1 siRNA 
siRNA transfections were carried out using validated siRNAs against target mRNAs. 
The transfection was performed in THP-1 monocytes prior to differentiation. The cells 
were seeded into 12-well plates for RT-qPCR (5 x 105 cells) and into 6 well plates for 
western blotting (1 x 106) in the presence of RPMI media with 10% (v/v) HI-FCS and 
no antibiotics at 37°C in a humidified, 5% (v/v) CO2 incubator for 4 hours prior to 
transfection.  
siRNA transfection were carried out using Interferin® transfection reagent. For RT-
qPCR, a transfection mix was prepared in 100 µl of minimal RPMI media (no HI-FCS 
or pen/strep) containing 7.5 nM siRNA (of each individual siRNA used) and 9 µl 
interferin. For western blotting, 7.5 nM siRNA and 12 µl interferin were made up to 
final volume of 200 µl in minimal RPMI media (no HI-FCS or pen/strep). The complete 
mixture was added drop wise to the wells and the plates placed at 37°C in a 
humidified, 5% (v/v) CO2 incubator for 4 hours. Following incubation, the cells were 
differentiated using 0.16 μM PMA for 24 hours. The cells were then subjected to pre-
incubation with DGLA or vehicle followed by cytokine stimulation (Section 2.2.4.1) 
before being harvested for RNA extraction (Section 2.2.7.2) or protein extraction 
(Section 2.2.9).  
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Figure 2.1 – siRNA transfections 
Diagram depicts the process of siRNA transfection 
 
2.2.7.2 RNA isolation 
For extraction of RNA, two methods were used. Initially RNA was isolated using Spin 
column RNA miniprep kit (NBS Biologicals) according to the manufacturer’s 
instructions. Briefly, after aspiration of the media, 350 µl of Lysis Buffer DR (provided 
in the kit) was added to the wells and the lysates were collected. The lysate could be 
stored at -80˚C for up to 6 months or used immediately in RNA extraction. The lysate 
was passed through a series of spin columns provided in the kit to first bind genomic 
THP-1 monocytes 
(RPMI + FCS, -Pen/Strep) 
 
Transfection mix 
(siRNA + Interferin + RPMI -FCS, -Pen/strep) 
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(0.16 µM) 
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(250U/ml, 3 hours) 
 
Extraction 
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DNA, then RNA and finally to elute high quality RNA. A flow diagram detailing 
experimental procedure is detailed in Figure 2.2.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 – Spin column RNA isolation method 
Flow diagram detailing the steps involved in extraction of RNA using Spin column minikit (NBS 
biologicals)  
 
 
 
 
 
 
 
 
 
 
 
 
Cells 
Buffer lysis-DRP 
DNA binding column 
Add ethanol to flow through 
RNA binding column 
Wash RNA column 
Elute RNA 
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Due to the high costs of spin column kits, RNA was then isolated using RiboZol™ 
according to the manufacturer’s instructions (Amersco, UK). In addition to the cost, 
extraction of RNA using RiboZol™ allows for simultaneous analysis of expression of 
miRNA as well as mRNA as miRNA are lost during RNA extraction using spin 
columns. RiboZol™ is a single-phase phenol which homogenises samples after 
passing lysate through a pipette a number of times and inhibits RNase activity. 
RiboZol™ (1 ml) was added per 10cm2 of culture dish area and cells were lysed by 
pipetting. Samples were left for 10-15 minutes at room temperature to allow complete 
dissociation of nucleoprotein complexes. Then, 200 µl of chloroform per 1ml of 
RiboZol™ was added and mixed vigorously. The samples were incubated for 2-3 
minutes at room temperature and subjected to centrifugation at 12,000 x g for 15 
minutes at 4ºC. Following centrifugation, the colourless upper aqueous phase 
containing RNA was transferred into a new tube. The RNA was precipitated by adding 
0.5 ml of isopropanol per 1 ml of RiboZol™. The samples were incubated for 10 
minutes at room temperature and then centrifuged at 12,000 x g for 10 minutes at 
4ºC to pellet the RNA. The pellet was washed three times with 75% (v/v) ethanol with 
the residual ethanol evaporated at room temperature after the final wash. The RNA 
was dissolved in nuclease free water and incubated for 10 minutes at 56ºC to 
completely re-dissolve the RNA.   
The RNA concentration was measured on NanoDrop™ ND2000. The A260/A280 and 
A230/A260 ratios were used to assess RNA purity. A ratio of 1.8 – 2.1 for both was 
indicative of high quality RNA. In addition, a small aliquot was analysed by agarose 
gel electrophoresis.  
2.2.7.3 Resolving RNA  
RNA extracts were size-fractionated on a 1.5% (w/v) agarose gel as an additional 
check on the quality of RNA. Agarose gels 1.5% (w/v) were made by dissolving 
agarose in 1 x tris/borate/EDTA (TBE) buffer with the addition of 0.5 µg/ml of ethidium 
bromide for visualisation. Quality of RNA was judged as good when two distinct bands 
were observable, the band corresponding to the 28S rRNA being twice as intense as 
that for 18S rRNA. 
 
 
 
 
61 
 
2.2.8 Gene expression analysis 
2.2.8.1 cDNA synthesis (SYBR green) 
RNA (typically 1 µg or 0.5 µg if the RNA yield was low) was mixed with 200 pmol of 
random hexamer primers and nuclease-free water to make a total volume of 14 µl. 
The mixture was then incubated at 70˚C for 5 minutes followed by a 5-minute period 
on ice. The following mixture was prepared and added to the reaction to make a final 
volume of 20 µl 
- 10 mM of each dNTPs (dATP, dGTP,dTTP,dCTP); 
- 200 U M-MMLV reverse transcriptase;  
- 40 U/ml recombinant RNase inhibitor; 
- 5X reverse transcription buffer  (50 mM Tris-HCl (pH 8.3 @ 25°C), 75 mM 
KCl, 3 mM MgCl2 and 10 mM DTT) 
A –RT sample (minus reverse transcriptase) was included in reaction as a negative 
control. The final reaction mix was incubated at 37˚C for 1 hour, followed by a 
termination period at 95˚C for 5 minutes. The cDNA was diluted with nuclease-free 
water to a final volume of 100 µl (or 50 µl if 0.5 µg of RNA was originally used). The 
samples were used immediately for real time quantitative polymerase chain reaction 
(RT-qPCR) or stored at -20˚C.  
2.2.8.2 Real time quantitative (RT –qPCR) 
RT-qPCR is a method whereby the amounts of PCR products are measured with 
each passing amplification cycle. Values are recorded once a pre-set threshold, in 
the exponential phase of amplification, has been exceeded. This is opposed to end 
point quantification RT-PCR where measurement endpoints could lie out of the 
exponential phase of the PCR reaction. This means that in some cases the semi-
quantification of the starting template could be inaccurate (Ginzinger 2002). The RT-
qPCR reactions were performed with SYBR Green Taq Readymix. SYBR Green 
Jumpstart Taq ReadyMix allows for quantification of any DNA sequence by binding 
to double stranded DNA sequences (Giulietti et al. 2001). SYBR green is a dye that 
intercalates into double stranded DNA (dsDNA) and fluoresces when bound to DNA 
thereby allowing monitoring of product throughout cycling. Although any dsDNA 
molecule can be bound by SYBR green, use of specific primers and optimised 
amplification conditions can prevent any formation of primer dimers and yield maximal 
product production (Giulietti et al. 2001). This can be observed through analysis of 
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product melting curves (product formed over time) to verify amplification of a major 
single product. Gene specific primer sequences are listed in Table 2.2. To ensure no 
amplification of genomic DNA, intron spanning primers were designed.  A hot start 
mechanism via the inclusion of Jumpstart Taq in the readymix allows for PCR 
reactions to be performed at room temperature as the reaction starts at an optimum 
temperature and therefore prevention of non-specific product formation. The SYBR 
green ready mix also contains deoxyribonucleotides and reaction buffer which saves 
a significant amount of preparation time when performing large-scale experiments. 
RT-qPCR samples were prepared as 25 µl reactions in a 96-well plate. Reaction mix 
is detailed in Table 2.3.  
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Table 2.2 – Primer sequences used in RT-qPCR  
 Species Forward sequence (5’-3’) Reverse Sequence (5’-3’) 
GAPDH Human CTTTTGCGTCGCCAGCCGAG GCCCAATACGACCAAATCCGTTGACT 
MCP-1 Human CGCTCAGCCAGATGCAATCAATG ATGGTCTTGAAGATCACAGCTTCTTTGG 
MCP-1 Mouse GCTCAGCCAGATGCAGTTAACG GCTTGGTGACAAAAACTACAGCTTC 
ICAM-1 Human GACCAGAGGTTGAACCCCAC GCGCCGGAAAGCTGTAGAT 
ICAM-1 Mouse ACGTGCTGTATGGTCCTCGG GTCCAGTTATTTTGAGAGTGGTACAGTA 
β Actin Mouse ACACCCGCCACCAGTTCGCCAT CACACCCTGGTGCCTAGGGCGGCCCACGATC 
COX-1 Human CTGGTTCTTGCTGTTCCTGC ATAAGGTTGGAGCGCACTGT 
COX-2 Human TCAGACAGCAAAGCCTACCC TGTGTTTGGAGTGGGTTTCA 
SRA Human GTCCAATAGGTCCTCCGGGT CCCACCGACCAGTCGAAC 
CD36 Human AGCCATTTTAAAGATAGCTTTCC AAGCTCTGGTTCTTATTCACA 
ACAT1 Human ATACTCAGCCCTCTGCGACC TCTTATTTCCTGCACCAGCCT 
NCEH Human CCTGGTCACCTTCAGATGAAAT TTGTGGCCCGTACAACATCA 
LXR-α Human CCTTCAGAACCCACAGAGATCC ACGCTGCATAGCTCGTTCC 
LXR-β Human GCTAACAGCGGCTCAAGAACT GGAGCGTTTGTTGCACTGC 
ABCA1 Human AGTGGAAACAGTTAATGACCAG GCAGCTGACATGTTTGTCTTC 
ABCG1 Human GGTGGACGAAGAAAGGATACAAGACC ATGCCCGTCTCCCTGTATCCA 
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Table 2.3 – Reaction mix for RT-qPCR using SYBR® Green 
 
 
 
 
 
 
 
 
RT-qPCR was performed on a Roche light cycler. A typical amplification cycle 
consisted of 2 minutes pre-incubation at 94ºC followed by 40 cycles of three-step 
amplification detailed in Table 2.4, followed by melting peak analysis.  
 
Table 2.4 – RT-qPCR conditions using SYBR® Green 
 
 
 
 
 
 
 
The comparative Ct method was used to measure gene expression (Livak and 
Schmittgen 2001). The Ct value is measured when the fluorescence signal from PCR 
amplification surpasses a pre-set threshold within the amplification stage.  Relative 
expression of genes of interest were normalised to that of housekeeping genes (Livak 
and Schmittgen 2001). In order for the Ct method to yield accurate values, the 
expression of housekeeping genes must remain constant under all experimental 
Reagent Volume (µl) 
SYBR® Green 12.5 
Forward primer (100 µM) 0.5 
Reverse primer (100 µM) 0.5 
cDNA  1 
Nuclease free water 10.5 
Stage Temperature (ºC) Duration 
(seconds) 
Denaturation 95 30 
Annealing 60 60 
Primer extension 72 60 
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conditions and the efficiency of primer sets used must be comparable (Ginzinger 
2002). Glyceraldehyde 3 phosphate dehydrogenase (GAPDH) and β-actin were used 
as the house keeping genes for human and mouse RNA respectively.  Both genes 
have frequently been utilised for this role in other studies (Wu et al. 1997; Li et al. 
2010; McLaren et al. 2011b). Once the PCR reaction was completed, Ct values were 
recorded and analysed in Microsoft Excel.  
2.2.9 Western blotting 
2.2.9.1 Protein extraction 
For extraction of proteins for western blotting, cells were washed in PBS and RIPA 
buffer (Sigma) was added to the wells. The cells were detached with a cell scraper 
into the buffer and collected in Eppendorf tubes. The cells were subjected to 
centrifugation at 9,000 x g at room temperature for 5 minutes to pellet the cells. The 
supernatant was collected in a new Eppendorf tube and a small volume was removed 
for determination of protein concentration. For separation of proteins by 
polyacrylamide gel electrophoresis (PAGE), the proteins need to be denatured and 
the disulphide bonds reduced. This was achieved by adding an equal volume of gel 
sample buffer (GSB) containing sodium dodecyl sulphate (SDS). Samples were 
heated for 5 minutes at 100⁰C and placed on ice before loading onto the gels. For 
compositions of reagents used in western blotting refer to Table 2.5.  
2.2.9.2 Determining protein concentration 
Total protein concentrations were determined using Micro BCATM Protein assay Kit in 
accordance to the manufacturer’s instructions (Thermo Fisher Scientific). Briefly, a 
standard curve was prepared by setting up a series of dilutions of bovine serum 
albumin (BSA) and plated in a 96 well plate along with protein samples diluted in 
nuclease free water. The BCA cocktail (containing reagents provided in the kit) was 
prepared following the manufacturer’s instructions and 150 µl was added to 150 µl of 
samples and standards. Plate was sealed and left at 37⁰C for 30 minutes to allow 
colour to develop.  Absorbance was read at 595 nm on a Dynex Technology MRX 
Model 680 Microplate reader from BioRad. A standard curve was compiled and 
unknown protein concentrations determined from this.  
2.2.9.3 Separation of proteins 
Separation of proteins was performed in XCell Surelock® Mini-Cell on NuPAGE® 4-
12% Bis-Tris gels. These pre-cast gels allow for optimum separation of small to 
medium sized proteins in a neutral pH environment. The electrophoresis tank was 
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filled with NuPAGE® MOPS SDS Running buffer (1X).  Magic Marker was used as a 
marker to determine size of proteins on membranes. Samples were subjected to 
electrophoresis for 1 hour at 150V and 400mA. The composition of all the reagents 
used for the western blotting techniques are shown in Table 2.5. 
 
Table 2.5 – Composition of buffers used in western blotting 
 
2.2.9.4 Blotting  
Following electrophoresis, the gel was removed from its casing and the proteins were 
transferred onto an Immobilon™ transfer membrane using XCell Surelock® Mini-Cell 
via XCell II™ Blot Module. Assembly of the transfer unit was performed in 
NuPAGE®Transfer buffer which was later used to “top up” the inner chamber. 
Assembly of transfer is detailed in Figure 2.3.  NuPAGE®gel was placed adjacent to 
membrane (after activation in 100% methanol for 1 minute at room temperature) 
between Whatman paper and sponge pads soaked in transfer buffer. Transfer was 
performed at 30V and 300mA for 2 hours.  
Reagent Composition 
RIPA buffer 150 mM NaCl, 1% (v/v) IGEPAL® CA-630, 0.5% 
(v/v) sodium deoxycholate, 0.1% (w/v) SDS, 50 mM 
Tris pH 8.0 
GSB 63 mM Tris HCl pH 6.8, 10% (v/v) glycerol, 5% (v/v) 
β mercaptoethanol, 2% (w/v) SDS, 0.0025% (w/v) 
bromophenol blue 
NuPAGE® MOPS SDS 
Running buffer 
50 mM MOPS, 50 mM Tris Base, 0.1% (w/v) SDS, 1 
mM EDTA, pH 7.7 
NuPAGE®Transfer buffer 500 mM Bicine, 500 mM Bis-Tris, 20.5 mM EDTA 
PBS Tween 1L ddH20, 10 PBS Tablets, 2 ml Tween20 
IBT blocking solution 0.5% (w/v) I BLOCK in PBS Tween 
Ponceau S 0.1% (w/v) Ponceau S, 5% (v/v) acetic acid, ddH20 
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Figure 2.3 – Configuration of transfer module 
Transfer membrane and gel were enclosed between Whatman papers. Sponge pads were 
used to package the remaining space in the module to ensure membrane and gel remained 
in constant contact throughout the transfer process.  
 
2.2.9.5 Immunodetection of proteins 
After the transfer process was complete, proteins could be visualised on the 
membrane by staining with Ponceau S to ensure they had successfully transferred 
onto the membrane. Following visualisation with Ponceau S, the membrane was 
washed in PBS-tween until all the stain had been removed. Membrane was then 
“blocked” in IBT solution for 1 hour at room temperature with constant shaking, to 
prevent any non-specific interactions with antibodies. Following this, the membrane 
was treated with a primary antibody for 1 hour at room temperature or overnight at 
40C (refer to Table 2.6 for antibody dilutions and incubation conditions). After 
incubation with a primary antibody, the membrane was washed three times in PBS-
Tween at room temperature with constant shaking. The membrane was next treated 
with a corresponding alkaline phosphate (AP)-conjugated secondary antibody diluted 
in IBT solution for 1 hour at room temperature, with constant shaking. The membrane 
was washed again as above and incubated for 30 minutes with Tropix®CDP Star®. 
Following this, the membrane was secured into a lightproof cassette (Kodak). 
Membranes were exposed to chemiluminescent X-ray films. A number of time points 
for exposure of membrane to X-ray film were taken to allow optimum exposure to be 
achieved. Exposure time varied between 5 minutes to overnight.  
 
 
Blot module: 
Blot module: 
Membrane Sponge pads 
Card Gel 
+ -
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Table 2.6 – Antibodies and conditions used in western blot analysis 
Primary 
antibody 
Dilution 
in IBT 
Incubation 
time (hours) 
Secondary 
antibody 
Dilution 
in IBT 
Size 
(kDa) 
Total STAT1 1/1000 1 hour Rabbit 1:5000 91 
Phospho STAT1 
Ser727 
1/1000 Overnight Rabbit 1:5000 91 
Phospho STAT1 
Tyr701 
1/1000 Overnight Rabbit 1:5000 91 
β-actin 1/5000 1 hour Mouse 1:10,000 42 
COX-1 1:500 Overnight Goat 1:2000 72 
COX-2 1:250 Overnight Goat 1:2000 70-72 
SRA 1:1000 Overnight Rabbit 1:5000 75 
CD36 1:250 Overnight Rabbit 1:3000 88 
ABCA1 1:1000 Overnight Rabbit 1:5000 220 
ABCG1 1:2000 Overnight Goat 1:5000 110 
ApoE 1:2000 Overnight Goat 1:5000 38 
 
2.2.10 Inflammasome activation 
2.2.10.1 Cholesterol crystals 
Cholesterol was dissolved in 95% (v/v) ethanol (12.5 g/L) and heated to 60ºC. 
Solution was filtered through Whatman paper to remove any undissolved cholesterol 
and left at room temperature overnight to allow for crystallisation. Crystals were 
collected and autoclaved. Crystals were ground with a dounce homogenizer to unify 
crystal size and stored at -20ºC for use in experiments.  
2.2.10.2 Enzyme linked immunosorbent assay (ELISA) 
An ELISA was used to determine the concentration of IL-1β expressed on stimulation 
of macrophages with cholesterol crystals to activate the inflammasome. THP-1 
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macrophages were cultured in 24 well plates at a density of 1.5 x 105 cells per well in 
RMPI media containing 0.2% (w/v) fatty acid free BSA. Following differentiation, 
macrophages were pre-treated with 50 µM DGLA for 24 hours followed by 1.0 mg/ml 
cholesterol crystals. Media was removed into Eppendorf tubes and subjected to 
centrifugation at 9,000 x g for 5 minutes to remove any cholesterol crystals in 
suspension. Supernatant was then measured for concentration of IL-1β by ELISA 
following manufacturer’s instructions (R&D systems). Briefly, ELISA plates were 
coated with 4.0 µg/ml human IL-1β capture antibody by overnight incubation. Plates 
were washed 3 times with wash buffer (provided in kit) and incubated with reagent 
diluent (provided in kit) for 2 hours. Washing of plates was repeated. Samples were 
diluted in reagent diluent and standards were made up in concentrations ranging from 
0 to 250 pg/ml with IL-1β standards. Samples and standards were added to plates 
and left for 2 hours. Washing of plates was repeated. IL-1β biotinylated antibody (200 
ng/ml) was then added to plates for two hours followed by another wash as above. 
Streptavidin-HRP was incubated on plates for 20 minutes, washed and substrate 
solution (provided in kit) was added for a further 20 minutes. Finally Stop solution 
(provided in kit) was added and optical density of plates was measured on a 
microplate reader at 450 nm with correction at 540 nm.  A standard curve was 
compiled and unknown IL-1β concentrations determined from this.  
2.2.11 Migration assay 
Migration was performed using a cell insert with 8 µm pore size placed within a 12 
well companion plate (modified Boyden chamber). THP-1 monocytes (5x105 cells) 
were suspended in RMPI media supplemented with 10% (v/v) FCS, pen/strep and 
DGLA or vehicle control and placed on top of the cell culture insert. In the bottom 
chamber, 0.5 ml of RMPI media supplemented with 10% (v/v) FCS, pen/strep, DGLA 
or vehicle control and MCP-1 (20 ng/ml) or vehicle control (refer to Figure 2.4 for 
experimental set up). Incubation of the modified Boyden chamber was then carried 
out at 37ºC for 3 hours. The remaining cell suspension on the top of the membrane 
was removed and discarded, and the underside of the membrane was washed with 
PBS to ensure all migrated cells were washed into the media underneath. The 
remaining media was transferred into Falcon tubes and subjected to centrifugation at 
110 x g for 5 minutes at room temperature to pellet the cells. The cell pellet was 
resuspended in 1ml PBS and cells were counted using a haemocytometer. Results 
were expressed as percentage migration in relation to total input cells. 
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Figure 2.4 – Experimental set up for migration assays 
Cell insert with 8 µm pores were used to mimic endothelial layer of arteries. Monocytes were 
placed in the top chamber and MCP-1 was used as a chemoattractant to stimulate migration.  
 
2.2.12 FACS analysis 
2.2.12.1 Macropinocytosis 
THP-1 macrophages were pre-incubated with 50 μM DGLA for 24 hours followed by 
100 µg/ml Lucifer yellow (LY) in RPMI medium supplemented with 0.2% (v/v) fatty 
acid free BSA. Overlying media was discarded and cells removed by treatment with 
0.05% (v/v) trypsin. Cells were collected in Eppendorphs and subjected to 
centrifugation at 9,000 x g for 5 minutes to pellet the cells. The supernatant was 
removed and the pellet was resuspended in 2% paraformaldehyde (PFA). LY 
incorporation was analysed by flow cytometry on a BD FACS Canto flow cytometer. 
At least 10,000 events were counted for each sample.  
2.2.12.2 Dil-oxLDL uptake 
THP-1 macrophages were pre-incubated with 50 μM DGLA for 24 hours followed by 
5 μg/ml Dil-oxLDL in RPMI medium supplemented with 0.2% (v/v) fatty acid free BSA. 
Overlying media was discarded and cells removed by treatment with 0.05% (v/v) 
trypsin. Cells were collected in Eppendorphs and subjected to centrifugation at 9,000 
x g for 5 minutes to pellet the cells. The supernatant was removed and the pellet was 
resuspended in 2% PFA. Dil-oxLDL uptake was analysed by flow cytometry on a BD 
FACS Canto flow cytometer. At least 10,000 events were counted for each sample.  
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2.2.13 Extraction of lipids from algal powder 
Freeze-dried powder of a green algae P. incisa was obtained from Ben-Gurion 
University (Israel) and lipids containing up to 30% of DGLA were extracted according 
to Iskandarov (2011), with minor modifications. 50 mg of biomass was weighed and 
mixed with 0.2 ml 100% (v/v) DMSO by vortexing followed by incubation for 10 
minutes at 80ºC. Methanol (6 ml) was then added, flushed with nitrogen and the 
incubation continued for 1 hour at 4ºC with continuous vortexing. The samples were 
centrifuged at 500 x g for 5 minutes and methanol fraction containing polar lipids was 
collected. The solvent was evaporated and lipids stored in glass vials at -20ºC.  
Extraction of non-polar lipids from the remaining pellet was performed by adding 0.2 
ml DMSO followed by 12 ml 100% (v/v) hexane: diethyl ether (1:1, v/v). Phase 
separation was achieved via adding 6 ml of dH2O and lipid-containing layer was 
collected. HCl (0.2M) was added until pH 3 was achieved and re-extraction was 
carried out once again using hexane: diethyl ether (1:1, v/v). Solvents were 
evaporated under a steam of nitrogen; lipids were combined, resuspended into known 
volumes of chloroform and stored at -20ºC prior to further analysis.  
2.2.13.1. Hydrolysis of algal total lipids 
Aliquots of total lipid extracts were taken for hydrolyses of algal lipids in order to 
cleave fatty acids (including about 30% DGLA) from the complex lipids. This was 
necessary for comparison of the effects of pure DGLA and DGLA-enriched fatty acid 
mixture from algae on macrophages.  The lipid extract was refluxed with 1M solution 
of KOH in 95% ethanol (5 ml) for 1 hour. After cooling, water (7 ml) was added, the 
aqueous layer was acidified with 6M HCl and extracted with hexane: diethyl ether 
(1:1, v/v; 2 x 5 ml). The solvent was evaporated under a stream of nitrogen and 
NEFAs were re-dissolved in DMSO for the further use in the cell treatment 
experiments.  
2.2.14 Animal feeding 
In vivo studies were employed to investigate the use of lipids extracted from P. incisa 
as a viable source of DGLA supplement for rodents. Since our preliminary 
experiment, when freeze-dried form of algae was used, did not show any detectable 
DGLA in mouse plasma, lipids extracted from the powder as detailed in Section 2.2.13 
were employed. Twelve week old male C57BL/6 mice were starved for 24 hours prior 
to being given either chow control diet or a diet containing lipids extracted from the 
algal powder (this diet had 4.4% (w/v) DGLA as the final relative concentration), for 
48 hours. Mice were sacrificed using schedule 1 procedures and samples of plasma 
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together with liver, kidney and adipose tissue were taken for lipid analysis. Lipids were 
extracted and analysed as in Section 2.2.15.  
2.2.15 Lipid analysis 
2.2.15.1 Lipid extraction from macrophages and plasma  
THP-1 cells (4 x 106 per well) were cultured as previously described (Section 2.2.4.1) 
in 6 well plates. Following experimental treatment, media was aspirated and the cells 
were washed and scraped from the wells using PBS. The cell suspension was 
transferred into plastic Eppendorf tubes and subjected to centrifugation at 9000 x g 
for 5 minutes to pellet the cells. The supernatant was removed, the pellet 
resuspended in 1ml of distilled water and transferred into a glass tube. Next, 2 ml of 
chloroform: methanol (2:1, v/v) solution was added to glass tube, vortexed and 
incubated for 15 minutes at room temperature. Then, 1ml  of chloroform and 2 ml of 
Garbus solution (2M KCl in 0.5M potassium phosphate buffer pH 7.6) (Garbus et al. 
1963) was added, vortexed and centrifuged at 220 x g for 3 minutes at room 
temperature to allow separation of the chloroform and the aqueous layers. The 
chloroform layer was removed into clean glass conical tube with a glass pipette, 
evaporated under nitrogen and reconstituted in 50 µl of chloroform.  
2.2.15.2 Lipid extraction from plasma 
After sacrifice of the animals using schedule 1 procedures, blood was collected from 
mice and centrifuged at 9,000 x g for 5 minutes at room temperature. Plasma fraction 
was removed into a clean glass tube and 2 ml of chloroform: methanol (2:1, v/v) 
solution was added. Lipids were extracted in an identical way to that previously 
described in Section 2.2.15.1.  
2.2.15.3 Lipid extraction from mouse tissue 
Samples of liver, adipose tissue and kidney were taken from mice for lipid and fatty 
acid analysis. Tissues were ground with a pestle and mortar in chloroform: methanol 
(2:1, v/v). Homogenised tissue was passed through glass wool to filter into a glass 
tube and a further 2 ml of chloroform: methanol (2:1, v/v) was added. Again, lipids 
were extracted in an identical way to that previously described in Section 2.2.15.1.  
2.2.15.4 Thin layer chromatography (TLC) 
To separate individual lipid classes, TLC was performed on 10 x 10 cm silica gel G 
Merck plates using different types of separation. One-dimensional separation was 
performed using hexane: diethyl ether; acetic acid (80:20:1, v/v/v). This allowed 
separation of the following lipid classes: TPL, TAG, FFA, free cholesterol and 
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cholesteryl esters. Polar lipids with PC and PE as two major classes were separated 
using boric acid impregnated plates (0.2% boric acid in water: ethanol (1:2, v/v)).  
Chloroform: methanol: ammonium hydroxide (65:25:4, v/v/v) was used as a solvent 
mixture for the 1st dimension and n-butanol: acetic acid: water (90:20:20, v/v/v) for the 
2nd dimension. After drying, the plates were sprayed with a 0.05% solution of 8-
anilino-4-naphthosulphonic acid (ANSA) in methanol which allows for visualisation of 
lipids under UV light. The position of the separated lipid fractions were identified and 
marked on the plate. Identification was made routinely by reference to authentic 
standards and confirmed using specific colour reagents (Kates 1986). The silica gel 
covering the plates contained within identified area was scraped. The separated 
spots/bands were used for further fatty acid analysis as described in the following 
Section.  
2.2.15.5 Fatty acid analysis 
Aliquots of the total lipid extracts and hydrolysed lipids from algae as well as individual 
lipid classes separated by TLC were used for fatty acid methyl esters (FAMEs) 
preparation. FAMEs were prepared using a solution of 2.5% H2SO4 in dry methanol: 
toluene (2:1, v/v). A known amount of an internal standard, heptadecanoic acid 
(C17:0), was added to each sample for fatty acid and lipid quantification.  Samples 
were heated to 700C for 2 hours, with occasional vortexing. FAMEs were then 
extracted by addition of 2 ml of 5% NaCl followed by 2 additions of 3 ml of hexane 
(HPLC grade). The hexane fractions were transferred into clean glass tubes, 
evaporated under a stream of nitrogen and reconstituted in 50 µl of hexane.  
2.2.15.6 Gas chromatography (GC) 
FAMEs for each individual lipid fraction were analysed using a Clarus 500 GC with a 
flame ionisation detector (Perkin-Elmer, Norwalk, Connecticut) and equipped with 
30m by 0.25mm id capillary column (Elite 225, Perkin-Elmer, Waltham, MA, USA). 
Samples were heated to 170oC for 3 minutes, heated to 220oC (at a rate of 4oC per 
minute) and held for 30 minutes. FAMEs were identified by comparison with retention 
times of known standards.  
2.2.15.7 Preparation of samples for HPLC-MS 
Hexane: isopropanol: 1M acetic acid (30:20:2) (v/v/v) was added to media collected 
from 4 x 106 cells in a ratio of 2.5 ml of solvent mixture to 1 ml of media. An internal 
standard containing 10 ng dimethylphosphinoethane (DMPE) and 5 ng of PGE2d4, 
5ng of 15-HETEd8 and d4-PGE1 was also included. Samples were thoroughly mixed 
by vortexing and 2.5 ml hexane was added followed by further vortexing. Samples 
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were subjected to centrifugation (900 x g for 5 minutes at room temperature) and the 
upper hexane layer transferred into a new glass tube. The hexane extraction was 
repeated as above. Samples were then evaporated under a stream of nitrogen and 
reconstituted in 200 µl of 100% HPLC grade methanol. Lipid extracts were separated 
on a Spherisorb C18 ODS2, 5 μM, 150 mm x 4.6 mm column (Waters Ltd) using a 
gradient of 50 – 90% mobile phase B (A: water: acetonitrile: acetic acid, 75:25:0.1 
(v/v/v), B: methanol; acetonitrile; acetic acid, 60:40:0.1 (v/v/v/)) over 20 minutes with 
a flow rate of 1 ml/min.  Products were quantified by LC-MS/MS electrospray 
ionisation on a Q-Trap (Applied Biosystems 4000 Q-Trap) with specific multiple 
reaction monitoring (MRM) transitions [M-H-] monitored as parent fragmenting to 
daughter with collisions energies of -20 to -28V. 
2.2.16 Cholesterol uptake and efflux assays 
2.2.16.1 Cholesterol uptake assay 
RAW264.7 macrophages were cultured in 6 well plates at a density of 2 x 106 per well 
in RPMI supplemented with 0.2% (v/v) fatty acid free BSA. Macrophages were pre-
treated with 100 µM DGLA or vehicle for 24 hours and then incubated in the absence 
or the presence of 50 µg/ml AcLDL and 1µCi [14C] acetate for a further 24 hours. The 
cells were scraped from the wells and collected in Eppendorf tubes. The cells were 
pelleted by centrifugation at 9,000 x g and resuspended in 1ml dH20. A sample was 
removed for protein analysis as previous described in Section 2.2.9.2. Lipids were 
extracted and separated as previously described in 2.2.15.1 and 2.2.15.4.  
2.2.16.2 Cholesterol efflux assay 
THP-1 macrophages were cultured in 12 well plates at a density of 5 x 105 per well in 
RPMI supplemented with 0.2% (v/v) fatty acid free BSA. Following differentiation, 
macrophages were pre-incubated with 50 µM DGLA or vehicle for 24 hours. Next, 
media was replaced with RPMI supplemented with 0.2% (v/v) fatty acid free BSA, 25 
µg acLDL and 0.5 µCi/ml [4-14C] cholesterol. After 24 hours cells were washed and 
media replaced with medium containing 10 µg/ml ApoA1 for a further 24 hours. The 
media fraction was removed into glass test tubes for use in scintillation counting. The 
remaining cells were treated with 0.2% NaOH to solubilise cells and again removed 
into glass tubes for use in scintillation counting (Section 2.2.16.3).  
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2.2.16.3 Preparation of samples for scintillation counting 
Samples collected for analysis were placed into 20 ml polyethylene vials with 10 ml 
OPTI-FLUOR®. Samples were counted on a Liquid scintillation analyser (TriCarb 
2800TR, Perkin Elmer) and recorded using Quanta Smart. Disintegrations per minute 
(dpm) were measured and transferred into Microsoft Excel for analysis.  
2.2.17 Statistical analysis 
Data was tested for normality using the Shapiro-Wilko test and data represented as 
mean +/- standard deviation. A two-tailed Student’s t-test was carried out using a 
spreadsheet package for single comparisons. For multiple comparisons with equal 
variances between groups, ANOVA was carried out in SPSS followed by Tukey’s post 
hoc analysis. For multiple comparisons with unequal variances, Welch’s test for 
equality of means was used followed by Games Howell/Dunnett’s T3 Post Hoc 
analysis in SPSS. P-value of <0.05 was considered significant.  
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CHAPTER 3 
UPTAKE AND METABOLISM OF DGLA IN IN VITRO AND IN 
VIVO MODELS  
3.1 Introduction 
3.1.1 PUFA uptake  
Fatty acids (or their metabolites) are important signalling molecules and are 
components of glycerophospholipids of membranes and TAG stores. The fatty acid 
compositions of phospholipids play important roles and can influence a number or 
processes in  different ways (Raphael and Sordillo 2013). For example, fluidity of 
membranes and lipid raft formation are influenced by fatty acids and can modify 
membrane induced signalling (Raphael and Sordillo 2013). In addition, when cleaved, 
NEFAs can directly, or indirectly through their metabolites, trigger a signalling 
cascade. Fatty acid signalling has been shown to play an important role in an 
inflammatory response (Foitzik et al. 2002; Simopoulos 2008; Jung et al. 2012; Enos 
et al. 2013; Yan et al. 2013; Williams-Bey et al. 2014). They have numerous roles, 
some pro-inflammatory while others produce anti-inflammatory actions. Table 1.5 
summarises the roles of fatty acids in relation to CVD. Classically, SFA have been 
linked to an increased risk of CVD while PUFA are inversely associated with the 
disease. The composition of fatty acids in lipid pools is therefore very important as to 
the effect on inflammation. Dietary supplementation with omega-3 and omega-6 
PUFAs increases their incorporation into lipid fractions resulting in an increase in their 
signalling responses and metabolite production (Chilton et al. 1993; Johnson et al. 
1997).  
Dietary omega-3 PUFAs have been used in numerous studies to determine uptake in 
vivo and in vitro. Supplementation with EPA rapidly induces incorporation into the 
phospholipid and TAG fractions of human neutrophils after 2 and 6 days respectively 
(Chilton et al. 1993). The omega-3 fatty acids EPA and DHA significantly increase 
their incorporation into lipid fractions of human serum following supplementation 
(Grimsgaard et al. 1997). The beneficial effects of supplementation on inflammation 
and CVD with EPA and DHA have been widely reported (Foitzik et al. 2002; Kris-
Etherton et al. 2003; Suresh and Das 2003a; Lundstrom et al. 2013; Yan et al. 2013; 
Williams-Bey et al. 2014). However, as a result of the increase in omega-3 fatty acids 
following supplementation, there is a decrease in levels of omega-6 incorporation into 
 
 
77 
 
lipid fractions. EPA and DHA reduced the concentration of DGLA and AA in serum 
phospholipids following supplementation in humans (Grimsgaard et al. 1997; Haglund 
et al. 1998; Mori et al. 2000). In addition to this, omega-3 fatty acids have been shown 
to decrease eicosanoid produced by metabolism of DGLA (Rubin and Laposata 
1992). Omega-6 fatty acids play important roles in inflammation and have been 
shown to be beneficial in a number of diseases (Kapoor and Huang 2006; Kawashima 
et al. 2008; Takai et al. 2009; Machado et al. 2013). Patients with atopic eczema have 
a reduced concentration of plasma omega-6 fatty acids GLA, DGLA and AA 
suggesting a role for these PUFA in the disease (Morse et al. 1989). Reducing the 
concentration of omega-6 fatty acids in lipid pools on supplementation with omega-3 
fatty acids may therefore have an adverse effect in inflammatory disease states.  
Oils rich in the omega-6 fatty acid GLA, such as primrose and borage oil, have been 
used to treat a number of inflammatory diseases. Supplementation with GLA in 
combination with EPA and DHA, significantly reduced LDL cholesterol levels, TAG 
levels and ratio of LDL: HDL cholesterol. This was not observed by EPA and DHA 
supplementation alone (Laidlaw and Holub 2003). GLA in the form of evening 
primrose oil has also been shown to significantly reduce the symptoms of atopic 
eczema including itching, inflammation and dryness (Wright and Burton 1982; Morse 
et al. 1989). Levels of DGLA and AA in plasma phospholipids were associated with 
an increased improvement of symptoms (Morse et al. 1989). Borage seed oil 
containing GLA improved signs of rheumatoid arthritis in patients diagnosed with the 
disease (Leventhal et al. 1993). Supplementation significantly reduced the number of 
swollen and tender joints on comparison to placebo control (Leventhal et al. 1993). 
GLA has also been used to target atherosclerosis. High fat diet induced 
atherosclerosis in rats was attenuated on supplementation with GLA (Shi et al. 2008). 
Also, in ApoE-/- mice, GLA attenuated SMC proliferation and the development of diet-
induced atherosclerosis (Fan et al. 2001).  
Despite these positive results, a number of studies have reported that GLA 
supplementation in atopic eczema failed to significantly improve symptoms of the 
disease (Henz et al. 1999; Takwale et al. 2003). Borage oil containing 23% GLA, a 
higher dose than previous studies, did not significantly improve symptoms of atopic 
eczema despite several clinical improvements (Henz et al. 1999). Additionally, borage 
oil supplementation in adults and children failed to improve atopic eczema, with the 
placebo control showing a larger improvement on symptoms (Takwale et al. 2003).  
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The physiological effects of GLA are thought to be attributed to its metabolites DGLA 
and PGE1 (Umeda-Sawada et al. 2006). GLA is a precursor of DGLA. Numerous 
studies have previously used supplementation with GLA to increase plasma and 
tissue levels of DGLA, due to the lack of a commercial source of this PUFA.  A few 
studies were performed in the 90’s using DGLA in the form of ethyl esters to feed rats 
and rabbits (Smith et al. 1989; Taki et al. 1993).  More recently, as new sources were 
developed, studies investigated the supplementation of DGLA isolated from mutants 
of algae, yeast and fungus and demonstrated a more efficient accumulation 
compared to GLA supplementation (Dooper et al. 2003; Miles et al. 2004; Umeda-
Sawada et al. 2006). For example, rats supplemented with a DGLA diet incorporated 
more of this PUFA into plasma and tissue lipid fractions, in comparison to GLA 
(Umeda-Sawada et al. 2006). DGLA incorporation into the liver, serum and brain 
lipids of rats was significantly higher in the DGLA oil diet compared to the GLA oil diet 
(Umeda-Sawada et al. 2006). Treatment with DGLA resulted in a significant increase 
(>5%) in fatty acid uptake into phospholipids of peripheral blood mononuclear cell 
(PBMCs), whereas treatment with GLA induced an increase of less than 3%, due to 
the restrictions in elongation products (Dooper et al. 2003).  Finally, supplementation 
with GLA in humans failed to significantly accumulate DGLA in lipid fractions of serum 
(Miles et al. 2004). Direct supplementation with DGLA is therefore more efficient at 
increasing the levels of this fatty acid in lipid fractions. 
3.1.2 DGLA in disease 
Fatty acids have both beneficial and potentially harmful effects in CVD and 
atherosclerosis. The roles of fatty acids in relation to atherosclerosis are detailed in 
Table 1.5 in the Introduction. In general SFA, fatty acids with no double bonds, 
increase cholesterol levels and promote pro-inflammatory conditions (Xu et al. 2006).  
MUFA and PUFA tend to have advantageous actions in relation to CVD and 
atherosclerosis by lowering cholesterol levels and exerting anti-inflammatory actions 
(Kris-Etherton et al. 2003; Takai et al. 2009). There are however exceptions to this 
generalisation, as shown in Table 1.5. For example, stearic acid (a SFA) lowers LDL 
cholesterol levels in vivo (Hunter et al. 2010), while AA (omega-6 PUFA) has 
numerous pro-inflammatory roles (Levin et al. 2002; Gomolka et al. 2011). DGLA is 
an omega-6 fatty acid but with numerous beneficial properties in CVD and other 
inflammatory diseases. The role of DGLA in disease is detailed in Table 3.1. 
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Table 3.1 – Role of DGLA in disease 
Role  Reference 
DGLA inhibits LBT4 production from rat macrophages. (Nakamura et al. 1993) 
Inhibition of human platelet aggregation and mitogen release from HMDMs with DGLA. (Smith et al. 1989) 
Hypertension induced by a saturated fat high diet in rats, was reversed by supplementation 
with DGLA. 
(Hassall and Kirtland 1984) 
Intravenous injection of DGLA into mice suppressed delayed type hypersensitivity, measured 
by swelling. 
(Taki et al. 1993) 
DGLA supplementation in NC/Tnd mice showed a significant accumulation of DGLA in the skin, 
which inhibited severity of atopic dermatitis 
(Amagai et al. 2015). 
 
DGLA exhibited cytotoxic action in drug-sensitive and resistant cancer cells in a free radical-
dependent process. Increased drug sensitivity in resistant cells increasing the drugs cytotoxic 
action.  
(Das and Madhavi 2011) 
Supplementation in humans reduced platelet aggregation. (Kernoff et al. 1977) 
Inhibited atherosclerosis in ApoE-/- mouse model. Reduced inflammatory markers. (Takai et al. 2009) 
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3.1.3 Eicosanoid production and role in disease 
Alteration in the dietary intake of fatty acids leads to changes in eicosanoid 
production. Eicosanoid production is dependent on the availability of fatty acid 
substrates from a lipid pool or cleaved from phospholipids (Wang et al. 2012). As 
discussed in Section 1.5.2.6, eicosanoids are produced from 20C fatty acids EPA, 
DGLA and AA and play an important role in inflammation and atherosclerosis (see 
Table 3.2 for the roles of eicosanoids produced from omega-6 PUFAs, DGLA and 
AA). The action of COX and LOX enzymes on DGLA and AA produce a wide variety 
of prostaglandins, lipoxins, leukotrienes, thromboxanes and hydroxy-eicosanoids.  
In Western countries AA is usually the most abundant 20C fatty acid present in the 
phospholipid membranes of immune cells. Eicosanoids derived from AA metabolism 
are therefore primarily produced in abundance during inflammation (Chapkin et al. 
1988; Dooper et al. 2003). Eicosanoid production from AA has various pro-
inflammatory roles. A number of prostanoids are produced from COX action on AA. 
These include members of the PG family (such as PGE2) and thromboxanes 
(Kobayashi et al. 2004) both with pro-inflammatory roles. AA is converted to 
leukotrienes by 5-LOX with further transformation into unstable LTA4 (Samuelsson et 
al. 1987). This can be converted to LTB4 by hydration and LTC4 by addition of 
glutathione. LTC4 can be further metabolised to LTD4 and LTE4 (Samuelsson et al. 
1987). Leukotrienes are potent pro-inflammatory mediators and can regulate a 
number of immune processes such as leukocyte cytokine production, differentiation 
and migration (Neels 2013). 
A number of AA metabolites however also possess anti-inflammatory properties. 
Lipoxins act to resolve inflammation. Lipoxins are formed by the action of a number 
of enzymes (5- and 15-LOX) both involving the insertion of molecular oxygen into AA 
(Samuelsson et al. 1987; Fierro and Serhan 2001). Metabolite 15-HETE can serve 
as a substrate for formation of lipoxin A4 (LXA4) and LXB4 (Fierro and Serhan 2001). 
Conversely, 5-LOX action on AA forming LTA4 followed by 12-LOX, can also lead to 
synthesis of LXA4 and LXB4. Therefore LTA4 can be converted to both pro-
inflammatory LTs and anti-inflammatory lipoxins (Fierro and Serhan 2001). The 
balance between LT and lipoxin formation may play an important role in the 
inflammatory potential of AA (Fierro and Serhan 2001). Finally, the COX metabolite 
prostacyclin has been indicated to play an anti-inflammatory role in atherosclerosis 
(Kobayashi et al. 2004).  Despite this, it is generally accepted that accumulation of 
AA and its metabolites contribute to an inflammatory response.  
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EPA and DGLA are both 20C fatty acids and compete with AA for incorporation into 
phospholipids (Dooper et al. 2003). This change in fatty acid composition of 
phospholipids can alter eicosanoid production which plays an important role in 
modifying the inflammatory response. Eicosanoid production from DGLA yields a 
number of anti-inflammatory mediators. The action of COX on DGLA produces 1-
series PGs. These include PGE1 and PGD1, which have both been demonstrated to 
play an anti-inflammatory role in a number of diseases (Table 3.2). In addition, the 
action of 15-LOX on DGLA produces 15-HETrE, a potent inhibitor of AA-derived pro-
inflammatory LTB4 metabolism (Iversen et al. 1992).   
As AA can be synthesised from DGLA in the omega-6 pathway through the action of 
a delta-5 desaturase, it is important to measure eicosanoid production in THP-1 
macrophages on treatment with DGLA not only to determine if DGLA products are 
accumulated, but to determine if AA metabolites were affected simultaneously. 
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Table 3.2 – Roles of selective COX and LOX metabolites from DGLA or AA  
Name Abbreviation LOX/COX Role 
5-hydroxyeicosatetraenoic acid 5-HETE 5-LOX from 
AA 
Neutrophil activator, vasoconstrictor, gives rise to 5-oxy-ETE 
which acts as a chemoattractant (Poeckel and Funk 2010). 
11-hydroxyeicosatetraenoic acid 11-HETE 11-LOX 
from AA 
Expressed in atherosclerotic lesions (Waddington et al. 2001).  
12-hydroxyeicosatetraenoic acid 12-HETE 12-LOX 
from AA 
Associated with insulin resistance and obesity   
Increased ICAM-1 expression and atherogenesis (Funk 2006; 
Kuehn and O'Donnell 2006). 
15-hydroxyeicosatetraenoic acid 15HETE 15-LOX 
from AA 
15 LOX products involved in oxidation of LDL (Funk 2006)  
Precursor for lipoxins (Samuelsson et al. 1987; Fierro and 
Serhan 2001). 
Prostaglandin E2 PGE2 COX from 
AA 
Key role in pathogenesis of atherosclerosis. Lack of PGE2 in 
LDLR knockout mice show significant plaque reduction (Suzuki 
et al. 2011). Increased levels linked to atopic dermatitis in mice 
(Amagai et al. 2015). 
Leukotriene B4 LTB4 5-LOX from 
AA 
Potent chemoattractant for monocytes, increases expression of 
MCP-1(Subbarao et al. 2004; Neels 2013).  
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Promotes conversion of monocytes to foam cells by increasing 
expression of CD36 (Subbarao et al. 2004).  
Thromboxane A2 TXA2  Vasoconstrictor and platelet aggregating agent (Kobayashi et 
al. 2004).  
Knockdown of TXA2 receptor in ApoE-/- mice exhibit a 
significant delay in atherosclerosis (Kobayashi et al. 2004). 
Lipoxin A4 LXA4 5,15-LOX 
from AA 
Evidence suggests a role in resolving inflammation. Block 
growth factor-stimulated SMC migration (Ho et al. 2010). 
Inhibited TNF-α simulated neutrophil adherence to endothelial 
monolayers and release of IL-8 and MCP-1 (Goh et al. 2001). 
Vasodilator (Fierro and Serhan 2001). 
Prostacyclin PGI2  Platelet inhibitor and vasodilator (Kobayashi et al. 2004). 
Knockdown of prostacyclin receptor in ApoE-/- mice show 
significant acceleration of atherosclerosis. Mice displayed 
increased expression of ICAM-1 and an increased number of 
leukocytes rolling along vessel wall (Kobayashi et al. 2004).  
Prostaglandin E1 PGE1 COX from 
DGLA 
Lowers blood pressure, inhibits platelet aggregation, promotes 
cholesterol efflux from cells and inhibits cholesterol 
biosynthesis (Horrobin 1991).  
Inhibits arthritis in rats (Zurier and Ballas 1973).  
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Anti-proliferation activities in cancer cell lines (Tabolacci et al. 
2010). 
PGE1 is protective against anaemia, clinical nephritis and death 
in mouse models of autoimmune disease lupus (Zurier et al. 
1977). 
PGE1 injected into rats completely supressed arthritis and 
cartilage destruction (Zurier and Ballas 1973). 
Prostaglandin D1 PGD1 COX from 
DGLA 
Prevents the development of atopic dermatitis in AC/Tnd mice 
(Amagai et al. 2015). 
15-hydroxyeicosatrienoic acid 15-HETrE 15-LOX 
from DGLA 
Inhibits 5-LOX and 12-LOX (Horrobin 1991).  
Potent inhibitor of LBT4 (Iversen et al. 1992). 
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3.2 Aims 
The aims of the studies in this chapter were to determine the uptake and metabolism 
of DGLA in vitro and in vivo. An overview of the experimental plan employed is 
provided in Figure 3.1. Initially pure DGLA was used to determine the uptake and 
metabolism of this lipid in vitro. This allowed for the effects of DGLA alone to be 
determined without potential indirect actions of other fatty acids in combination 
products. THP-1 macrophages were primarily employed throughout the study and 
were used for in vitro analysis. DGLA uptake was measured into TPL and TAG 
fractions by GC following TLC separation. TPL were further separated by TLC into 
individual phospholipids and incorporation of DGLA into the major membrane 
phospholipids was once again measured by GC. Eicosanoid production from THP-1 
macrophages was measured by high performance liquid chromatography - mass 
spectrometry (HPLC-MS).  
Collaboration with Ben Gurion University (Israel) provided a new source of DGLA in 
the form of a mutant algae P. incisa (Iskandarov et al. 2011). An additional aim of the 
project was to evaluate the role of this alternative source as part of a collaborative 
project. The mutant algae accumulate a large proportion of DGLA in TAG stores 
(Iskandarov et al. 2011). Total lipids extracted from this source, containing DGLA, 
were used for in vivo studies in mice. Following feeding of DGLA-containing diet for 
48 hours, blood plasma was collected along with samples of liver, kidney and adipose 
tissue. Lipids were extracted and the incorporation of DGLA into different fractions 
was measured using GC.   
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3.3 Experimental plan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 – Overview of experimental strategy for chapter 3  
Uptake of DGLA was analysed in THP-1 macrophages and C57BL/6 mice using TLC and GC. 
Measurement of eicosanoid production from THP-1 macrophages was achieved using HPLC-
MS. 
Incubation/feeding 
with DGLA 
Analysis of TPL, 
TAG and individual 
PL fatty acid profiles 
Analysis of 
eicosanoid 
production using 
HPLC-MS 
 
THP-1 macrophages C57BL/6 mice 
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3.4 Results 
3.4.1 Dose-response uptake of DGLA into THP-1 macrophages 
To determine a concentration of DGLA to be used in future lipid uptake experiments, 
a dose-response experiment was carried out. The following experiments were 
performed with pure DGLA purchased from Nu-Chek (purity was validated at 99% by 
GC). Pure DGLA was initially used to allow for the specific uptake and metabolism of 
this PUFA to be established. Many supplementation studies use a combination of a 
number of omega-6 and omega-3 fatty acids along with others (such as Oleic acid 
and LA), so it is difficult to establish the specific roles of each individual component. 
Initial work in the laboratory used concentrations ranging from 10 µM to 100 µM in 
which higher doses of 50 µM and 100 µM showed a significant increase in DGLA in 
both TAG and TPL fractions (data not shown). To demonstrate this, the two most 
effective doses of DGLA were repeated in a single experiment as shown in Figure 
3.2. DGLA was incubated with THP-1 macrophages for 24 hours (a time point 
previously optimised) prior to lipid extraction, separation and fatty acid analysis using 
GC. Lipids were separated into two fractions; TPL and TAG.  
The levels of DGLA (C20:3n6) in TPL increased in a dose-dependent manner 
following incubation of the cells with this fatty acid. Base levels of DGLA (C20:3n6) 
were 1.5% of total fatty acids in this fraction (Figure 3.2). This increased to 5.5% and 
8.6% with doses of 50 µM and 100 µM DGLA, respectively. In addition to this, there 
was a dose-dependent decrease in palmitic acid (C16:0) and oleic acid (C18:1n9). 
Levels of AA (C20:4n6) increased by <1% at the highest concentration of DGLA used. 
There was no change in the relative level of DHA (C22:6n3) and DPA (C22:5n3).  
In the TAG fraction there was a smaller increase in DGLA incorporation. Basal levels 
were 0.67% on average which increased to 0.94% and 2.89% respectively after 
incubation with the two doses of DGLA. This was accompanied by a decrease in the 
relative levels of ALA (C18:3n3), oleic acid (C18:1n9) and vaccenic acid (C18:1n7) 
and an increase in LA (C18:2n6) and myristic acid (C14:0) at both doses. There was 
no change in the relative levels of AA (C20:4n6) in TAG.  
Given the dose-dependent increase of DGLA, the higher of the two concentrations 
was selected to use in further experiments due to more pronounced changes in the 
fatty acid profiles of lipids.  
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Figure 3.2 – DGLA is taken up in a dose-dependent manner into THP-1 
macrophages TPL and TAG fractions  
THP-1 macrophages were incubated with 50 µM or 100 µM DGLA or vehicle control for 24 
hours. Lipids were extracted and separated using 1-dimensional TLC. Fatty acid profiles were 
determined using GC. Graphs display fatty acid composition of fraction as a percentage (+/- 
SD) of one experiment carried out in duplicate. C14:0, myristic acid; C14:1, myristoleic acid; 
C16:0, palmitic acid; C16:1n7, palmitoleic acid; C18:0, stearic acid; C18:1n9, oleic acid; 
C18:1n7, cis-vaccenic acid; C18:2n6, LA; C18:3n3, ALA; C20:3n6, DGLA; C20:4n6, AA; 
C22:5n3, DPA; C22:6n3, DHA; C24:0, lignoceric acid.      
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3.4.2 DGLA uptake into THP-1 macrophages 
Following on from the dose response of DGLA, further repeats were performed for 
statistical analysis using 100 µM DGLA. THP-1 macrophages were incubated with 
DGLA or vehicle as in previous experiment.  
Over 50% of the TPL and TAG fatty acids of THP-1 macrophages were composed of 
palmitic acid (C16:0), stearic acid (C18:0) and oleic acid (C18:1n9). Following 
incubation with DGLA, there was a significant increase from 2.6% to 8.7% in DGLA 
(C20:3n6) levels in TPL. This was accompanied by a significant 0.5% decrease in 
vaccenic acid (C18:1n7) (Figure 3.3). There were also non-significant decreases in 
EPA (C20:5n3), DPA (C22:5n3), DHA (C22:6n3), oleic acid (C18:1n9) and AA 
(C20:4n6) and an increase in LA (C18:2n6).  
In the TAG fraction, there was a significant increase in DGLA (C20:3n6) incorporation 
from 1.3% to 8.9% on average and a significant decrease in vaccenic acid (C18:1n7) 
and ALA (C18:3n3) (Figure 3.3). In addition to this there were non-significant 
decreases in palmitic acid (c16:0), stearic acid (C18:0), DPA (C22:5n3) and DHA 
(C22:6n3). A small increase in AA (C20:4n6) was also observed but this was not 
significant.  
  
 
 
90 
 
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
%
 t
o
ta
l f
at
ty
 a
ci
d
s
TAG
Control
DGLA
* 
 * 
* 
 
 
 
 
 
 
 
 
Figure 3.3 – Incubation with DGLA significantly increases its incorporation into 
TPL and TAG fractions 
THP-1 macrophages were incubated with 100 µM DGLA or vehicle control for 24 hours. Lipids 
were extracted and separated using 1-dimensional TLC. Fatty acid profiles were determined 
using GC. Graphs display fatty acid composition of the two fractions as a percentage (+/- SD) 
from four experiments. Statistics were performed using a Student’s two-tailed t test. * P ≤0.05, 
** P ≤0.01 in relation to control. C14:0, myristic acid; C14:1, myristoleic acid; C16:0, palmitic 
acid; C16:1n7, palmitoleic acid; C16:1n9, cis-7 hexadecenoic acid; C18:0, stearic acid; 
C18:1n9, oleic acid; C18:1n7, cis-vaccenic acid; C18:2n6, LA; C18:3n3, ALA; C20:3n6, DGLA; 
C20:4n6, AA; C20:5n3, EPA; C22:5n3, DPA; C22:6n3, DHA; C24:0, lignoceric acid.  
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3.4.3 DGLA uptake into individual phospholipid classes 
TPL, which consist mainly of phospholipids, can be further separated into individual 
phospholipid classes. To determine the incorporation of DGLA into individual 
phospholipids, THP-1 macrophages were incubated with 100 µM DGLA for 24 hours 
prior to lipid extraction and 2-dimensional separation by TLC. Individual phospholipids 
were identified by reference to the standards and their fatty acid profiles were 
analysed by GC. The main phospholipids found in eukaryotic cells are PC, PE, PS, 
and PI. They are located mainly in the cell membranes and usually esterified  with 
fatty acids  of variable lengths (carbon numbers) and saturation levels (double bonds) 
(van Meer et al. 2008). These four phospholipids were found in abundance in THP-1 
macrophages together with cardiolipin and sphingomyelin to a lesser extent (Figure 
3.4). These two lipids were not included in fatty acid analysis due to their small 
concentrations and high variability between experiments.  
 
Figure 3.4 – Composition and relative content of phospholipids in THP-1 
macrophages   
Lipids were extracted from THP-1 macrophages and individual TPL were separated by two-
dimensional TLC. Quantification was made on the basis of their fatty acid content. The results 
are expressed as percentages of total phospholipids. Percentages represent an average of 3 
experiments 
  
8%
7%
4%
48%
28%
5%
PI
PS
Sphingo
PC
PE
CL
 
 
92 
 
Palmitic acid (C16:0) and oleic acid (C18:1n9) were the major fatty acids in PC, 
accounting for over 50% of the fatty acid content. Following treatment with DGLA 
(C20:3n6), the relative level of this fatty acid increased from 2.5% to 6.7% on average. 
There was a small increase in AA (C20:4n6) from 5.3% to 6.7%. There was no change 
in EPA (C20:5n3), DHA (C22:6n3) and DPA (C22:5n3) contents. In addition, there 
was a 3.4% reduction in the relative amount of palmitic acid (C16:0), although this 
was highly variable.  
For PS, the main fatty acid present was stearic acid (C18:0) accounting for 
approximately 40% of total fatty acids. Again, oleic acid (C18:1n9) was also present 
in abundance constituting approximately 20% of total fatty acids. Following treatment 
with DGLA (C20:3n6), the percentage of this fatty acid increased from 3.9% to 9% on 
average. There was a very small increase in AA (C20:4n6) from 3.2% to 3.4% on 
average and a small decrease in EPA (C20:5n3) (0.9% to 0.7%), DPA (C22:5n3) 
(1.4% to 1.1%) and DHA (C22:6n3) (2.9% to 2.2%). Finally, there was a decrease in 
the level of palmitic acid (C16:0) (6.6% to 3.7%), an increase in stearic acid (C18:0) 
(43.1% to 46.7%) and a decrease in oleic acid (C18:1n9) (21.7% to 19.2%). 
Similar to PS, PI contained high levels of stearic acid (C18:0) (approximately 35-
40%). AA (C20:4n6) was the second most abundant fatty acid accounting for 
approximately 20% of total fatty acids. Following treatment with DGLA (C20:3n6), this 
fatty acid increased from 6.3% to 13.4% of total fatty acids on average. There was no 
change in AA (C20:4n6) observed, a small decrease in EPA (C20:5n3) (2.2% to 1.8%) 
and no change in DPA (C22:5n3) or DHA (C22:6n3). In addition, following treatment 
with DGLA the relative amount of palmitic acid (C16:0) was reduced from 8.7% to 
2.4% and stearic acid (C18:0) was increased from 38.8% to 43.1%.  
The major fatty acid present in PE was AA (C20:4n6), attributing to approximately 20-
25% of total fatty acids and to a lesser extent stearic acid (C18:0) (17%) and oleic 
acid (C18:1n9) (11%). Following treatment with DGLA (C20:3n6), the percentage of 
this fatty acid into PE, increased from 3.8% to 8.6%. There was a small increase in 
AA (C20:4n6) from 23.1% to 23.7%. A decrease in EPA (C20:5n3) was observed 
from 8.4% to 4.4%. However this was highly variable. There was no change in DPA 
(C22:5n3) and a small decrease in DHA (C22:6n3) (6.7% to 5.9%). Finally, a small 
increase was observed in stearic acid (C18:0) (17.1% to 18.6%) and a small decrease 
in oleic acid (C18:1n9) (11.1% to 10.1%).  
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Figure 3.5 – Uptake of DGLA into individual phospholipids 
THP-1 macrophages were incubated with 100 µM DGLA or vehicle control for 24 hours. Lipids were extracted and separated using 2-dimensional TLC. Fatty acid profiles of 
each individual phospholipid were analysed by GC. Graphs display average fatty acid composition of phospholipids as a percentage (+/- SD) of two independent experiments. 
C16:0, palmitic acid; C16:1n7, palmitoleic acid; C18:0, stearic acid; C18:1n9, oleic acid; C18:1n7, cis-vaccenic acid; C18:2n6, LA; C18:3n3, ALA; C18:3n6, GLA; C20:3n6, DGLA; 
C20:4n6, AA; C20:5n3, EPA; C22:5n3, DPA; C22:6n3, DHA. 
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 3.4.4 Eicosanoid production 
Following supplementation of THP-1 macrophages with DGLA, it was clear that this 
fatty acid was incorporated into TPL and TAG fractions with no significant change in 
the level of AA (Figure 3.3). DGLA and AA, through the action of LOX and COX 
enzymes produce a wide variety of eicosanoids. Given the incorporation of DGLA into 
THP-1 macrophage lipid fractions, as well as its possible conversion into AA, it was 
important to measure eicosanoid production to establish if these changes translated 
to a change in eicosanoid production. The production of important COX and LOX 
metabolites were measured using HPLC-MS.  
THP-1 macrophages were incubated with 100 µM DGLA for 24 hours. In the 
experiment an inflammatory mediator was included, IFN-γ, to determine eicosanoid 
production in an inflammatory environment and the relationship with DGLA. IFN-γ is 
a pro-inflammatory cytokine and has been described as a master regulator of 
atherosclerosis due to its wide variety of roles in the disease (McLaren and Ramji 
2009). More detail on IFN-γ can be found in Section 1.4.1.1. Following incubation with 
DGLA, macrophages were stimulated with 250 U/ml IFN-γ for 3 hours. Media was 
collected and lipid extracted for measurement by HPLC-MS.  
Metabolism of AA by LOX enzymes can produce a number of 
hydroxyeicosatetraenoic acids (HETE), while hydroxyeicosatrienoic acids (HETrE) 
are produced from DGLA. A number of these eicosanoids were detected in the 
macrophage conditioned medium (Figure 3.6). AA metabolites 5-, 11-, 12- and 15-
HETE were detected. The only DGLA LOX metabolite detected was 15-HETrE. There 
was no change in the average expression of 5- and 12-HETE between any of the four 
conditions. IFN-γ had no effect on any of the HETE and HETrE eicosanoids identified. 
On treatment with DGLA and IFN-γ the levels of 11- and 15-HETE increased on 
average, however this was not significant on comparison to any other condition and 
was highly variable between experiments. The only significant change was observed 
in 15-HETrE production. DGLA significantly induced production of the eicosanoid: 
approximately 3-fold. IFN-γ had no effect on its formation, moreover, when in 
combination with DGLA, 15-HETrE production increased to a level not significantly 
different to that for DGLA alone.  
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Figure 3.6 – Eicosanoid production from LOX enzymes in THP-1 macrophages 
THP-1 macrophages were pre-treated with 100 µM DGLA or DMSO control for 24 hours prior 
to 24 hour stimulation with vehicle or 250 U/ml IFN-γ. Media was collected and lipids extracted 
for analysis by HPLC-MS. Concentrations were measured in pg per ml of media from 4 x 106 
cells and expressed as fold-change with values from control samples arbitrarily assigned as 
1. Data represents average of 3 independent experiments (+/- SD). Assumptions of ANOVA 
were not fulfilled therefore Robust equality of means test was used followed by Dunnett’s post 
hoc analysis. * P ≤0.05 in relation to control. 
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A major prostaglandin produced via metabolism of AA by COX enzymes, is PGE2. It 
was hypothesised that there would be no to little change in PGE2 production on 
treatment of the cells with DGLA, as fatty acid analysis did not show any conversion 
of DGLA into AA in TPL or TAG fractions of THP-1 macrophages (Figure 3.3). On 
treatment with DGLA alone, there was no increase in the production of PGE2 
compared to control (Figure 3.7). Concentration of PGE2 was expressed as pg/ml 
from 4 x 106 cells, as reported previously (Clark et al. 2011; Aldrovandi et al. 2013). 
Basal level of expression of PGE2 was measured at 500 pg/ml. IFN-γ also had no 
effect on PGE2 accumulation. However, when macrophages were pre-incubated with 
DGLA followed by stimulation with IFN-γ, there was a significant increase of 500 pg/ml 
on average in PGE2, on comparison to all other treatments.  
 
 
 
 
 
 
 
 
 
Figure 3.7 – PGE2 production from THP-1 macrophages 
THP-1 macrophages were pre-treated with 100 µM DGLA or DMSO control for 24 hours prior 
to 24 hour stimulation with vehicle or 250 U/ml IFN-γ. Media was collected and lipids extracted 
for measurement using HPLC-MS. Concentrations were measured in pg per ml of media from 
4 x 106 cells. Data represents average of 3 independent experiments (+/- SD). Assumptions 
of ANOVA were not fulfilled therefore Robust equality of means test was used followed by 
Dunnett’s post hoc analysis. * P ≤0.05 in relation to control.   
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COX metabolism of DGLA produces prostaglandins of the 1-series including PGE1. 
PGE1 is an anti-inflammatory mediator with numerous beneficial actions; therefore its 
production from THP-1 macrophages was measured. Concentration of PGE1 was 
expressed as pg/ml from 4 x 106 cells as reported previously (Clark et al. 2011; 
Aldrovandi et al. 2013). Treatment with IFN-γ did not significantly induce PGE1 
production with an increase of less than 1 pg/ml (Figure 3.8). Treatment of the cells 
with DGLA significantly induced PGE1 production from negligible to 180 pg/ml on 
average, and in combination with IFN-γ, up to 356 pg/ml on average. The differences 
between the DGLA groups however were not significantly different. The concentration 
of PGE1 did not exceed that of PGE2 in any individual experiment.  
 
 
 
 
 
 
 
 
 
Figure 3.8 – PGE1 production from THP-1 macrophages 
THP-1 macrophages were pre-treated with 100 µM DGLA or DMSO control for 24 hours prior 
to 24 hour stimulation with vehicle or 250 U/ml IFN-γ. Media was collected and lipids extracted 
for measurement using HPLC-MS. Graphs display concentration of PGE1 (pg/ml from 4 x 106 
cells) as an average of 3 independent experiments (+/- SD). Assumptions of ANOVA were not 
fulfilled therefore robust equality of means test was used followed by Dunnett’s post hoc 
analysis. For statistical tests to be performed a small number (0.0001) was added to all 
measurements as control group measured zero. ** P ≤0.01 in relation to control.    
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3.4.5 COX expression 
Given the important role of COX enzymes in the production of prostaglandins and the 
changes observed in Figures 3.7 and 3.8, it was of interest to determine the 
expression of the two COX enzymes. THP-1 macrophages were pre-treated with 100 
µM DGLA or vehicle control for 24 hours prior to stimulation with IFN-γ. RNA was 
extracted and subjected to reverse transcription to make cDNA. RT-qPCR was 
performed using specific primers for COX-1 and COX-2.  
Treatment with IFN-γ had no significant effect on the expression of COX-1 or COX-2 
in THP-1 macrophages, in comparison to control (Figure 3.9). DGLA had no effect on 
COX-2 expression; however it did significantly attenuate expression of COX-1 by 
32%. A combination of pre-treatment with DGLA followed by stimulation with IFN-γ, 
the expression of COX-1 was again significantly reduced by 50%, in comparison to 
control. Under the same conditions, the expression of COX-2 was significantly 
increased by 2.5-fold.  
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Figure 3.9 – COX-2 gene expression was induced on treatment of THP-1 
macrophages with DGLA and IFN-γ 
THP-1 macrophages were incubated with vehicle or 100 µM DGLA for 24 hours prior to 
treatment with vehicle or 250 U/ml IFN-γ for 24 hours. Total RNA was subjected to reverse 
transcription and RT-qPCR with primers specific for human COX-1, COX-2 or GAPDH. 
Graphs display average gene expression (mean +/- SD) (control arbitrarily assigned as 1) 
from 3 independent experiments. Statistical analysis was performed using a one-way ANOVA 
followed by Tukey’s post-hoc test. *P≤0.05 ***P≤0.001 in relation to control.  
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3.4.6 Uptake of DGLA from algal powder in vivo  
The previous uptake and metabolic experiments described above were performed 
with pure DGLA. This allowed for the uptake and metabolism, following incubation 
with DGLA only, to be determined. Following on from DGLA uptake in vitro it was 
important to determine the uptake on this fatty acid in vivo. To evaluate this, mice 
were supplemented with DGLA in their diet to investigate uptake of the PUFA. As 
previously discussed in Section 1.5.3, there are a number of new potential 
commercial sources of DGLA which have been developed through genetic or 
metabolic manipulation of yeast, fungus and algae (Kawashima et al. 2000; 
Iskandarov et al. 2011; Watanabe et al. 2014). The current project was in 
collaboration with Ben Gurion University (Israel) who supplied a mutant form of the 
microgreen algae P. incisa which accumulates large amounts of DGLA. This was the 
source of DGLA used for in vivo experiment and allowed for the evaluation of the 
algae as a useful commercial source of DGLA.  
To determine the uptake of DGLA from the algae P. incisa, six C57BL/6 mice were 
starved 24 hours prior to the experiment. Mice were separated into two groups; 
control (fed on a normal chow diet, see the fatty acid composition in the Table 3.3) 
and DGLA-enriched diet. For the first experiment, animals from DGLA-enriched diet 
group were supplemented with 2% (w/w) freeze-dried algal powder, containing about 
30% DGLA, which was added to the normal chow diet. After 48 hours of feeding, 
samples of plasma, liver, kidney and faeces were collected. Analysis of the fatty acids 
of tissues and plasma showed no accumulation of DGLA (Appendix 1). Fatty acid 
analysis of faeces showed that practically all supplemented DGLA was discharged 
indicating that algal powder could not be assimilated by mice (Figure 3.10).  
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Figure 3.10 –DGLA was not absorbed in vivo following feeding of mice with 
freeze-dried algal powder 
Male C57BL/6 mice were split into 2 groups; Control (3) and DGLA (3). For DGLA group, 
normal chow diet was supplemented with 2% (w/w) freeze-dried algal powder containing this 
PUFA. Mice were starved for 24 hours prior to feeding. Mice were fed control or DGLA 
containing diet for 48 hours. Following this, a sample of faeces was collected from each group, 
lipids extracted and fatty acids analysed using GC. Graphs indicate the average percentage 
fatty acid composition of faeces (+/- SD) performed in triplicate. C16:0, palmitic acid; C18:0, 
stearic acid; C18:1n9, oleic acid; C18:2n6, LA; C18:3n3, ALA; C20:3n6, DGLA; C20:4n6, AA.     
 
As mice were unable to digest the freeze-dried algal powder and assimilate DGLA 
from this source, total lipids were next extracted from the algal powder prior to 
feeding. Lipid extraction from algal powder is detailed in Section 2.2.13 of the 
methods chapter. Total lipids were isolated from the algal powder and added to the 
chow diet. The fatty acid profile of the chow diet (control) and DGLA-containing diet 
are presented in Table 3.3. The main fatty acid present in the control diet was LA 
(C18:2n6), followed by oleic acid (C18:1n9), palmitic acid (C16:0), ALA (C18:3n3) 
and stearic acid (C18:0). No DGLA was present in the control diet. Diet containing 
total lipid extracts from freeze-dried algal powder contained 4.4% of DGLA in TFA. 
There were relatively minor changes in the relative content of LA (C18:2n6), oleic acid 
(C18:1n9), palmitic acid (C16:0) and ALA (C18:3n3) between the two diets.   
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Table 3.3 – Fatty acid composition of control and DGLA diets used in in vivo 
experiments following extraction from algal powder 
 
 
 
 
 
 
 
 
For feeding experiments with lipids extracted from algal powder, seven mice were 
split into 2 groups: Control (3) and DGLA (4). Mice were starved for 24 hours prior to 
feeding. Lipid composition of diets of control and DGLA group are detailed in Table 
3.3. Following 48 hours of feeding, plasma and faeces (Appendix 3) were collected 
followed by samples of liver, kidney and adipose tissue. Depending on the amount of 
lipids extracted from plasma and tissues, total fatty acids and fatty acids of TPL, TAG 
and individual phospholipids were analysed by GC.  
 
 
 
 
 
 
 
Fatty acid Control diet DGLA diet 
Palmitic acid (C16:0) 14.4% 15.7% 
Stearic acid (C18:0) 2.9% 3.1% 
Oleic acid (C18:1n9) 21.6% 25.5% 
LA (C18:2n6) 
 
51.4% 43.6% 
ALA (C18:3n3) 
 
5.7% 4.5% 
DGLA (C20:3n6) - 4.4% 
Other 4.0% 3.2% 
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3.4.6.1 Plasma 
Plasma was collected from mice and total lipids extracted as detailed in Section 
2.2.15.2. An aliquot of total lipids was taken to analyse total fatty acids; the rest of the 
lipid extracts were separated by 1-dimensional TLC into TPL, TAG and steryl ester 
fractions. The fatty acid composition of each of the fractions was analysed by GC.  
In total fatty acids, the percentage of DGLA (C20:3n6) incorporation significantly 
increased from 1.2% to 3.1% in the DGLA group (Figure 3.11). There was no 
significant increase in AA (C20:4n6) levels but a significant decrease from 0.3% to 
0.1% in EPA (C20:5n3). When total lipids were further separated by TLC, it was 
observed that DGLA was significantly incorporated into TPL with an increase from 
1.5% to 4.5% in the DGLA group. This was also accompanied by an increase in AA 
(C20:4n6) from 6.6% to 10.5%. However this was not significant between the groups. 
There was also a significant decrease in the relative amount of stearic acid (C18:0) 
in DGLA group. In TAG fraction, DGLA was significantly increased from 0.2% to 1.4%, 
with no significant change in AA (C20:4n6) or any other fatty acids identified. Finally, 
in steryl esters, DGLA (C20:3n6) was again significantly increased from 0% to 2.6% 
in DGLA group. AA (C20:4n6) increased from 20% to 25.6%, however this was not 
statistically significant. The relative amount of EPA (C20:5n3) was also significantly 
decreased by from 2.3% to 1.6%.  
 
 
104 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 – Uptake of DGLA into plasma lipid fractions in vivo 
Mice were supplemented with 4% DGLA diet for 48 hours. Animals were sacrificed and the plasma fraction of blood collected. Lipids were extracted and separated using 1-
dimensional TLC. Fatty acid profiles of each lipid fraction were analysed by GC. Graphs display average fatty acid composition as a percentage (+/- SD) from 3 mice (Control) 
and 4 mice (DGLA diet). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc analysis. * P <0.05. *** P <0.001. C14:0, myristic acid; C16:0, 
palmitic acid; C16:1n7, palmitoleic acid; C16:1n9, cis-7 hexadecenoic acid ; C18:0, stearic acid; C18:1n9, oleic acid; C18:1n7, cis-vaccenic acid; C18:2n6, LA; C18:3n3, ALA; 
C18:3n6, GLA; C20:3n6, DGLA; C20:4n6, AA; C20:5n3, EPA; C22:6n3, DHA.     
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3.4.6.2 Liver 
Incorporation of DGLA into the lipid classes of liver was also investigated. The liver is a 
very important organ which is involved in the regulation of many processes such as TAG 
and fatty acid metabolism and together with cholesterol synthesis, transport and 
catabolism. Given its role in lipid metabolism, the fatty acid composition of liver is 
commonly investigated in uptake studies. Liver was isolated from mice and lipids 
separated as detailed in Section 2.2.15.3. Total fatty acid composition of liver was 
analysed by GC; TPL, TAG and steryl esters were separated by TLC and the fatty acid 
profile of these fractions was also analysed by GC. In addition, individual phospholipids 
were also separated by 2-dimensional TLC into individual phospholipids PC, PS, PI and 
PE. 
In total liver fatty acids, DGLA (C20:3n6) was increased significantly from 1.5% to 2.5% 
and stearic acid (C18:0) decreased from 13.1% to 11.7% in the DGLA group (Figure 
3.12). There was no significant change in AA (C20:4n6) levels in total fatty acids. 
Following this, total fatty acids were separated by 1-dimensional chromatography. In TPL, 
DGLA (C20:3n6) was significantly increased from 1.8% to 2.7% while stearic acid (C18:0) 
and DHA (C22:6n3) were both significantly decreased in the DGLA group from 17.7% to 
15.1% and 11.9% to 10.3% respectively. In the TAG fraction of the liver, DGLA was 
significantly increased from 1.1% to 1.6% in the DGLA group. This was accompanied by 
a significant increase in AA (C20:4n6) from 1.8% to 2.7%. DGLA also significantly 
increased from 0% to 1.4% in steryl ester fraction in DGLA group. There were no other 
significant changes in this lipid fraction.  
To utilise the large concentration of lipid isolated from the liver, TPL were further 
separated into individual phospholipids for analysis (Figure 3.13). The four main 
phospholipids were identified and their fatty acid compositions measured in control and 
DGLA groups. There was a significant increase in DGLA into PS, PE and PC from 1.6% 
to 2.4%, 0.9% to 1.3% and 2.4% to 3.7% respectively in DGLA treatment groups. There 
was an increase from 3% to 3.8% of DGLA (C20:3n6) into PI; however, this was not 
significant. There was no significant change in AA (C20:4n6) levels into any phospholipid 
fraction measured despite an increase of 9.7% to 11.9% in AA with PC. There were also 
changes in other fatty acids observed in phospholipid fractions. In PS there was a 
significant increase in vaccenic acid (C18:1n7) from 0.7% to 1.4% in DGLA group. In PE, 
a significant decrease in both EPA (C20:5n3) and DHA (C22:6n3) was measured, from 
1% to 0.6% and 19.9% to 17.5% respectively. Finally, in PC, there was a significant 
decrease from 11.9% to 9.4% in stearic acid (C18:0) and 11.9% to 9.7% in DHA 
(C22:6n3).  
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Figure 3.12 – Uptake of DGLA into liver lipid fractions in vivo 
Mice were supplemented with 4% DGLA diet for 48 hours. Animals were sacrificed and liver tissue collected. Lipids were extracted and separated using 1-dimensional TLC. 
Fatty acid profiles of each lipid fraction were analysed by GC. Graphs display average fatty acid composition as a percentage (+ SD) of 3 mice (Control) and 4 mice (DGLA diet). 
Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc analysis. * P<0.05. ** P <0.005, *** P<0.001. C16:0, palmitic acid; C16:1n7, palmitoleic 
acid; C16:1n9, cis-7 hexadecenoic acid; C18:0, stearic acid; C18:1n9, oleic acid; C18:1n7, cis-vaccenic acid; C18:2n6, LA; C18:3n3, ALA; C20:3n6, DGLA; C20:4n6, AA; 
C20:5n3, EPA; C22:6n3, DHA.     
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Figure 3.13 – Uptake of DGLA into liver individual phospholipids in vivo 
Mice were supplemented with 4% DGLA diet for 48 hours. Animals were sacrificed and liver tissue collected. Lipids were extracted and separated using 2-dimensional TLC for 
individual phospholipids. Fatty acid profiles of each phospholipid fraction were analysed by GC. Graphs display average fatty acid composition as a percentage (+ SD) of 3 mice 
(Control) and 4 mice (DGLA diet). Statistical analysis was performed using a one-way ANOVA followed by Tukey’s post hoc analysis. * P <0.05. ** P<0.005, *** P <0.001. C16:0, 
palmitic acid; C18:0, stearic acid; C18:1n9, oleic acid; C18:1n7, cis-vaccenic acid; C18:2n6, LA; C18:3n3, ALA; C20:3n6, DGLA; C20:4n6, AA; C20:5n3, EPA; C22:6n3, DHA.     
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3.4.6.3 Kidney and adipose tissue 
In addition to plasma and liver, samples of kidney and adipose tissue were also taken 
for analysis. In the total fatty acids of kidney, DGLA (C20:3n6) was significantly 
increased from 1.1% to 1.8% in the DGLA group (Figure 3.14). Total fatty acids were 
further separated into TPL and TAG fractions. In TPL, there was a non-significant 
increase in DGLA (C20:3n6) from 1.2% to 1.8% in the DGLA group. There was 
however, a significant increase in AA (C20:4n6) incorporation from 17.6% to 18.9%. 
In the TAG fraction of kidney, there was a significant increase in DGLA (C20:3n6) 
from 0.7% to 1.2% and LA (C18:2n6) from 22.2% to 27.7% in the DGLA group. This 
was accompanied by significant decreases in AA (C20:4n6), palmitic acid (C16:0) 
and oleic acid (C18:1n9) from 2.8% to 2%, 26.7% to 23% and 22.2% to 27.7%, 
respectively.   
In adipose tissue, only total fatty acids were measured due to the small amount of 
tissue collected on dissection. The incorporation of DGLA (C20:3n6) in the DGLA-
fed-group increased significantly from 0.3% to 0.8%. There were no other significant 
changes in the fatty acid composition of adipose tissue.  
Table 3.4 summarises percentage changes in DGLA and AA across all plasma, liver, 
kidney and adipose lipid fractions measured.  
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Figure 3.14 – Uptake of DGLA into kidney and adipose tissue lipid fractions in vivo 
Mice were supplemented with 4% DGLA diet for 48 hours. Animals were sacrificed and tissues collected. Lipids were extracted and separated using 1-dimensional TLC for TPL 
and TAG. Fatty acid profiles of each fraction were analysed by GC. Graphs display average fatty acid composition as a percentage (+ SD) of 3 mice (Control) and 4 mice (DGLA 
diet). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc analysis. * P<0.05. ** P <0.005. C14:0, myristic acid; C16:0, palmitic acid; C16:1n7, 
palmitoleic acid; C18:0, stearic acid; C18:1n9, oleic acid; C18:1n7, cis-vaccenic acid; C18:2n6, LA; C18:3n3, ALA; C20:1n9, eicosenoic acid; C20:3n6, DGLA; C20:4n6, AA; 
C22:6n3, DHA; C24:0, lignoceric acid.  
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Table 3.4 – Summary of changes in DGLA and AA in different lipid fractions in 
vivo 
Percentage changes in DGLA and AA are displayed as the difference between control 
and DGLA group. Statistically significant changes (p≤0.05) are underlined.  
 
 
 
 
 
 
 
 
 
 
 
 
 Plasma Liver Kidney Adipose 
 DGLA AA DGLA AA DGLA AA DGLA AA 
TFA 158% 14% 60% 20% 63% 5% 200% 0% 
TPL 200% 58% 50% 5% 50% 7% - - 
TAG 600% 85% 55% 50% 86% -29% - - 
SE 260% 28% 140% 45% - - - - 
PC - - 33% 22% - - - - 
PE - - 44% 6% - - - - 
PS - - 81% 12% - - - - 
PI - - 26% -1.4% - - - - 
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3.5 Discussion 
3.5.1 DGLA is incorporated into TPL and TAG fractions of THP-1 macrophages 
Initial experiments were performed to determine an optimum dose for DGLA to use 
for lipid analysis studies in THP-1 macrophages. First, a time point of 24 hour 
incubation with DGLA was optimised to achieve maximum uptake into TPL and TAG 
fractions. Two concentrations were selected based on common doses used in 
previous experiments (Iversen et al. 1991; Iversen et al. 1992; Dooper et al. 2003). 
Incorporation of DGLA into TPL and TAG fractions showed a dose-dependent 
increase (Figure 3.2). After 24 hours, DGLA had increased by 4% and 7% in TPL on 
incubation with 50 μM and 100 μM of this fatty acid. Results were comparable to data 
reported in previous studies. Neutrophils isolated from human subjects taking 
supplements containing GLA showed a dose-dependent increase in DGLA (Johnson 
et al. 1997). A dose-dependent increase in DGLA in total neutrophil lipids was 
observed on supplementation with 3.0 g/day and 6.0 g/day (Johnson et al. 1997). 
Human PBMC treated with 100 µM DGLA for 24 hours resulted in a dramatic rise in 
relative amount of DGLA (10% into TPL) (Dooper et al. 2003). After 48 hours there 
was only a further 2-3% increase in DGLA incorporation, with saturation reached at 
72 hours  (Dooper et al. 2003). Due to the larger increase in incorporation of DGLA 
with a concentration of 100 μM and the supporting data in the literature using this 
concentration, 100 µM was used in further experiments.  
Following on from the dose response data, the incorporation of DGLA into TPL and 
TAG was analysed further using only the selected concentration (Figure 3.3). 
Treatment with DGLA significantly increased its incorporation into TPL and TAG 
fractions of THP-1 macrophages. Previous lipid uptake studies with the omega-6 fatty 
acids DGLA and GLA have shown comparable results. Treatment of PBMC with 100 
µM DGLA increased incorporation of DGLA and LA into phospholipids (Dooper et al. 
2003). Supplementation of mouse peritoneal macrophages with DGLA in vitro, 
showed rapid incorporation of DGLA after 3 hours and neutrophils isolated from 
human subjects taking supplements containing GLA also showed increased 
concentration of DGLA (Chapkin and Coble 1991).  
In addition to this, on treatment of THP-1 macrophages with 100 μM DGLA there was 
a small (<1%) but non-significant reduction in the incorporation of EPA, DPA, DHA 
and an increase in LA into TPL (Figure 3.3). This was also observed in TAG fractions 
where there was a small non-significant decrease in DPA and DHA. This again was 
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comparable to previous studies. Treatment of PBMC with 100 µM DGLA led to no 
significant change in EPA, DPA and DHA incorporation (Dooper et al. 2003). 
Given that DGLA can be metabolised to AA by the action of delta-5 desaturase, it was 
important to determine the incorporation of this fatty acid into lipid profiles of THP-1 
macrophages due to its links to a pro-inflammatory status. On treatment with DGLA, 
AA levels in TPL were reduced by less than 1% (Figure 3.3), moreover this was not 
significant. In TAG lipid fractions there was a small increase of less than 0.3%. 
Previous work has shown small changes in the incorporation of AA on treatment with 
GLA or DGLA in macrophage and neutrophil cell lines. Supplementation of mouse 
peritoneal macrophages with GLA in vitro resulted in rapid increase in DGLA after 3 
hours. This was accompanied by a small increase in AA at a later time of 20 hours 
(Chapkin and Coble 1991). Neutrophils isolated from human subjects taking 
supplements containing GLA showed increased concentrations of DGLA in lipid 
fractions. This was accompanied by an increase in AA. However, this was not 
significant at concentration used (Johnson et al. 1997). The AA:DGLA ratio decreased 
from 5.4:1 to 2.3:1 in three weeks following supplementation with 6.0 g/day GLA 
(Johnson et al. 1997). Conversely, treatment of PBMC with 100 µM DGLA was 
associated with a decrease in the levels of AA in TPL (Dooper et al. 2003). 
Macrophages and neutrophils rapidly elongated GLA to DGLA, with some limitations 
seen in the further desaturation to AA (Chapkin and Coble 1991; Johnson et al. 1997). 
This indicates macrophages possess an extremely active elongase and modest delta-
5 desaturase activity (Chapkin and Coble 1991).  
Previously it had been shown that the AA present in macrophages was not 
synthesised by the macrophage itself but acquired from a secondary source (Chapkin 
et al. 1988). AA can be synthesised in liver from LA or obtained directly through the 
diet. It is packaged into serum lipoproteins as NEFA, TAG, cholesteryl ester or 
phospholipids and delivered to cells, including inflammatory cells. AA can then be 
incorporated into phospholipid and non-polar lipid pools (Chilton et al. 1996). Mouse 
peritoneal macrophages were shown to have limited desaturase activity which leads 
to an inability of DGLA to be readily metabolised to AA. This limitation was also 
observed in neutrophils and platelets (Chapkin et al. 1988). This indicates that once 
DGLA is taken up into macrophage and other inflammatory cells, it’s conversion to 
AA will be very limited or non-existent.  
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3.5.2 DGLA is incorporated into individual phospholipids of THP-1 
macrophages 
TPL can be separated into individual lipid classes by 2-dimensional TLC. Following 
on from DGLA accumulation into TPL, analysis was expanded to determine the extent 
of incorporation into individual phospholipids classes. TPL were separated into 6 
classes of phospholipids, PC, PS, PI, PE, sphingomyelin and cardiolipin (Figure 3.4). 
The majority of THP-1 macrophage membranes were composed of PC and PE with 
smaller amounts of PS and PI. Sphingomyelin and cardiolipin were minor classes and 
were not included in fatty acid analysis.  
PE contained the highest proportion of DGLA and AA in the fatty acid profile of THP-
1 macrophages (Figure 3.5). This was also observed in human neutrophils whereby 
more than 60% of AA from TFAs was located in PE. Similarly, over 40% of DGLA was 
also associated with PE (Johnson et al. 1997). This indicates AA and DGLA reside in 
similar lipid pools. On treatment of THP-1 macrophages with DGLA, there was an 
increase of this PUFA into PC, PS, PI and PE (Figure 3.5). No statistics could be 
performed due to lack of sufficient independent experiments. In all classes there was 
either no change or an increase of less than 1% in AA levels. The same was observed 
for omega-3 fatty acids EPA, DPA and DHA. Comparable results have been observed 
previously. Following supplementation of GLA in humans, there was an  increase in 
the incorporation of DGLA into PE, PI, PS and PC in isolated neutrophils (Johnson et 
al. 1997). There was no significant increase in AA observed. In addition, three weeks 
supplementation with GLA actually reduced the ratio of AA:DGLA from 8.3:1 to 4:1 in 
PE. This may suggest that prolonged supplementation with DGLA in macrophages 
would continue to elevate DGLA levels with no subsequent increase in AA.   
Lipid analysis indicates that in THP-1 macrophages, there was a significant 
accumulation of DGLA in TPL and TAG fractions with no significant change in omega-
3 fatty acids or increase in AA accumulation. The latter may be attributed to the low 
activity of delta-5 desaturase in macrophages as reported previously (Chapkin et al. 
1988; Chapkin and Coble 1991; Johnson et al. 1997). This selective accumulation of 
DGLA without a subsequent increase in incorporation of AA may result in an alteration 
in the inflammatory potential of macrophages. Changes in the fatty acid composition 
of lipids alter the pattern of release of fatty acids and, hence, eicosanoid production. 
In one study, following supplementation with GLA, there was a dramatic increase of 
up to 200% in DGLA released from the phospholipids of neutrophils following 
stimulation of the cells with this fatty acid. There was no change in the release of AA 
(Johnson et al. 1997). As discussed previously in Section 3.1.3, AA classically gives 
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rise to pro-inflammatory eicosanoids while metabolism of DGLA gives rise to anti-
inflammatory mediators. Therefore, increasing the incorporation of DGLA into lipid of 
THP-1 macrophages may increase the accumulation of anti-inflammatory mediators. 
To test this hypothesis, eicosanoid production was measured from THP-1 
macrophages and is discussed in the following section.   
3.5.3 Eicosanoid production from THP-1 macrophages  
To determine if changes in fatty acid incorporation of DGLA into lipid fractions of THP-
1 macrophages affected the production of eicosanoids, their synthesis was measured 
by HPLC-MS.  
3.5.3.1 COX metabolites 
DGLA and AA are substrates for COX enzymes and are converted to series 1 and 2 
prostaglandins, respectively. The major species of PGs detected from THP-1 
macrophages were PGE1 and PGE2. The various roles of these two eicosanoids are 
detailed in Table 3.2. It was hypothesised that due to the increase in DGLA 
incorporation into THP-1 macrophage lipid fractions, DGLA metabolites would 
increase. Conversely, there was no observed change in AA uptake into TPL and TAG 
fractions of THP-1 macrophages following DGLA treatment and, therefore, it was 
hypothesised that PGE2 synthesis from these cells would remain constant.  
On treatment with 100 μM DGLA, there was a significant increase in the concentration 
of PGE1 from negligible to 180 pg/ml. Following supplementation, there was no 
difference in the concentration of PGE2 from vehicle treated to DGLA treated 
macrophages (Figure 3.7-3.8). Similar observations have been reported both in in 
vitro and in vivo studies. On treatment of mouse peritoneal macrophages with GLA 
there was a significant increase in PGE1 following stimulation with this fatty acid 
(Chapkin and Coble 1991). No series 2 prostaglandins were detected in the study 
(Chapkin and Coble 1991). In human mononuclear leukocytes, incubation with DGLA 
resulted in no change in the levels of PGE2 but a dose-dependent increase in PGE1 
(Iversen et al. 1992). NC/Tnd mice, a model of atopic dermatitis, fed a diet containing 
DGLA induced the production of lipid mediators in the skin. DGLA induced synthesis 
of series 1 prostaglandins; PGE1, PGD1, PGF1α. However in contrast to in vitro 
studies, DGLA feeding in vivo also significantly induced the synthesis of series 2 
prostaglandins, PGD2 and PGE2 (Amagai et al. 2015). Despite this, the study reported 
a significant role for DGLA in inhibition of atopic eczema, attributed to the production 
of PGD1. Similarly, in rats supplemented with DGLA, the levels of both PGE1 and 
PGE2 were induced (Umeda-Sawada et al. 2006). However, the induction of PGE1 in 
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comparison to PGE2 was substantially larger. DGLA increased the levels of PGE1 in 
rat plasma to four times of that seen in control diet (Umeda-Sawada et al. 2006). 
There was an increase of less than 2-fold in the concentration of PGE2 (Umeda-
Sawada et al. 2006). In addition to this, the ratios of PGE1:PGE2 and PGD1:PGE2 
were significantly increased on DGLA supplementation (Umeda-Sawada et al. 2006). 
This indicates that in vivo the balance between the production of DGLA and AA-
derived eicosanoids plays an important role. As shown in Figure 3.7 and 3.8, the 
concentration of PGE1 did not exceed that of PGE2 in any experiment. However the 
ratio of PGE2:PGE1 on supplementation with DGLA reduced dramatically from 500:1 
to 2.6:1. Supplementation with DGLA may therefore offset the balance of pro- and 
anti-inflammatory prostaglandin production, resulting in an overall anti-inflammatory 
effect (Umeda-Sawada et al. 2006).  
Pro-inflammatory cytokine IFN-γ was also included in experiments to evaluate the 
effect of an inflammatory background on eicosanoid synthesis and the role of DGLA 
in an inflammatory state. IFN-γ alone had no effect on the production of PGE1 and 
PGE2 in comparison to control. However, there was a significant change when THP-
1 macrophages were pre-treated with DGLA followed by stimulation with IFN-γ. On 
treatment with a combination of DGLA and IFN-γ in THP-1 macrophages, the 
concentration of PGE1 was approximately twice that of DGLA-only treated 
macrophages; however the groups were not significantly different. Similarly, under 
the same conditions, there was a significant induction in the production of PGE2 in 
comparison to all other treatments. Fatty acid analysis of THP-1 macrophages treated 
with DGLA followed by IFN-γ stimulation showed no increase in incorporation of AA 
into TPL or TAG in comparison to control (Appendix 2). This indicated that the 
increase in PGE2 production was not as a result of an increase in AA incorporation 
into lipid pools and, therefore, suggesting that DGLA and IFN-γ were having a 
synergistic effect on prostaglandin synthesis. To begin to understand this effect, the 
mRNA expression of COX enzymes was measured using RT-qPCR. 
COX enzymes have two isoforms; COX-1 and COX-2. The expression patterns differ 
between cell types. COX-1 is constitutively expressed, while COX-2 is inducible 
(Matsuura et al. 1999; Levin et al. 2002). Both forms of the enzyme have been 
implicated in the production of prostaglandins to varying degrees (Matsuura et al. 
1999; Noguchi et al. 1999; Caughey et al. 2001; Levin et al. 2002). For COX-1, IFN-
γ had no effect on mRNA expression, however both DGLA and DGLA in combination 
with IFN-γ stimulation, reduced the mRNA expression of the gene. For COX-2, IFN-γ 
and DGLA treatments in isolation had no effect on the mRNA levels in comparison to 
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control. However in combination, treatment with DGLA followed by IFN-γ significantly 
induced the expression of COX-2 mRNA.  Future work should confirm changes in 
COX-1 and COX-2 expression at the protein level and determine enzyme activity. 
The relationship between IFN-γ and COX expression as reported in the literature is 
controversial. In human epidermal keratinocytes, treatment with the pro-inflammatory 
cytokines induced the mRNA and protein expression of COX-2 (Matsuura et al. 1999). 
COX-1 expression was reduced with IFN-γ treatment (Matsuura et al. 1999). In 
mouse peritoneal macrophages, IFN-γ induced the expression of COX-2 at the mRNA 
and protein levels, with a modest decrease in COX-1 expression (Blanco et al. 2000). 
Other studies reported opposing results. In human fibroblasts, IFN-γ had no effect on 
COX-1 or COX-2 expression (Noguchi et al. 1999) and in human macrophages the 
cytokine dose-dependently reduced COX-2 levels induced by IL-1β  (Barrios-Rodiles 
and Chadee 1998). The data presented in Figure 3.9 indicated that both DGLA and 
IFN-γ were required for the increase in COX-2 expression. This may be explained by 
IFN-γ priming. Thus, previous studies, many of which reported no effect of IFN-γ on 
COX-2 expression, have found induction of expression following priming of the cells. 
IFN-γ significantly increased the expression of COX-2 in human macrophages 
following priming with LPS or TNF-α (Ariasnegrete et al. 1995; Barrios-Rodiles and 
Chadee 1998). COX-1 expression was unchanged (Ariasnegrete et al. 1995). This 
may suggest that pre-treatment with DGLA acts to prime THP-1 macrophages so that 
IFN-γ can induce COX-2 expression, as seen in Figure 3.9.  
The significant increase in the expression of COX-2 following treatment with DGLA 
and IFN-γ coincides with the increase in the production of PGE1 and PGE2 under 
identical conditions. In addition, the decrease in COX-1 expression in DGLA treatment 
and in DGLA followed by IFN-γ treatment is accompanied by an increase in the 
production of PGE1 under these conditions. This suggests that in THP-1 
macrophages, COX-2 may be responsible for PGE2 production and in part, PGE1. As 
mentioned previously, COX-1 and COX-2 differ in their expression between cell types. 
The specific role of each isoform in formation of prostaglandins has not been fully 
established. A study investigating the role of COX-1 and COX-2 in DGLA and AA 
metabolism indicated that COX-2 predominates over COX-1 in production of 
prostaglandins (Levin et al. 2002). Production of PGE1 from DGLA via COX-1 peaked 
at 40 ng/ml, while metabolism via COX-2 peaked at 120 ng/ml (Levin et al. 2002). It 
was also observed that COX-2 had a higher affinity for DGLA and AA than COX-1 
and increasing the concentrations of the two PUFAs, decreased COX-1 activity (Levin 
et al. 2002). In addition, a study reporting eicosanoid synthesis from HUVEC cells, 
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unstimulated cells (which constitutively express COX-1) produced predominantly 
TXA2 (Caughey et al. 2001). Following induction of COX-2 expression with pro-
inflammatory cytokine IL-1β, there was a large increase in the production of PGE1 
and PGE2, 54-fold and 84-fold respectively on comparison to untreated cells 
(Caughey et al. 2001). Finally, selective COX-2 inhibitors in human fibroblasts 
specifically reduced the production of PGE2 following stimulation (Noguchi et al. 
1999).  
Taken together the data presented in Figures 3.7-3.9 and previous studies, allow a 
number of conclusions can be drawn. DGLA may act to prime THP-1 macrophages 
to induce COX-2 expression, which mirrors an increase in the production of PGE2 
under the same conditions. Treatment with DGLA attenuates the expression of COX-
1 in macrophages, which under the same conditions significantly induced the 
production of PGE1. This suggests that COX-2 predominates over COX-1 in the 
production of PGE1 and PGE2 by THP-1 macrophages.  
3.5.3.2 LOX metabolites 
LOX metabolism of DGLA and AA produces a wide variety of hydroxyeicosanoids. 
They have a range of actions, as detailed in Table 3.2. Hydroxyeicosanoids produced 
from AA play a number of pro-inflammatory roles. They can also act as substrates to 
yield a number of other eicosanoids, with both pro- and anti-inflammatory roles. For 
example, the action of 5-LOX on AA produces 5-HPETE which is a precursor for pro-
inflammatory LT production (Samuelsson et al. 1987; Neels 2013). In contrast, 
metabolism of 15-HETE from AA, acts as a precursor for lipoxin production, that has 
been attributed to resolving inflammation (Goh et al. 2001; Ho et al. 2010).  
The effect of DGLA supplementation on the synthesis of hydroxyeicosanoids was 
measured by HPLC-MS (Figure 3.6). There was no effect on the production of AA 
metabolites (5-, 11-, 12- and 15-HETE) on treatment with DGLA when compared to 
control. This result indicates that there was no increase in metabolism of AA through 
LOX pathways on treatment with DGLA. Again, given the significant increase in the 
accumulation of DGLA and no change in AA, this result was as expected.  
There was, however, a significant increase in the production of the DGLA metabolite 
15-HETrE. This has also been observed previously in vivo. DGLA significantly up-
regulated 8-HETrE and 15-HETrE in NC/TnD mice (Amagai et al. 2015). 15-HETrE 
has been well documented to inhibit the production of pro-inflammatory LTB4. 
Supplementation of 3.0 g/day of GLA reduced the levels of LBT4 from human 
neutrophils (Johnson et al. 1997) while DGLA significantly reduced the production of 
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LBT4 from rat macrophages (Nakamura et al. 1993). Dose-dependent decreases in 
LTB4 formation from human mononuclear leukocytes was associated with a dose-
dependent increase in 15-HETrE formation (Iversen et al. 1992). Incubation with 15-
HETrE did not change PGE2 production but was a potent inhibitor of LBT4 production, 
more so than incubation with DGLA (Iversen et al. 1992). The anti-inflammatory roles 
of 15-HETrE may be an effect of reducing the production of LBT4 and, therefore, its 
pro-inflammatory roles. LTB4 production was not measured in the present study and 
could potentially be included in future work. Overall, the data indicate a potential anti-
inflammatory role for DGLA through the production of eicosanoids.  
3.5.4 Uptake of algal sourced DGLA in vivo 
In vivo studies were performed to determine the uptake of dietary DGLA. In addition 
to this, the study provided insight into the use of a potential new source of DGLA in 
the form of mutant algae P. incisa. Initially, the standard chow diet of mice was 
supplemented with 2% (w/w) freeze-dry algal powder containing approximately 30% 
DGLA, to determine if this could be digested in vivo and utilised as a dietary source 
of fatty acids. Mice were sacrificed using schedule 1 procedures and a sample of 
plasma was analysed following 48 hours feeding to determine fatty acid profile. It was 
that observed there were no significant differences between the profiles of control and 
DGLA-fed groups (Appendix 1). Faeces were next analysed. As shown in Figure 3.10, 
the DGLA group excreted an increased amount of DGLA in comparison to the control 
group. This indicated that mice could not digest the whole algae and were unable to 
utilise fatty acids contained within.  
Following this, lipids were extracted from algal powder prior to feeding as detailed in 
Section 2.2.13. The fatty acid composition of the diet of control and the DGLA-fed 
groups is detailed in Table 3.3. DGLA content in the control group was negligible. On 
addition of the lipid extracts from P. incisa, the overall percentage of DGLA accounted 
for 4.4% of total fatty acids. Male C57BL/6 mice were starved for 24 hours prior to 
being given either control chow diet or the diet containing 4.4% (w/v) DGLA for 48 
hours. Mice were sacrificed using schedule 1 procedures and samples of plasma 
together with liver, kidney and adipose tissue were taken for lipid analysis. Table 3.4 
summarises the changes observed in the incorporation of DGLA and AA from in vivo 
feeding studies. Values that are underlined indicate statistically significant changes. 
The relative amount of DGLA significantly increased in all of the lipid fractions 
measured except kidney TPL and TAG, where the increases were not significant. For 
AA, despite a general trend of increased incorporation in DGLA group, only 
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incorporation into liver TAG fraction and kidney total phospholipids was significant. 
The results are discussed in more detail in the following sections.  
3.5.4.1 Plasma 
On feeding with diet containing 4.4% DGLA extracted from P. incisa, the levels of this 
PUFA were significantly increased in the plasma of mice. DGLA was significantly 
increased by 2% in TFA isolated from the plasma (Figure 3.11). When separated by 
1-dimensional TLC there was an increase of 3%, 1.2% and 2.6% in TPL, TAG and 
steryl ester fractions respectively. This indicated that incorporation of DGLA was 
primarily associated with the polar lipid fraction of plasma, followed by steryl esters 
and TAG. There was no significant increase in the levels of AA into any of these 
fractions despite a general trend to increase. In the DGLA group there was also a 
significant decrease in the levels of EPA in TFA and steryl ester fractions of the 
plasma. Similar results have been observed in previous studies. Single doses of 0.1-
2.0 g of DGLA in humans increased the plasma concentrations of the PUFA in plasma 
lipid fractions (Kernoff et al. 1977). Studies in rats showed significant increase in the 
concentration of DGLA in the plasma when infused with an emulsion containing 10% 
tridihomo-gamma-linolenoyl-glycerol (Nakamura et al. 1993). DGLA supplementation 
significantly increased the levels of this PUFA in the serum of rats, along with an 
increase in AA (Umeda-Sawada et al. 2006). There was also a significant decrease 
in oleic acid, LA, EPA and DHA (Umeda-Sawada et al. 2006). Following 
supplementation with GLA, levels of GLA, DGLA and AA all significantly increased in 
human serum lipids. The increases were significant after 2 weeks supplementation 
(Johnson et al. 1997). In addition to this, the increase in DGLA and AA was found 
specifically to phospholipids and no other lipid classes (Johnson et al. 1997).  
3.5.4.2 Tissues 
Samples of liver, kidney and adipose tissue were taken to determine the effect of a 
DGLA-containing diet on the lipids of these tissues. In the liver, the DGLA-fed group 
showed a 1% increase in the incorporation of DGLA into TFA (Figure 3.12). On further 
analysis it was found that DGLA was increased by 0.9%, 0.5% and 2.2% into TPL, 
TAG and steryl esters respectively. There was a significant increase in AA in TAG 
fraction of liver of 0.9% and an increase of 0.9% and 2.2% in TPL and steryl esters 
respectively. However these were not significant. This suggested that DGLA and AA 
were primarily associated with steryl esters in the liver, followed by TPL and TAG. In 
addition, there was also a decrease in the level of DHA into TPL.  
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Due to the large amount of lipid extracted from the liver, further analysis was 
performed to establish the effect of the DGLA diet on fatty acid profiles of individual 
phospholipid classes. It was found that there was a significant increase in DGLA into 
PS, PE and PC (Figure 3.13). There was also an increase in incorporation into PI. 
However, this was not significant. DGLA primarily accumulated in PC, with the largest 
increase of 1.2%. This was also the case for AA, with an increase of 2.2%. However 
this was not significant. In addition, there was also a significant decrease in the level 
of DHA and EPA into PE, along with a decrease in DHA incorporation into PC.  
In the kidney, DGLA increased by 0.7% into TFA in the DGLA group; however, there 
were no significant increases in the TPL or TAG fractions (Figure 3.14). Levels of AA 
into TPL increased significantly by 1.3%. However, in the TAG fraction, there was a 
significant decrease in the relative amount of AA by 0.8%. Finally in adipose tissue, 
DGLA levels significantly increased by 0.5% into TFA. Given the small amount of 
tissue isolated during dissection, no further analysis was performed on adipose 
tissue. There were no other significant changes in fatty acid profiles observed.  
Previous work detailing the incorporation of DGLA into tissues has been limited with 
relatively few studies having reported results. Fatty acid composition in the liver of 
rats supplemented with DGLA (in the form of TAG) showed a significant increase in 
the accumulation of the PUFA. The accumulation of AA also increased significantly 
(Umeda-Sawada et al. 2006). In a dose-response experiment, AA levels were not 
significantly different from control at lower levels of DGLA supplementation in the liver 
and plasma. However AA levels increased in a dose-dependent manner. There was 
also a dose-dependent decrease in the concentration of DHA (Umeda-Sawada et al. 
2006). In ApoE deficient mice supplemented with DGLA for 6 months, the percentage 
of DGLA in liver phospholipids increased significantly (Takai et al. 2009). There was 
no increase in the levels of AA after 6 months (Takai et al. 2009).  
In human cells, isolated steryl esters will be almost entirely in the form of cholesteryl 
esters. Accumulation of PUFA in cholesteryl esters has previously been shown to 
alter its accumulation and metabolism. In one study, on incubation of macrophages 
with omega-3 fatty acids, EPA and DHA were significantly accumulated in the 
cholesteryl ester fraction (Lada et al. 2003). This was accompanied by a physical 
change in the fluidity of cholesteryl ester droplets resulting in increased hydrolysis 
and efflux of cholesterol from the cell (Lada et al. 2003). Omega-6 fatty acids were 
also used in the study, with LA the major component. There was a significant 
accumulation of LA in cholesteryl ester fractions, with no elevation of other omega-6 
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fatty acids measured. Omega-6 supplementation had a significant effect on 
cholesterol efflux, however this was not as pronounced as seen in omega-3 group 
(Lada et al. 2003). Given the accumulation of DGLA into cholesteryl esters in vivo 
observed in Figures 3.11 and 3.12, it would be interesting to determine the effect of 
this accumulation on cholesteryl ester physical state and any resulting changes in 
metabolism and efflux.  
In vivo feeding studies with DGLA have previously been limited, particularly in 
measuring the effect of supplementation on fatty acid profiles of tissues. Overall, 
results of in vivo studies presented in this chapter indicated that a 4.4% DGLA-
containing diet, extracted from mutant algae P. incisa, allowed for significant 
incorporation of DGLA into plasma and tissues of liver, kidney and adipose lipid 
fractions after just 48 hours feeding. In most cases this was accompanied by no 
significant increase in AA incorporation. However, the general trend suggested that a 
DGLA diet increased AA incorporation in the majority of lipid fractions measured. This 
is shown in Table 3.4. An increase in AA incorporation following DGLA 
supplementation has also been observed in previous studies. In plasma, 
supplementation with DGLA increases the concentration of the PUFA in lipid fractions 
including an increase of AA (Johnson et al. 1997; Umeda-Sawada et al. 2006). In 
addition, rats supplemented with dietary DGLA significantly accumulated both DGLA 
and AA in liver (Umeda-Sawada et al. 2006).  
It is known that different cell types have different desaturase and elongase activities 
(Johnson et al. 1997), which may act to explain the differences in the accumulation 
of DGLA and AA seen in in vitro and in vivo experiments presented in this chapter. 
As previously discussed in Section 3.5.1, macrophages, among other cell types, have 
been reported to have limited desaturase activity (Chapkin et al. 1988; Johnson et al. 
1997). Several tissues however, contain both high activities of elongase and 
desaturase enzymes including the liver, kidney, brain and intestines (Johnson et al. 
1997). This may suggest that in cell types and tissues such as those with active 
desaturase activity, DGLA would be metabolised to AA and both PUFAs would be 
accumulated. Despite this, another study performed in an atherosclerotic mouse 
model supplemented with DGLA, indicated an accumulation of DGLA in liver 
phospholipids with no subsequent AA accumulation after 6 month feeding (Takai et 
al. 2009).  Given the relatively short feeding time adopted in our experiments it is 
difficult to assess the long term effect of DGLA and AA accumulation into lipid 
fractions of mouse tissue following feeding. A larger period of feeding in the 
experiment may have also significantly increased levels of AA as well as DGLA, given 
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the trend of increase observed. Future experiments could act to establish the 
incorporation of DGLA and AA in a time-dependent manner.  
3.5.4.3 Omega-3 incorporation 
It was observed in vivo that on feeding with a DGLA diet, there were percentage 
changes in the levels of omega-3 fatty acids EPA and DHA into lipid fractions. For 
example in liver phospholipids, percentage level of DHA was decreased in TPL 
(Figure 3.13) and EPA in the total fatty acids of plasma (Figure 3.11). A general trend 
of reduced levels of omega-3 fatty acids was observed in the DGLA group. This has 
also been shown previously in vitro. Analysis in a mouse fibrosarcoma cell line 
indicated that omega-6 fatty acids reduced the levels of EPA into cellular 
phospholipids and promoted their re-distribution to TAG fractions (Rubin and 
Laposata 1992). This adverse effect on PUFA incorporation has also been observed 
in omega-3 studies. EPA and DHA supplementation in humans, lowered the 
production of 15-HETrE in blistering wounds suggesting these PUFA compete directly 
for fatty acid incorporation and metabolism with DGLA (McDaniel et al. 2011). 
However, in addition to reducing the incorporation and metabolism of DGLA, omega-
3 supplementation changes AA levels. It has previously been shown that omega-3 
fatty acids compete with omega-6 fatty acids for delta 5 desaturase, the enzyme 
responsible for the conversion of DGLA to AA (Rubin and Laposata 1992; Barham et 
al. 2000). Supplementation of EPA in humans significantly increased plasma levels 
of EPA, while reducing AA levels and the AA:EPA ratio. This was accompanied by an 
increase in EPA metabolites through LOX and COX pathways (McDaniel et al. 2011).  
Co-supplementation studies with both omega-3 and -6 fatty acids have combined the 
benefits of accumulation of DGLA, EPA and DHA while reducing the accumulation of 
AA in lipid fractions. Co-supplementation of GLA and EPA significantly increased the 
accumulation of these two PUFA in human serum and neutrophil phospholipids, with 
no increase in AA (Barham et al. 2000). Although isolated neutrophils from patients 
supplemented with GLA and EPA had similar amounts of AA, there was a significant 
reduction in leukotrienes released in comparison to control (Barham et al. 2000). 
GLA-containing oils increased AA incorporation into cholesteryl esters and 
phospholipid fractions of human serum. However, this was not observed on co-
supplementation with EPA (Miles et al. 2004). Similarly, GLA co-supplemented with 
EPA and DHA dose-dependently increased DGLA and decreased AA levels in the 
TPL fraction of human serum (Laidlaw and Holub 2003). Supplementation with a 
combination of GLA and DHA containing oils in healthy women, significantly 
increased the levels of GLA, DGLA and DHA in plasma total lipids, TPL and TAG 
 
 
123 
 
fractions (Geppert et al. 2008). There was no increase in AA observed in total lipids 
and TPL but a small accumulation in TAG fraction, which returned to control levels 
after further supplementation (Geppert et al. 2008).   
Taken together the results presented in this chapter and previous studies show that 
supplementation with both omega-3 (EPA and DHA) and -6 (GLA/DGLA) fatty acids 
can increase accumulation of both these desirable anti-inflammatory PUFAs with no 
rise in the accumulation of AA. This may prove beneficial in disease. Co-
supplementation with omega-3 and -6 fatty acids produced more favourable results 
on risk factors of atherosclerosis compared to omega-3 supplementation alone.  In 
humans the atherosclerotic index decreased by 12% on supplementation with a 
combination diet, compared to a 6% decrease with omega-3 fatty acids alone 
(Haglund et al. 1998). Future work may act to establish the role of co-supplementation 
with certain omega-3 and -6 PUFAs and evaluate their combined role on 
inflammation.  
3.5.4.4 P.incisa as a source of DGLA 
Extraction of total lipids from P. incisa (containing DGLA) provided a source of the 
PUFA in the form of TAG. Studies in vitro (Appendix 4) and in vivo (presented in this 
chapter) indicated that DGLA isolated from P. incisa increased the levels of DGLA in 
polar, TAG and steryl ester lipid fractions of macrophages and mouse plasma and 
tissues. In addition to this, a preliminary experiment indicated that DGLA (hydrolysed 
from the total lipid extracts of mutated algae: method detailed in 2.2.13.1) inhibited 
pro-inflammatory gene expression in THP-1 macrophages (Appendix 5) comparable 
to that observed with pure DGLA (data presented in Chapter 4).  
Previously there has been some controversy regarding the use of polar lipid or TAG 
as dietary sources of fatty acids. A number of studies have investigated the effects of 
omega-3 PUFAs, EPA and DHA, when administered as polar lipid or TAG. In mice 
fed a high fat diet, omega-3 fatty acids administered in polar lipids were observed to 
reduce obesity and glucose intolerance more so than TAG derived fatty acids 
(Rossmeisl et al. 2012). Omega-3 fatty acids in polar lipids showed better 
accumulation and bioavailability in comparison to the TAG. However, it was also 
observed that omega-3 fatty acids from TAG lowered cholesterol levels more than 
using the polar lipid (Rossmeisl et al. 2012). In addition, it was observed that in mice 
fed polar lipid and TAG forms of omega-3 fatty acids, both had similar effects on 
inflammatory profiles (Awada et al. 2013) but concentrations of EPA and DHA in the 
plasma were higher in the TAG group to that of polar lipid group. There was however 
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a significant effect on adipose tissue cell size in the polar lipid diet, which was not 
significant in the TAG diet despite an observed decrease (Awada et al. 2013). This 
suggested that polar lipid carrier was more effective at reducing body fat deposition 
than the TAG carrier (Awada et al. 2013).  
Fish oils are a rich source of omega-3 fatty acids in the TAG form, whereas krill oil 
contains omega-3 fatty acids primarily in the polar lipid form. On feeding mice with 
these two forms of omega-3 fatty acids, it was observed that they were comparable 
dietary sources (Vigerust et al. 2013). There was no difference between carriers on 
the effects of lowering inflammation and cholesterol levels. However there was a 
small preference for krill oil over fish oil in promoting lipid catabolism (Vigerust et al. 
2013). Finally, another study investigating the role of krill oil and fish oil reported, 
again, that both sources were comparable (Ulven et al. 2011). They observed a 
significant increase in EPA, DHA and DPA incorporation into plasma lipid fractions of 
humans following supplementation, which was not significantly different between krill 
oil and fish oil groups (Ulven et al. 2011). However, lower doses of krill oil were 
needed in comparison to fish oil (Ulven et al. 2011).  
Taken together, previous studies suggest that dietary sources of fatty acids from polar 
lipid and TAG are comparable and there is no significant difference between their 
effect on the regulation of inflammation and cholesterol homeostasis (Ulven et al. 
2011; Rossmeisl et al. 2012; Awada et al. 2013). However, studies suggest a slight 
advantage of PUFA in polar lipid form on obesity and regulation of adiposity 
(Rossmeisl et al. 2012; Awada et al. 2013). Despite this, TAG remains a good dietary 
source of PUFA in vivo and studies utilising DGLA contained in TAG form from P. 
incisa provide promising insight into its commercial use as source of the PUFA. 
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CHAPTER 4  
THE ROLE OF DGLA ON THE PROPERTIES OF 
MACROPHAGES AND THEIR FUNCTION IN 
ATHEROSCLEROSIS  
 
4.1 Introduction 
4.1.1 Role of macrophages in atherosclerosis 
Macrophages are key players in diseases associated with chronic inflammatory 
disorders such as atherosclerosis (Moore and Tabas 2011). Understanding the role 
of macrophages in atherosclerosis is important in advancing our knowledge of the 
molecular basis of this disease and for the development of preventative/therapeutic 
approaches (Dickhout et al. 2008). Macrophage foam cell formation is a hallmark of 
the early stages of atherosclerosis and lays the foundation for advanced plaque 
development. This process is discussed in further detail in Section 4.1.2. 
Macrophages also continue to play an important role once an atherosclerotic plaque 
with foam cells has formed. An on-going release of pro-inflammatory cytokines and 
pro-apoptotic factors from macrophages continues to increase lesion size and trigger 
apoptosis of SMCs (Moore and Tabas 2011). In addition, secretion of MMPs 
destabilises the plaque via degradation of the extracellular matrix increasing the risk 
of plaque rupture (Dickhout et al. 2008). Finally, defective clearance of 
macrophages/apoptotic cells (i.e. efferocytosis) from advanced plaques results in 
plaque necrosis and rupture (Moore and Tabas 2011). Targeting macrophages can 
therefore be of therapeutic interest given their important role in atherosclerosis 
pathology.     
4.1.2 Foam cell formation 
Atherosclerosis is a complex multi-stage disease with numerous factors contributing 
to its pathogenesis. The initial stage of atherosclerosis involves formation of lipid 
loaded macrophages, commonly referred to as foam cells. Foam cells accumulate in 
the walls of large arteries and build up to form fatty streaks (Lusis 2000). Although 
not clinically significant, fatty streaks provide the underlying basis for the maturation 
of atherosclerotic lesions (Lusis 2012). Targeting foam cell formation as a primary 
event in atherosclerosis to attenuate or prevent progression of this disease is 
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therefore of therapeutic interest. In this chapter, the effect of DGLA on numerous 
stages of foam cell formation and macrophage behaviour was investigated.  
4.1.2.1 Initiation and lipoprotein modification 
ROS are increased in a number of cardiovascular diseases, including atherosclerosis, 
which suggests that they play an important role in the pathogenesis of the disease 
(Heistad et al. 2009). Several factors have been linked to increased ROS production 
including hypercholesterolemia, hypertension, diabetes, obesity, smoking and age, 
which are also common risk factors in atherosclerosis (Lusis et al. 2004). According 
to the oxidative modification hypothesis, atherosclerosis is the result of oxidative 
modification of LDL in the arterial wall by ROS (Singh and Jialal 2006; Vogiatzi et al. 
2009). Accumulation and retention of oxLDL in the arterial wall and oxidative stress 
can induce the overlying endothelium to release factors promoting an inflammatory 
response and initiate the process of foam cell formation (Libby 2012). Attenuating 
ROS production may reduce the formation of oxLDL and prevent the initiation of foam 
cell formation.  
4.1.2.2 Monocyte recruitment and migration 
Damage to the endothelial wall of arteries, as a result of high oxidative stress, 
activates endothelial cells, which express a number of chemokines and adhesion 
molecules, to recruit and adhere circulating monocytes to the site of activation 
(Bobryshev 2006). MCP-1 plays a key role in monocyte recruitment. Release of MCP-
1 recruits monocytes from the circulation. Once recruited, monocytes roll across the 
endothelium and firmly adhere to the surface tethered by various adhesion proteins 
including selectins, integrins, ICAM-1 and VCAM-1 (Lusis 2000; Bobryshev 2006). 
Monocytes transmigrate through the intracellular junctions of endothelial cells into the 
arterial intima where they are stimulated to differentiate into macrophages, largely 
under the control of the chemokine M-CSF (Bobryshev 2006). Subsequent 
description will focus on two key factors implicated in the recruitment of monocytes, 
MCP-1 and ICAM-1.  
4.1.2.2.1 MCP-1 
Chemokines (chemotactic cytokines) are small heparin binding proteins whose main 
function is to regulate cell trafficking (Deshmane et al. 2009). MCP-1 is an 
inflammatory chemokine, 76 amino acids in length, 13k Da in size and a member of 
the C-C chemokine family (Deshmane et al. 2009). It is expressed by the various cells 
involved in atherosclerosis following the initiation of a chronic inflammatory response 
by the activated endothelium in the disease and is a potent chemoattractant for 
 
 
127 
 
circulating monocytes. In vivo studies have shown that MCP-1 deficiency significantly 
reduces the extent of atherosclerosis in ApoE knockout mice  (Gosling et al. 1999). 
These mice showed smaller, less extensive lesions, with a significantly lower content 
of macrophages (Gosling et al. 1999). In addition, increasing expression of MCP-1 by 
leukocytes significantly increases the size of atherosclerotic lesions in ApoE knockout 
mice (Aiello et al. 1999). These findings indicate MCP-1 as a potentially promising 
therapeutic target in atherosclerosis. 
4.1.2.2.2 ICAM-1 
ICAM-1 is an inducible cell surface glycoprotein belonging to the immunoglobulin 
supergene family and is expressed on endothelial cells to facilitate the attachment of 
monocytes recruited to the activated endothelium during the inflammatory response 
in atherosclerosis (Roy et al. 2001). Binding of monocytes to the endothelium allows 
for their transmigration into the arterial intima where they can differentiate into 
macrophages and progress to foam cells (Lusis 2000). ICAM-1 is strongly expressed 
at the sites of atherosclerotic lesions indicating the important role of this adhesion 
molecule in the pathology of this disease. In addition to this, studies have shown that 
ApoE-/- ICAM-1-/- mice have significantly smaller lesions in comparison to ApoE-/- 
ICAM-1+/+ mice (Kitagawa et al. 2002). As with MCP-1, the important role of ICAM-1 
in the early inflammatory response indicates that therapeutic targeting of this 
adhesion protein could play an important role in the prevention of atherosclerosis.  
4.1.2.3 Cytokine induced pro-inflammatory gene expression 
Cytokines play an important role in foam cell formation by orchestrating an 
inflammatory response. They include more than 50 secreted factors and have 
numerous roles in cellular communication (Tedgui and Mallat 2006; Ramji and Davies 
2015). Cytokines can be classified into two groups based on their role in inflammation; 
pro-inflammatory and anti-inflammatory (Tedgui and Mallat 2006). See Section 1.4.1 
for more detail on cytokine signalling in atherosclerosis. The expression of many pro-
inflammatory cytokines are up regulated in atherosclerosis and contribute significantly 
to foam cell formation and plaque development (Gupta et al. 1997; Kirii et al. 2003; 
Popa et al. 2007). Inhibition of pro-inflammatory cytokine signalling is therefore 
another potential therapeutic target in the prevention and treatment of 
atherosclerosis. Subsequent description will focus on three important pro-
inflammatory cytokines employed in the studies in this chapter and have key roles in 
atherosclerosis; IFN-γ, IL-1β and TNF-α. See Table 4.1 for the role of the cytokines 
in pro-inflammatory gene expression.  
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Table 4.1 – Role of IFN-γ IL-1β and TNF-α in pro-inflammatory gene expression 
 
 
4.1.2.4 Inflammasome IL-1β production  
Before it can elicit its pro-inflammatory signalling actions, the various cell types must 
first secrete IL-1β. This involves a multi protein complex known as the inflammasome. 
The release of mature IL-1β is a multi-step process involving up regulation of the 
expression of pro-IL-1β followed by inflammasome activation, which allows for 
caspase-1 dependent cleavage of pro-IL-1β into its active form (Moore et al. 2013). 
The NLRP3 inflammasome has been described as the key regulator of IL-1β 
production from macrophages and plays an important role in many inflammatory 
diseases including atherosclerosis (Moore et al. 2013). Activation of the 
inflammasome and their role in IL-1β activation is discussed in more detail in Section 
1.4.1.2.1. Studies in THP-1 macrophages have determined the role of the NLRP3 
inflammasome in production of IL-1β (Rajamaki et al. 2010). Omega-3 fatty acids EPA 
and DHA have been shown to inhibit inflammasome dependent IL-1β production, 
indicating PUFAs can play an important role in the process (Yan et al. 2013; Williams-
Bey et al. 2014).  
Cholesterol crystals are components of atherosclerotic plaques and were first thought 
to be deposited in plaques as pathology progressed to later stages and therefore 
weren’t a primary initiating factor of atherosclerosis. Using laser reflection and 
fluorescence confocal microscopy, cholesterol crystals were observed within 2 weeks 
Cytokine Role in pro-inflammatory gene expression 
IFN-γ Induce expression of adhesion molecules ICAM-1 and VCAM-1 (Li et 
al. 1993; Chung et al. 2002). Increase scavenger receptor CXCL 
16/SR-PSOX (Wuttge et al. 2004) but down regulate SRA and CD36 
(Nakagawa et al. 1998; Grewal et al. 2001) 
IL-1β mRNA levels of VCAM-1 and MCP-1 reduced in ApoE-/- IL-1β-/- 
deficient mice (Kirii et al. 2003).  
TNF-α ApoE-/- TNF-α-/- decreased expression of VCAM-1, MCP-1, GM-CSF 
(Xiao et al. 2009). Using the same knockout system, ICAM-1 and SRA 
expression were also reduced (Ohta et al. 2005).  
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of fat feeding ApoE-/- mice with a high fat diet (Duewell et al. 2010). They were 
localised to immune cells in the sub endothelial arterial layer. Immune cell recruitment 
and cholesterol crystal deposition progressively increased through feeding (Duewell 
et al. 2010). In human atherosclerotic lesions cholesterol crystals were rich in areas 
abundant in immune cells. Cholesterol crystals have been observed to induce 
inflammasome activation in in vivo mouse models and in vitro THP-1 macrophages 
(Duewell et al. 2010). Given the role of PUFAs and cholesterol crystals in 
inflammasome activation, the role of DGLA in cholesterol crystal-induced 
inflammasome activation and IL-1β regulation was investigated.  
4.1.2.5 LDL uptake and cholesterol cycle 
Once monocytes have migrated across the endothelium layer and into the arterial 
intima, they are stimulated to differentiate into macrophages. Normally, LDL is taken 
up by the LDLr expressed on macrophages, which is subject to feedback inhibition at 
the transcriptional level so limits the uptake of this lipoprotein. Macrophages however 
also express scavenger receptors that can recognise, bind and internalise modified 
forms of LDL in an unregulated manner. Once internalised, the cholesteryl ester 
contained within the LDL is digested to unesterified/free cholesterol by an acid 
cholesterol ester hydrolase in lysosomes (Daugherty et al. 2008). This free 
cholesterol is re-esterified to cholesteryl esters by the enzyme ACAT (Ghosh et al. 
2010). Further detail on macrophage cholesterol homeostasis is described in Section 
1.2.2.1. This esterified cholesterol has two fates: first it is once again hydrolysed to 
free cholesterol by one of a group of enzymes collectively referred to as neutral 
cholesterol ester hydrolase (nCEH) (Sekiya et al. 2009) and removed from the 
macrophage by several extracellular transporters. Second; it is stored as cholesteryl 
esters in the cytoplasm as lipid droplets (Daugherty et al. 2008). The rate-limiting step 
in the cholesteryl ester cycle in macrophages is the nCEH enzyme reaction allowing 
for clearance of free cholesterol from the macrophage. Excessive uptake of modified 
LDL therefore increases the storage of cholesteryl esters in lipid droplets. An 
increased amount of lipid in the cytoplasm of macrophages promotes the conversion 
of macrophages to lipid loaded foam cells (Ghosh et al. 2010).  Inhibition of 
cholesteryl ester accumulation would therefore attenuate foam cell formation.  
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4.2 Aims 
Atherosclerosis is an inflammatory disorder regulated by cytokines such as IFN-γ, IL-
1β and TNF-α. Nutraceuticals represent a promising therapeutic avenue in preventing 
and limiting atherosclerosis. It is therefore important that a thorough understanding of 
their actions in atherosclerosis together with the underlying molecular mechanisms is 
attained. Previous studies have revealed an anti-atherogenic role of DGLA. However, 
its actions on several key macrophage processes associated with atherosclerosis is 
poorly understood and formed the basis of studies in this chapter. The major focus 
was to delineate its effect in pro-inflammatory gene expression and several 
macrophage properties in this disease in vitro. Macrophages play a key role in the 
initiating stage of atherosclerosis, foam cell formation, right through to plaque 
progression and rupture (Moore and Tabas 2011; Michael et al. 2012). Given their 
important role in the disease, the action of DGLA on macrophages was the main focus 
of the project (see Figure 4.1 for the experimental plan employed for studies in this 
chapter).  
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4.3 Experimental plan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 – Overview of experimental strategy to determine the effect of DGLA 
on key steps involving macrophages during atherosclerosis 
Top (blue); experiments performed in THP-1 cell line. Experiments include in monocytes -
migration and ROS production; and in macrophages – ROS production, gene expression and 
inflammasome activation. Bottom (red); experiments performed in RAW264.7 cell line, 
including gene expression and acLDL induced cholesteryl ester accumulation.   
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THP-1 monocytes 
THP-1 macrophages 
RT-qPCR analysis of 
DGLA action on IFN-γ, 
TNF-α and IL-1β induced 
gene expression 
Confirm key results 
in HMDMs 
Effect of DGLA on 
monocyte migration 
Measure the effect of 
DGLA on ROS 
production 
DGLA effect on IL-1β 
release via activation 
of inflammasome 
RAW264.7 macrophages 
Effect of DGLA on acLDL 
induced cholesteryl ester 
formation 
RT-qPCR analysis of 
DGLA action on IFN-γ 
induced gene 
expression 
 
 
132 
 
4.4 Results 
4.4.1 Optimisation of PCR conditions 
4.4.1.1 Designing PCR primers 
Initial optimisation of gene expression was performed using RNA from THP-1 
macrophages. RT-qPCR was performed using gene-specific primers. Primers were 
sourced from literature searches or designed through an online primer design tool. 
Optimisation of human MCP-1 gene will be used as an example of primer 
optimisation, which is representative of the steps taken with every sourced or self-
designed primer. Primers were first validated using an online primer-blast program to 
ensure primer sequences were specific to the intended gene. Figure 4.2 depicts an 
example of the result of a primer-blast search for MCP-1 primers.  
 
Figure 4.2 – MCP-1 primer blast results 
Primer sequences for MCP-1 were analysed by primer-blast online tool. Results indicate that 
the primers show 100% homology to human chemokine (C-C motif) ligand 2 (CCL2) more 
commonly referred to as MCP-1. 
 
4.4.1.2 Optimising primer annealing temperatures 
Concentrations of cDNA and primers used in RT-qPCR remained the same between 
every experiment; however primer-annealing temperatures could differ. Primers 
designed using an online tool were designed to anneal at 60ºC. However, in order to 
ensure this was indeed the optimum temperature, a PCR was performed with a range 
of annealing temperatures and the amplification products size fractioned by agarose 
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gel electrophoresis. Figure 4.3 displays the results of size fractionation of products 
from a PCR reaction using MCP-1 primers and different annealing temperatures. 
Bands were quantified and annealing temperature of 60ºC gave the greatest amount 
of MCP-1 product. This annealing temperature was therefore used in subsequent 
experiments.  
 
 
 
 
 
 
 
Figure 4.3 – Size fractionation of PCR products 
cDNA was subjected to PCR using MCP-1 primers at a range of annealing temperatures (59-
62ºC). PCR products were subjected to gel electrophoresis on a 1.5% (w/v) agarose gel for 1 
hour at 150V. An optimal annealing temperature of 60ºC was chosen for subsequent studies. 
The expected product size for MCP-1 is 141bp; the sizes of key markers that migrated near 
the amplification product are shown on the left of image. –RT; minus reverse transcriptase.   
 
4.4.1.3 Quality of RNA 
Before carrying out PCR reactions, RNA preparations were analysed for quality by 
resolving a small aliquot on a 1.5% (w/v) agarose gel. Good quality undegraded RNA 
generally produces two distinct bands corresponding to the 28S and 18S rRNA in a 
2:1 ratio. An example of such quality of RNA, which was obtained for studies 
presented throughout this thesis, is shown in Figure 4.4. The data for all the RNA 
preparation are therefore not shown for subsequent studies.  
  
59º     60º     61º     62º    -RT  
141bp   
150bp 
100bp 
50bp 
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Figure 4.4 – Agarose gel for the assessment of RNA quality  
Small aliquots of RNA were resolved on a 1.5% (w/v) agarose gel to assess RNA quality. 
Samples used were representative of RNA quality throughout experiments carried out in this 
thesis. Positions of the 28S and 18S rRNA bands are indicated on the right of the image. 
 
4.4.1.4 Melting peak analysis 
RT-qPCR was subsequently performed on RNA extracts using SYBR green, which 
interacts with double stranded DNA and fluoresces. The point at which the level of 
fluorescence surpasses a set threshold level is termed the Ct value and is used to 
calculate gene expression. See Section 2.2.8.2 for more detail on RT-qPCR. 
Amplification curves for GAPDH and MCP-1 are shown in Figure 4.5 (A and C). 
Following completion of RT-qPCR, melting curve analysis was carried out to ensure 
a single major peak corresponding to the amplification product. PCR products were 
subjected to a gradual increase in temperature whereby at a particular temperature 
the two strands in the DNA molecule dissociates and a drop in florescence is 
measured. Plotting the change in fluorescence against the change in temperature 
allows for a graph to be produced with a peak corresponding to the melting 
temperature of the product. One peak resulting from melting peak analysis indicates 
one product has been formed.  Figure 4.5 (B and D) indicates the melting peaks for 
RT-qPCRs performed using GAPDH and MCP-1. In each case, single peaks were 
observed indicating that a single product is being produced and the primers were 
specific and of high quality. Graphs shown in Figure 4.5 are representative of 
amplification curves and melting peaks obtained with other primers.   
28S rRNA 
18S rRNA 
band 
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Figure 4.5 – Melting curve analysis 
RT-qPCR was performed using GAPDH (A and B) and MCP-1 (C and D) primers. Graphs A 
and C display sigmoidal curves representative of amplification during the PCR reaction. 
Melting peaks (B and D) for both GAPDH and MCP-1 respectively indicate that one major 
product is formed due to the single peak.   
 
4.4.2 IFN-γ dose response experiments in THP-1 macrophages 
IFN-γ has been widely utilised previously in the laboratory and is a well-characterised 
pro-inflammatory cytokine in atherosclerosis. Due to its numerous roles in the 
initiation and the progression of the disease, the cytokine is often described as a 
master regulator of atherosclerosis (McLaren and Ramji 2009).  IFN-γ was therefore 
the main focus for the action of DGLA on pro-inflammatory signalling. Previous 
studies had used a relatively high concentration of IFN-γ (1000 U/ml). A dose 
response experiment using the IFN-γ inducible MCP-1 as a model gene was carried 
out to determine if a lower concentration could be used. THP-1 macrophages were 
treated with 100 U/ml, 250 U/ml, 500 U/ml and 1000 U/ml IFN-γ. MCP-1 mRNA levels 
were determined by RT-qPCR after 3 hours stimulation with the cytokine, a time point 
based on previous optimisation experiments in the laboratory monitoring induction of 
MCP-1 expression. As expected, all concentrations of IFN-γ induced the expression 
of MCP-1 (Figure 4.6). On treatment with 100 U/ml IFN-γ, the expression of MCP-1 
A B 
C D 
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was induced about 24-fold though this was not significant. Increasing the 
concentration of IFN-γ to 250 U/ml increased the induction level to 165-fold. 
Treatment with 500 U/ml and 1000 U/ml of the cytokine induced MCP-1 expression 
by 200-fold and 260-fold respectively. There was no significant difference between 
the three highest doses of IFN-γ (i.e. 250 U/ml, 500 U/ml and 1000 U/ml). Due to this, 
and the dramatic increase in the induction of MCP-1 expression when the 
concentration of IFN-γ was increased from 100 U/ml to 250 U/ml, the latter was 
selected as the optimum IFN-γ concentration and was used in all further experiments.  
 
 
 
 
 
 
 
 
 
 
Figure 4.6 – The expression of MCP-1 is induced by several concentrations of 
IFN-γ 
THP-1 macrophages were incubated for 3 hours with 100 U/ml, 250 U/ml, 500 U/ml and 1000 
U/ml of IFN-γ or the vehicle control as shown. RNA was extracted and subjected to reverse 
transcription and RT-qPCR using primers specific for MCP-1 or housekeeping gene GAPDH. 
Graph displays average fold-change in normalised MCP-1 expression (mean +/- SD) in 
comparison to control (arbitrarily assigned as 1) from three independent experiments. 
Statistical analysis was performed using a one-way ANOVA with Tukey’s post hoc analysis. 
*** P ≤ 0.001  
  
*** 
*** 
*** 
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4.4.3 Dose response experiments with DGLA 
After determining a suitable dose of IFN-γ for use in subsequent experiments, a range 
of concentrations of DGLA from 10 µM to 100 µM were evaluated with 250 U/ml of 
IFN-γ to establish a concentration for optimum inhibition of gene expression. 
Following PMA differentiation, THP-1 macrophages were pre-incubated with 10 μM, 
25 μM, 50 μM and 100 µM of DGLA or the DMSO vehicle control for 24 hours (a time 
point previously optimised by investigation of DGLA incorporation into polar lipids), 
followed by treatment with vehicle or 250 U/ml IFN-γ for a further 3 hours. The 
expression of MCP-1 and ICAM-1, another pro-inflammatory gene known to be up-
regulated by IFN-γ (Li et al. 2010), was measured by reverse transcription and RT-
qPCR. As expected, MCP-1 and ICAM-1 expression was significantly induced by IFN-
γ. DGLA at concentrations of 25 μM, 50 μM and 100 µM produced significant inhibition 
of the IFN-γ-induced expression of MCP-1 by an average of 32%, 46% and 76% 
respectively (Figure 4.7). A similar trend in the suppression of IFN-γ-induced ICAM-1 
expression was also observed with all the concentrations of DGLA used (Figure 4.7). 
However, the only concentration of DGLA to significantly inhibit the IFN-γ-induced 
ICAM-1 expression was 50 µM, where an average decrease of 31% was observed. 
Given the significant inhibition of IFN-γ-induced expression of two key pro-
inflammatory genes by 50 μM DGLA, this concentration was used for further gene 
expression analysis.  
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Figure 4.7 – Concentration-dependent inhibition of IFN-γ-induced MCP-1 and 
ICAM-1 expression by DGLA 
THP-1 macrophages were pre-incubated with 10 μM, 25 μM, 50 μM and 100 µM DGLA or 
DMSO vehicle for 24 hours followed by incubation in the presence of vehicle (Control) or 250 
U/ml IFN-γ for 3 hours. Total RNA was subjected to reverse transcription and RT-qPCR with 
primers specific for MCP-1, ICAM-1 or GAPDH control. Graphs display average normalised 
gene expression (mean +/- SD) (control arbitrarily assigned as 1) from three independent 
experiments. Statistical analysis was performed using a one-way ANOVA (equal variances) 
with Tukey’s post hoc for MCP-1. For statistical analysis for ICAM-1, due to unequal variances, 
Welch’s test followed by Dunnett’s T3 post hoc analysis was performed. * P ≤ 0.05, *** P ≤ 
0.001 
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4.4.4 Viability assays 
After determining the optimum concentrations of DGLA and IFN-γ, the viability of 
THP-1 macrophages under these conditions was assessed. For this, two tests of 
cellular viability were employed. LDH is a cytosolic enzyme present in numerous cell 
types and extracellular release of LDH is an indication of damage to the cellular 
membrane. Measuring LDH release from THP-1 macrophages into the overlying 
media, in comparison to a positive and negative control, was used as an indication of 
cellular damage. The optimised concentration of DGLA and IFN-γ were used in these 
experiments (i.e. 50 μM and 250 U/ml respectively). As shown in Figure 4.5, no effect 
on LDH release was observed by incubation of the cells with IFN-γ and DGLA when 
compared to the negative control (i.e. vehicle-treated cells) (Figure 4.8). In addition 
to the LDH release assay, crystal violet staining was utilised. Crystal violet is used to 
stain adherent cells. It binds to DNA in the nucleus of the cell and therefore correlates 
to cell numbers. Cells that detach from plastic surface of tissue culture flasks are 
assumed non-viable, remain in the supernatant and are washed away before 
quantification. There was no difference observed in cell viability/proliferation as 
determined by this method between control and IFN-γ and/or DGLA treated THP-1 
macrophages under all experimental conditions (Figure 4.8). Taken together, the 
results from the LDH and crystal violet assay suggest that there is no adverse effect 
of 50 μM DGLA and/or 250 U/ml IFN-γ on cell viability. These conditions were 
therefore employed throughout study.   
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Figure 4.8 – DGLA and/or IFN-γ has no effect on cell viability of THP-1 
macrophages 
THP-1 macrophages were incubated with 50 µM DGLA or the DMSO vehicle control for 24 
hours and then in the presence of 250 U IFN-γ or vehicle for a further 3 hour. Media was 
removed and used to determine LDH release. The remaining THP-1 macrophages were then 
used in the crystal violet assay. Both graphs display average fold-change of absorbance 
values (mean +/- SD) in comparison to control (arbitrarily assigned as 1) from three 
independent experiments. Statistics were performed using one-way ANOVA, comparing each 
individual treatment to control. N.S – not significant 
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4.4.5 The effect of DGLA on ROS production 
ROS production plays an important role in the pathology of atherosclerosis by 
modifying LDL, which can then be recognised by macrophage scavenger receptors. 
The effect of DGLA on ROS production from THP-1 monocytes and macrophages 
was measured to determine if the lipid possessed any anti-oxidant capacity. 
Monocytes and macrophages produce and release ROS in response to stimulation 
with pro-inflammatory agents and oxidants such as hydrogen peroxide (Forman and 
Torres 2001). The assay was performed as per manufacturer instructions (AbCam), 
including concentrations and incubation times. Briefly, monocytes or macrophages 
were incubated with DCFDA, which diffuses into cells and is oxidised by ROS to a 
fluorescent compound that can be measured by fluorescence spectroscopy. A 
positive control supplied by the kit, TBHP, was used to induce ROS production by 
monocytes and macrophages and therefore increased production of fluorescent 
compound. DGLA was co-incubated with monocytes and TBHP whereas 
macrophages were pre-incubated with DGLA for 24 hours (as in gene expression 
studies) prior to the addition of TBHP, to determine the effect on ROS production. As 
shown in Figure 4.9, TBHP significantly induced ROS production in both monocytes 
(A) and macrophages (B). However, co-incubation with DGLA in monocytes or pre-
incubation in macrophages had no effect on the increase in ROS production.  
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Figure 4.9 – DGLA has no effect on the TBHP-induced ROS production in THP-
1 monocytes or macrophages 
THP-1 monocytes (A) were incubated with 35 µM DCFDA for 30 minutes followed by 100 µM 
TBHP in the presence of 50 µM DGLA or the vehicle control for 3 hours.  THP-1 macrophages 
(B) were pre incubated with 50 µM DGLA or vehicle control for 24 hours prior to incubation 
with 35 µM DCFDA for 30 minutes and 100 µM TBHP for 3 hours. Cells incubated with vehicle 
in the absence of TBHP were included as control. Fluorescence was measured at 495 nm and 
529 nm for excitation and emission spectra respectively. Graph displays average mean +/- 
SD from three independent experiments. The value in the TBHP positive control has been 
arbitrarily assigned as 100%. Statistical analysis was performed using a one-way ANOVA 
followed by Tukey’s post hoc. ** P ≤ 0.01, *** P ≤ 0.001, N.S – not   significant. 
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4.4.6 The effect of DGLA on the expression of MCP-1 and ICAM-1 induced by 
different pro-inflammatory cytokines in human macrophages 
4.4.6.1 IFN-γ 
4.4.6.1.1 THP-1 
IFN-γ has been well documented in the laboratory to induce the expression of MCP-
1 and ICAM-1 in THP-1 macrophages (Li et al. 2010). THP-1 macrophages were pre-
incubated with vehicle or DGLA for 24 hours followed by incubation for 3 hours in the 
presence of vehicle or IFN-γ. MCP-1 and ICAM-1 mRNA expression was significantly 
induced by IFN-γ in THP-1 macrophages by about 46-fold and 4-fold respectively 
(Figure 4.10). Pre-treatment of the cells with DGLA produced a significant reduction 
of approximately 24% and 32% respectively of the IFN-γ-induced MCP-1 and ICAM-
1 expression. Interestingly, there was also a significant difference between the basal 
expression levels of MCP-1 between cells treated with vehicle or DGLA. Thus, there 
was an average of 46% reduction in MCP-1 expression produced by treatment of the 
cells with DGLA when compared to the vehicle control (Figure 4.10). Such an action 
of DGLA was specific to MCP-1 and not seen with ICAM-1 expression, where there 
was no significant difference between control and DGLA treatment (Figure 4.10).  
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Figure 4.10 – DGLA significantly inhibits the IFN-γ-induced expression of MCP-
1 and ICAM-1 in THP-1 macrophages 
THP-1 macrophages were incubated with vehicle or 50 µM DGLA for 24 hours prior to 
treatment with vehicle or 250 U/ml IFN-γ for 3 hours. Total RNA was subjected to reverse 
transcription and RT-qPCR with primers specific for human MCP-1, ICAM-1 or GAPDH. 
Graphs display average normalised gene expression (mean +/- SD) (control arbitrarily 
assigned as 1) from three independent experiments. Homogeneity of variances were not met 
for ANOVA therefore Welch’s test followed by Dunnett’s T3 post hoc tests were used ** P≤0.01 
*** P≤0.001. 
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4.4.6.1.2 RAW264.7 
Mouse models are commonly used in atherosclerosis research. However species-
specific regulation of gene expression between human and mouse have been found 
in some cases (Lin et al. 2014). In addition, differentiation of THP-1 monocytes into 
macrophages required PMA and it was possible that this could influence the results 
obtained. In order to rule out these possibilities, the experiments were repeated in the 
mouse RAW264.7 cell line that does not require PMA-mediated differentiation. 
Conservation of responses in RAW264.7 macrophages would allow use of this cell 
line to investigate the actions of DGLA if required. RAW264.7 macrophages were pre-
incubated with vehicle or DGLA for 24 hours followed by incubation in the presence 
of vehicle or IFN-γ for 3 hours. The concentrations of DGLA and IFN-γ used were 
identical to that optimised for THP-1 cells and so should allow direct comparison 
between the responses in the two cell types. Treatment of the cells with IFN-γ 
produced a significant induction of MCP-1 and ICAM-1 expression (Figure 4.11). Pre-
treatment of the cells with 50 μM DGLA followed by incubation with IFN-γ produced 
a significant attenuation of the expression of MCP-1 and ICAM-1 by an average of 
61% and 52% respectively. In addition, there was a 44% reduction in basal MCP-1 
expression on treatment of the cells with DGLA, as observed in THP-1 macrophages, 
however this was not significant. There was no observable difference in ICAM-1 
expression between vehicle and DGLA treated cells.  
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Figure 4.11 – DGLA significantly inhibits the IFN-γ-induced expression of MCP-
1 and ICAM-1 in RAW264.7 macrophages 
RAW264.7 macrophages were incubated with vehicle or 50 µM DGLA for 24 hours prior to 
treatment with vehicle or 250 U/ml IFN-γ for 3 hours. Total RNA was subjected to reverse 
transcription and RT-qPCR with primers specific mouse MCP-1, ICAM-1 or β actin. Graphs 
display average normalised gene expression (mean +/- SD) (control arbitrarily assigned as 1) 
from 3 independent experiments. Statistical analysis was performed using a one-way ANOVA 
and Tukey’s post hoc analysis. ** P≤0.01  
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4.4.6.1.3 HMDM 
Given the significant inhibition in expression by DGLA of two key IFN-γ induced 
inflammatory genes in both THP-1 and RAW264.7 macrophages, the experiments 
were repeated in primary cultures of HMDM. These experiments were carried out to 
rule out the possibility that the observed results are peculiar to the cell line. HMDM 
were pre-treated with 50 µM DGLA or vehicle for 24 hours followed by vehicle or 250 
U/ml IFN-γ for further 3 hours (identical conditions to that used for THP-1 and 
RAW264.7 macrophages). As shown in Figure 4.12, IFN-γ significantly induced the 
expression of both MCP-1 and ICAM-1 genes. Due to variability between IFN-γ 
induction of MCP-1 and ICAM-1 between experiments, the values obtained from cells 
treated with this cytokine was arbitrarily assigned as 1. Treatment with 50 µM DGLA 
produced a significant reduction of the IFN-γ-induced expression of MCP-1 by an 
average of 55% (Figure 4.12). There was no significant difference in basal MCP-1 
expression between the vehicle control and DGLA, as seen for THP-1 and RAW264.7 
macrophages. The IFN-γ-induced ICAM-1 expression was also reduced by DGLA by 
approximately 43%. However due to a high variability between experiments, this 
reduction was not significant though a trend in the inhibitory action of DGLA was 
observed in all experiments.  
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Figure 4.12 – DGLA inhibits the IFN-γ induced expression of MCP-1 and ICAM-
1 in HMDMs 
HMDMs were incubated with 50 µM DGLA or vehicle for 24 hours prior to treatment with 
vehicle or 250 U/ml IFN-γ for 3 hours. Total RNA was subjected to reverse transcription and 
RT-qPCR with primers specific for MCP-1, ICAM-1 or GAPDH. Graphs display average 
normalised gene expression (mean +/SD) (value from IFN-γ treated cells arbitrarily assigned 
as 1) from three independent experiments.  Statistical analysis was performed using a one-
way ANOVA and Tukey’s post hoc analysis. * P≤0.05, *** P≤0.001, N.S – not significant.  
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4.4.6.2 IL-1β and TNF-α 
Following on from the successful attenuation of IFN-γ induced expression of 
inflammatory genes MCP-1 and ICAM-1 by DGLA, it was of interest to determine if 
this inhibition was specific to IFN-γ induction of these genes or it extended to other 
pro-inflammatory cytokines. Two cytokines were selected, IL-1β and TNF-α, due to 
their important roles in the control of inflammation during atherosclerosis. Both 
cytokines have also been shown to induce the expression of MCP-1 and ICAM-1 in 
vitro and in vivo (Myers et al. 1992; Pal et al. 1996; Ohta et al. 2005; Lim et al. 2009; 
Yang et al. 2010).  
THP-1 macrophages were treated with 1000 U/ml of IL-1β or TNF-α for 24 hours, a 
dose and time point previously used in the laboratory. As shown in Figure 4.13, IL-1β 
and TNF-α significantly induced both MCP-1 and ICAM-1 expression in THP-1 
macrophages. IL-1β induced MCP-1 expression by 3.5-fold and ICAM-1 by 1.3-fold. 
Similarly, TNF-α induced MCP-1 and ICAM-1 expression by 1.6-fold and 1.7-fold, 
respectively. Pre-treatment of the cells with 50 μM DGLA significantly inhibited the IL-
1β and TNF-α induced MCP-1 and ICAM-1 expression. The levels of MCP-1 and 
ICAM-1 were reduced to that observed in vehicle treated cells in the case of IL-1β. 
Similarly TNF-α induction of MCP-1 expression was reduced to control basal levels 
following pre-treatment of the cells with DGLA. On the other hand, the TNF-α induced 
ICAM-1 expression was reduced by 25% following pre-treatment of the cells with 
DGLA and remained at slightly elevated levels in comparison to control levels of 
ICAM-1 observed in vehicle-treated cells. There was no effect on the constitutive 
expression of MCP-1 or ICAM-1 observed in these experiments. 
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Figure 4.13 – DGLA significantly inhibits the IL-1β and TNF-α induced expression of MCP-1 and ICAM-1 in THP-1 macrophages 
THP-1 macrophages were incubated with 50 uM DGLA or vehicle control for 24 hours prior to treatment with 1000 U/ml of IL-1β or TNF-α for 24 hours. Total 
RNA was subjected to reverse transcription and RT-qPCR with primers specific for MCP-1, ICAM-1 or GAPDH. Graphs display average normalised gene 
expression (mean +/- SD) (control arbitrarily assigned as 1) from three independent experiments. Statistical analysis was performed using a one-way ANOVA 
and Tukey’s post hoc analysis. * P≤0.05, *** P≤0.001 
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4.4.7 Inflammasome induced IL-1β release in THP-1 macrophages  
Given the important role of DGLA in inhibiting the IL-1β induced pro-inflammatory 
signalling, it was of interest to determine the role of DGLA in the release of IL-1β by 
macrophages. IL-1β is released in its active form following the activation of caspase-
1-dependent NLRP3 inflammasome (Franchi et al. 2009). Cholesterol crystals 
present in atherosclerotic plaque have been shown to activate the NLRP3 
inflammasome in mouse models and in THP-1 macrophages which up regulates the 
release of IL-1β (Duewell et al. 2010; Rajamaki et al. 2010). The effect of DGLA on 
cholesterol crystal induced inflammasome mediated IL-1β release was measured by 
ELISA in THP-1 macrophages (Figure 4.14).  
On treatment with 1 mg/ml cholesterol crystals, the concentration of IL-1β was 
increased from approximately 100 pg/ml to 480 pg/ml. Pre-treatment of the cells with 
DGLA did not inhibit the cholesterol crystal induced IL-1β secretion.  
 
 
 
 
 
 
 
 
 
Figure 4.14 – Cholesterol crystals increase IL-1β secretion in THP-1 
macrophages, was not inhibited by DGLA  
THP-1 macrophages were incubated with 50 μM DGLA or vehicle control for 24 hours prior to 
treatment with 1 mg/ml of cholesterol crystals for 8 hours (time point previously optimised in 
the laboratory). Media was collected and subjected to ELISA following the manufacturer 
instructions (R&D systems). Graphs display average IL-1β levels (mean +/- SD) from 2 
independent experiments performed in triplicate.    
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4.4.8 Monocyte migration 
Given the ability of DGLA to inhibit the expression of MCP-1 independently and in an 
inflammatory setting (Figures 4.10, 4.11, 4.12), it was hypothesised that the fatty acid 
would also attenuate monocyte migration, given the key role of MCP-1 in this process. 
Cell inserts with 8 μm pores were used to mimic an arterial endothelial layer and the 
analysis was carried out as detailed in Section 2.2.11. As shown in Figure 4.15, 
migration of THP-1 monocytes across the cell insert was increased significantly in the 
presence of MCP-1. Inclusion of DGLA produced a significant reduction of this MCP-
1 driven monocytic migration by an average of about 60%. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 – DGLA significantly inhibits the MCP-1-induced migration of THP-
1 monocytes 
THP-1 monocytes were co incubated with +/ - MCP-1 (20 ng/ml) and 50 μM DGLA or vehicle 
control, for 3 hours. Monocyte migration was calculated by counting the number of cells that 
had migrated across a cell insert and expressed as a percentage of total input cells. Graph 
displays mean percentage migration, with values from the MCP-1 positive control arbitrarily 
assigned as 100%. Error bars indicate mean +/- SD for three independent experiments.  
Statistical analysis was performed using a one-way ANOVA followed by Tukey’s post hoc 
analysis. *** P≤0.001 
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4.4.9 acLDL uptake 
To determine the action of DGLA on the accumulation of cholesteryl esters in 
macrophages, the cells were incubated with vehicle as a control and compared to 25 
µg/ml acLDL and 25 µg/ml acLDL plus 100 µM DGLA. The incorporation of [14C]-
acetate into lipid fractions separated and identified by TLC were measured by 
scintillation counting (Figure 4.16). THP-1 macrophages were initially utilised for the 
study however it was found that they did not accumulate large amounts of cholesteryl 
ester (Appendix 6). Alternatively, loading of RAW264.7 macrophages with acLDL 
showed a large increase in the accumulation of cholesterol esters (Appendix 6). Time 
points of 24 and 48 hours were used for both cell lines (Appendix 6). There was no 
substantial difference in cholesteryl ester accumulation between 24 and 48 hour 
incubation with acLDL. Given this, mouse RAW264.7 macrophages were 
subsequently used for such studies with 24 hour loading of acLDL. Given the 
conserved responses seen between THP-1 macrophages and RAW264.7 
macrophages, particularly in gene expression, the two cell lines could be used 
interchangeably. In addition, a concentration of 50 μM DGLA as gene expression 
studies was initially used in preliminary experiments. However, it was observed that 
50 μM DGLA showed only a small decrease in cholesteryl ester accumulation and 
100 μM DGLA inhibited this to a greater extent (Appendix 7). The latter concentration 
was therefore used for cholesteryl ester accumulation studies.   
As shown in Figure 4.16A, there was no observable difference between percentage 
lipid composition of polar lipids, free fatty acids or TAGs following incubation of the 
cells with acLDL when compared to the control. However, there was a significant 
decrease in the percentage lipid composition of free cholesterol by 14.6% and a 
significant increase in the accumulation of cholesteryl esters by 16.9%. Pre-treatment 
of the cells with DGLA prior to acLDL addition produced no difference between the 
percentage composition of polar lipids, free fatty acids and TAGs. However, 
differences in the levels of free fatty acids and cholesteryl esters were observed. 
Thus, the percentage lipid composition of free cholesterol was increased by 1.2%, 
however, this was not significant. On the other hand cholesteryl ester accumulation 
significantly decreased by 11.6%, in comparison to the presence of acLDL only. 
Figure 4.16B presents the data as a ratio of cholesteryl ester: total cholesterol (CE: 
TC). Total cholesterol is the sum of free cholesterol and cholesteryl esters. The CE: 
TC ratio was 0.8 in the presence of acLDL alone and this was reduced to 0.4 in the 
presence of DGLA, however due to high variability between replicates this was not 
significant.  
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Figure 4.16 – DGLA inhibits acLDL induced cholesteryl ester formation in 
RAW264.7 macrophages 
The cells were incubated with 100 μM DGLA for 24 hours prior to the addition of 50 µM acLDL 
and 1µCi [14C] acetate for a further 24 hours. Lipids were extracted, separated via TLC and 
radioactive incorporation into lipid fractions, identified by comparison with known standards, 
was measured by scintillation counting. Panel A – percentage incorporation of [14C] per mg of 
protein, into total polar lipids (PL), free cholesterol (FC), free fatty acids (FFA), triacylglycerols 
(TAG) and cholesteryl esters (CE). Panel B – ratio of CE/TC under different experimental 
conditions. Error bars indicate +/- SD from 4 experiments. Statistical analysis was performed 
using a one-way ANOVA followed by Tukey’s post hoc analysis for FC and Welch’s test 
followed by Dunnett’s T3 post hoc tests for CE and CE:TC ratios (conditions for ANOVA not 
met) * P≤0.05. ** P≤0.01. *** P≤0.001. N.S – not significant. 
  
0
10
20
30
40
50
60
70
80
PL FC FFA TAG SE
%
 in
co
p
o
ra
ti
o
n
 o
f 
C
1
4
ac
e
ta
te
 p
e
r 
m
g Control
AcLDL
DGLA + AcLDL
***
TPL
 ** 
* 
*** 
N.S 
CE 
 
 
155 
 
4.5 Discussion 
Data obtained in the studies presented in this chapter indicate that DGLA inhibits a 
number of steps leading to the formation of lipid loaded foam cells including; cytokine 
induced expression of MCP-1 and ICAM-1, monocyte migration and acLDL induced 
cholesteryl ester accumulation, but has no effect on ROS production or 
inflammasome activation. This suggests that DGLA may attenuate foam cell 
formation through one of these numerous mechanisms.  
4.5.1. ROS production 
Increased production of ROS has been observed in atherosclerosis and has been 
linked to various signalling pathways involved in vascular inflammation in the disease 
(Singh and Jialal 2006). One such pathway involves oxidative modifications of LDL. 
Native LDL is internalised by macrophages though an LDL receptor, which is subject 
to negative feedback inhibition. Oxidative modifications to LDL allow recognition by 
scavenger receptors, also expressed on macrophages, which take up excess 
amounts of modified LDL in an unregulated manner. This causes transformation of 
macrophages into lipid loaded foam cells (Singh and Jialal 2006). Given scavenger 
receptors only recognise modified forms of LDL, including oxidised LDL, reducing 
LDL oxidation by decreasing ROS levels would have a beneficial effect on inhibiting 
foam cell formation. ROS production was stimulated with TBHP (hydrogen peroxide) 
in THP-1 monocytes and macrophages and the effect of DGLA was determined. As 
shown in Figure 4.9, DGLA did not inhibit ROS production from either monocytes or 
macrophages. This initial study suggests that acting as an anti-oxidant is not the likely 
mechanism for the anti-atherogenic action of DGLA. However, numerous other 
experiments will be required to conclusively delineate the relationship between DGLA 
and oxidative stress. This may include the effect of DGLA on modification of LDL and 
other sources capable of oxidative stress such as nitric oxide production. To date 
there has been little data published on the effect of DGLA on ROS production. One 
such study indicated that treatment of omega-6 fatty acids in rats had no effect on 
ROS production but did enhance the activity of antioxidant enzymes (Suresh and Das 
2003b). In addition, supplementation of GLA in rats with high fat diet induced 
atherosclerosis saw a reduction in the serum levels of oxLDL, NO and iNOS (Shi et 
al. 2008). A potential future avenue of research could establish the effect of DGLA on 
anti-oxidant levels and levels of other oxidising species such as NO in macrophages. 
Anti-oxidants have been suggested as a potential therapeutic avenue in 
atherosclerosis; however results from clinical trials largely contradict one another 
(Stephens et al. 1996; Yusuf et al. 2000). For example, while dietary supplementation 
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with antioxidants has in some studies shown to reduce atherosclerotic related 
incidences (Stephens et al. 1996; Boaz et al. 2000), others have shown that they 
have no beneficial effect on the disease (Yusuf et al. 2000; Investigators 2007). Given 
the controversial role of antioxidants in atherosclerosis and the negative result 
obtained in the preliminary ROS experiment with DGLA; this avenue was not pursued 
further. 
4.5.2 Cytokine induced pro-inflammatory gene expression 
4.5.2.1 IFN-γ 
Given the important role of pro inflammatory cytokine signalling in atherosclerosis, it 
was of interest to investigate the role of DGLA on this. Due to the involvement of a 
large number of cytokines in atherosclerosis, three major pro-inflammatory cytokines 
were selected for study. The main focus was on IFN-γ, which has been described 
potentially as a master regulator of atherosclerosis due to its pro-inflammatory role in 
all the stages of disease progression, from foam cell formation through to lesion 
rupture (McLaren and Ramji 2009). IFN-γ up regulates the expression of many pro-
inflammatory genes including MCP-1 and ICAM-1 (Rimbach et al. 2000; Li et al. 
2010), which play an important role in monocyte recruitment and adhesion 
(Grandaliano et al. 1994; Lusis 2000; Chang et al. 2002). This has been shown in 
vitro where an IFN-γ dependant increase in ICAM-1 augmented the binding of 
monocyte to endothelial cells (Chang et al. 2002). DGLA significantly attenuated the 
IFN-γ induced expression of MCP-1 and ICAM-1 in THP-1 macrophages, RAW264.7 
cell line and primary cultures of HMDM (Figure 4.10 - 4.12). This inhibition of IFN-γ 
induced pro-inflammatory signalling by DGLA is of importance as deficiency of IFN-γ 
signalling in in vivo mouse models showed a significant reduction in atherosclerotic 
lesions (Gupta et al. 1997) and targeting IFN-γ actions has been investigated in depth 
as a potential therapeutic avenue in atherosclerosis (Gotsman and Lichtman 2007). 
Targeting IFN-γ signalling may therefore play a role in the anti-inflammatory and anti-
atherogenic action of DGLA.  
4.5.2.2 IL-1β 
In addition to IFN-γ signalling, the effect of DGLA on the action of other pro-
inflammatory cytokines was also investigated. Previous studies have shown DGLA 
inhibited IL-1β stimulated adipose stromal cell (ASC) proliferation, a hallmark of 
rheumatoid arthritis (Baker et al. 1989). It is well documented that IL-1β plays a pro 
inflammatory role in atherosclerosis and potentiates the disease (Kirii et al. 2003; 
Fearon and Fearon 2008). In addition, IL-1β has also been shown to increase the 
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expression of MCP-1 and ICAM-1 (Myers et al. 1992; Lim et al. 2009; Yang et al. 
2010). For these reasons, IL-1β was selected for this study. IL-1β significantly 
induced the expression of MCP-1 and ICAM-1 in THP-1 macrophages in comparison 
to control (Figure 4.13). Pre-incubation of the cells with DGLA significantly inhibited 
the induction of MCP-1 and ICAM-1 by IL-1β. Pre-treatment of the cells with DGLA 
returned the MCP-1 and ICAM-1 levels to that of basal control levels. This indicates 
that DGLA inhibits IL-1β signalling. Previous studies have shown knockout of IL-1β in 
mouse models of atherosclerosis show a reduction in lesion size when compared to 
control mice (Kirii et al. 2003). This was accompanied by a decrease in mRNA 
expression of MCP-1 and VCAM-1 (Kirii et al. 2003). Similarly an antibody targeting 
IL-1β in ApoE knockout mice reduced lesion size, macrophage plaque infiltration and 
secretion of MCP-1 in isolated primary macrophages (Bhaskar et al. 2011). This not 
only indicates the important role of IL-1β in atherosclerosis, but also in the recruitment 
and adhesion of monocytes through regulation of MCP-1 and ICAM-1 expression. 
The inhibition of expression of these two genes through an IL-1β induced pathway 
therefore supports an anti-inflammatory role of DGLA. 
4.5.2.3 TNF-α 
The third cytokine selected for this study was TNF-α. This pro-inflammatory cytokine 
has been well documented in promoting foam cell formation and augmenting 
atherosclerosis (Popa et al. 2007; Kleinbongard et al. 2010). As with IFN-γ and IL-1β, 
it has also been shown to increase the expression of MCP-1 and ICAM-1 in vitro and 
in vivo (Myers et al. 1992; Murao et al. 2000; Xiao et al. 2009). The effect of DGLA 
on this induced expression of these two genes was determined in THP-1 
macrophages. As shown in Figure 4.13, TNF-α significantly increased the expression 
of MCP-1 and ICAM-1. Pre-treatment of the cells with DGLA produced a significant 
attenuation of this TNF-α-induced expression of these two genes. In the case of MCP-
1, pre-treatment of the cells with DGLA returned MCP-1 levels to that seen in control. 
ICAM-1 expression remained slightly raised in comparison to control; however these 
were not significantly different. In addition to the benefits of reducing the induction of 
MCP-1 and ICAM-1 expression, inhibition of TNF-α signalling also has other anti-
atherosclerotic effects. ApoE-/- TNF-α-/- mice show a reduction in fatty streaks in the 
intima of aorta when compared to control mice (Xiao et al. 2009). In addition there 
was a decrease in the levels of IL-1β, IFN-γ, ICAM-1, VCAM-1 and MCP-1 observed 
(Xiao et al. 2009).  Comparable results were also observed in another study using 
ApoE-/- TNF-α-/- mice. Such ApoE-/- TNF-α-/- mice displayed reduced atherosclerotic 
plaque area at the aortic luminal surface and aortic sinus when compared to the 
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controls (Ohta et al. 2005). Again, a decrease in the expression of inflammatory 
markers ICAM-1, VCAM-1 and MCP-1 was also observed along with decreases in 
both the uptake of oxLDL and the expression of scavenger receptor A (Ohta et al. 
2005). There has been no work published in the literature on the effect of DGLA on 
TNF-α pro-inflammatory signalling. There has however been a study on TNF-α 
production in PBMC treated with a number of different fatty acids (Dooper et al. 2003). 
It was observed that DGLA inhibited LPS induction of TNF-α production by an 
average of 60% in PBMC. In addition, DGLA was the only fatty acid to have 
pronounced effects on cytokine production (Dooper et al. 2003). This suggests a key 
role of DGLA in the inhibition of TNF-α release and pro-inflammatory signalling 
induced by this cytokine during atherosclerosis.  
4.5.2.4 MCP-1 and ICAM-1 
As previously discussed, MCP-1 and ICAM-1 are key pro-inflammatory genes in 
atherosclerosis involved in monocyte recruitment and subsequent adhesion to the 
activated endothelium. It is clear from the results obtained in this study (Figures 4.10-
4.13) that DGLA has a role in inhibiting the induction of both these markers in 
macrophages produced by IFN-γ, IL-1β and TNF-α signalling.  DGLA has previously 
been shown to attenuate atherosclerosis in in vivo models of the disease (Takai et al. 
2009). There was also an observed reduction in ICAM-1 expression and macrophage 
accumulation in plaques (Takai et al. 2009). In addition, mice with orally administered 
DGLA showed a reduction in circulating levels of MCP-1 (Watanabe et al. 2014). The 
in vitro results presented in this chapter and the in vivo observations reported 
previously clearly indicate a role for DGLA in the attenuation of MCP-1 and ICAM-1 
expression in relation to atherosclerosis. This is an important role for DGLA as 
previous studies have shown that reducing MCP-1 and ICAM-1 expression in vivo 
significantly inhibits the progression of atherosclerosis (Gosling et al. 1999; Kitagawa 
et al. 2002).  
Taking together the results presented in this chapter and previously published work 
suggest a pivotal role of DGLA in decreasing pro-inflammatory cytokine release and 
the subsequent induction of pro-inflammatory markers in atherosclerosis. This may in 
part account for the anti-atherosclerotic effects of DGLA seen in in vivo studies (Takai 
et al. 2009).  
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4.5.3 Inflammasome-mediated IL-1β expression 
Leading on from the inhibition of cytokine induced pro-inflammatory gene expression 
by pro-inflammatory cytokine IFN-γ, IL-1β and TNF-α, it was of interest to determine 
the role of DGLA in cytokine production in macrophages. IL-1β was of particular 
interest due the role of multi-protein complexes, inflammasomes. A number of studies 
have detailed the role of inflammasomes, particularly the NLRP3 inflammasome, in 
IL-1β production in macrophages (Duewell et al. 2010; Rajamaki et al. 2010; Schroder 
and Tschopp 2010; Liu et al. 2014). Inflammasomes have been linked to an increase 
in atherosclerosis. Inhibition of the NLRP3 inflammasome, which plays a role in IL-1β 
processing, in ApoE-/- mice fed a high fat diet significantly prevented plaque 
progression and induction of inflammatory cytokines (Zheng et al. 2014). Macrophage 
plaque content was reduced, an increase in ABC transporter genes ABCA1 and 
ABCG1 and an increase in plaque stability was also observed (Zheng et al. 2014). 
THP-1 macrophages treated with oxLDL induced NLRP3 inflammasome related 
protein levels and caspase-1 activation. This resulted in an increase in IL-1β 
production, which promoted foam cell formation (Liu et al. 2014).  
Omega-3 fatty acids have been shown to play a role in inhibiting inflammasome 
activation and IL-1β production in macrophages. In THP-1 macrophages, DHA 
reduced IL-1β production by attenuating inflammasome activation (Williams-Bey et 
al. 2014). Reduction of ligands that stimulated activation of the NLRP3, NLRC4 and 
AIM2 inflammasomes was observed. This inhibition required GPCR120 and 
attenuation of NF-κB signalling (Williams-Bey et al. 2014). In addition, in BMDMs 
primed with LPS, DHA inhibited nigericin induced caspase-1 activation, IL-1β 
secretion and TNF-α production (Yan et al. 2013). This was also observed in THP-1 
macrophages. Treatment with EPA and ALA also attenuated nigericin induced IL-1β 
production. DHA inhibited all agonists of NLRP3 inflammasomes tested along with 
NLRP1b agonists (Yan et al. 2013). 
Given the role omega-3 fatty acids play in inhibiting inflammasome induced IL-1β 
secretion in macrophages, it was of interest to determine the role of DGLA in the 
process. Cholesterol crystals were used to stimulate inflammasome activation in 
THP-1 macrophages. It has previously been observed that cholesterol crystals 
injected into LDLr-/- mice induced acute inflammation which was attenuated when 
mice were also deficient in NLRP3 inflammasome (Duewell et al. 2010). Bone marrow 
transplant into LDLr-/- mice with NLRP3-/- and ASC-/- deficiency had significantly 
reduced atherosclerotic lesions and inflammation (Duewell et al. 2010) In vitro studies 
also reported similar results. THP-1 macrophages phagocytose cholesterol crystals 
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and store them as cholesteryl esters. This induced secretion of IL-1β. This process 
was caspase-1 dependent and silencing of NLRP3 receptor abolished cytokine 
induction (Rajamaki et al. 2010). This suggests that cholesterol crystal treatment in 
THP-1 macrophages induces IL-1β secretion by activation of NLRP3 inflammasome. 
In addition, inflammasome activation in macrophages requires priming before 
stimulation. Previous studies have used LPS primed macrophages followed by 
stimulation with ATP or nigericin (Yan et al. 2013; Williams-Bey et al. 2014). However, 
in PMA stimulated macrophages it was shown that THP-1 macrophage 
inflammasome activation was independent to LPS priming and that PMA induced 
expression of IL-1β (Rajamaki et al. 2010). Using PMA stimulated THP-1 
macrophages therefore eliminates the need for additional priming.  
As shown in Figure 4.14, treatment of THP-1 macrophages with cholesterol crystals 
induced IL-1β secretion 5-fold. Pre incubation of the cells with DGLA prior to 
cholesterol crystal stimulation failed to inhibit IL-1β secretion, with the trend 
suggesting an increase in production. The data indicates that DGLA may enhance 
inflammasome activation and IL-1β production in THP-1 macrophages. Previous 
studies have indicated contrasting roles for DGLA in the regulation of IL-1β secretion. 
DGLA failed to inhibit NLRP3 inflammasome dependent IL-1β secretion from BMDMs 
primed with LPS and stimulated with nigericin (Yan et al. 2013). The PUFA also had 
no effect on NLRP1b inflammasome activation (Yan et al. 2013). In both cases, no 
increase in IL-1β production or inflammasome activation was observed. However, 
addition of GLA to peripheral blood monocytes supressed the release of LPS-
stimulated IL-1β (Furse et al. 2001). It was shown that 40% of LPS stimulated IL-1β 
release was attributed to auto induction. GLA inhibited auto induction of IL-1β while it 
had little effect on LPS stimulated release (Furse et al. 2001). GLA induced a protein 
which reduced pro-IL-1β mRNA stability (Furse et al. 2001).GLA acts through its 
metabolite DGLA; however the direct effect of DGLA was not evaluated in the study. 
Taken together the data indicates that DGLA is unable to inhibit inflammasome 
dependent IL-1β secretion from macrophages and may potentially have an opposing 
affect. Further investigation will need to be undertaken to determine the role, including 
response to alternative agonists of inflammasomes in THP-1 macrophages and the 
effect of cholesterol crystals in HMDMs, in response to DGLA.  
4.5.4 Monocyte migration 
Expression of MCP-1 in atherosclerosis recruits circulating monocytes to the 
endothelium where they transmigrate through the endothelium into the arterial intima 
(Bobryshev 2006). Given the inhibition of pro-inflammatory cytokine induced 
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expression of MCP-1, along with an attenuation of basal expression of this chemokine 
by DGLA (Figure 4.10), it was of interest to determine whether this fatty acid could 
inhibit the role of MCP-1 in inducing the migration of monocytes across a barrier that 
mimics arterial endothelial cells. As shown in Figure 4.15, monocyte migration was 
significantly induced by treatment of THP-1 monocytes with MCP-1. On co-incubation 
with DGLA, the monocyte migration was attenuated, on average, by 60% in 
comparison to the MCP-1 positive control. In vivo inhibition of monocyte migration in 
ApoE-/- mouse models of atherosclerosis has been shown to be atheroprotective. For 
example, gremlin-1 inhibited monocyte migration in vivo resulting in decreased 
content of monocytes and macrophages in plaques and reduced atheroprogression 
(Mueller et al. 2013). In addition, a compound VB-201 selectively inhibited monocyte 
chemotaxis by 90% in vitro. Administration of this compound to ApoE-/- mice  in vivo 
inhibited atheroma development (Feige et al. 2013). The role of DGLA in the inhibition 
of monocyte migration presented here may be responsible for the reduced 
macrophage accumulation seen in previous in vivo studies.  
4.5.5 AcLDL induced cholesteryl ester accumulation 
The uptake of modified forms of LDL in an unregulated manner by macrophages, 
which transforms them into lipid loaded foam cells, is a critical early step in 
atherosclerosis (Ghosh et al. 2010). Cholesterol contained within the LDL molecule 
is in the form of cholesteryl ester. Once internalised, cholesteryl esters are hydrolysed 
to cholesterol in the lysosomal compartment and undergo a continual intracellular 
cycle of re-esterification and hydrolysis (Brown et al. 1980). The cholesterol can be 
stored as cholesteryl esters in the cytoplasm or removed from the cell in the form of 
free cholesterol (Brown et al. 1980). Excessive uptake of modified forms of LDL by 
macrophage scavenger receptors promotes the accumulation of cholesteryl esters, 
which are stored as lipid droplets in the cytoplasm of the macrophage giving them a 
foamy, vacuolated appearance (Brown et al. 1980). Given the important role of 
modified LDL in inducing cholesteryl ester accumulation in foam cell formation, it was 
of interest to determine the role of DGLA in this process. AcLDL, a form of modified 
LDL commonly used in LDL uptake experiments (Henson et al. 1989; Jones et al. 
2000; Dai et al. 2012), was used to induce cholesteryl ester accumulation in 
RAW264.7 macrophages. Initially THP-1 macrophages were employed in uptake 
studies (Appendix 6), however despite accumulation of cholesteryl esters; levels were 
still low in comparison to RAW264.7 cells. This was unusual as previous studies have 
used THP-1 macrophages for various cholesterol studies (Draude and Lorenz 2000; 
Lada et al. 2003) and have been shown to express a number of genes related to 
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cholesterol metabolism (Kritharides et al. 1998; McLaren et al. 2010; McLaren et al. 
2011b). Given the larger increase in cholesteryl esters in RAW264.7 macrophages, 
this system was employed for uptake experiments. As shown in Figure 4.16A, the 
percentage lipid composition of cholesteryl ester in RAW264.7 macrophages 
significantly increased by an average of 16.9% on treatment of the cells with acLDL. 
This increase was significantly attenuated by 11.6% following pre-incubation of the 
cells with 100 µM DGLA. In Figure 4.16B, cholesteryl ester is expressed as a ratio of 
total cholesterol. When loaded with acLDL, the ratio of cholesteryl ester: total 
cholesterol was 0.8. On pre-incubation with DGLA followed by loading, the ratio was 
reduced to 0.4. Due to high variability between replicates this decrease was not 
significant despite an obvious trend of reduction. This indicates a role of DGLA in the 
inhibition of cholesteryl ester accumulation and thereby a potential mechanism by 
which DGLA inhibits macrophage foam cell formation. The exact mechanism by which 
DGLA exerts such an inhibitory effect is unclear. There are a number of points at 
which DGLA could act; uptake of LDL by receptor-mediated and -independent 
pathways, cholesteryl ester synthesis and/or free cholesterol synthesis and efflux. 
Figure 4.16A also shows that lipid composition of free cholesterol was significantly 
reduced by 14.6% on incubation of the cells with acLDL, and this decrease was 
slightly attenuated by pre-treatment of the cells with DGLA where free cholesterol 
levels were increased by 1.2% in comparison to acLDL treatment only (not 
significant). The trend may, however, suggest that DGLA plays a role in promoting 
free cholesterol accumulation that can then be effluxed out from the cell and thereby 
prevent the intracellular accumulation of cholesteryl esters. The role of DGLA on each 
of these mechanisms will be investigated in the next chapter.  
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4.5.6 Future perspective  
The results presented in this chapter suggest a key role for DGLA in inhibiting a 
number of key steps leading to foam cell formation during atherosclerosis. DGLA 
inhibited the induction of MCP-1 and ICAM-1 expression by the pro-inflammatory 
cytokines IFN-γ, IL-1β and TNF-α. In addition, DGLA reduced monocytic migration 
and acLDL induced accumulation of cholesteryl esters. This raises a number of 
questions; 
1. How does DGLA inhibit cytokine induced MCP-1 and ICAM-1 expression? 
2. Is the inhibition of acLDL-induced cholesteryl ester accumulation by DGLA 
due to decreased uptake of the modified lipoprotein or increased efflux of free 
cholesterol? 
3. Does DGLA achieve these actions directly or indirectly though the metabolites 
produced following the uptake of the fatty acid into the cells? 
In the next chapter, these questions will be addressed and the underlying molecular 
mechanisms behind DGLAs actions shown here will be investigated.  
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CHAPTER 5  
MOLECULAR MECHANISM UNDERLYING THE ANTI-
INFLAMMATORY ACTIONS OF DGLA IN MACROPHAGES 
5.1 Introduction 
As presented in Chapter 4, DGLA played an important role in attenuation of pro-
inflammatory cytokine induced gene expression and cholesteryl ester accumulation 
in macrophages in vitro. The purpose of the studies in this chapter was to further 
investigate the role of DGLA in these two processes, both of which play key roles in 
foam cell formation, in order to pin point any underlying molecular mechanisms. The 
attenuation of IFN-γ induced gene expression by DGLA was chosen for further 
investigation due to the important and well characterised role the cytokine plays 
throughout the pathology of atherosclerosis (Gupta et al. 1997; McLaren and Ramji 
2009). The effect of DGLA on the activation of gene transcription through the 
JAK/STAT pathway was determined and discussed in more detail in Section 5.1.1. 
To attempt to understand the role of DGLA in the attenuation of cholesteryl ester 
accumulation, a number of mechanisms of cholesterol regulation in macrophages 
were studied. These included the effect of DGLA on the expression of scavenger 
receptors, uptake of lipoproteins through macropinocytosis, the expression of key 
genes involved in cholesterol metabolism and cholesterol efflux (Section 5.1.2).  
In addition, data presented in Chapter 3 showed that macrophages significantly 
induced the production of PGE1 following treatment with DGLA. Eicosanoid 
production plays an important role in fatty acid signalling (Johnson et al. 1997; Norris 
and Dennis 2012) and PGE1 has previously been indicated to play an anti-
inflammatory role in atherosclerosis (Sinzinger et al. 1991; Palumbo et al. 2000; Bai 
et al. 2012). It was therefore hypothesised that metabolism of PGE1 from DGLA in 
macrophages may be in part responsible for some of the effects the PUFA has on 
aspects of foam cell formation. The role of PGE1 in DGLA signalling was further 
investigated in macrophages.  
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5.1.1 IFN-γ signalling 
Data presented in the previous chapter demonstrated that DGLA attenuated the IFN-
γ induced pro-inflammatory gene expression in THP-1 macrophages, RAW264.7 
macrophages and HMDMs. This indicated that DGLA may have an inhibitory effect 
on the IFN-γ signalling pathway. IFN-γ signals through the JAK-STAT pathway 
(McLaren and Ramji 2009). Signalling through the JAK/STAT pathway is addressed 
in more detail in Section 1.4.1.1.1. Briefly, IFN-γ binding to the IFN-γR induces 
dimerisation of the receptor subunits leading to the phosphorylation of JAK1 and 
JAK2, which in turn phosphorylates the IFN-γR subunits (McLaren and Ramji 2009). 
The phosphorylated subunits can now bind STAT1. STAT1 is phosphorylated at 
TYR701 and triggers its release into the cytoplasm where it can dimerise and migrate 
into the nucleus (McLaren and Ramji 2009). STAT1 initiates transcription of IFN-γ 
inducible genes. Further phosphorylation of STAT1 at position SER727 can occur by 
the action of a number of other kinases, mainly members of the MAPK family. STAT1 
phosphorylation at this position is required for maximal activity of STAT1 (McLaren 
and Ramji 2009). STAT1 plays an important role in IFN-γ  signalling as well as 
signalling induced by other pro-atherogenic pathways such as IL-6 and TLR4 
(Sikorski et al. 2011b). Given the role of STAT1 in these pro-atherogenic pathways, 
inhibition of STAT1 has been implicated as a potential therapeutic target in 
atherosclerosis. 
5.1.1.1 Role of STAT1 
STAT1 belongs to the STAT family of seven well conserved transcription factors 
(Sikorski et al. 2011b). The structure of STAT1 is detailed in Figure 5.1. The N 
terminal region of STAT1 allows formation of a dimer complex; this is followed by a 
coiled region which interacts with other transcription factors and then a highly 
conserved DNA binding domain and a linker domain, which bridges to SH2 domains 
for STAT1 interactions with receptors. Finally, there is a C terminal transcriptional 
activation domain (Sikorski et al. 2011b). Two phosphorylation sites are also present 
at TYR701 and SER727. Phosphorylation at TYR701 by JAKs allows for dimerisation of 
STAT1, translocation into the nucleus and activation of target gene transcription (Li 
et al. 2010). Phosphorylation at SER727 is not essential for the role of STAT1 as a 
transcription factor; however it is required for maximal activity (Varinou et al. 2003). 
Inhibition of STAT1 activation and signalling has previously proved beneficial in 
atherosclerosis. Attenuation of STAT1 signalling in THP-1 macrophages significantly 
inhibited the expression of scavenger receptor CD36 and prevented foam cell 
formation (Agrawal et al. 2007). In addition, STAT1 deficiency in ApoE-/- mice 
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significantly reduced atherosclerotic lesion size (Agrawal et al. 2007). Given the role 
of STAT1 in IFN-γ signalling, the effect of DGLA on phosphorylation of the 
transcription factor was investigated in the studies presented in this chapter.  
 
 
 
Figure 5.1 – Structure of STAT1 transcription factor 
Figure adapted from (Sikorski et al. 2011b). N - N terminal domain; CC – coiled coil; DNA – 
DNA binding domain; LK – linker; SH2 – Src homology 2; Y – TYR701 phosphorylation site; S 
– SER727 phosphorylation site; TA - transcriptional activation site.  
 
5.1.2 Modified LDL uptake and cholesteryl ester accumulation 
Data presented in the previous chapter demonstrated that DGLA attenuated acLDL 
induced cholesteryl ester formation in macrophages. To determine the mechanisms 
underlying this observation, experiments were designed to test the effect of DGLA at 
a number of steps involved in the uptake of modified LDL and accumulation of 
cholesteryl esters. This included the effect of DGLA on the uptake and efflux of 
cholesterol, receptor independent uptake (macropinocytosis) and the expression of 
key genes involved in scavenger receptor-mediated uptake, cholesteryl ester 
synthesis and cholesterol efflux. Figure 5.2 depicts an overview of modified LDL 
uptake, cholesterol esterification cycle and efflux that were targeted in studies 
presented in this chapter.   
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Figure 5.2 – Overview of cholesteryl ester accumulation and cholesterol efflux 
in macrophages 
The figure provides an overview of the underlying mechanisms that are potentially involved in 
the attenuation of cholesteryl ester accumulation by DGLA and investigated in the studies 
presented in this chapter. First, the uptake of modified LDL was investigated, followed by 
determination of the effect of DGLA on scavenger receptor expression (SRA and CD36) and 
macropinocytosis. Second, the expression of key genes involved in cholesteryl ester 
accumulation (ACAT) and production of free cholesterol (NCEH) were analysed. Finally, the 
effects of DGLA on cholesterol efflux from macrophages were determined, along with the 
expression of key ABC transporter proteins (ABCA1 and ABCG1).  
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5.1.2.1 Cholesterol uptake 
5.1.2.1.1 Scavenger receptors 
Macrophages express scavenger receptors on their cell surface. Scavenger 
receptors are cell surface glycoproteins which can bind and internalise modified LDL 
such as oxLDL and acLDL (Goldstein et al. 1979; Peiser and Gordon 2001; Park 
2014). They are a broad family of receptors and are classified into six groups (Class 
A-F) depending on their tertiary structure (Peiser and Gordon 2001). Scavenger 
receptors have been intensively studied in relation to atherosclerosis due to their role 
in foam cell formation. Recognition and internalisation of modified LDL is unregulated 
and leads to excessive accumulation in macrophages (Kzhyshkowska et al. 2012). 
This results in accumulation of cholesteryl esters, a hallmark of foam cells. Specific 
focus was on two important scavenger receptors extensively characterised in 
atherosclerosis foam cell formation; CD36 and SRA.  
CD36 is a Class B scavenger receptor expressed on the surface of monocytes, 
macrophages, endothelial cells, adipocytes and platelets (Park 2014). The receptor 
is organised into two transmembrane domains, two cytoplasmic domains and a large 
glycosylated extracellular domain (Park 2014). CD36 binds and internalises oxLDL 
and has been implicated to contribute to foam cell formation and atherosclerosis 
(Endemann et al. 1993; Febbraio et al. 2000; Park 2014). Mouse models of the 
disease deficient in CD36 show a significant decrease in plaque formation and 
progression (Nozaki et al. 1995; Febbraio et al. 2000; Febbraio et al. 2004; Guy et al. 
2007; Kuchibhotla et al. 2008). 
SRA is a class A scavenger receptor found mainly expressed on the surface of 
macrophages (de Winther et al. 2000). The receptor was first classified in 1979 in 
mouse peritoneal macrophages and was shown to bind and internalise acLDL, 
leading to a  significant increase in cellular cholesteryl ester and cholesterol content 
(Goldstein et al. 1979). Increased expression has been identified in atherosclerotic 
lesions (Matsumoto et al. 1990; Ylaherttuala et al. 1991) and mouse models deficient 
in SRA show significant protection against atherosclerotic lesion development 
(Sakaguchi et al. 1998; Kuchibhotla et al. 2008).  
Given the importance of SRA and CD36 in the uptake of modified forms of LDL, these 
two genes were selected for further study. 
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5.1.2.2 Macropinocytosis 
Receptor-mediated endocytosis of modified LDL has been extensively studied in 
macrophages and is often regarded as the main pathway leading to cholesterol 
accumulation. Another endocytic pathway however, has been implicated to play a 
role in LDL uptake by macrophages. Macropinocytosis is a form of endocytosis 
providing non-selective uptake of solute macromolecules, by a process dependent on 
the formation of macropinosomes formed from membrane ruffling (Swanson and 
Watts 1995). This process has largely been shown to take up excessive amounts of 
native forms of LDL leading to foam cell formation (Kruth et al. 2002; Kruth et al. 2005; 
Zhao et al. 2006). Other studies have also reported a contribution of macropinocytosis 
to the uptake of oxLDL and acLDL (Jones and Willingham 1999; Yao et al. 2009). 
Previous work has indicated that inhibiting macropinocytosis in macrophages 
decreases foam cell formation (Yao et al. 2009) and therefore may be a potential 
target in atherosclerosis.  
5.1.2.3 Cholesteryl ester synthesis 
Following internalisation of the LDL particle by an endocytic pathway described in 
Sections 5.1.2.1 and 5.1.2.2, the cholesteryl ester contained within the LDL particle 
is digested to unesterified/free cholesterol by an acid cholesterol ester hydrolase in 
the lysosome (Daugherty et al. 2008). This free cholesterol is re-esterified to 
cholesteryl esters by a microsomal ACAT protein (Brown et al. 1980; Ghosh et al. 
2010). This esterified cholesterol has one of two fates: first it is once again hydrolysed 
to free cholesterol by  one of a group of enzymes collectively referred to as neutral 
cholesterol ester hydrolase (nCEH) (Sekiya et al. 2009) and removed from the 
macrophage by several extracellular transporters. Second, it is stored in the 
cytoplasm as lipid droplets (Daugherty et al. 2008). The rate-limiting step in the 
cholesteryl ester cycle is the nCEH enzyme reaction that allows for the clearance of 
free cholesterol from the macrophage. Excessive uptake of modified LDL therefore 
increases the storage of cholesteryl esters as lipid droplets. An increased amount of 
lipids in the cytoplasm of macrophages promotes the conversion of macrophages to 
lipid loaded foam cells (Ghosh et al. 2010). Inhibition of cholesteryl ester accumulation 
would therefore attenuate foam cell formation. The effect of DGLA in the expression 
of two key genes involved in the re-esterification and hydrolysis steps of the 
cholesterol cycle in macrophages was investigated.  
5.1.2.3.1 ACAT1 
ACATs are a family of membrane bound proteins which utilise long chain fatty acid-
CoA and cholesterol to form cholesteryl esters (Chang et al. 2009). ACAT is 
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responsible for the storage of cholesteryl esters within lipid droplets found in the 
cytoplasm of macrophage foam cells (Dove et al. 2006). There are two isoforms of 
the ACAT protein; ACAT1 and ACAT2 (Chang et al. 2009). Although similar in 
function, the two proteins have different membrane topology and localisation of 
expression (Chang et al. 2009). Expression of ACAT1 in particular has been shown 
in macrophages and linked to atherosclerosis. The protein has been identified in 
atherosclerotic lesions, localised specifically to macrophages (Miyazaki et al. 1998).  
A number of studies have investigated the role of ACAT1 in cholesterol metabolism 
in macrophages (Kusunoki et al. 2001; Yang et al. 2004; Dove et al. 2005). In ACAT1-
/- peritoneal macrophages loaded with acLDL, efflux of cholesterol derived from this 
modified lipoprotein was increased while overall cellular efflux was reduced (Dove et 
al. 2005). In addition, in peritoneal macrophages from ACAT1-/-  mice, cholesterol 
esterification was reduced by 93% (Yang et al. 2004; Dove et al. 2006), while in THP-
1 macrophages an ACAT1 inhibitor decreased cholesteryl ester accumulation (Yang 
et al. 2004). Given the already established link between ACAT1, macrophages and 
atherosclerosis, this isoform of the ACAT family was selected for further study.  
5.1.2.3.2 NCEH 
The hydrolysis of cholesteryl esters is critical for cholesterol removal from the 
macrophage. This is achieved by the action of nCEH enzymes (Igarashi et al. 2010). 
In macrophages three enzymes have been identified as nCEHs;  hormone-sensitive 
lipase (LIPE), cholesterol ester hydrolase (CEH) and NCEH1 (Igarashi et al. 2010). 
All three enzymes have been characterised to some extent in human and mouse 
macrophages to play a role in cholesteryl ester hydrolysis and increase cholesterol 
efflux (Igarashi et al. 2010). In ApoE-/- NCEH1-/- mice, atherosclerosis was aggravated 
in comparison to controls. In addition, NCEH1-/- mouse peritoneal macrophages 
incubated with acLDL showed an increase in cholesteryl ester accumulation and 
decrease in cholesterol efflux (Sekiya et al. 2009). In the same study ApoE-/-, NCEH1-
/- mice were crossed with LIPE knockout mice. In these mice nCEH activity was 
dramatically reduced, to 10% of that of wild type mice suggesting that both these 
enzymes play an important role in the nCEH activity of macrophages (Sekiya et al. 
2009). In human macrophages however, LIPE and CEH activity was barely detectable 
and inhibition of both had no effect on nCEH activity (Igarashi et al. 2010). The pattern 
of NCEH1 expression however was similar to that of nCEH activity in human 
macrophages and knockdown specifically inhibited this activity (Igarashi et al. 2010). 
NCEH1 was also identified to be expressed in macrophage foam cells from 
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atherosclerotic lesions (Igarashi et al. 2010). Given the role of NCEH1 in nCEH 
activity of mouse and human macrophages, this nCEH was selected for further study.  
5.1.2.4 Cholesterol efflux 
Cholesterol efflux is essential to prevent the accumulation of cholesteryl esters. 
Cholesterol is removed from macrophages as free cholesterol to lipoprotein carriers 
such as HDL, where it is transported to the liver for catabolism (Phillips 2014). There 
are a number of mechanisms by which cholesterol can be removed from 
macrophages. These include passive diffusion, facilitated diffusion by SR-B1 and 
active diffusion using the ABC transporter proteins; ABCA1 and ABCG1 (Phillips 
2014). Passive diffusion accounts for a large amount of cholesterol efflux from non-
cholesterol loaded macrophages; however in macrophage foam cells active transport 
is crucial. ABCA1 and ABCG1 transporter proteins play a pivotal role in cholesterol 
efflux from macrophages (Yvan-Charvet et al. 2010). 
5.1.2.4.1 ABC transporters 
The ABC transporter proteins utilise ATP to transport molecules across the plasma 
membrane (Soumian et al. 2005). ABCA1 and ABCG1 are expressed in 
macrophages and aid in reverse cholesterol transport (Soumian et al. 2005). There 
are a number of proposed mechanisms by which ABCA1 and ABCG1 have been 
suggested to remove cholesterol from macrophages and where they are localised, 
however the process is still not fully understood (Yvan-Charvet et al. 2010). The ABC 
transporters have been well characterised in their role in cholesterol efflux and have 
been suggested to play a protective role in atherosclerosis (Singaraja et al. 2002; 
Yvan-Charvet et al. 2007; Tarling et al. 2010). In vivo mouse models demonstrated 
that knockout of these transporter proteins in macrophages resulted in significant 
reduction of cholesterol efflux (Wang et al. 2007). In LDLr-/- mouse models, ABCA1 
and ABCG1 deficiency increased atherosclerosis and infiltration of foam cells. 
Isolated macrophages from these mice showed impaired cholesterol efflux (Yvan-
Charvet et al. 2007). Similarly, over expression of ABCA1 in ApoE-/- mice results in 
development of smaller lesions and increased cholesterol efflux from isolated 
macrophages (Singaraja et al. 2002). ABCA1 and ABCG1 expression and their 
influence on cholesterol homeostasis also play a role in modulating the inflammatory 
response in atherosclerosis, such as an increase in pro-inflammatory gene 
expression (Yvan-Charvet et al. 2008; Zhu et al. 2008). Given the important role of 
the ABC transporters in cholesterol efflux, the effect of DGLA on their expression in 
macrophages was of interest.  
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5.1.2.4.2 ApoE 
A number of other factors also play a role in cholesterol efflux from the macrophage 
in addition to ABC transporters. ApoE is a multi-functional protein which plays a role 
in the maintenance of plasma cholesterol levels (Curtiss 2000). It is a component of 
plasma lipoproteins (HDL, VLDL) that carry cholesterol to the liver for clearance. The 
ApoE-/- knockout mouse model is commonly used in atherosclerosis as the resulting 
hypercholesterolemic state allows for the development of spontaneous 
atherosclerosis (Curtiss 2000). The majority of ApoE is synthesised in the liver, 
however the protein can also be produced locally by macrophages (Zhu et al. 1998). 
Macrophage ApoE has little effect of plasma cholesterol levels, but still proved to have 
an anti-atherogenic effect in a number of studies (Zhu et al. 1998; Boisvert et al. 1999; 
Hasty et al. 1999). No correction of hyperlipidaemia was observed in ApoE-/- knockout 
mice expressing ApoE specifically in macrophages in comparison to control mice, 
however there was a significant reduction in lesion size (Zhu et al. 1998). Similarly, in 
ApoE-/- mice (5-13 weeks) expressing ApoE from arterial macrophages, there was a 
significant reduction in lesion size with no change in plasma cholesterol levels from 
control ApoE-/- mice (Hasty et al. 1999). This suggests that there are other 
mechanisms, independent to plasma cholesterol levels, in which ApoE acts to 
attenuate atherosclerosis. In macrophages, production of ApoE has been shown to 
increase cholesterol efflux. A 10% increase in cholesterol efflux was observed from 
macrophage of ApoE-/- mice expressing an ApoE gene in macrophages (Zhu et al. 
1998). This was also observed in mice expressing ApoE from the arterial wall. It was 
observed there was a reduced amount of cholesterol in the arterial wall of transgenic 
mice suggesting ApoE induces reverse cholesterol transport from the arterial wall 
(Shimano et al. 1995). Given the role of ApoE in inducing cholesterol efflux from 
macrophages, it was hypothesised that DGLA may have an effect on its expression.  
5.1.3 DGLA metabolites 
The final aim of the chapter was to determine the role of eicosanoids produced from 
DGLA to identify the molecular mechanism underlying the action of the PUFA. Fatty 
acids can induce signalling mechanisms directly or indirectly through the production 
of eicosanoids (Johnson et al. 1997; Levin et al. 2002; Norris and Dennis 2012; 
Raphael and Sordillo 2013). As shown previously in Chapter 3, DGLA was 
metabolised to PGE1 and 15-HETrE in THP-1 macrophages (Section 3.4.4). In 
macrophages treated with vehicle, there was no basal production of PGE1. Only on 
treatment with DGLA did the production of the eicosanoid increase dramatically, 
offsetting the ratio of PGE2:PGE1 production in the macrophage. PGE1 is a product of 
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COX metabolism on DGLA (Calder 2001; Levin et al. 2002; Wang et al. 2012) and it 
has been documented as having anti-inflammatory actions in a number of diseases. 
In rabbit models of atherosclerosis, PGE1 decreased the accumulation of LDL in the 
arterial wall and increased the stability of atherosclerotic plaques (Sinzinger et al. 
1991; Bai et al. 2012). In addition, the eicosanoid has been implicated to have 
beneficial actions in models of myocardial infarction, heart failure and cancer 
(Tabolacci et al. 2010; Li et al. 2011; Hou et al. 2013). This indicates that metabolites 
of DGLA may play a role in the anti-inflammatory/atherogenic actions observed in 
macrophages. Given the important role of PGE1 reported previously in numerous 
diseases, this prostaglandin was a key focus in understanding the molecular 
mechanisms underlying the action of DGLA. The role of PGE1 in THP-1 macrophages 
was investigated through inhibition of COX enzymes.   
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5.2 Aims 
Following on from results obtained with DGLA presented in Chapters 3 and 4, the aim 
of studies in this chapter was to determine the mechanisms underlying some key 
findings. As shown in the studies presented in the previous chapters, DGLA inhibited 
the IFN-γ induced expression of key pro-inflammatory genes in a number of 
macrophage cultures. AcLDL uptake and cholesteryl ester accumulation was also 
attenuated in macrophages by DGLA. Lastly, DGLA metabolised to PGE1, a 
prostaglandin with anti-inflammatory actions. These three key points were chosen for 
further investigations. Detailed aims were as follows; 
1. DGLA inhibition of IFN-γ  induced gene expression 
- Effects of DGLA on STAT1 phosphorylation at positions TYR701 and 
SER727 
2. Attenuation of modified LDL induced cholesteryl ester accumulation by DGLA 
- Effect of DGLA on uptake of oxLDL 
- Effect of DGLA on receptor-mediated uptake (scavenger receptors) and 
fluid phase uptake (macropinocytosis) 
- Effect of DGLA on expression of key genes involved in cholesteryl ester 
accumulation and free cholesterol formation (ACAT1 and NCEH1) 
- Effect of DGLA on cholesterol efflux and key genes involved in the process 
(ABCA1, ABCG1 and ApoE) 
3. Determine the role of PGE1 in the anti-inflammatory effect of DGLA 
- Effect of PGE1 on the IFN-γ induced MCP-1 expression 
- Effect of PGE1 on monocyte migration 
- Effect of knockdown of PGE1 formation from DGLA on the IFN-γ induced 
MCP-1 expression 
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5.3 Experimental plan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 - Overview of experimental strategy 
THP-1 monocytes and macrophages were used to investigate three key results; inhibition of 
IFN-γ signalling, acLDL uptake and cholesteryl ester accumulation together with the actions 
of DGLA metabolites.  
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5.4 Results 
 
5.4.1 The effect of DGLA on IFN-γ signalling through the JAK/STAT pathway  
5.4.1.1 Effect of DGLA on IFN-γ dependant STAT1 phosphorylation 
As described in Chapter 4, DGLA inhibited the IFN-γ induced expression of two key 
pro-inflammatory genes; MCP-1 and ICAM-1 in THP-1 macrophages, RAW264.7 cell 
line and primary cultures of HMDM (Section 4.4.6). It was therefore of interest to 
determine the precise effect of DGLA on the IFN-γ signalling pathway. The cytokine 
signals through the JAK/STAT pathway and the initial focus was on STAT1 and its 
activation by phosphorylation. The effect of DGLA on STAT1 phosphorylation at two 
sites, SER727 and TYR701, was determined by western blotting. THP-1 macrophages 
were pre-treated with DGLA or DMSO control for 24 hours prior to addition of 250 
U/ml IFN-γ  or vehicle control for 30 minutes, a time point previously optimised in the 
laboratory for maximal STAT1 phosphorylation (Li et al. 2010). STAT1 
phosphorylation at SER727 and TYR701 was significantly induced on treatment of the 
cells with IFN-γ by 2.3-fold and 7.9-fold respectively (Figure 5.4). On pre-treatment 
with DGLA followed by IFN-γ stimulation, STAT1 phosphorylation at SER727 was 
significantly inhibited by an average of 31%. This attenuation was not seen in 
phosphorylation of TYR701.  
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Figure 5.4 - DGLA attenuates the IFN-γ induced STAT-1 phosphorylation at 
SER727 but not TYR701 
THP-1 macrophages were pre-treated with 50 µM DGLA (DGLA, DGLA + IFN-γ) or DMSO 
vehicle control (Control, IFN-γ) for 24 hours. Following this, macrophages were stimulated 
with 250 U/ml IFN-γ or vehicle for 30 minutes. Proteins were extracted and separated by gel 
electrophoresis and transferred onto a membrane. Membranes were probed with antibodies 
specific for STAT1 SER727, STAT1 TYR701 and total STAT1. Membranes were exposed to X-
ray film and bands were analysed by densitometry for quantification. Graphs indicate the 
average of three independent repeats (mean +/- SD), control arbitrarily assigned as 1. 
Statistical analysis was performed using a one way ANOVA followed by Tukey’s post hoc 
analysis ** P <0.01, *** P ≤ 0.001, N.S – Not significant  
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5.4.2 Molecular mechanism underlying the attenuation of modified LDL uptake 
and cholesteryl ester accumulation in macrophages 
5.4.2.1 Uptake of Dil-oxLDL 
To determine the mechanisms underlying the effect of DGLA on cholesteryl ester 
accumulation in macrophages, uptake of cholesterol was determined. To do so, 
uptake of oxLDL labelled with a fluorescent marker (Dil-oxLDL) was measured by 
FACS. The initial study investigating the accumulation of cholesteryl esters in 
macrophages utilised acLDL as a form of modified cholesterol. Both acLDL and 
oxLDL are commonly used in cholesterol uptake and efflux studies, acLDL is more 
avidly taken up in comparison to oxLDL, however, both show comparable actions and 
induce macrophage foam cell formation in vitro (McLaren et al. 2010; McLaren et al. 
2011b). Despite this, oxLDL is the major form of modified LDL found in 
atherosclerosis in vivo (Lusis 2000; Nishi et al. 2002; Shashkin et al. 2005) and 
therefore more clinically relevant.   
THP-1 macrophages were pre-treated with 50 μM DGLA or vehicle control for 24 
hours prior to loading with 5 μg/ml Dil-oxLDL for a further 24 hours. Cells were 
collected, resuspended in 2% PFA and uptake was measured by determining 
fluorescence by FACS. As shown in Figure 5.5, on treatment with Dil-oxLDL, uptake 
was significantly increased in comparison to unloaded macrophages. Following pre-
treatment with 50 μM DGLA followed by loading with Dil-oxLDL, this increase was 
significantly attenuated by an average of 21%.     
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Figure 5.5 – DGLA significantly attenuated Dil-oxLDL uptake in THP-1 
macrophages 
THP-1 macrophages were incubated with 50 μM DGLA or DMSO for 24 hours prior to 
treatment with 5 μg/ml Dil-oxLDL for a further 24 hours (control cells were pre-treated with 
DMSO without further incubation with Dil-oxLDL). Cells were collected, resuspended in 2% 
PFA and uptake was measured using FACS analysis counting 10,000 events. DMSO in the 
presence of Dil-oxLDL was used as a positive control and arbitrarily assigned as 100%. Graph 
indicated the average uptake (+/- SD) from 4 independent experiments. Statistics were 
performed using a one-way ANOVA followed by Tukey’s post hoc analysis. ** P <0.01, *** P 
<0.001. 
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5.4.2.2 Scavenger receptor expression  
Scavenger receptors are expressed on the surface of macrophages and recognise 
and internalise large, unregulated amounts of modified LDL leading to the formation 
of foam cells (de Winther et al. 2000; Shashkin et al. 2005; Park 2014). CD36 and 
SRA are key scavenger receptors expressed by macrophages in atherosclerotic 
lesions and mice lacking these genes show significant protection to atherosclerosis 
(Endemann et al. 1993; Sakaguchi et al. 1998; Kunjathoor et al. 2002; Febbraio et al. 
2004). Given the role of DGLA in oxLDL uptake and acLDL induced cholesteryl ester 
accumulation in macrophages, it was hypothesised that the levels of these scavenger 
receptors on the surface of the cells may play an important role. The mRNA and 
protein expression of CD36 and SRA were measured by RT-qPCR and western 
blotting respectively.  
THP-1 macrophages were incubated with vehicle or 50 µM DGLA for 24 hours prior 
to RNA or protein extraction. On incubation with DGLA, the mRNA expression of SRA 
and CD36 was attenuated by an average of 22% and 20% respectively (Figure 5.5). 
Unfortunately due to time constraints and difficulties in optimisation of antibodies, only 
SRA was measured at the protein level. On pre-treatment with 50 μM DGLA, there 
was a significant reduction of approximately 40% in the protein expression of SRA.   
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Figure 5.6 - DGLA significantly inhibited the expression of CD36 and SRA in 
THP-1 macrophages 
THP-1 macrophages were pre-incubated with 50 μM DGLA or DMSO vehicle (Control) for 24 
hours.  A - Total RNA was subjected to reverse transcription and RT-qPCR with primers 
specific for CD36, SRA or GAPDH control. Graphs display average gene expression (mean 
+/- SD) (control arbitrarily assigned as 1) from four independent experiments. B – Total protein 
was extracted, subjected to gel electrophoresis and immunodetection with antibodies specific 
for SRA and β-actin. Graph indicates the average protein expression from 4 independent 
repeats (+/- SD) with control arbitrarily assigned as 1. Statistical analysis was performed using 
a Students two tailed t test. * P ≤ 0.05. 
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5.4.2.3 – Macropinocytosis 
In addition to receptor-mediated uptake by scavenger receptors, macrophages have 
been shown to take up large amounts of native LDL and modified LDL by bulk fluid 
phase macropinocytosis (Kruth et al. 2005; Michael et al. 2013). The endocytic 
pathway has also been implicated to play a role in foam cell formation (Kruth et al. 
2002; Yao et al. 2009). To measure the effect of DGLA on macropinocytosis, the 
uptake of Lucifer yellow (LY) was measured by FACS. LY is a florescent dye 
commonly used in the literature as a marker to measure uptake by macropinocytosis 
(Swanson 1989; Jones and Willingham 1999; Michael et al. 2013). THP-1 
macrophages were pre-incubated with the DMSO vehicle or 50 µM DGLA followed 
by 100 µg/ml LY for 24 hours. Macrophages were fixed and samples prepared for 
FACS analysis. LY uptake from vehicle treated cells was arbitrarily assigned as 100% 
LY uptake. On pre-treatment with DGLA, LY uptake was significantly attenuated by 
an average of 17% (Figure 5.7).  
 
 
 
 
 
 
 
 
Figure 5.7 - DGLA inhibits LY uptake by macropinocytosis in THP-1 
macrophages 
THP-1 macrophages were incubated with 50 µM DGLA or DMSO for 24 hours followed by 
100 µg/ml LY. LY uptake was analysed using flow cytometry (FACS Canto). LY uptake is 
represented as a percentage with vehicle control as 100%, error bars indicate +/- SD from 
three independent experiments. Statistics was performed using a Students two tailed t-test, 
*** P ≤ 0.001. 
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5.4.2.4 – Cholesterol ester synthesis 
Once LDL has undergone endocytosis, the lipoprotein is broken down and cholesteryl 
ester contained within it undergoes a cycle of hydrolysis and re-esterification in the 
macrophage (Brown et al. 1980). To investigate the role of DGLA on cholesteryl ester 
accumulation, RT-qPCR was used to measure the effect of the fatty acid on the 
expression of two enzymes responsible for esterification and hydrolysis in the 
macrophage. THP-1 macrophages were treated with vehicle or 50 µM DGLA for 24 
hours before RT-qPCR using specific primers for ACAT1 and NCEH1. DGLA had no 
effect on the gene expression of ACAT1 and NCEH1 when compared to the DMSO 
control.  
 
 
 
 
 
 
 
Figure 5.8 - DGLA has no effect on mRNA expression of ACAT1 and NCEH1 
THP-1 macrophages were incubated with DMSO vehicle or 50 µM DGLA for 24 hours. Total 
RNA was subjected to reverse transcription and RT-qPCR with primers specific for human 
ACAT1, NCEH1 or GAPDH. Graphs display average gene expression (mean +/- SD) (control 
arbitrarily assigned as 1) of 4 independent experiments. Statistical analysis was performed 
using a two tailed Students t-test. N.S – Not significant  
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5.4.2.5 – Cholesterol efflux 
Macrophages can efflux cholesterol with the aid of cholesterol carriers. Free 
cholesterol can be removed from the cell to HDL, the main component of which is 
ApoA1 (Phillips 2014). It has been shown previously that ApoA1 mediates cholesterol 
efflux in macrophages (Yvan-Charvet et al. 2010). To determine if DGLA plays a role 
in cholesterol efflux from macrophages, THP-1 macrophages were loaded with acLDL 
and 14C-Cholesterol. Following this, macrophages were treated with ApoA1 to induce 
cholesterol efflux or vehicle control to determine basline cholesterol efflux. Efflux was 
measured using scintillation counting. Radioactivity was measured in both the cell 
fraction and overlaying media and efflux was calculated as a percentage of counts in 
the media fraction to total counts.  Cholesterol efflux measured in acLDL loaded 
macrophages unstimulated with ApoA1 allowed for a basal level of efflux to be 
measured and was substracted from all other samples (data not shown). Graph 
displays ApoA1 stimulated cholesterol efflux as percentage efflux. Macrophages pre-
treated with DGLA before loading with acLDL and stimulation with ApoA1, showed a 
significant increase of approximately 10% in cholesterol efflux in comparison to 
macrophages with vehicle control (Figure 5.9).  
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Figure 5.9 - DGLA increased ApoA1 stimulated cholesterol efflux from THP-1 
macrophages 
THP-1 macrophages were incubated with 50 µM DGLA or DMSO vehicle for 24 hours prior to 
treatment with 25 µg/ml acLDL and 0.5 µCi 14C-cholesterol in RPMI media with 0.2% (w/v) 
BSA for a further 24 hours. Following this incubation, cells were washed with PBS; media was 
replaced in the presence of 10 µg/ml ApoA1 for 24 hours. Media was collected in Eppendorf 
tubes and cells treated with 0.2% (w/v) NaOH until macrophages had detached. Cell 
suspension was removed into Eppendorf tubes. Radioactivity from media and cell suspension 
was measured using scintillation counting. Background cholesterol efflux (unstimulated with 
ApoA1, not displayed on graph) was subtracted from ApoA1 stimulated cells. Results 
expressed as percentage cholesterol efflux. Error bars indicate +/- SD from three independent 
repeats. Statistics were performed using a Students two tailed t-test. ** P ≤0.01.  
0
2
4
6
8
10
12
14
16
18
20
AcLDL DGLA
%
 c
h
o
le
st
e
ro
l e
ff
lu
x
** 
AcLDL + Vehicle AcL L + DGLA 
 
 
186 
 
5.4.2.6 Expression of key genes implicated in cholesterol efflux 
Given the ability of DGLA to increase ApoA1 stimulated cholesterol efflux, it was of 
interest to determine the specific role of the fatty acid in this complex process. It has 
been shown that the ABC transporter proteins play a crucial role in transport of free 
cholesterol from the cytoplasm of the macrophage to the plasma membrane for 
transfer to cholesterol carriers. In addition to this, expression of macrophage ApoE 
has been previously shown to promote cholesterol efflux (Hasty et al. 1999; Curtiss 
2000; Su et al. 2003; Baitsch et al. 2008). The effect of DGLA on the mRNA 
expression of ABCA1 and ABCG1 and the protein expression of ABCA1 and ApoE 
was measured in cholesterol loaded THP-1 macrophages.  
THP-1 macrophages were pre-incubated with 50 μM DGLA or vehicle control for 24 
hours prior to cholesterol loading with 25 μg/ml of acLDL. The mRNA expression was 
measured by RT-qPCR using primers specific for ABCA1 and ABCG1 (Figure 5.10A). 
Protein expression of ABCA1, ApoE and β actin was determined by western blot 
analysis (Figure 5.10B). Each graph represents the average of one independent 
experiment performed in triplicate.  
It was found that on cholesterol loading of THP-1 macrophages, mRNA and protein 
expression of ABCA1 was induced. At the mRNA level, this was attenuated by an 
average of 30% on pre incubation with DGLA. However at the protein level, 
expression of ABCA1 was not affected by pre-incubation with DGLA. The mRNA 
expression of ABCG1 was induced on average 1.5 fold following cholesterol loading 
in macrophages. Pre-treatment of the cells with DGLA followed by cholesterol loading 
had no effect on ABCG1 expression. Finally, ApoE was measured at the protein level. 
Expression of ApoE remained constant under all conditions.  
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Figure 5.10 – Effect of DGLA on the expression of ABCA1, ABCG1 and ApoE in acLDL loaded macrophages 
THP-1 macrophages were incubated with DMSO vehicle or 50µM DGLA for 24 hours followed by 25 μg/ml acLDL for a further 24 hours (control cells 
were pre-treated with DMSO followed by further incubation in the absence of acLDL). A - RNA was extracted, subjected to reverse transcription and RT-
qPCR with primers specific for ABCA1, ABCG1 and GAPDH. B - Proteins were extracted, separated by gel electrophoresis and transferred onto a 
membrane. Membranes were probed with antibodies specific for ABCA1, ApoE and β actin. Membranes were exposed to X-ray film and bands were 
analysed by densitometry for quantification. Graphs display the average of one independent experiment performed in triplicate (+/- SD). 
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5.4.2.6.1 LXR gene expression 
Expression of ABCA1, ABCG1 and ApoE are regulated by LXRs (Schwartz et al. 
2000; Laffitte et al. 2001). Given the relationship between the cholesterol efflux genes 
measured in Figure 5.10 and LXRs, the effect of DGLA on the expression of these 
receptors was measured by RT-qPCR. THP-1 macrophages were incubated with 50 
μM DGLA for 24 hours prior to RNA extraction and reverse transcription. RT-qPCR 
was performed using primers specific for LXR-α, LXR-β and GAPDH.  
As shown in Figure 5.11, incubation of macrophages with DGLA significantly 
attenuated the expression of LXR-α and -β by an average of 70% and 55% 
respectively.  
 
 
Figure 5.11 – DGLA significantly inhibits LXR-α and -β mRNA expression in 
THP-1 macrophages 
THP-1 macrophages were incubated with vehicle or 50 µM DGLA for 24 hours. Total RNA 
was subjected to reverse transcription and RT-qPCR with primers specific for human LXR-α 
or LXR-β. Graphs display average gene expression (mean +/- SD) (control arbitrarily assigned 
as 1) from 3 experiments. Statistical analysis was performed using a two tailed Students t-
test. * P ≤0.05, *** P ≤ 0.001 
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5.4.3 DGLA metabolites 
5.4.3.1 Effect of PGE1 on MCP-1 expression and monocyte migration  
PGE1 is a product of DGLA (produced by the action of COX) with beneficial anti-
inflammatory actions in number of diseases (Sinzinger et al. 1991; Palumbo et al. 
2000; Wang et al. 2012). To determine the role of this prostaglandin in the anti-
inflammatory actions of DGLA, key experiments were repeated using PGE1 to 
determine if the metabolite mimicked the actions of DGLA. Two key parameters that 
showed positive results with DGLA were chosen; the inhibition of IFN-γ induced MCP-
1 and ICAM-1 expression and monocyte migration. For gene expression, THP-1 
macrophages were pre-treated with PGE1 for 1 hour prior to the addition of 250 U/ml 
of IFN-γ for 3 hours. A shorter pre-incubation time of PGE1, compared to DGLA, was 
chosen due to the short half-life of the prostaglandin (Fan and Chapkin 1998). 
Concentrations of 10 to 100 µM were used initially to determine the optimum 
concentrations for use in further experiments.  
Treatment of THP-1 macrophages with IFN-γ significantly increased the expression 
of MCP-1 and ICAM-1. On pre-incubation with PGE1, significant inhibition of the IFN-
γ induced expression of MCP-1 and ICAM-1 was observed with all the concentrations 
used (Figure 5.12). Treatment with PGE1 inhibited the IFN-γ induced expression of 
MCP-1 and ICAM-1 by an average of approximately 80% and 45% respectively 
across all concentrations. There was no significant difference between doses for 
either MCP-1 or ICAM-1 expression observed. This was also repeated in HMDMs 
where comparable results were obtained (Figure 5.13). In HMDMs, PGE1 inhibited 
the IFN-γ induced MCP-1 expression by an average of 80% across all concentrations. 
For ICAM-1, PGE1 had a dose response effect on IFN-γ induced expression 
attenuating expression by 17%, 22%, 30% and 40% on average for the 
concentrations used. A concentration of 10 µM was carried forward for future 
experiments as this was the lowest concentration at which marked effects were 
observed and there was no significant difference found between various 
concentrations. 
For monocytic migration, THP-1 monocytes were co-incubated with 10 µM PGE1 (or 
vehicle control) and MCP-1. MCP-1 significantly increased monocyte migration by 
70% (Figure 5.14). On co-incubation with PGE1 this increase was completely inhibited 
and levels of monocyte migration returned to that of the control.   
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Figure 5.12 – PGE1 significantly inhibits the IFN-γ-induced expression of MCP-
1 and ICAM-1 in THP-1 macrophages 
THP-1 macrophages were incubated with vehicle or 10-100 µM PGE1 for 1 hour prior to 
treatment with vehicle or 250 U/ml IFN-γ for 3 hours. Concentration of vehicle control was 
used to match that of highest concentration of PGE1.  Total RNA was subjected to reverse 
transcription and RT-qPCR with primers specific for human MCP-1 (panel A), ICAM-1 (panel 
B) or GAPDH. Graphs display average normalised gene expression (mean +/- SD) (control 
arbitrarily assigned as 1) from three independent experiments. For MCP-1, statistical analysis 
was performed using a robust equality of means test followed by Dunnetes T3 post hoc 
analysis, as conditions for ANOVA were not met. For ICAM-1, ANOVA was used followed by 
Tukey’s post hoc analysis. * P≤0.05 ** P≤0.01 
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Figure 5.13 – PGE1 inhibits the IFN-γ-induced expression of MCP-1 and ICAM-1 
in HMDMs 
THP-1 macrophages were incubated with vehicle or 10-100 µM PGE1 for 1 hour prior to 
treatment with vehicle or 250 U/ml IFN-γ for 3 hours. Concentration of vehicle control was 
used to match that of highest concentration of PGE1. Total RNA was subjected to reverse 
transcription and RT-qPCR with primers specific for human MCP-1 (panel A), ICAM-1 (panel 
B) or GAPDH. Graphs display average normalised gene expression (mean +/- SD) (control 
arbitrarily assigned as 1) from two independent experiments.  
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Figure 5.14 – PGE1 significantly inhibits the MCP-1 induced migration of THP-1 
monocytes  
THP-1 monocytes were incubated with 10 μM PGE1 or vehicle control and +/- MCP-1 (20 
ng/ml), for 3 hours. Monocyte migration was calculated by counting the number of monocytes 
that have migrated across a cell insert and expressed as a percentage of total cells. Statistical 
analysis was performed using a robust equality of means test followed by Dunnetes T3 post 
hoc analysis. *** P≤0.001 
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5.4.3.2 COX knockdown 
Given the ability of PGE1 to mimic key responses as observed with DGLA, it was 
hypothesised that metabolism of the PUFA to the prostaglandin may be the 
mechanism by which DGLA exerts its anti-inflammatory/anti-atherogenic actions. To 
test this experimentally, THP-1 monocytes were transfected with siRNA to 
knockdown the expression of COX-1 and COX-2 enzymes and then differentiated into 
macrophages. As shown in Chapter 3, COX-2 plays an important role in PGE1 
production in THP-1 macrophages, with a lesser role for COX-1. Previous work 
however has indicated a role for both COX isoforms in the metabolism of DGLA to 
PGE1 therefore both enzymes were targeted to ensure maximum knockdown of 
production of the prostaglandin. IFN-γ induced expression of MCP-1 was then 
measured by RT-qPCR. THP-1 monocytes were transfected with COX-1 and COX-2 
siRNA or a negative control siRNA for 24 hours prior to differentiation into 
macrophages.  Following knockdown, macrophages were incubated with 50 µM 
DGLA or vehicle control for 24 hours, followed by 250 U/ml IFN-γ or vehicle control, 
for a further 3 hours. Before measuring MCP-1 expression, the knockdown of COX-1 
and COX-2 was validated at the mRNA and protein level by RT-qPCR and western 
blotting, respectively. Figure 5.15 depicts the knockdown of COX-1 and COX-2. For 
COX-1, there was an average 75% knockdown at the mRNA level accompanied by a 
50% average knockdown at the protein level. COX-2 showed a 60% and 20% 
knockdown on average at the mRNA and protein levels respectively. COX-2 is an 
inducible enzyme, the detection of COX-2 was low at both the protein and mRNA 
levels. 
Following confirmation of knockdown of COX-1 and COX-2, MCP-1 gene expression 
was measured by RT-qPCR. As shown in Figure 5.16, in macrophages expressing a 
negative siRNA, IFN-γ significantly stimulated the expression of MCP-1. On pre 
incubation with DGLA, this expression was attenuated by approximately 30%. In cells 
where the expression of both COX-1 and COX-2 was knocked down, IFN-γ once 
again increased the expression of MCP-1 significantly. In DGLA pre-treated, ‘COX 
knockdown’ macrophages however, there was no attenuation of MCP-1 expression. 
The attenuation of IFN-γ induced MCP-1 signalling by DGLA was completely 
abolished on knockdown of COX-1 and COX-2 enzymes.   
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Figure 5.15 - COX1/2 knockdown by siRNA at mRNA and protein level 
THP-1 monocytes were incubated for 24 hours with 7.5 nM COX-1 and COX-2 siRNA or a control siRNA followed by differentiation with PMA for 24 hours. 
Following differentiation, macrophages were pre-treated with 50 µM DGLA or vehicle control for 24 hours prior to addition of IFN-γ or vehicle control for a 
further 3 hours. For gene expression, RNA was extracted and subjected to reverse transcription and RT-qPCR with primers specific to COX-1, COX-2 and 
GAPDH (A). For protein analysis, protein was extracted and subjected to western blot analysis with antibodies specific to COX-1, COX-2 and βactin (B). Each 
knockdown was compared to its negative siRNA counterpart, which has been arbitrarily assigned as 1. Graph displays average of 4 independent repeats (+/- 
SD). Statistics were performed using a Student’s two tailed Ttest. * P≤0.05. N.S – not significant 
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Figure 5.16 – Knockdown of COX-1 and COX-2 abolishes the attenuation of IFN-
γ induced MCP-1 expression by DGLA 
THP-1 monocytes were incubated for 24 hours with control siRNA (panel A) or  7.5 nM COX-
1 and COX-2 siRNA (panel B) followed by differentiation with PMA for 24 hours. Following 
differentiation, macrophages were pre-treated with 50 µM DGLA or vehicle control for 24 hours 
prior to addition of IFN-γ or vehicle control for a further 3 hours. Following validating of 
knockdown of COX-1 and COX-2, RNA was extracted and subjected to reverse transcription 
and RT-qPCR with primers specific to MCP-1 and GAPDH. Graph displays average of 4 
independent repeats (+/- SD).Statistics were performed using a one-way ANOVA followed by 
Tukey’s post-hoc analysis. ** P≤0.01, *** P≤0.001. N.S – not significant 
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5.5 Discussion  
5.5.1 IFN-γ induced STAT1 activation  
Data presented in the previous chapter indicated that DGLA inhibited the IFN-γ 
induced expression of two pro-inflammatory genes in macrophages; MCP-1 and 
ICAM-1. To understand the molecular mechanisms underlying this effect, IFN-γ 
signalling through the JAK/STAT pathway was investigated. Signalling through 
STAT1 plays an important role in IFN-γ actions and has been implicated to play a role 
in atherosclerosis (Li et al. 2010; Sikorski et al. 2011a). In addition to IFN-γ signalling, 
STAT1 has been described as a point of convergence and signalling integration for 
other pro-inflammatory signalling pathways, namely TLRs and IL-6, resulting in 
increased SMC and leukocyte activation and migration (Sikorski et al. 2011a; Sikorski 
et al. 2011b). Therapeutic inhibition of STAT1 with a decoy oligonucleotide has 
implicated it to play a role in myocardial graft tissue survival (Hoelschermann et al. 
2006). Targeting STAT1 prolonged cardiac graft survival by 40% due to a reduction 
in the recruitment of leukocytes, a process which causes acute myocardial rejection. 
It was observed that the expression of adhesion molecules VCAM-1 and ICAM-1 were 
reduced (Hoelschermann et al. 2006). In addition, induction of foam cells with oxLDL 
in THP-1 macrophages was reduced on treatment with a STAT1 inhibitor (Agrawal et 
al. 2007). This was also observed in BMDM from STAT1-/- mice and in vivo in ApoE-/- 
STAT1-/- mice. Deficiency of STAT1 reduced oxLDL induced cholesteryl ester and 
lipid accumulation in comparison to wild type animals (Agrawal et al. 2007).  To 
determine the role of DGLA on activation of STAT1, the phosphorylation of key sites 
TYR701 and SER727 were determined by western blotting.  
As shown in Figure 5.4, treatment of THP-1 macrophages significantly increased the 
phosphorylation of STAT1 at TYR701 and SER727 sites. On pre-treatment with DGLA, 
the induction of SER727 phosphorylation was attenuated by approximately 31%. There 
was no effect on phosphorylation at the TYR701 site. As previously described in 
Section 5.1.1.1, phosphorylation at TYR701 is required for transcriptional activity of 
STAT1, however this can occur independent of SER727 phosphorylation (McLaren and 
Ramji 2009; Li et al. 2010). Despite this, phosphorylation at SER727 is required for 
maximum transcriptional activity of STAT1 and inhibition of the process attenuates 
IFN-γ induced pro-inflammatory gene expression (Varinou et al. 2003).  Knock-in 
mice were used to study the effect of loss of STAT1 SER727 phosphorylation in vivo. 
The SER727 site in the transactivation domain of STAT1 was substituted for an alanine 
residue, preventing phosphorylation and maximal activity of STAT1 (Varinou et al. 
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2003). This resulted in a decrease in IFN-γ  induced gene expression in macrophages 
and transcription factor activity of STAT1 (Varinou et al. 2003). In addition, attenuation 
of SER727 phosphorylation in human macrophages by inhibition of upstream kinases 
attenuated the IFN-γ induced expression of ICAM-1, MCP-1, IP-10 and MIP-1β at the 
mRNA and protein level (Li et al. 2010). IFN-γ induced uptake of acLDL and oxLDL 
was also reduced (Li et al. 2010). Given the results presented in Figure 5.4, this 
indicates a role for DGLA in the attenuation of STAT1 activity which can lead to a 
reduction in IFN-γ-mediated pro-inflammatory gene expression. The data highlights 
a new potential mechanism by which DGLA may aid in the attenuation of foam cell 
formation and atherosclerosis. 
A number of kinases have been implicated in the phosphorylation of STAT1 at 
SER727. Inhibition of ERK and JNK selectively decreased the IFN-γ induced SER727 
phosphorylation in human macrophages (Li et al. 2010). PKCδ and CAMK II inhibited 
phosphorylation at both sites while p38 had no effect (Li et al. 2010). Given the 
selective role of ERK and JNK phosphorylation of SER727, future avenues could 
evaluate the effect of DGLA on the activity of these kinases to further elucidate the 
role of the fatty acid in IFN-γ signalling through the JAK/STAT pathway.  
5.5.2 Modified LDL uptake in macrophages 
As reported in Chapter 4, DGLA attenuated the accumulation of cholesteryl esters in 
macrophages following cholesterol loading with a modified form of LDL, acLDL. In an 
attempt to delineate the mechanisms underlying this action, a number of processes 
were targeted for investigation including cholesterol uptake, metabolism and efflux. 
In atherosclerosis, macrophages recognise and internalise excess amounts of 
modified forms of LDL in an unregulated manner. As a result, excess cholesterol is 
stored as cholesteryl esters in lipid droplets which are deposited in the cytoplasm, a 
hallmark of foam cell formation (Shashkin et al. 2005; Lusis 2012). Inhibiting the 
uptake of modified forms of LDL would therefore prevent the accumulation of excess 
cholesterol in macrophages and their transformation into foam cells. Uptake was 
measured using a fluorescently labelled modified form of LDL; Dil-oxLDL. As shown 
in Figure 5.5, DGLA inhibited the uptake of Dil-oxLDL by 21% on average. Previous 
studies have reported comparable results using omega-3 fatty acid DHA (McLaren et 
al. 2011b). DHA inhibited Dil-acLDL and Dil-oxLDL uptake in THP-1 macrophages. 
This process was found to be dependent on both scavenger receptors and 
macropinocytosis (McLaren et al. 2011b). The data presented in Figure 5.5 indicates 
that the decrease in cholesteryl ester accumulation observed in Chapter 4, may be in 
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part as a result of a reduction in modified LDL uptake. Cholesteryl ester studies were 
performed using acLDL, in contrast uptake was measured using oxLDL. Both 
modified forms of LDL have been used extensively in lipid uptake and foam cell 
formation studies, yielding comparable results in mechanisms of uptake, cholesterol 
accumulation and efflux (McLaren et al. 2010; McLaren et al. 2011b). This suggests 
that the both acLDL and oxLDL can be interchangeable when studying these 
processes.   
5.5.2.1 Scavenger receptors 
Receptor-mediated endocytosis is an important mechanism by which macrophages 
bind and internalise a number of molecules, including pathogens and LDL. Scavenger 
receptors are expressed on the surface of macrophages and internalise unregulated 
amounts of modified forms of LDL. CD36 and SRA have been shown to take up large 
amounts of oxLDL and acLDL and contribute to foam cell formation and 
atherosclerosis (Febbraio et al. 2000; Kunjathoor et al. 2002; Kuchibhotla et al. 2008). 
The effect of DGLA on the expression of these two receptors in THP-1 macrophages 
at the mRNA (SRA and CD36) and protein level (SRA) was measured by RT-qPCR 
and western blotting respectively (Figure 5.6). On treatment with DGLA, the mRNA 
expression of CD36 and SRA was reduced by approximately 20%. The protein 
expression of SRA was decreased by 40%. No previous work has detailed the effect 
of DGLA on the expression of SRA and CD36. However, a previous study 
investigating the role of omega-6 PUFA, LA, demonstrated comparable results. LA 
treatment in THP-1 macrophages and HMDMs significantly decreased the expression 
of SRA and CD36. This was accompanied by a significant decrease in the cholesterol 
content of foam cells (Song et al. 2013).  
As reported in the previous chapter, DGLA reduced the acLDL induced cholesteryl 
ester accumulation in macrophages. The data presented in Figure 5.6 indicates this 
may be in part due to a reduced expression of scavenger receptors on treatment with 
DGLA which may potentially result in a reduction in uptake of modified LDL. Previous 
studies evaluating the role of SRA and CD36 knockdown have shown comparable 
results. Cholesteryl esters fail to accumulate in macrophages from SRA and CD36 
knockout mice (Kunjathoor et al. 2002). SRA-/- macrophages degraded 70% less 
acLDL in comparison to wild type animals and specific binding of acLDL was reduced 
by 44% (Kunjathoor et al. 2002). CD36 plays a lesser role in acLDL binding and 
degradation with CD36-/- macrophages accounting for 28% less binding and 13% less 
degradation (Kunjathoor et al. 2002). There was however a bigger effect on oxLDL 
degradation and binding in these macrophages. CD36-/- macrophages reduced 
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binding of oxLDL by 90% and degradation by 68% (Kunjathoor et al. 2002). Again, 
SRA-/- played a lesser role in oxLDL metabolism, reducing binding by 40% and 
degradation by 25% (Kunjathoor et al. 2002). Therefore both scavenger receptors 
play a role in internalisation and degradation of modified LDL, but have different 
preferences for acLDL and oxLDL. Uptake of oxLDL by CD36, in addition to its 
function in foam cell formation, has also been indicated to play other pro-inflammatory 
roles. CD36 uptake of oxLDL decreased macrophage efflux from atherosclerotic 
plaques, promoted macrophage trapping and increased plaque progression (Park et 
al. 2009). Also, oxLDL binding to CD36 has been shown to activate platelets and 
contribute to pro-thrombotic state (Chen et al. 2008). Finally, CD36-/- macrophages 
expressed reduced levels of IFN-γ, MCP-1 and TNF-α in the presence or absence of 
oxLDL (Kennedy et al. 2011).  
The uptake assay and cholesteryl ester accumulation assay were performed with 
oxLDL and acLDL respectively. Given the data presented in Figures 4.16, 5.5 and 
5.6, taken together with previous studies, it suggests that DGLA can reduce modified 
LDL uptake and cholesteryl ester accumulation by reducing the uptake of acLDL and 
oxLDL though the reduction in the expression of scavenger receptors SRA and CD36. 
The data highlights a potential new mechanism for the anti-inflammatory and anti-
atherogenic action of DGLA.  
5.5.2.2 Macropinocytosis 
Macrophages can also take up molecules by receptor independent mechanisms. 
Macropinocytosis is a form of non-selective endocytosis for solute macromolecules 
(Swanson and Watts 1995). Following stimulation with M-CSF or phorbol esters, 
ruffling at the cell surface of macrophages can be observed which gives rise to 
macropinosomes (Swanson and Watts 1995). Macropinocytosis has been linked to 
LDL uptake by macrophages and foam cell formation. An inhibitor of 
macropinocytosis, cytochalasin D, attenuated the uptake of acLDL in THP-1 
macrophages which translated to reduced intracellular cholesterol levels (McLaren et 
al. 2011b; Michael et al. 2013). This result was conserved in HMDMs (Michael et al. 
2013). Treatment with the inhibitor increased the expression of SRA and CD36 which 
suggested the reduction in uptake and accumulation of acLDL was receptor 
independent (Michael et al. 2013). Macrophages incubated with acLDL and oxLDL 
increased membrane ruffling and formed macropinosomes resulting in a 1.5 fold 
increase in fluid phase uptake (Jones and Willingham 1999) suggesting a role for the 
pathway in modified LDL uptake. OxLDL induced foam cell formation was also 
reduced by an inhibitor of macropinocytosis in RAW264.7 macrophages (Yao et al. 
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2009).  In addition to uptake of modified forms of LDL, macropinocytosis has also 
been shown to take up native LDL. M-CSF differentiated macrophages showed an 
increased uptake of native LDL in the fluid phase which increased cholesterol 
accumulation (Zhao et al. 2006). Similarly, M-CSF stimulated HMDMs treated with a 
macropinocytosis inhibitor showed a 40% decrease in LDL uptake (Anzinger et al. 
2010). Uptake of LDL by macropinocytosis can therefore be independent of 
modification and still induce cholesterol accumulation in macrophages.  
Previous work has indicated a role for PUFAs in macropinocytosis. Treatment of THP-
1 macrophages with EPA and DHA reduced acLDL uptake. This was accompanied 
by a reduction in the uptake of a marker of macropinocytosis on treatment with the 
PUFAs (McLaren et al. 2011b). The effect of DGLA on macropinocytosis was 
measured in PMA differentiated macrophages. PMA, a phorbol ester, has been used 
frequently in the literature to induce macropinocytosis in differentiated macrophages. 
PMA increased macropinosomes in BMDMs (Swanson 1989) and induced LDL and 
modified LDL uptake in HMDMs (Kruth et al. 2002; Kruth et al. 2005) and THP-1 
macrophages (McLaren et al. 2011b; Michael et al. 2013). To measure 
macropinocytosis, LY was used as a marker which can be measured by FACS 
analysis. LY has been commonly used in measuring macropinocytosis in previous 
studies (Swanson 1989; Jones and Willingham 1999; McLaren et al. 2011b; Michael 
et al. 2013). As shown in Figure 5.7, pre incubation with DGLA inhibited LY uptake 
by approximately 17% in PMA differentiated macrophages. Given the role of 
macropinocytosis in the uptake of modified forms of LDL including acLDL, this may 
indicate another mechanism, independent of receptor-mediated uptake, in which 
DGLA inhibits the uptake and accumulation of cholesteryl esters as seen previously. 
In addition, DGLA may also attenuate the uptake of native forms of LDL through 
inhibiting macropinocytosis. Despite the effect of DGLA on LY uptake by 
macropinocytosis, it will need to be directly assessed if this translates to uptake of 
modified LDL and native LDL.  
5.5.3 Cholesterol metabolism  
In addition to uptake mechanisms of modified LDL, it was of interest to determine the 
role of DGLA in the metabolism of internalised cholesterol in macrophages. Free 
cholesterol is removed from the cell by RCT transport, a process dependent on the 
nCEH enzymes. nCEH enzymes hydrolyse cholesteryl esters to free cholesterol 
which can be removed from the cell through transporter proteins (Okazaki et al. 2008). 
Of the numerous nCEH enzymes, NCEH1 is highly expressed in macrophages and 
plays an important role in foam cell formation and atherosclerosis (Okazaki et al. 
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2008; Sekiya et al. 2009; Igarashi et al. 2010) (see Section 5.1.2.3.2. for more details). 
NCEH1-/- macrophages show an increase in cholesterol esters and a decrease in 
cholesterol efflux, key features of foam cell formation (Sekiya et al. 2009). In addition, 
overexpression of NCEH1 in THP-1 macrophages decreased the accumulation of 
cholesteryl esters induced by acLDL uptake (Igarashi et al. 2010). The effect of DGLA 
on this enzyme was therefore of interest.  
Excess free cholesterol is stored as cholesteryl esters in lipid droplets within the 
cytoplasm. This accumulation of cholesteryl esters is a key feature of macrophage 
foam cells and gives them their foamy appearance under the microscope (Ghosh et 
al. 2010). ACAT1 is responsible for cholesteryl ester formation in macrophage foam 
cells. ACAT1 is expressed in human atherosclerotic lesions and macrophages 
including the THP-1 cell line (Miyazaki et al. 1998; Yang et al. 2004; Wan et al. 2009). 
ACAT1-/- macrophages treated with acLDL showed an increase in the efflux of acLDL 
derived cholesterol and an increase in free cholesterol (Ghosh et al. 2010). Inhibition 
of ACAT1 is therefore expected to attenuate atherosclerotic lesion development by 
preventing the formation and storage of cholesteryl esters and increase free 
cholesterol for efflux (Ghosh et al. 2010).  
THP-1 macrophages were treated with DGLA for 24 hours before measuring gene 
expression by RT-qPCR. As shown in Figure 5.8, DGLA did not affect the basal 
expression of NCEH1 and ACAT1 in THP-1 macrophages. Given this, no further 
experiments were carried out. Potential future follow-up experiments could measure 
the expression of the two genes at the protein level by western blotting. In addition, 
the role of DGLA on the expression of NCEH1 and ACAT1 could be determined in 
cholesterol-loaded macrophages.  
Despite the promising role of ACAT1 as a target to prevent cholesteryl ester 
accumulation and development of foam cells, disruption of the gene in mouse models 
has proved controversial. The subsequent increase in free cholesterol as a result of 
disruption of ACAT1 can also contribute to atherosclerosis. LDLr-/- ACAT1-/- deficient 
mice displayed increased lesion sizes in comparison to wild type controls despite a 
decrease in the number of plaque macrophages (Fazio et al. 2001). Free cholesterol 
accumulated in arterial wall promoted atherogenesis (Fazio et al. 2001). In mouse 
peritoneal macrophages from ACAT-/- mice, efflux of cholesterol was increased along 
with a decrease in esterification. Despite this, there was also a 134% increase in 
cholesterol synthesis in macrophages, which may contribute to atherogenesis (Dove 
et al. 2005). Partial inhibition of ACAT1 in the liver and intestine of ApoE-/- mice 
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however significantly reduced atherosclerosis. Mice treated with ACAT1 inhibitor 
showed a significant reduction in lesion size and immune-staining of macrophages 
(Kusunoki et al. 2001). The controversial results obtained from disruption of ACAT1 
in relation to atherosclerosis highlights the drawbacks of targeting the gene as a 
potential therapeutic mechanism. Clinical trials evaluating the use of ACAT inhibitors 
as a therapeutic in atherosclerosis have also proved unsuccessful (Nissen et al. 2006; 
Meuwese et al. 2009).  
5.5.4 Cholesterol efflux 
The final mechanism targeted in the studies in this chapter to understand the 
molecular basis underlying the action of DGLA on cholesteryl ester accumulation in 
macrophages, was cholesterol efflux. RCT from macrophages is discussed in more 
detail in Sections 1.2.2.3 and 5.1.2.4. The effect of DGLA on cholesterol efflux was 
measured in THP-1 macrophages. The cells were incubated with acLDL to induce 
the accumulation of intracellular cholesterol and stimulated with ApoA1. ApoA1 is the 
apolipoprotein constituent of HDL and acts to promote cholesterol efflux from 
macrophages via ABC transporter proteins (Yvan-Charvet et al. 2008). A number of 
studies utilise ApoA1 as a positive control in cholesterol efflux assays (McLaren et al. 
2010; Ouimet et al. 2011; Sene et al. 2013). Concentrations of acLDL and ApoA1 
used in the assays and analysis of results were as previously reported (McLaren et 
al. 2010; Ouimet et al. 2011; Sene et al. 2013). On loading with acLDL and treatment 
with ApoA1, cholesterol efflux increased in comparison to unloaded macrophages 
(data not shown). Pre-treatment with DGLA followed by acLDL loading and ApoA1 
stimultion, significantly increased cholesterol efflux from THP-1 macrophages by 
approximately 10% (Figure  5.9).   
The inverse correlation between HDL and CHD has been widely recognised in 
numerous studies (Gordon et al. 1977; Gordon et al. 1989; Feig et al. 2014). HDL and 
its component ApoA1 act to remove cholesterol from macrophages by RCT and 
transport it to the liver for degradation, therefore reducing the accumulation of 
cholesterol in periperhal cells including macrophages. ApoE-/- ApoA1-/- mice showed 
an increase in free cholesterol accumulation and lesion area (Boisvert et al. 1999). In 
addition BMDMs expressing a macrophage ApoA1 gene were transplated into ApoE-
/- mice with pre exisiting atherosclerosis. Transplant mice in comparison to ApoE-/- 
mice showed a significant increase in cholesterol efflux and the expression of ABC 
transporter genes  which lead to a reduction in atherosclerosis lesions in the proximal 
aorta (Su et al. 2003). Efflux of cholesterol to ApoA1 can therefore reduce the 
accumulation of cholesterol in macrophages and protect against atherosclerosis. The 
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data in Figure 5.9 shows that DGLA significanly increases cholesterol efflux to ApoA1 
in THP-1 macrophages. This indicates a potential mechanism by which cholesteryl 
ester accumulation is attenuated in THP-1 macrophages incubated with DGLA, which 
can lead to a reduction in foam cell formation and atherosclerosis.  
To date, no study has investigated the role of DGLA in cholesterol efflux in 
macrophages. A handful of studies however have addressed the role of omega-6 
PUFA LA, with contrasting results. In THP-1 macrophages and HMDMs, LA 
significantly decreased the cholesterol content of foam cells and increased 
cholesterol efflux to lipid free ApoA1 (Song et al. 2013) comparable to that seen in 
Figure 5.9.  In contrast however, LA treatment of murine macrophages had an 
opposing effect. In RAW264.7 macrophages, LA decreased ApoA1-mediated 
cholesterol and phospholipid efflux (Wang and Oram 2002). In addition, LA treatment 
of mouse BMDM significantly decreased HDL-mediated efflux (Wang and Oram 
2002). Future experiments may act to determine the effect of DGLA in cholesterol 
efflux from murine macrophages to evaluate any species specific roles.  
5.5.4.1 ABC transporter proteins and ApoE 
To attempt to determine the mechanisms underlying the increase in cholesterol efflux 
from macrophages on treatment with DGLA in THP-1 macrophages, the protein 
expression of key genes involved in RCT were measured by western blotting. Initially 
the study focused on the ABC transporter proteins. Increased expression of ABCA1 
and ABCG1 has previously been shown to increase cholesterol efflux from 
macrophages and significantly prevent atherosclerosis (Singaraja et al. 2002; 
Burgess et al. 2008). In contrast, disruption of these transporter proteins has opposing 
effects resulting in an increase in atherosclerosis (Yvan-Charvet et al. 2007; Tarling 
et al. 2010; Westerterp et al. 2013). ABCA1 and ABCG1 have different mechanisms 
for removal of cholesterol. ABCA1 promotes cholesterol and phospholipids efflux to 
lipid poor ApoA1. In contrast, cholesterol efflux to HDL specifically required ABCG1 
(Kennedy et al. 2005). Given the use of ApoA1 as a cholesterol acceptor used in 
efflux experiments (Figure 5.9), it was hypothesised that DGLA may act through 
increasing expression of ABCA1. The expression of ABCA1 was measured in THP-1 
macrophages loaded with acLDL in an independent experiment, by RT-qPCR and 
western blotting. It was found that on cholesterol loading with acLDL, the mRNA and 
protein expression of ABCA1 was increased in comparison to un-loaded 
macrophages (Figure 5.10). This has also been observed in previous studies (Uehara 
et al. 2007). On pre-treatment with DGLA followed by acLDL loading, the protein 
expression of ABCA1 was not different to acLDL only loaded macrophages, but 
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decreased at the mRNA level. The results are based on a single experiment 
performed in duplicate; further repeats must be performed to establish any significant 
changes.  Previously, no studies have directly measured the effect of DGLA on 
ABCA1 expression. However, studies have reported the effect of other omega-6 and 
omega-3 PUFA with contrasting results. LA treatment  decreased  the expression of 
ABCA1 and reduced ApoA1 binding activity in RAW264.7 macrophages (Wang and 
Oram 2002). A decrease in ABCA1 expression was also observed in EPA and AA 
treated macrophages (Uehara et al. 2002; Uehara et al. 2007). In BMDMs, ABCA1 
expression was significantly inhibited by 95% following LA treatment (Spartano et al. 
2014). However in THP-1 macrophages, endogenous ABCA1 expression  was not 
affected by conjugated LA (CLA) (Salehipour et al. 2010) or LA (Song et al. 2013), 
comparable to results observed in Figure 5.10.  
Following this, the expression of ABCG1 was also measured at the mRNA level. 
Protein level of the transporter protein was not measured due to time constraints. The 
trend observed from a single experiment, suggested that the expression of ABCG1 
was significantly increased on cholesterol loading of macrophages with acLDL 
(Figure 5.10). Pre-treatment with DGLA followed by cholesterol loading had no 
observed effect on ABCG1 mRNA expression. To date, no study has provided insight 
into the effect of DGLA on ABCG1 expression in macrophages. A previous study has 
however investigated the role of omega-6 PUFA, LA on ABCG1 expression in 
RAW264.7 macrophages (Uehara et al. 2007). Comparable to results presented in 
Figure 5.10, cholesterol loading of RAW264.7 macrophages dramatically induced the 
activity of the ABCG1 promoter. However in contrast, it was observed that LA 
significantly supressed ABCG1 promoter activity. In addition, in unloaded 
macrophages, LA significantly decreased endogenous ABCG1 protein expression 
(Uehara et al. 2007). Data presented in Figure 5.10 need further repeats to clarify the 
expression of ABCG1 at the mRNA and the protein level.  
In addition to ABC transporter genes, ApoE has been indicated to play a role in 
cholesterol efflux in macrophages. ApoE is a component of lipoprotein particles and 
aids in transport of cholesterol as well as their clearance in the liver (Curtiss 2000). 
However, in macrophages it has been shown to have an additional role. ApoE 
expression from arterial macrophages in ApoE-/- mice show a significant reduction in 
atherosclerosis, despite plasma cholesterol levels comparable to that of control 
(Hasty et al. 1999). Expression of ApoE in macrophages in vivo has also been shown 
to increase cholesterol efflux in macrophages (Zhu et al. 1998) and to reduce free 
cholesterol accumulation in lesions (Boisvert et al. 1999). In addition to macrophages, 
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ApoE expression in the arterial wall of transgenic mice also decreased atherosclerotic 
lesion sizes and reduced cholesterol content (Shimano et al. 1995). Given this, the 
role of DGLA on the expression of ApoE in cholesterol loaded macrophages was 
determined by western blotting. It was observed that acLDL treatment of THP-1 
macrophages had no effect on the protein expression of ApoE. There was also no 
change in expression on pre-treatment with DGLA followed by acLDL loading. 
Previous studies however, indicate that ApoE expression is increased on cholesterol 
loading. In hypercholesterolemic rabbits, ApoE mRNA expression was increased and 
localised to cholesterol loaded macrophages (Polanco et al. 1995). In mouse 
peritoneal macrophages loaded with 25 μg acLDL, mRNA expression of ApoE was 
also up regulated (Mazzone et al. 1989). In addition, in THP-1 macrophages loaded 
with 100 μg acLDL, the expression of ApoE was significantly increased (Garner et al. 
2002). The induction of ApoE on cholesterol loading was not observed in this study 
(Figure 5.10). The experiment however was performed in isolation and further repeats 
would be needed to determine a more accurate understanding of ApoE expression. 
In addition, Garner et al (2002) observed an increase of ApoE protein expression in 
THP-1 macrophages at a much larger concentration of 100 μg of acLDL compared to 
a concentration of 25 μg used for the studies in Figure 5.10 which may explain in part 
the differences observed between the studies. Further experiments are required to 
determine the effect of concentration of acLDL on ApoE expression in THP-1 
macrophages.  
ABC transporters are LXR regulated genes. Agonists of LXRs activate ABC1 gene 
expression and induce cholesterol-mediated transport (Schwartz et al. 2000). In 
addition LXR ligands are key regulators of ApoE expression in macrophages (Laffitte 
et al. 2001). As shown in Figure 5.11, DGLA significantly inhibited LXR gene 
expression in un-loaded THP-1 macrophages. Previously it has been documented 
that PUFAs inhibit LXR activation. In RAW264.7 macrophages, EPA and LA inhibit 
LXR activity (Uehara et al. 2007) while in rat hepatoma cells AA antagonise LXR 
activation (Pawar et al. 2003). Taken together, the results presented in this chapter 
and previous studies suggest that the increase in cholesterol efflux from THP-1 
macrophages on treatment with DGLA is independent of ABC transporter protein and 
ApoE expression. Data presented in Figure 5.10 and Figure 5.11 and previous work 
indicates that DGLA may in fact inhibit LXR activation and the induction of ABC 
transporter genes and ApoE, however further experiments will need to be performed 
to determine this directly.  
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Alternative mechanisms of cholesterol efflux induced by PUFAs, independent of ABC 
transporters and ApoE, have been suggested previously. In THP-1 macrophages 
treated with LA there was no effect on ABCA1 expression but an increase in 
cholesterol efflux. This was associated with specific effects on gene profiles of genes 
involved in lipid droplet metabolism including cell death inducing DFF45 like effector 
(CIDE) and perilipin adipophilin TIP47 (PAT) family members following PUFA 
treatment (Song et al. 2013). In addition, ALA treatment in macrophage foam cells 
significantly increased cholesterol efflux and decreased cholesterol storage. This was 
associated with a decrease in the expression of stearoyl CoA desaturase (SCD1), the 
rate limiting enzyme in synthesis of MUFA (Zhang et al. 2012).  In addition to this, 
future work could explore the role of DGLA metabolites in cholesterol efflux. As shown 
previously in Chapter 3, DGLA metabolises to PGE1, a COX metabolite. Studies have 
indicated a role for COX metabolites in cholesterol efflux in macrophages. In THP-1 
macrophages, inhibition of COX enzymes with inhibitors significantly decreased 
cholesterol efflux and increased foam cell formation (Chan et al. 2007). In addition, in 
skin fibroblasts, stimulation of cAMP by PGE1 enhanced cholesterol efflux to HDL3 
(Middleton and Middleton 1998). It is therefore possible that DGLA is acting through 
PGE1 to induce cholesterol efflux.  
5.5.5 DGLA metabolite PGE1 
An important feature of PUFA signalling in disease is their ability to form eicosanoids. 
As shown previously in Chapter 3, administration of DGLA to THP-1 macrophages 
increases the production of the COX metabolite PGE1. PGE1 has been well 
documented to play a number of anti-inflammatory roles, discussed in detail in 
Section 3.1.3. Given the effect of DGLA on aspects of foam cell formation, it was of 
interest to determine if these effects were due to the action of DGLA or its metabolite 
PGE1. The effects of PGE1 on IFN-γ induced MCP-1 and ICAM-1 gene expression, 
along with MCP-1 induced monocyte migration, were measured.  
THP-1 macrophages were pre-treated with PGE1 for one hour prior to treatment with 
IFN-γ. Doses of PGE1 ranging from 10-100 µM were used to determine the optimum 
concentration for use in further experiments. Gene expression was measured using 
RT-qPCR. IFN-γ invreased MCP-1 and ICAM-1 expression by 62% and 55% 
respectively (Figure 5.12). When pre-incubated with PGE1 prior to cytokine 
stimulation, MCP-1 induction was inhibited, returning to a level below basal 
expression in a dose-dependent manner. ICAM-1 expression was attenuated by an 
average of 40-55% at all doses.  Both results were significant at the lowest dose used 
(10 µM) and this concentration was employed in further experiments. This result was 
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confirmed in HMDMs (Figure 5.13). As shown in Figure 5.14, MCP-1 induced 
monocyte migration significantly by 70% as observed previously. On co-incubation 
with 10 µM PGE1, monocyte migration was inhibited and returned to levels observed 
in un-stimulated cells.  
Similar results have been previously observed in vivo. PGE1 has been shown to inhibit 
MCP-1 expression in mice with induced glomerular immune injury (Jocks et al. 1996). 
In addition, patients with peripheral vascular disease receiving PGE1 therapy showed 
a significant decrease in circulating levels of adhesion molecules ICAM-1, VCAM-1 
and E-selectin (Palumbo et al. 2000). In mouse macrophages, PGE1 inhibited PMA-, 
IFN-γ- and LPS-mediated induction of MIP-1β and MIP-1α inflammatory genes 
expressed in atherosclerosis (Martin and Dorf 1991). PGE1 was also shown to inhibit 
the expression of pro-inflammatory genes induced by numerous other cytokines 
(Martin and Dorf 1991). 
To determine if the anti-inflammatory actions of DGLA were as a result of production 
of PGE1, RNA interference techniques were used to knockdown the expression of 
COX enzymes. As discussed previously in Chapter 3, there is some debate as to the 
specific role of the COX isoforms in PGE1 formation. Nevertheless, both COX-1 and 
COX-2 have been shown to metabolise DGLA to PGE1 (Levin et al. 2002) therefore 
both enzymes were targeted to ensure that synthesis was inhibited at the maximum 
level. To evaluate the role of PGE1 synthesis from DGLA in inflammation, the robust 
IFN-γ induced MCP-1 response was initially investigated. siRNA techniques were 
used to target COX-1 and COX-2 enzymes prior to differentiation into macrophages, 
incubation with DGLA and stimulation with IFN-γ. Following knockdown, the levels of 
COX-1 and COX-2 were measured at the mRNA and protein level (Figure 5.15). 
COX-1 was knocked down by an average of 75% and 50% at the mRNA and protein 
level, respectively. COX-2 knockdown was 60% at mRNA level and 20% at protein 
level (Figure 5.15). COX-2 knockdown seemed less efficient than COX-1 knockdown; 
however COX-2 is an inducible enzyme while COX-1 is constitutively expressed. 
Basal levels of COX-2 mRNA and protein were very low in unstimulated 
macrophages. Absolute quantification of COX-1 and COX-2 was not determined; 
however in doing so it may be possible to more accurately compare the levels of 
COX-1 and COX-2 knockdown. Despite this, knockdown of COX-1 and COX-2 
enzymes were sufficient to see changes in IFN-γ induced MCP-1 expression.  
As expected, IFN-γ induced MCP-1 expression which was significantly attenuated on 
pre-treatment with DGLA (Figure 5.16). In macrophages where the expression of 
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COX-1 and COX-2 was knocked down, MCP-1 was still significantly induced by IFN-
γ. However, pre-treatment with DGLA did not significantly reduce MCP-1 expression. 
The effect of DGLA on reducing MCP-1 induction was abolished following knockdown 
of COX-1 and COX-2. This indicates that on treatment of the cells with DGLA, the 
COX metabolites PGE1 plays a role in the inhibition of IFN-γ induced MCP-1 gene 
expression. Future experiments may explore the use of the COX inhibitor naproxen 
to evaluate ICAM-1 gene expression and monocyte migration.  
Previous research supports the data presented in Figure 5.16. Oral administration of 
DGLA to mice, significantly reduced the induction of inflammation in the ears, 
triggered by application of an inflammatory agent (Watanabe et al. 2014). DGLA 
reduced infiltration of cells, swelling and chemokine production (Watanabe et al. 
2014). When mice were administered COX inhibitor naproxen prior to DGLA feeding, 
this reduction in inflammation was attenuated (Watanabe et al. 2014). Naproxen 
prevented a reduction in infiltration of cells to the inflamed areas along with the 
reduction in the levels of MCP-1 (Watanabe et al. 2014). This indicates a role of the 
COX DGLA metabolite PGE1 in migration and MCP-1 production in vivo. In addition, 
ApoE deficient mice fed DGLA significantly reduced lipid accumulation in the mouse 
aortas (Takai et al. 2009). Following treatment with naproxen, lesion size was reduced 
so that there was no significant difference between the vehicle and DGLA and 
naproxen treated groups (Takai et al. 2009). The inhibition of inflammatory markers 
ICAM-1 and VCAM-1 in mice supplemented with DGLA was also reversed with 
naproxen treatment (Takai et al. 2009). 
In addition to metabolising DGLA into PGE1, COX enzymes can also metabolise AA 
into PGE2 (Levin et al. 2002). As previously shown, in macrophages pre-treated with 
DGLA and then stimulated with IFN-γ there was a significant induction of PGE2 
(Figure 3.9). It can be assumed therefore that knockdown of the two enzymes would 
limit the production of both prostaglandins. As the knockdown is not specific to 
inhibition of individual prostaglandins, the experiment cannot specifically identify 
which is responsible for the results observed. However, given the roles of PGE1 on 
MCP-1 and ICAM-1 expression presented in this report (Figure 5.12 and 5.13) and in 
the literature (Martin and Dorf 1991; Jocks et al. 1996; Watanabe et al. 2014), the 
induction of PGE1 on treatment of DGLA in macrophages and the widely reported pro-
inflammatory actions of PGE2, it can be assumed with confidence that the results 
shown in Figure 5.16 are due to the inhibition of PGE1 production from DGLA.  
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The anti-inflammatory actions of DGLA are not solely dependent on PGE1 production 
however. DGLA inhibited TNF-α release from PBMCs, as did PGE1. However 
inhibiting PGE1 production, did not affect the reduction of TNF-α after DGLA 
supplementation (Dooper et al. 2003). This indicates DGLA has a direct effect or is 
acting through the production of an alternative eicosanoid. Another series 1 
prostaglandin synthesised from DGLA, PGD1 has previously been shown to reduce 
severity of atopic dermatitis in mice, reducing scratching and scores (Amagai et al. 
2015). Future work could include determining the roles of other eicosanoids 
metabolised from DGLA in the regulation of the inflammatory response in 
atherosclerosis, to obtain a better understanding of the role of the PUFA and its 
metabolites.  
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CHAPTER 6 
GENERAL DISCUSSION 
6.1 Introduction 
In 2008 it was estimated that 17.8 million people died of CVD related disease, more 
than any other disease in the Western society. With mortality rates predicted to 
increase in the coming years, the need for new therapeutic advances is crucial. 
Atherosclerosis is the primary cause of CVD. It is characterised by the accumulation 
of lipid-rich plaques in the walls of large and medium arteries as a result of a chronic 
inflammatory response (Buckley and Ramji 2015). Atherosclerosis is a progressive, 
mutli-factorial disease, with complex pathology. A key feature is the formation of lipid-
loaded macrophages, termed foam cells, which accumulate in the walls of arteries 
and form the underlying basis for the development of plaques (Michael et al. 2012). 
Targeting the early stages of atherosclerosis and the ongoing inflammatory response 
is of therapeutic interest in the prevention and management of the disease.  
Statins are the primary drug therapy used in the management of atherosclerosis 
(Michael et al. 2012). Use of statins has been well documented to have had a marked 
impact in reducing the mortality rates from the disease, however there are a number 
of limitations and drawbacks to the therapy (Mishra and Routray 2003). The maximum 
reduction in mortality rates that can be attributed to statins is about 30%, with many 
studies reporting issues such as side effects and tolerability (Mishra and Routray 
2003). In addition to this, the result of a number of clinical trials investigating key 
targets in the disease (PPAR agonists, inhibitors of CETP and ACAT-1) have been 
disappointing (Fazio et al. 2001; Weber and Noels 2011; Michael et al. 2012; Ramji 
and Davies 2015). The need for new preventative and therapeutic agents is therefore 
essential. 
Nutraceuticals are potentially promising drug alternatives, as prevention or limiting 
agents. It is important to determine the beneficial effect of these agents by 
understanding the molecular mechanisms underlying their actions in vitro and in vivo. 
DGLA is an omega-6 PUFA which has been implicated to play an anti-inflammatory 
role in a number of diseases such as atopic eczema and atherosclerosis (Kawashima 
et al. 2008; Takai et al. 2009). In addition to this, the PUFA has been shown to reduce 
SFA induced hypertension in rats (Hassall and Kirtland 1984), inflammatory 
responses induced by croton oil in mice (Watanabe et al. 2014) and promote 
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antithrombotic effects in humans (Kernoff et al. 1977). In vivo studies have indicated 
that DGLA is well tolerated in mice, rats and humans, with no side effects reported 
(Umeda-Sawada et al. 2006; Takai et al. 2009; Teraoka et al. 2009; Tanaka et al. 
2012).  
The project was based on two broad aims. First; determine the uptake and 
metabolism of DGLA in vitro and in vivo. Second, delineate the molecular 
mechanisms underlying the anti-inflammatory action of DGLA, in relation to 
atherosclerosis. For in vitro analysis, macrophage cell lines and HMDMs were used 
throughout the study due to the key roles of these cells in foam cell formation and the 
pathology of atherosclerosis.  
6.2 Results 
6.2.1 Summary of key findings with DGLA 
In vitro 
1. Supplementation with DGLA significantly increased the incorporation of the 
PUFA into TPL and TAG fractions of THP-1 macrophages. There was no 
increase in the incorporation of AA into lipid fractions. 
 
2. Attenuated MCP-1 induced monocytic migration of THP-1 monocytes. 
 
3. Inhibited pro-inflammatory cytokine (IFN-γ, IL-1β, TNF-α) induced expression of 
MCP-1 and ICAM-1, two robust markers of inflammation, in THP-1 
macrophages. Inhibition of IFN-γ response was also confirmed in RAW264.7 
and HMDMs.  
 
4. Inhibited STAT-1 SER727 phosphorylation, involved in activation of IFN-γ 
signalling in THP-1 macrophages. 
 
5. Attenuated acLDL induced cholesteryl ester accumulation in RAW264.7 
macrophages. 
 
6. Decreased Dil-oxLDL uptake by THP-1 macrophages. 
 
7. Decreased scavenger receptor expression and uptake by macropinocytosis in 
THP-1 macrophages. 
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8. Increased cholesterol efflux in cholesterol-loaded THP-1 macrophages 
stimulated with ApoA1. 
 
9. Increased production of eicosanoids PGE1 and 15-HETrE in THP-1 
macrophages. 
 
10. PGE1 inhibited IFN-γ induced MCP-1 and ICAM-1 expression and monocyte 
migration in THP-1 macrophages. 
 
11. Knockdown of COX enzymes abolished the inhibition of DGLA on IFN-γ induced 
MCP-1 expression in THP-1 macrophages. 
In vivo 
12. Mice supplemented with 4.4 % (w/w) DGLA (isolated from mutant algal powder) 
in their diet increased the relative amount of this PUFA in plasma, liver and 
kidney lipid fractions.  
 
6.2.2 Lipid uptake in vitro 
In Chapter 3, initial studies focused on determining the uptake of DGLA into THP-1 
macrophage lipid fractions. Lipid analysis was performed using TLC and GC. A time 
point of 24 hour incubation with DGLA had been optimised previously in the 
laboratory. Using this time point a dose response experiment was performed based 
on concentrations used previously in the laboratory and other studies (Iversen et al. 
1991; Iversen et al. 1992; Dooper et al. 2003). It was found that DGLA levels 
increased in a dose-dependent manner into TPL and TAG fractions of THP-1 
macrophages (Figure 3.2). A concentration of 100 µM was used in further 
experiments due to the more pronounced lipid changes observed in comparison to 
lower concentrations.  
Lipid analysis following treatment of THP-1 macrophages with 100 µM DGLA (or 
vehicle control) was repeated for statistical analysis. It was found that treatment of 
the cells with 100 µM DGLA resulted in a significant increase in the level of the PUFA 
into TPL and TAG fractions in equal proportions (Figure 3.3). In addition there was an 
increase into individual phospholipids PC, PS, PE and PI (Figure 3.5). It was also 
observed that in all the lipid fractions analysed, there was no significant increase in 
the level of AA. This indicated that in THP-1 macrophages, treatment with DGLA 
resulted in a specific accumulation of the PUFA and that it was not rapidly desaturated 
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to AA. The result was comparable to previous studies in vitro (Johnson et al. 1997; 
Dooper et al. 2003). It has previously been shown that macrophages have limited 
desaturase activity (Chapkin et al. 1988; Chapkin and Coble 1991; Johnson et al. 
1997) which may explain the resulting lack of an increase in the levels of AA on 
supplementation with DGLA. This was a positive result as fatty acid composition of 
lipid pools directly influences the production of eicosanoids. DGLA gives rise to anti-
inflammatory eicosanoids, while AA produces classically pro-inflammatory 
eicosanoids. The selective increase in the level of DGLA over AA, may therefore 
affect the inflammatory potential of THP-1 macrophages by altering eicosanoid 
production. Given the important role of macrophages in the chronic inflammatory 
response in atherosclerosis, altering the production of eicosanoids from these cells 
may potentially have an important impact on the disease.  
6.2.3 Eicosanoids production 
Following on from the changes in fatty acid composition of THP-1 macrophages 
observed on treatment of the cells with DGLA, HPLC-MS was used to measure 
eicosanoid production. This would determine if changes in lipid composition of THP-
1 macrophages translated to a change in eicosanoid production. Prostaglandins, 
produced from the metabolism of DGLA and AA by COX, were measured. In DGLA 
treated macrophages, there was a significant increase in the concentration of PGE1, 
with no change in the levels of PGE2 (Figures 3.7 and 3.8). The concentration of PGE1 
did not exceed that of PGE2 in any experiment. However, the ratio of PGE2:PGE1 was 
dramatically reduced on treatment of the cells with DGLA. This indicated that the 
accumulation of DGLA into THP-1 macrophages did influence the production of 
eicosanoids with the significant increase in its COX metabolite PGE1. As expected, 
there was no rise in the production of AA metabolite PGE2. Similar results were also 
observed in vitro in mouse peritoneal macrophages (Chapkin and Coble 1991; 
Iversen et al. 1992). In addition to this, DGLA supplementation also significantly 
increased the production of LOX metabolite 15-HETrE, with no increase in AA LOX 
metabolites 5-, 11-, 12- and 15-HETE (Figure 3.6). PGE1 and 15-HETrE have been 
well documented to play a number of anti-inflammatory roles (Zurier and Ballas 1973; 
Zurier et al. 1977; Horrobin 1991). This suggested that supplementation of 
macrophages with DGLA can influence the inflammatory potential by increasing the 
production of anti-inflammatory mediators PGE1 and 15-HETrE.   
Eicosanoid production, on induction of an inflammatory state, was also measured. 
IFN-γ is a well-established pro-inflammatory cytokine (McLaren and Ramji 2009) and 
has been used routinely in the laboratory and throughout this study. IFN-γ stimulation 
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of macrophages did not significantly change the production of any eicosanoids 
measured. However, pre-treatment with DGLA followed by stimulation with IFN-γ 
significantly increased the production of PGE2 which was not seen in any other 
treatment (Figure 3.7). In addition to this, production of PGE1 in DGLA and IFN-γ 
stimulated macrophages, also increased to almost twice that seen in DGLA only 
treated macrophages (Figure 3.8). However, this difference was not significant due 
to a high variability between individual repeats. 
It was hypothesised that IFN-γ stimulation following DGLA pre-treatment may-be 
increasing the desaturation of the PUFA to AA and its accumulation into THP-1 lipid 
fractions. However, fatty acid analysis indicated that IFN-γ alone, and pre-treatment 
with DGLA followed by IFN-γ stimulation, did not result in an increase in the relative 
amount of AA into lipid fractions (Appendix 2). The next hypothesis was that IFN-γ 
affects the expression of COX enzymes, responsible for the production of 
prostaglandins. RT-qPCR was used to measure the effect of the cytokine on COX 
gene expression. It was observed that IFN-γ stimulation only, had no effect on the 
expression of COX-1 and COX-2 (Figure 3.9). On incubation with DGLA followed by 
stimulation with IFN-γ however, there was a significant decrease in COX-1 expression 
and a significant increase in COX-2 expression. There was also a significant decrease 
in COX-1 expression in DGLA only treated macrophages. These data indicated that 
DGLA in combination with IFN-γ was significantly increasing the expression of COX-
2 which, under identical conditions, was also increasing the production of PGE2 and 
to some extent PGE1. This suggested that COX-2, not COX-1 was primarily 
responsible for prostaglandin synthesis in THP-1 macrophages. The result was 
supported by data presented in previous studies (Ariasnegrete et al. 1995; Barrios-
Rodiles and Chadee 1998; Caughey et al. 2001; Levin et al. 2002). Future work would 
need to confirm these changes at the protein level.  
Despite the increase in PGE2 on treatment with DGLA and IFN-γ, results presented 
in Chapter 4 indicated an overall anti-inflammatory role in DGLA treated 
macrophages. For example, attenuation of IFN-γ induced gene expression on pre-
treatment with DGLA was observed in THP-1 macrophages, a condition in which 
PGE1 and PGE2 production was induced (Figure 3.7 and 3.8). This suggests that the 
role macrophages play in inflammation may be as a result of the ratios of PGE1 to 
PGE2 produced. Supplementation with DGLA, and induction of PGE1, may prove 
sufficient to offset any pro-inflammatory actions that may be promoted through the 
induction of PGE2.  
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6.2.3.1 Role of PGE1 
Given the induction of PGE1 production from macrophages treated with DGLA, and 
the anti-inflammatory roles of the eicosanoid reported previously (Martin and Dorf 
1991; Palumbo et al. 2000) the role of PGE1 was investigated in Chapter 5. Initially it 
was observed that DGLA inhibited IFN-γ induced gene expression and monocyte 
migration (Figure 4.10 and 4.15). The experiments were mimicked using PGE1. It was 
observed that PGE1 attenuated the IFN-γ induced expression of MCP-1 and ICAM-1 
in THP-1 macrophages and HMDMs (Figure 5.12 and 5.13) and inhibited MCP-1 
induced monocyte migration (Figure 5.14) comparable to that of DGLA. It was 
therefore hypothesised that the production of PGE1 from DGLA was playing a role in 
these processes.  
To test this hypothesis, the effect of DGLA on IFN-γ induced MCP-1 expression was 
measured in macrophages following siRNA-mediated knockdown of COX genes. 
COX-1 and COX-2 were both targeted for knockdown as both genes have been 
implicated in prostaglandin synthesis (Levin et al. 2002). As presented in Chapter 5 
(Figure 5.16), in macrophages containing COX-1 and COX-2, DGLA attenuated IFN-
γ induced MCP-1 gene expression. In macrophages with COX-1 and COX-2 
knockdown, this response was abolished. This indicated that metabolism of DGLA to 
PGE1 played a key role in IFN-γ mediated changes in gene expression. The data was 
supported by results published previously in vivo (Takai et al. 2009; Watanabe et al. 
2014). Given the inhibition of monocyte migration with PGE1 observed in Chapter 5, 
future work could aim to establish the role of the eicosanoid in the effect of DGLA on 
this process. This could be achieved by utilising the COX inhibitor naproxen.  
6.2.4 Cytokines 
Cytokines play an important role in regulating the inflammatory response in 
atherosclerosis. The effect of DGLA on signalling by pro-inflammatory cytokines IFN-
γ, IL-1β and TNF-α was investigated. The three cytokines have been studied 
previously in the laboratory and their roles in atherosclerosis are well documented 
(Gupta et al. 1997; Kirii et al. 2003; McLaren and Ramji 2009; Xiao et al. 2009). The 
induction of two key genes in atherosclerosis, MCP-1 and ICAM-1, was used as 
robust markers of inflammation. The expression of MCP-1 and ICAM-1 is up-
regulated in atherosclerosis and contributes to the pathology of the disease by 
recruiting monocytes and promoting their transmigration into the arterial intima 
(Gosling et al. 1999; Lusis 2000; Kitagawa et al. 2002). RT-qPCR was used to 
measure MCP-1 and ICAM-1 gene expression in response to pro-inflammatory 
cytokine signalling in THP-1 macrophages.  
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6.2.4.1 IFN-γ 
IFN-γ was the primary cytokine employed throughout this study as it has previously 
been extensively studied in the laboratory and has been described as a master 
regulator of atherosclerosis (McLaren and Ramji 2009). IFN-γ significantly induced 
the expression of MCP-1 and ICAM-1 in THP-1 macrophages (Figure 4.10). On pre-
incubation with DGLA, the induction of expression of these genes was significantly 
attenuated. The findings were also replicated in RAW264.7 macrophages and 
HMDMs (Figure 4.11 and 4.12). This indicated that DGLA potentially inhibited IFN-γ 
signalling and the regulation of inducible genes by this cytokine. IFN-γ signals through 
the JAK/STAT pathway. A key step in the pathway is the phosphorylation of STAT1 
molecules. This allows for STAT1 transcription factors to dimerise, translocate into 
the nucleus and activate gene transcription (Varinou et al. 2003). Two 
phosphorylation sites are present on the STAT1 molecule at positions TYR701 and 
SER727. Phosphorylation at TYR701 is crucial for STAT1 function as a transcription 
factor. For maximum activity of STAT1, phosphorylation at both sites is needed. Given 
the important role of STAT1 phosphorylation in IFN-γ signalling through the 
JAK/STAT pathway, the effect of DGLA on this process was determined by western 
blotting. Stimulation of the cells with IFN-γ significantly increased the phosphorylation 
of STAT1 at both phosphorylation sites in THP-1 macrophages (Figure 5.4). On pre-
treatment of the cells with DGLA followed by IFN-γ stimulation, the phosphorylation 
at SER727 was attenuated. There was no effect on phosphorylation at TYR701. 
Although STAT1 translocation into the nucleus and activation of transcription can 
occur independently of SER727 phosphorylation, it has previously been found that 
inhibiting phosphorylation at this site attenuates IFN-γ induced pro-inflammatory gene 
expression including MCP-1 and ICAM-1 (Varinou et al. 2003; Li et al. 2010). The 
data presented in Chapter 5 therefore indicates that DGLA inhibits IFN-γ induced 
gene expression by suppressing the phosphorylation of STAT1 at SER727 thereby 
attenuating the maximum activity of the transcription factor. This is a novel 
mechanism identified for the role of DGLA in pro-inflammatory signalling in 
atherosclerosis. Signalling through STAT1 also plays a role in the regulation of other 
pro-inflammatory pathways including IL-1 and TLR4 (Sikorski et al. 2011b). Given the 
role of DGLA in STAT1 regulation, signalling through these STAT1 dependent pro-
inflammatory pathways may also be affected. Future work may investigate the role of 
DGLA in other STAT1 dependent pathways.  
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6.2.4.2 IL-1β 
Following on from the inhibition of IFN-γ induced gene expression, the effect of the 
PUFA on other pro-inflammatory cytokine signalling was determined. The expression 
of the two inflammatory markers MCP-1 and ICAM-1 induced through IL-1β signalling 
was measured by RT-qPCR. IL-1β significantly induced the expression of the two 
genes in THP-1 macrophages (Figure 4.13). This has been observed in previous 
studies (Myers et al. 1992; Lim et al. 2009; Yang et al. 2010). Pre incubation of the 
cells with DGLA significantly inhibited the IL-1β induced expression of MCP-1 and 
ICAM-1 and returned to levels comparable to that of control. Inhibition of IL-1β 
signalling in vivo has been shown to have athero-protective effects, reducing plaque 
formation, macrophage infiltration and pro-inflammatory gene expression, including 
that of MCP-1 and VCAM-1 (Kirii et al. 2003; Bhaskar et al. 2011). The effect of DGLA 
on IL-1β signalling in vitro has not previously been established. Given the athero-
protective role of inhibiting IL-1β signalling in atherosclerosis, this may therefore be a 
novel mechanism by which DGLA exerts anti-inflammatory and anti-atherosclerotic 
effects.  
In addition to IL-1β signalling, the production of the cytokine from macrophages was 
also of interest. The production of an active form of IL-1β is under the control of a 
multi protein complex termed the inflammasome. A number of inflammasome 
complexes have been identified, however the NLRP3 inflammasome has been 
described as a key regulator of IL-1β production and documented to play a role in 
atherosclerosis (Moore et al. 2013). The role of the NLRP3 inflammasome in IL-1β 
production has also been documented in THP-1 macrophages (Rajamaki et al. 2010). 
ELISA was used to measure the effect of DGLA on the production of IL-1β through 
the activation of the NLRP3 inflammasome. The inflammasome was activated by 
cholesterol crystals, which have previously been demonstrated to induce 
inflammasome activation in vivo  and in vitro, including THP-1 macrophages (Duewell 
et al. 2010). Data presented in Chapter 4 showed that on treatment with cholesterol 
crystals, IL-1β production was induced from THP-1 macrophages as previously seen 
(Duewell et al. 2010) (Figure 4.14). On pre-treatment of the cells with DGLA followed 
by stimulation with cholesterol crystals, IL-1β expression was induced further in 
comparison to cholesterol crystal treatment only. This suggested DGLA induced IL-
1β expression through NLRP3 inflammasome activation. Previous work has proved 
controversial. Some studies have reported similar results with no effect of DGLA on 
LPS and nigericin induced NLRP3 or NLRP1b inflammasome activation (Yan et al. 
2013). In addition, GLA treatment of peripheral blood monocytes failed to inhibit the 
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LPS induced IL-1β induction (Furse et al. 2001). However GLA did inhibit IL-1β 
induction in an LPS independent manner. GLA reduced the stability of pro-IL-1β 
mRNA and attenuated auto induction of IL-1β (Furse et al. 2001). Data presented in 
Chapter 4 and previous studies (Furse et al. 2001; Yan et al. 2013), indicate that 
DGLA has no inhibitory effect on IL-1β production through inflammasome activation. 
Future work with DGLA may focus on evaluating IL-1β production in inflammasome 
independent mechanisms, given the role for GLA previously reported (Furse et al. 
2001).  
6.2.4.3 TNF-α 
Finally, the effect of DGLA on the induction of MCP-1 and ICAM-1 expression by TNF-
α was determined in THP-1 macrophages. Data presented in Chapter 4 demonstrated 
that TNF-α significantly induced the expression of the two genes (Figure 4.13). The 
cytokine has also previously been shown to induce the expression of the two genes 
in vitro and in vivo (Myers et al. 1992; Murao et al. 2000; Xiao et al. 2009). On pre-
treatment of the cells with DGLA followed by TNF-α stimulation, the induction of MCP-
1 and ICAM-1 expression was significantly inhibited. In both cases, the expression of 
genes in DGLA and TNF-α stimulated macrophages was not significantly different to 
that of the vehicle control. Inhibiting signalling through TNF-α in vivo has been shown 
to reduce plaque formation and decrease the levels of pro-inflammatory cytokines 
and chemokines (Ohta et al. 2005; Xiao et al. 2009). DGLA has also been shown to 
attenuate the production of TNF-α from PBMCs (Dooper et al. 2003). Data presented 
in Chapter 4 and previous studies have indicated a role for DGLA in the attenuation 
of TNF-α induced pro-inflammatory signalling and production. Further experiments 
will need to be carried out to determine the role of DGLA on TNF-α production in 
macrophages and in vivo.  
6.2.5 Monocyte migration 
As previously described (Section 4.1.2.2.1), MCP-1 plays an important role in 
monocyte recruitment (Gosling et al. 1999). Given the role of DGLA in inhibiting the 
induction of MCP-1 expression by a number of pro-inflammatory cytokines, it was of 
interest to determine if DGLA had a direct effect on the role of MCP-1. Monocyte 
migration was measured using cell inserts, to mimic endothelial layer of arteries, and 
THP-1 monocytes stimulated with MCP-1. MCP-1 significantly induced monocyte 
migration across the cell insert (Figure 4.15). On co-incubation with DGLA, this 
induction was significantly attenuated. This effect of DGLA on MCP-1 induced 
monocyte migration was a novel finding. Previous work has indicated that inhibiting 
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monocyte migration can significantly protect against the development of 
atherosclerosis in vivo (Feige et al. 2013; Mueller et al. 2013).  
The majority of experiments performed throughout this project, involved pre-
incubation with DGLA which allowed for uptake of the PUFA into THP-1 lipid fractions. 
However, DGLA was co-incubated with MCP-1 for 3 hours in migration studies due 
to the experimental set up. During this time it is hypothesised that there would be a 
lower level of uptake and metabolism of DGLA by monocytes. This may indicate that 
DGLA is having a direct effect on monocyte migration as opposed to a potentially 
indirect effect through its metabolites. This could be the result of DGLA acting on a 
number of fatty acid receptors including PPARs, TLRs, GPCR or SREBPs (as 
discussed in Section 1.4.2). However, data presented in chapter 5 (Figure 5.14) 
showed that PGE1 also inhibited monocyte migration suggesting a role for the 
eicosanoid. Future study could act to elucidate the mechanism by which DGLA 
inhibits monocyte migration. The role of DGLA metabolism to PGE1 in monocyte 
migration could be determined with the use of COX inhibitor naproxen. In addition, 
the role of fatty acid receptors could be evaluated through employing gene silencing 
techniques.  
Taken together, data presented in Chapter 4 indicates that DGLA inhibits the 
induction of MCP-1 expression through the inhibition of pro-inflammatory cytokine 
signalling and its ability to recruit monocytes. Inhibition of MCP-1 and monocyte 
recruitment has been previously shown to attenuate monocyte and macrophage 
content of plaques and significantly reduce atherosclerosis (Gosling et al. 1999; Feige 
et al. 2013; Mueller et al. 2013). Inhibition of MCP-1 induction and function by DGLA 
may be one mechanism by which the fatty acid exerts anti-inflammatory and anti-
atherosclerotic actions.  
6.2.6 Cholesterol uptake and efflux 
The next step following monocyte migration into the arterial intima, is their 
differentiation into macrophages. Macrophages can take up modified forms of LDL in 
an unregulated manner, accumulate cholesterol and store any excess as cholesteryl 
esters in lipid droplets in the cytoplasm (Ghosh et al. 2010). Viewing lipid loaded 
macrophages under the microscope has led to the term foam cells, due to their foamy 
appearance (Brown et al. 1980). The effect of DGLA on modified LDL induced 
cholesteryl ester accumulation was assessed in Chapter 4. Using acLDL as a 
modified form of LDL, the effect of DGLA on cholesteryl ester accumulation was 
determined in RAW264.7. It was found that on treatment with acLDL, RAW264.7 
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macrophages accumulated a significant amount of cholesteryl esters (Figure 4.16). 
On pre-treatment of the cells with DGLA followed by acLDL loading, this accumulation 
was significantly attenuated. In addition, the relative amount of free cholesterol was 
reduced in acLDL treated macrophages. This was slightly rescued on pre-treatment 
of the cells with DGLA, however this was not significant. The trend, however, 
suggested that DGLA played a role in inhibiting the uptake and/or accumulation of 
cholesteryl esters in macrophages. Studies in Chapter 5 aimed to determine the 
underlying molecular mechanisms behind this effect. 
6.2.6.1 Endocytosis 
In Chapter 5, the uptake of modified LDL by macrophages was investigated. Using a 
fluorescent form of oxLDL, Dil-oxLDL, the effect of DGLA on cholesterol uptake was 
measured by FACS. It was found that on treatment of the cells with DGLA, the uptake 
of Dil-oxLDL was significantly reduced by an average of 21% (Figure 5.5). This 
suggested that DGLA had an effect on the mechanisms underlying uptake. The 
uptake by receptor-dependent and -independent endocytosis was therefore 
determined in THP-1 macrophages. Scavenger receptors are expressed on the 
surface of macrophages and take up unregulated amounts of modified LDL. CD36 
and SRA were selected for study due to their key roles in the uptake of acLDL and 
oxLDL as reported previously (Febbraio et al. 2000; Kunjathoor et al. 2002; 
Kuchibhotla et al. 2008). Gene and protein expression of scavenger receptors was 
measured by RT-qPCR and western blotting respectively. It was found that on 
treatment with DGLA, the mRNA and protein expression of SRA was significantly 
attenuated in comparison to the control (Figure 5.6). The mRNA expression of CD36 
was also significantly reduced.  
In addition to receptor-mediated endocytosis, receptor-independent uptake through 
macropinocytosis was determined by FACS analysis of a marker, LY. 
Macropinocytosis has been documented to uptake native and modified forms of LDL 
and to contribute significantly to foam cell formation in macrophages (McLaren et al. 
2011b; Michael et al. 2013). On treatment of the cells with DGLA, the uptake of LY 
by macropinocytosis was significantly reduced (Figure 5.7).  
Inhibiting these two uptake pathways has been shown to significantly reduce the 
uptake of acLDL, oxLDL and the accumulation of cholesteryl esters in macrophages 
(Kunjathoor et al. 2002). This suggests that DGLA attenuates cholesteryl ester 
accumulation as seen in Chapter 4, by attenuating modified LDL uptake through 
scavenger receptor mediated pathways and macropinocytosis.  
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6.2.6.2 Efflux 
Macrophages efflux cholesterol by a mechanism known as RCT. An imbalance 
between cholesterol influx and efflux leads to an accumulation of cholesteryl esters 
and macrophage foam cell formation in atherosclerosis (Ono 2012). Efflux of 
cholesterol from acLDL loaded THP-1 macrophages was measured using radioactive 
14C cholesterol and scintillation counting. Following incubation with acLDL, ApoA1 
was used to stimulate efflux from macrophages, which has been shown previously 
(McLaren et al. 2010; Ouimet et al. 2011; Sene et al. 2013). It was found that ApoA1 
increased the efflux of cholesterol from acLDL-loaded THP-1 macrophages in 
comparison to the control (Figure 5.9). When macrophages were pre-treated with 
DGLA followed by acLDL loading and ApoA1 stimulation, efflux was significantly 
increased. No study to date has documented the role of DGLA in RCT from 
macrophages. Increase in cholesterol efflux to ApoA1 in vivo was shown to 
significantly reduce atherosclerosis (Su et al. 2003). This suggests that DGLA may 
decrease cholesteryl ester accumulation and foam cell formation by increasing 
cholesterol efflux from macrophages. 
There are a number of mechanisms by which macrophages remove cholesterol. ABC 
transporters ABCA1 and ABCG1 have been well documented to play an important 
role in macrophage RCT (Singaraja et al. 2002; Wang et al. 2007; Yvan-Charvet et 
al. 2007; Yvan-Charvet et al. 2010). Specifically, ABCA1 plays an important role in 
efflux of cholesterol to ApoA1, while ABCG1 is required to efflux to HDL (Kennedy et 
al. 2005). In addition to this, macrophage expressed ApoE has also been indicated to 
play a role in cholesterol efflux (Zhu et al. 1998). Given the role of DGLA in cholesterol 
efflux, the effect of the PUFA on the mRNA and protein expression of ABCA1, ABCG1 
and ApoE was measured by RT-qPCR and western blotting to attempt to establish 
the underlying mechanisms. Due to time constraints, one experiment was performed 
in triplicate for both RT-qPCR and western blotting. From the results of this 
experiment it was found that in THP-1 macrophages, cholesterol loading with acLDL 
induced ABCA1 (mRNA and protein) and ABCG1 (mRNA) expression but not ApoE 
(protein) (Figure 5.10). On pre-treatment of the cells with DGLA, there was no 
observable difference in expression ABCG1 or ApoE in comparison to only 
cholesterol loaded macrophages. For ABCA1, pre-treatment with DGLA decreased 
mRNA expression, however there was no change observed at the protein level.  
Previous studies on the role of omega-6 PUFAs on the expression of ABC transporter 
genes have proved controversial, with some reporting an inhibition of gene and 
protein expression (Uehara et al. 2002; Wang and Oram 2002; Uehara et al. 2007) 
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and other showing no effect (Salehipour et al. 2010; Song et al. 2013). In addition, 
ABC transporters and ApoE are LXR inducible genes. PUFAs have previously been 
demonstrated to inhibit LXR activation and activity (Pawar et al. 2003; Uehara et al. 
2007). The expression of LXR isoforms LXR-α and –β was measured by RT-qPCR in 
unloaded THP-1 macrophages. It was observed that pre-incubation of DGLA 
significantly attenuated LXR-α and -β mRNA expression (Figure 5.11). This suggests 
that DGLA may inhibit LXR activity in THP-1 macrophages, and that the PUFA may 
have an adverse effect on the expression of ABC transporter genes and ApoE on 
further investigation. This also indicates that DGLA is not acting through mechanisms 
dependent on these two proteins. Future work will need to establish the effect of 
DGLA on the expression of LXR genes in cholesterol loaded macrophages.  
Taken together, the increase in cholesterol efflux on treatment with DGLA observed 
in THP-1 macrophages may not be dependent on LXR regulated genes, ABCA1, 
ABCG1 and ApoE. However further investigation will be needed to confirm this. In 
addition, future work will need to identify any alternative mechanisms by which an 
increase in efflux is achieved by DGLA. This may include determining the role of the 
COX metabolite PGE1 which has previously been indicated to increase cholesterol 
efflux in macrophages and fibroblasts (Middleton and Middleton 1998; Chan et al. 
2007).  
6.2.7 Lipid uptake in vivo 
Initial lipid analysis utilised THP-1 macrophages to determine the uptake and 
metabolism of DGLA. Following on from this, mouse feeding studies were performed 
to determine the uptake of the PUFA in vivo. In vitro work used a pure form of DGLA 
(as a free fatty acid) to determine the specific role of the PUFA in inflammation. 
Alternatively, DGLA was also sourced from a mutant form of the green algae P. incisa, 
obtained from collaboration with Ben-Gurion University, Israel. An additional aim of 
the study was to evaluate the algae as a potential new commercial source of DGLA. 
Initially, freeze dried algal powder was added directly to mouse diet. It was found that 
the algal powder was not digested by the mice and the DGLA contained within the 
algal bodies was not absorbed and incorporated into any lipid fractions (Appendix 1).  
Following this, total lipids were extracted from the algal powder and added directly to 
mouse chow diet. Male C57BL/6 mice were starved for 24 hours prior to being given 
either chow control diet or a diet containing 4.4% (TFA) DGLA for 48 hours. Mice 
were sacrificed using schedule 1 procedures and samples of plasma, together with 
tissue samples, were taken for lipid analysis.  
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Plasma was separated into four lipid fractions; TFA, TPL, TAG and steryl esters. In 
the DGLA group, the level of the PUFA was significantly increased into all lipid 
fractions measured, in comparison to control group. There was no significant increase 
in AA level in any lipid fraction of plasma. In addition, lipid fractions of liver, kidney 
and adipose tissue were analysed. Similar to plasma, the level of DGLA was 
significantly increased in TFA, TPL, TAG and steryl ester lipid fractions in DGLA diet 
group. There was a significant rise in the level of AA in TAG fraction only. Individual 
phospholipids were also analysed from the liver. DGLA was significantly incorporated 
into PS, PE and PC in the DGLA group. In the kidney, DGLA level was significantly 
increased in TFA in the DGLA group, but not TPL or TAG. There was however a 
significant increase in AA in the TPL fraction. Finally, in adipose tissue, DGLA 
significantly increased in TFA in the DGLA group, with no significant increase of AA.  
Results are summarised in Table 6.1.  
 
Table 6.1 – Summary of key findings in vivo 
 
Summary of the significant changes in incorporation of DGLA and AA into lipid fractions, 
following DGLA feeding, in vivo. Tick indicates significant increase in incorporation. Cross 
indicates no significant increase. 
Overall, after 48 hours of DGLA supplemented diet, mice incorporated the PUFA into 
the majority of lipid fractions measured in the plasma, liver, kidney and adipose tissue. 
The only significant increase in AA level observed was in liver TAG and kidney TPL 
fractions. Despite this, there was a general trend observed indicating an increase in 
the level of AA on feeding with DGLA in the majority of lipid fractions. Initial in vitro 
                     DGLA                   AA 
 TFA PL TAG SE TFA PL TAG SE 
Plasma     x x x x 
Liver     x x  x 
Kidney  x x - x  x - 
Adipose  - - - x - - - 
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work in macrophages indicated that DGLA was actively incorporated into membranes 
with no subsequent increase in AA. In contrast, in vivo there was a clear trend of 
increase in AA level in lipid fractions on DGLA feeding. This may be explained by the 
different activities of desaturase enzymes found in different cell types. For example, 
it has been reported that desaturase activity in macrophages is low, preventing rapid 
desaturation of DGLA to AA in these cells (Chapkin et al. 1988; Johnson et al. 1997). 
However, liver and kidney have been reported to have both active elongase and 
desaturase (Johnson et al. 1997) and therefore result in an increase in AA level in 
addition to DGLA, following DGLA feeding, in these tissues. The role of DGLA and 
AA incorporation and eicosanoid production in vivo will need to be further investigated 
to understand the role these two PUFA play and the result on inflammation and 
atherosclerosis.   
6.3 Future perspective 
6.3.1 In vitro assays 
Data presented throughout the thesis have provided key insight into the role of DGLA 
in a number of aspects contributing to macrophage foam cell formation in vitro. This 
includes attenuation of monocyte migration, pro-inflammatory gene expression and 
accumulation of cholesteryl esters. A number of experiments could potentially be 
performed to expand on findings presented in the experimental chapters. Some 
examples have been discussed previously (Sections 3.5, 4.5, 5.5, 6.2) relating to 
each key finding in macrophages and are summarised and expanded below. 
It was found in studies presented in Chapter 4 that DGLA inhibited the IFN-γ induced 
expression of key pro-inflammatory genes in THP-1 macrophages. Data presented in 
Chapter 5 indicated that this may be a result of the attenuation of STAT1 
phosphorylation at SER727 preventing maximum transcriptional activity of IFN-γ 
inducible genes. Following on from this, the effect of DGLA could be investigated on 
other aspects of IFN-γ signalling. Given the action of DGLA on STAT1 a number of 
techniques could be used to determine the subsequent effect of the inhibition of 
STAT1 phosphorylation. Translocation into the nucleus could be measured using 
immunofluorescence. STAT1 binding to DNA may also be analysed using chromatin 
immuno-precipitation (ChIP) assays. In addition, BMDMs isolated from STAT1 knock-
in mice, a mouse colony already present in the laboratory, could be utilised to 
investigate any DGLA mechanisms dependent on STAT1. This would provide further 
understanding into the precise mechanisms underlying DGLAs action in inflammatory 
processes.  
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Previous research has indicated that incorporation of omega-3 fatty acids EPA and 
DHA into cholesteryl esters can alter its physical state and increase hydrolysis and 
efflux of cholesterol from THP-1 macrophages (Lada et al. 2003). Unfortunately, due 
to the insufficient concentration of cholesteryl ester accumulated in unloaded THP-1 
macrophages observed in experiments and in previous studies (Lada et al. 2003), it 
was not possible to carry out lipid analysis of cholesteryl esters in these cells. There 
was however a significant increase of DGLA incorporation into cholesteryl esters into 
liver and plasma lipid fractions of mice in vivo (Chapter 3). This indicates that DGLA 
is actively incorporated into steryl esters and may also accumulate in macrophages. 
In addition to this, data presented in Chapter 4 showed an increase in cholesterol 
efflux from THP-1 macrophages loaded with acLDL. Given the data presented in the 
thesis and previous studies (Lada et al. 2003) detailing the effects of PUFAs on 
cholesteryl ester metabolism and efflux, DGLA may play a similar role. Future work 
could act to determine the incorporation of DGLA into THP-1 macrophage steryl ester 
lipid fraction by GC, following cholesterol loading with acLDL. This could also be 
determined in HMDMs.  
In addition to macrophages, a number of other cell types play an important role in 
atherosclerosis pathology, for example endothelial cells and SMCs. Endothelial 
dysfunction is a key early event in the initiation of atherosclerosis while SMC migration 
and proliferation is characteristic of advancing plaques (McLaren et al. 2011a; 
Michael et al. 2012). Future work could include the effect of DGLA on key events 
related to atherosclerosis in these two cell types. The effect of DGLA on endothelial 
dysfunction could be analysed by techniques measuring cell viability, apoptosis, ROS 
and NO production and expression of pro-inflammatory markers. For SMCs, the effect 
of DGLA on proliferation could be measured by incorporation of bromo-2’-
deoxyuridine which is incorporated into cells during cell division. In addition, migration 
could be measured using an in vitro scratch assay (Liang et al. 2007). This would 
allow for a better understanding of the wider role of DGLA in atherosclerosis 
pathology.  
6.3.2 In vivo experiments 
In vivo studies presented in Chapter 3 were used to analyse the uptake of DGLA 
isolated from an algal source provided by collaborators at Ben-Gurion University, 
Israel. Despite the results of the experiment indicating that this novel source could be 
potentially credible, the study provided no investigation into the mechanistic role of 
DGLA in vivo. Data presented in experimental chapters indicate a number of 
beneficial anti-inflammatory and anti-atherogenic roles for DGLA in macrophages in 
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vitro. Future work will need to expand to in vivo models of the disease to evaluate if 
the mechanistic roles of DGLA are conserved. In vivo models of atherosclerosis can 
be utilised to determine if DGLA has the same effect on monocyte migration, cytokine 
production, pro-inflammatory gene expression and modified LDL uptake and efflux as 
reported in macrophage cell lines. Cytokine expression in vivo could be determined 
by the use of multiplex cytokine assays on plasma and plaques isolated from mouse 
models. In addition, cholesterol efflux can be determined in vivo following peritoneal 
injection of cholesterol loaded macrophages in the presence of radiolabeled 
cholesterol. Determining radioactivity of tracer in plasma, faeces and liver lipids would 
allow for measurement of cholesterol efflux (Wang et al. 2014; Xu et al. 2014a).  
In vitro studies in Chapter 3 of eicosanoid production showed that supplementation 
with DGLA resulted in the selective increase in the production of PGE1, with no 
change in PGE2. However, previous studies in vivo have also suggested that DGLA 
supplementation leads to an increase in PGE2 production (Umeda-Sawada et al. 
2006; Amagai et al. 2015). Again, in vivo models could be utilised to measure 
eicosanoid production in response to DGLA feeding and how this impacts on 
atherosclerosis. Plasma levels of eicosanoids isolated from in vivo models could be 
measured by HPLC-MS.  
Previous in vivo research with DGLA has been limited. Relatively few studies have 
investigated the role of DGLA in vivo in diseases such as atopic dermatitis, cancer 
and atherosclerosis. As previously described, DGLA attenuated the development of 
atherosclerosis in an ApoE-/- mouse model (Takai et al. 2009). Despite this beneficial 
insight into the role of DGLA in atherosclerosis, the study provided little mechanistic 
insight.  For example, a limited number of inflammatory genes were measured by 
semi quantitative reverse transcription PCR and the study was performed at a single 
time point using the ApoE-/- mouse model, a more aggressive model of 
atherosclerosis (Plump et al. 1992; Ishibashi et al. 1993) . In addition there was no 
investigation into processes involved in foam cell formation, cytokine levels or plaque 
composition, stability and plaque regression.  
Future work in vivo with DGLA could be performed to expand on the preliminary work 
detailed on the roles of this PUFA in atherosclerosis. The effect of DGLA on plaque 
morphology, regression and stabilisation could be investigated by a number of plaque 
morphometric and immunohistochemistry techniques. This could include determining 
plaque cell content by staining for cells such as macrophage, SMCs and T-cells, foam 
cell quantification and collagen staining (Miller et al. 2008; McLaren et al. 2010). In 
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addition to this, the effect of DGLA on a number of other parameters could also be 
measured. Plasma lipid profiles could be analysed by TLC and GC and immune cell 
profiles measured by FACS. Plasma concentrations of cytokines and chemokines 
could also be measured in vivo using multiplex ELISAs or microarrays, in response 
to DGLA feeding.  
6.2 Conclusions 
Investigation in vitro has indicated an anti-inflammatory and anti-atherogenic role for 
DGLA. Supplementation with DGLA regulates several key pro-atherosclerotic 
processes involved in foam cell formation, a key step in atherosclerosis. These 
include attenuation of monocyte migration, pro-inflammatory cytokine signalling, pro-
inflammatory gene expression, modified LDL uptake through receptor-dependent and 
-independent mechanisms, cholesteryl ester accumulation and increasing cholesterol 
efflux. Supplementation with DGLA in macrophages also alters the production of 
eicosanoids, inducing anti-inflammatory mediators PGE1 and 15HETrE. Metabolism 
of DGLA to PGE1 in macrophages was also shown to play a key role in cytokine 
induced pro-inflammatory gene expression and monocyte migration and therefore 
maybe one mechanism in which the PUFA elicits anti-inflammatory responses. In 
addition, in vitro and in vivo studies showed DGLA was actively incorporated into 
macrophage, plasma, liver and kidney lipid fractions respectively.  
The data presented in the thesis complements previous limited in vitro and in vivo 
studies carried out with DGLA. Taken together, they indicate a positive role for the 
PUFA in the inhibition of foam cell formation and prevention of atherosclerosis.  
However future work will need to be performed in vivo to further understand the 
mechanistic role and potential use of DGLA as a nutraceutical in the prevention and 
treatment of atherosclerosis. 
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APPENDIX 
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Appendix 1 – Uptake of DGLA into plasma lipid fractions in vivo with 
algal powder 
Mice were supplemented with 2% (w/w) algal powder (containing approximately 
30% DGLA) into diet for 48 hours. Animals were sacrificed and plasma fraction of 
blood collected. Lipids were extracted and separated using 1-dimensional TLC. 
Fatty acid profiles of each lipid fraction were analysed by GC. Graphs display 
average fatty acid composition as a percentage (+ SD) of 3 mice (Control) and 3 
mice (DGLA diet). Statistical analysis was performed using a one-way ANOVA 
followed by Tukey’s post hoc analysis. No significant changes were observed. 
C16:0, palmitic acid; C16:1n7, palmitoleic acid; C18:0, stearic acid; C18:1n9, oleic 
acid; C18:1n7, cis-vaccenic acid; C18:2n6, LA; C18:3n3, ALA; C20:3n6, DGLA; 
C20:4n6, AA; C20:5n3, EPA; C22:6n3, DHA;  
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Appendix 2 – Stimulation with IFN-γ has no effect on AA incorporation in THP-
1 macrophage TPL and TAG fractions  
THP-1 macrophages were pre-incubated with 100 µM DGLA or vehicle control for 24 hours 
followed by 250 U/ml IFN-γ or vehicle control for a further 24 hours. Lipids were extracted and 
separated using 1-dimensional TLC. Fatty acid profiles were determined using GC. Graphs 
display fatty acid composition of fraction as a percentage (+/- SD) of one experiment 
performed in duplicate. C14:0, myristic acid; C16:0, palmitic acid; C16:1n7, palmitoleic acid; 
C18:0, stearic acid; C18:1n9, oleic acid; C18:1n7, cis-vaccenic acid; C18:2n6, LA; C18:3n3, 
ALA; C20:3n6, DGLA; C20:4n6, AA; C20:5n3, EPA; C22:5n3, DPA; C22:6n3, DHA; C24:0, 
lignoceric acid.       
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Appendix 3 – Significant increase of less than 1% in DGLA and AA in faeces 
following 4.4% DGLA diet 
Male C57BL/6 mice were split into 2 groups; Control (3) and DGLA (4). For DGLA group, 
normal chow diet was supplemented with 4.4% (TFA) DGLA. Mice were starved for 24 hours 
prior to feeding. Mice were fed control or DGLA containing diet for 48 hours. Following this, 
faeces were collected, lipids extracted and analysed using GC. Statistical analysis was 
performed using a one-way ANOVA followed by Tukey’s post hoc analysis. * P<0.05. ** P 
<0.01. C16:0, palmitic acid; C18:0, stearic acid; C18:1n9, oleic acid; C18:2n6, LA; C18:3n3, 
ALA; C20:3n6, DGLA; C20:4n6, AA. 
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Appendix 4 – DGLA uptake into THP-1 macrophages from algal lipid extract 
THP-1 macrophages were incubated with 100 µM total fatty acids (extract from algal powder) 
or vehicle control for 24 hours. Lipids were extracted and separated using 1-dimensional TLC. 
Fatty acid profiles were determined using GC. Graphs display fatty acid composition of fraction 
as an average percentage (+/- SD) from two independent experiments. C14:0, myristic acid; 
C16:0, palmitic acid; C16:1n7, palmitoleic acid; C18:0, stearic acid; C18:1n9, oleic acid; 
C18:1n7, cis-vaccenic acid; C18:2n6, LA; C18:3n3, ALA; C20:3n6, DGLA; C20:4n6, AA; 
C20:5n3, EPA; C22:5n3, DPA; C22:6n3, DHA; C24:0, lignoceric acid.        
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Appendix 5 – DGLA (hydrolysed from algal lipid extract) attenuated the IFN-γ 
induced expression of MCP-1 
THP-1 macrophages were incubated with vehicle or 100 µM TFA (hydrolysed from total lipid 
extract of algal powder) for 24 hours prior to treatment with vehicle or 250 U/ml IFN-γ for 3 
hours. Total RNA was subjected to reverse transcription and RT-qPCR with primers specific 
for human MCP-1 or GAPDH. Graphs display average normalised gene expression (mean +/- 
SD) (control arbitrarily assigned as 1) from one experiment performed in triplicate. 
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Appendix 6 – Time course in THP-1 and RAW264.7 macrophages 
THP-1 and RAW246.7 macrophages were incubated with 50 μM DGLA for 24 hours and 48 hours prior to the addition of 50 µM AcLDL and 1µCi [14C] acetate 
for a further 24 hours. Lipids were extracted, separated via TLC and radioactive incorporation into lipid fractions, identified by comparison with known standards, 
was measured by scintillation counting. Graphs display percentage incorporation of [14C] into polar lipids (PL), free cholesterol (FC), free fatty acids (FFA), 
triacylglycerols (TAG) and cholesteryl esters (CE) from a single experiment   
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Appendix 7 – Time course in THP-1 and RAW264.7 macrophages 
RAW246.7 macrophages were incubated with 50 μM or 100 μM DGLA for 24 hours prior to the addition of 50 µM AcLDL and 1µCi [14C] acetate for a further 24 
hours. Lipids were extracted, separated via TLC and radioactive incorporation into lipid fractions, identified by comparison with known standards, was measured 
by scintillation counting. Graphs display percentage incorporation of [14C] into polar lipids (PL), free cholesterol (FC), free fatty acids (FFA), triacylglycerols 
(TAG) and cholesteryl esters (CE) from a single experiment 
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